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THE INTERFACE OF NEUROLOGY AND PSYCHAITRY. 
MODERN EPIDEMIOLOGIC APPROACHES 
Mental disorders comprise a heterogeneous group of disorders, which have in common, 
their effect on mental well-being. Almost 15% of adults over the age of 60 suffer from a 
mental disorder.1 Two of the most common disorders are dementia and affective 
disorders.2 Dementia refers to a group of diseases that have effects on memory, thinking, 
behavior, and daily functioning, in common.3 The most common causes of dementia are 
Alzheimer’s disease and vascular dementia. Dementia affects 47 million people 
worldwide, and this burden is expected to double every 20 years because the population 
is aging rapidly and no treatment is available so far for dementia.3 Similarly, affective 
disorders are also a group of disorders that have in common effects on behavior, daily 
functioning, and thinking. The two most common affective disorders are depression and 
anxiety. Depression affects approximately 7% of the elderly population and accounts for 
1.6% of total disability among over 60 year olds.1 For both dementia and affective 
disorders, the frequency increases sharply with age.  
Depression, anxiety, and dementia very often co-occur.4 At the same time, there is an 
overlap between symptoms of dementia with symptoms of affective disorders, for 
instance, apathy, loss of interest, social withdrawal, isolation, impaired thinking and 
concentration, agitation, restlessness, sleep disturbance, hence a demarcation between 
the two entities is difficult.5 Comorbid affective symptoms in demented patients lead to 
poorer prognosis of dementia due to accelerated deterioration,6 and comorbid affective 
symptoms in patients with mild cognitive impairment lead to an accelerated progression 
to dementia.7 This association between affective disorders and dementia is a complex 
one, and the boundaries are ill-defined. Many studies suggest that depression and anxiety 
are risk factors for dementia, but given the long preclinical phase of dementia, it is equally 
possible that affective symptoms appear in response to the ongoing cognitive impairment, 
implying reverse causation.8 Therefore, whether late-onset depression and anxiety are risk 
factors of dementia, or it’s prodrome, remains debated. If depression and anxiety mark 
the preclinical phase of dementia, meaningful pharmacological or non-pharmacological 
interventions might be possible. In addition to affective symptoms, the underlying 
cognitive decline might also reflect in subtle changes in lifestyle or everyday habits of 
individuals. In view of a rapidly aging population, a better understanding of these 
disorders is the key to tackle the devastating consequences associated with them. It is also 
suggested that affective disorders and dementia are consequences of a common 
pathological process(es).9 Of the several pathways proposed, vascular impairment is the 
 
 
 
most studied, and has been implicated as a risk factor, not only for vascular dementia, but 
for Alzheimer’s disease as well.10 If dementia and affective disorders have a shared 
etiology, identification of such common pathways will open avenues for joint etiological 
research, which may lead to effective prevention or treatment strategies.  
The overall aim of this thesis was to study how late-onset affective symptoms relate with 
dementia. Studies described in this thesis were all embedded within the Rotterdam Study, 
an established cohort of 14,926 persons aged 45 years and older. In addition to detailed 
interviews and examinations every 3-4 years, all participants are continuously monitored 
for all major life events via a computerized linkage of the study database with the files 
from general practitioners.11 I used various established and novel methodological 
techniques to answer my research question, including Latent-Class Analyses and flexible 
parametric method of survival analysis. 
Specifically, in Chapter 2 of this thesis, I studied the associations of depression and anxiety 
with dementia. In Chapter 2.1, I studied the short- and long-term associations between 
depression and dementia. However, since depression has a remitting and relapsing 
nature, risk of dementia might differ with different courses of depression, especially over 
a long follow-up. Therefore, in Chapter 2.2 and 2.3, I studied how risks of dementia and 
mortality differ across different trajectories of depressive symptoms. In Chapter 2.4 and 
2.5, I studied the association of anxiety with dementia and mortality. Subsequently, I 
studied mild cognitive impairment in relation to risk of affective disorders in Chapter 2.6. 
In Chapter 3, I studied the role of lifestyle factors in relation to incident dementia. As a 
part of lifestyle, coffee has been of considerable interest in relation to dementia because 
of its neurostimulatory effects.12 The beneficial effect of coffee has been largely reported 
by epidemiological studies with short follow-up, whereas studies with a longer follow-up 
show no protective association.13 Therefore, the protective effects of coffee on dementia 
remain debated. In Chapter 3.1, I studied coffee consumption and risk of dementia over 
both short and long-term follow-up periods. Extending these analyses, in Chapter 3.2, I 
studied associations of coffee consumption with cognitive function and MRI markers of 
brain volumes and brain pathology. In Chapter 3.2, I studied the role of cognitive reserve 
(operationalized by educational level) in protection against dementia after a stroke or TIA. 
In Chapter 4, I studied serum biomarkers in relation to incident dementia and depression. 
In Chapter 4.1, I studied NT-proBNP, which is a marker of cardiovascular disease, in 
relation to incident dementia, Alzheimer’s disease, and cognitive decline. In Chapter 4.2, I 
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12
Introduction
13
 
 
 
THE INTERFACE OF NEUROLOGY AND PSYCHAITRY. 
MODERN EPIDEMIOLOGIC APPROACHES 
Mental disorders comprise a heterogeneous group of disorders, which have in common, 
their effect on mental well-being. Almost 15% of adults over the age of 60 suffer from a 
mental disorder.1 Two of the most common disorders are dementia and affective 
disorders.2 Dementia refers to a group of diseases that have effects on memory, thinking, 
behavior, and daily functioning, in common.3 The most common causes of dementia are 
Alzheimer’s disease and vascular dementia. Dementia affects 47 million people 
worldwide, and this burden is expected to double every 20 years because the population 
is aging rapidly and no treatment is available so far for dementia.3 Similarly, affective 
disorders are also a group of disorders that have in common effects on behavior, daily 
functioning, and thinking. The two most common affective disorders are depression and 
anxiety. Depression affects approximately 7% of the elderly population and accounts for 
1.6% of total disability among over 60 year olds.1 For both dementia and affective 
disorders, the frequency increases sharply with age.  
Depression, anxiety, and dementia very often co-occur.4 At the same time, there is an 
overlap between symptoms of dementia with symptoms of affective disorders, for 
instance, apathy, loss of interest, social withdrawal, isolation, impaired thinking and 
concentration, agitation, restlessness, sleep disturbance, hence a demarcation between 
the two entities is difficult.5 Comorbid affective symptoms in demented patients lead to 
poorer prognosis of dementia due to accelerated deterioration,6 and comorbid affective 
symptoms in patients with mild cognitive impairment lead to an accelerated progression 
to dementia.7 This association between affective disorders and dementia is a complex 
one, and the boundaries are ill-defined. Many studies suggest that depression and anxiety 
are risk factors for dementia, but given the long preclinical phase of dementia, it is equally 
possible that affective symptoms appear in response to the ongoing cognitive impairment, 
implying reverse causation.8 Therefore, whether late-onset depression and anxiety are risk 
factors of dementia, or it’s prodrome, remains debated. If depression and anxiety mark 
the preclinical phase of dementia, meaningful pharmacological or non-pharmacological 
interventions might be possible. In addition to affective symptoms, the underlying 
cognitive decline might also reflect in subtle changes in lifestyle or everyday habits of 
individuals. In view of a rapidly aging population, a better understanding of these 
disorders is the key to tackle the devastating consequences associated with them. It is also 
suggested that affective disorders and dementia are consequences of a common 
pathological process(es).9 Of the several pathways proposed, vascular impairment is the 
 
 
 
most studied, and has been implicated as a risk factor, not only for vascular dementia, but 
for Alzheimer’s disease as well.10 If dementia and affective disorders have a shared 
etiology, identification of such common pathways will open avenues for joint etiological 
research, which may lead to effective prevention or treatment strategies.  
The overall aim of this thesis was to study how late-onset affective symptoms relate with 
dementia. Studies described in this thesis were all embedded within the Rotterdam Study, 
an established cohort of 14,926 persons aged 45 years and older. In addition to detailed 
interviews and examinations every 3-4 years, all participants are continuously monitored 
for all major life events via a computerized linkage of the study database with the files 
from general practitioners.11 I used various established and novel methodological 
techniques to answer my research question, including Latent-Class Analyses and flexible 
parametric method of survival analysis. 
Specifically, in Chapter 2 of this thesis, I studied the associations of depression and anxiety 
with dementia. In Chapter 2.1, I studied the short- and long-term associations between 
depression and dementia. However, since depression has a remitting and relapsing 
nature, risk of dementia might differ with different courses of depression, especially over 
a long follow-up. Therefore, in Chapter 2.2 and 2.3, I studied how risks of dementia and 
mortality differ across different trajectories of depressive symptoms. In Chapter 2.4 and 
2.5, I studied the association of anxiety with dementia and mortality. Subsequently, I 
studied mild cognitive impairment in relation to risk of affective disorders in Chapter 2.6. 
In Chapter 3, I studied the role of lifestyle factors in relation to incident dementia. As a 
part of lifestyle, coffee has been of considerable interest in relation to dementia because 
of its neurostimulatory effects.12 The beneficial effect of coffee has been largely reported 
by epidemiological studies with short follow-up, whereas studies with a longer follow-up 
show no protective association.13 Therefore, the protective effects of coffee on dementia 
remain debated. In Chapter 3.1, I studied coffee consumption and risk of dementia over 
both short and long-term follow-up periods. Extending these analyses, in Chapter 3.2, I 
studied associations of coffee consumption with cognitive function and MRI markers of 
brain volumes and brain pathology. In Chapter 3.2, I studied the role of cognitive reserve 
(operationalized by educational level) in protection against dementia after a stroke or TIA. 
In Chapter 4, I studied serum biomarkers in relation to incident dementia and depression. 
In Chapter 4.1, I studied NT-proBNP, which is a marker of cardiovascular disease, in 
relation to incident dementia, Alzheimer’s disease, and cognitive decline. In Chapter 4.2, I 
Chapter 1
14
Introduction
15
 
 
 
studied many cardiovascular, metabolic, and renal biomarkers individually, and jointly, in 
relation to incident depression. 
Finally, in Chapter 5, I discuss the main findings of these studies with certain 
methodological considerations, and provide a general outlook for future research. 
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ABSTRACT 
Background: Whether depression is a long term risk factor for dementia or represents a 
prodrome of dementia is unclear. Therefore, we examined the relationship between 
depressive symptoms and dementia both during short and long follow-up in a population-
based cohort. 
Methods: In The Rotterdam Study 4,393 non-demented individuals were followed for 
incident dementia for 13.7 years by continuous monitoring. Cox proportional-hazards 
models for different time intervals were used to estimate the risk of incident dementia.  
Results: 582 participants developed dementia during 13.7 years. Persons with depressive 
symptoms had an 8% increased risk of dementia compared to those without depressive 
symptoms during the over-all follow up. The risk was highest in the short and intermediate 
follow-up, particularly in men. We did not find an association in the follow-up period 
beyond 10 years.  
Conclusions: Our results suggest that late-life depressive symptoms are part of a dementia 
prodrome rather than an independent risk factor of dementia. 
 
 
 
INTRODUCTION 
Dementia poses a high burden on society and health care, both in terms of financial costs 
as well as suffering for patients and care-givers. Current estimates indicate a prevalence of 
35.6 million patients worldwide with another 7.7 million incident cases occurring 
annually.1 In order to develop effective preventive and therapeutic strategies, it is crucial 
to unravel the multi-factorial etiology of dementia. 
Depression and depressive symptoms are very common in the elderly and often co-occur 
with dementia.2 Depression and dementia share many vascular risk factors3 and various 
studies have shown that depression in late life is associated with a 2 to 5 fold increased 
risk of dementia.4-8 Most studies investigated this association over a follow-up period of at 
most 7 years. In contrast, The Framingham Study studied a follow-up period of 17 years 
and reported a 70% greater risk of incident dementia in depressed individuals; however, 
the investigators did not distinguish the risk between short and long-term follow-up. 
Taken together, current data suggest a strong association between depression and 
incident dementia, but the question remains whether depression is a risk factor for 
dementia or merely a prodromal symptom of underlying dementia.9 Given the long pre-
clinical phase of dementia, it is conceivable that subclinical dementia causes depressive 
symptoms rather than depression being a true risk factor for dementia. One way to 
address this issue is to study the association of depression and dementia during a long 
follow-up and then explore the association over separate incremental periods of follow-
up. The hypothesis to be tested is that there is a strong association between depression 
and dementia over a short follow-up period which attenuates with longer follow-up. 
Also, some studies have suggested a difference between men and women in the 
association of depression with dementia, but data are still scarce. 
Therefore, we studied the relationship of depressive symptoms and dementia both over 
long and short follow-up periods in a population based cohort. We further examined if the 
relationship between depression and dementia differs between men and women. 
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METHODS  
Setting 
This study was embedded in the Rotterdam Study; an ongoing population-based 
prospective study of the elderly that started 1990 and studies the incidence and 
determinants of chronic diseases in late life.10 The Medical Ethics Committee of Erasmus 
Medical Center Rotterdam approved the study and written informed consent was 
obtained from all participants. 
Every 3 to 4 years, all participants undergo an extensive home interview and a physical 
examination at the research center. In addition, all participants are continuously 
monitored for the occurrence of all major events during follow-up by linkage of the study 
database with medical files from general practitioners. The third examination round of 
Rotterdam study constituted the baseline of this study, because the data on depressive 
symptoms were complete and uniformly collected (using CES-D for the whole cohort).  
Study population 
Of the original cohort of 7,983 persons in 1990, 4,797 surviving persons participated in the 
third examination which took place from 1997-1999. From these 4,797 individuals, 4,602 
(96%) completed the depression assessment questionnaire. Of these 4,602, 110 
participants did not consent to undergo dementia screening and were excluded. We also 
excluded 92 participants who were demented at baseline and 7 who were lost to follow 
up. This yielded a total of 4,393 individuals (92% of total survivors) available for final 
analysis, who were followed for a maximum of 13.7 years (mean 8.7, SD 3.5 years) for 
incident dementia. Follow- up started from the day of depressive symptom screening to 
the date of incident dementia, date of death, or the censor date January 1st, 2011, 
whichever occurred first.  
Assessment of depression 
We used the validated Dutch version of the Center for Epidemiology Depression Scale 
(CES-D) for assessment of depressive symptoms at baseline. The CES-D comprises of 20 
questions, each with a possible score of 0-3, and the score indicates clinically relevant 
depressive symptoms. Depressive symptom scores were used as a standardized 
continuous variable. Z scores were calculated as weighted individual score minus mean 
score, divided by the standard deviation. CES-D scores were weighted by missing values 
 
 
 
only if missing values did not exceed 25%. For descriptive purposes however, a score of 16 
or higher is considered suggestive of depressive symptoms.11 
Assessment of incident dementia 
Participants were screened for dementia at baseline and follow-up examinations using a 
three-step protocol.12 Screening was done using the Mini Mental State Examination 
(MMSE) 13 and the Geriatric Mental Schedule (GMS) organic level.14 Screen-positives 
(MMSE<26 or GMS organic level>0), subsequently underwent an examination and 
informant interview with the Cambridge Examination for Mental Disorders in the Elderly 
(CAMDEX).15 Participants who were suspected of having dementia, underwent, if 
necessary, further neuropsychological testing. Additionally, the total cohort was 
continuously monitored for dementia through computerized linkage between the study 
database and digitized medical records from general practitioners and the Regional 
Institute for Outpatient Mental Health Care. In the end, a consensus panel, led by a 
neurologist, decided on the final diagnosis in accordance with standard criteria using the 
DSM-III-R criteria for dementia and the NINCDS-ADRDA for Alzheimer disease.16 If required 
for differential diagnosis, neuro-imaging was used. Follow-up for incident dementia was 
virtually complete (98.63%) till January 1st, 2011. 
Covariates 
In addition to age and gender, education level, smoking, cognition level at baseline, 
hypertension, diabetes mellitus, prevalent stroke, and use of antidepressant medication 
were considered possible confounders. Smoking, hypertension, diabetes and stroke are 
well documented risk factors for all types of dementia. A low education level has been 
found to be associated with increased risk of dementia, especially in females. 17 In 
subsequent models, we adjusted for marital status, APOE-ɛ4 carrier status, cognitive 
complains at baseline, and psychotropic medication use. 
Education level was assessed during the interview and people were classified into two 
categories; low level of education (primary only or primary and unfinished secondary) and 
intermediate to high (primary and secondary, vocational or university). Cognition was 
assessed by the MMSE at baseline.13 Inquiring about smoking habits, participants were 
categorized into current, former and never smokers. Hypertension was defined as systolic 
blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg, or use of 
antihypertensive medication assessed by interview and pharmacy records.18 Diabetes 
Mellitus type II was diagnosed as fasting blood glucose ≥ 126.13 mg/dl (multiply by factor 
0.0555 to covert to mmol/l) or use of anti-diabetic medication evaluated by interview and 
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pharmacy records.19 Previous stroke was determined by reported events on interview and 
confirmed by medical records. In addition, participants are continuously monitored for all 
major events through automated linkage of study database with GP files.20 Information on 
use of antidepressants (ATC code n06) was obtained by interview, medical and pharmacy 
records.  
Statistical analysis 
We used Cox proportional-hazards model to assess the relationship between clinically 
relevant depressive symptoms and incident dementia (all-cause). We investigated not only 
the total follow-up period as a whole, but also separate 5-year time periods (0-5 years, 5-
10 years and more than 10 years of follow up). This analysis was performed to study the 
timing of incident dementia in relation to the appearance of depressive symptoms. 
Several studies have used a follow-up time range of 1 to 5 years to study the short-term 
effect of depression on dementia incidence5,6,21-24; but there is no recommended cut-off of 
follow-up time to study depression as a dementia prodrome. In an alternative analysis, 
time periods were defined by ensuring equal number of 100 cases in each period (five 
periods 100 incident cases, the last period only counted 82 cases). This approach allows a 
more detailed assessment of risk ratio change over time and increases the power to 
detect changes. Hazard ratios of dementia for each time period of 100 cases were 
calculated separately as well as cumulatively. The cumulative time approach in both the 
main analysis and in the 100 case-analysis was a method carried out to ensure 
comparability with other studies, as most studies have examined the association of 
depressive symptoms and dementia using a Cox model and with using variable follow-up 
periods. Therefore, we first used a cumulative follow-up approach in which we examined 
the association between depression and dementia by increasing the years of follow-up by 
not changing the baseline. i.e. 0-5 years, 0-10 years, and 0-13.7 years. Similarly, for the 
100-case analysis, we examined association of depression and dementia by increasing 100 
cases in every subsequent step without changing our baseline. i.e. baseline to 100 cases, 
baseline to 200 cases, baseline to 300 cases and so on. As secondary analyses, we 
explored effect modification by gender and age (median age used as cut-off) using 
stratification and interaction terms. Additionally, we analyzed our data, using only 
Alzheimer’s disease as outcome. 
We ran an additional analysis to test sensitivity of our findings. Analysis was repeated 
excluding persons with clinically relevant depressive symptoms occurring prior to baseline. 
Depressive symptoms were also assessed, 4 years prior to baseline either with the CES-D 
(cut-off ≥ 16) in 48% of participants, or the Hospital Anxiety and Depression Scale, HADS-D 
 
 
 
(cut-off ≥ 9) in 52% of participants, as part of a pilot.25 In this sensitivity analysis, the effect 
of more chronic depressive symptoms, which are less likely to be an indicator of dementia 
prodrome, is reduced. If there were an effect of depression as part of a dementia 
prodrome only, our hazard ratios for the short follow-up would be expected to increase 
slightly if chronic cases are excluded.  
Since, depressive symptoms in The Rotterdam study were re-measured at a follow-up 
round in 2002-2004, we also repeated our analysis using depressive symptoms assessed at 
this follow-up round as our baseline.  
Although we have used depression as a standardized continuous variable in all analyses, 
we also performed our main analysis using CES-D score dichotomized at 16 points. 
Results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). All 
analyses were adjusted for age and gender in the first model and additionally for 
education, smoking, hypertension, diabetes, prevalent stroke, MMSE score and 
antidepressants’ use in the second model. Data were analyzed using the Stata Software 
Version 12 (StataCorp, College Station, TX, USA).  
 
RESULTS 
Baseline characteristics of the study population are summarized in Table 1. The study 
included 4,393 individuals comprising 59% females (n=2,599). Mean age at baseline was 
73 years (SD 7.3 years; range 61.1-105.8) and participants were followed for a maximum 
of 13.7 years (mean 8.7, SD 3.5 years). Applying the accepted cut-off of ≥ 16 for CES-D, 
seven percent (n=323) of the study population had clinically relevant depressive 
symptoms at baseline, however, we used continuous depression scores for all analyses.  
Of the 4,393 individuals, 13% (n=582) developed dementia (all cause); 84% of those were 
Alzheimer’s disease cases (n=489). Mean age of dementia diagnosis was 83 years (SD 6.3; 
range 65.5-102 years).  
When investigating each time period with 100 subsequent cases separately, the risk of 
dementia decreased gradually from HR 1.24 (95% CI: 1.06, 1.44) in the first period, to HR 
0.89 (95% CI: 0.69, 1.15) in the last period. Similar pattern was observed when we 
calculated hazards for cumulative time periods of 100 cases; HR 1.24 (95% CI: 1.06, 1.44) 
in the first period to HR 1.11 (95% CI: 1.03, 1.20) in the last period (Figure 1).  
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In the overall follow-up of 13.7 years, depressive symptoms were associated with a 
moderately increased risk of incident dementia (Table 2). 
 
 
 
Table 1. Baseline characteristics of the study population, N=4,393. 
Characteristics  Descriptives 
Age, years 72.7 (7.3) 
Women 2,599 (59.2) 
Body mass index, kg/m2 26.9 (3.7) 
Education  
Low  1,350 (31.2) 
Intermediate to high  2,980 (68.8) 
Smoking   
Never  1,520 (34.6) 
Former 2,157 (49.1) 
Current 716 (16.3) 
Diabetes mellitus type 2 534 (12.2) 
Stroke 338 (7.7) 
Myocardial Infarction 427 (9.7) 
Hypertension 2,990 (68.1) 
Total cholesterol, mmol/L 5.82 (0.9) 
HDL cholesterol, mmol/L 1.4 (0.4) 
Antipsychotic use 642 (14.6) 
Antidepressant use 135 (3.1) 
Clinically Relevant Depressive Symptoms 323 (7.4) 
 
Abbreviations: HDL High density lipoprotein. 
Values are means (standard deviation) or counts (percentage). 
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1a: Depressive symptoms and risk of incident dementia per follow-up interval
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1b: Depressive symptoms and risk of incident dementia with cummulatively increasing follow-up
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Figure 1. Depressive symptoms and risk of incident dementia-Effect estimates per 100 
consecutive incident dementia cases. 
Fully adjusted hazard ratios for risk of dementia at different time points in depressed individuals (N=4,393). Total 
number of dementia cases (N=582) were split into groups of 100 patients according to dementia incidence, and 
hazard ratios were calculated for each group of 100 cases. The circles represent the hazard ratios and the lines 
represent the 95 % confidence intervals.
 
 
 Table 2. Clinically relevant depressive sym
ptom
s and risk of incident dem
entia-overall and gender stratified analysis, N
=4,393. 
Depressive sym
ptom
s 
Follow
-up tim
e in years 
Total population (N
=4,393) 
O
verall 
follow
-up 
0-5 years 
5-10 years 
10-13.7 years 
 
Hazard ratios (95%
 confidence intervals) 
Cases/N
 
582/4,393 
222/4,393 
238/3,529 
122/2,554 
Depressive score, (per SD) a 
1.11 (1.03, 1.20) 
1.19 (1.07, 1.33) 
1.15 (1.03, 1.29) 
0.84 (0.68, 1.05) 
Depressive score, (per SD) b 
1.08 (1.00, 1.17) 
1.13 (1.01, 1.27) 
1.14 (1.01, 1.29) 
0.83 (0.66, 1.04) 
M
ales (N
=1,794) 
 
Cases/N
 
176/1,794 
62/1,794 
71/1,416 
43/985 
Depressive score, (per SD) a 
1.20 (1.02, 1.41) 
1.51 (1.23, 1.86) 
1.20 (0.91, 1.58) 
0.40 (0.17, 0.93) 
Depressive score, (per SD) b 
1.04 (0.88, 1.24) 
1.31 (1.04, 1.66) 
1.06 (0.79, 1.41) 
0.38 (0.16, 0.93) 
Fem
ales (N
=2,599) 
 
Cases/N
 
406/2,599 
160/2,599 
167/2,113 
79/1,569 
Depressive score, (per SD) a 
1.09 (1.01, 1.19) 
1.12 (0.99, 1.27) 
1.14 (1.01, 1.30) 
0.94 (0.75, 1.18) 
Depressive score, (per SD) b 
1.09 (1.00, 1.18) 
1.10 (0.96, 1.26) 
1.15 (1.01, 1.31) 
0.92 (0.73, 1.15) 
 Depression score is taken as a continuous standardized variable, and cases refer to incident dem
entia cases. 
a M
odel 1: age and gender adjusted. 
b M
odel 2: additionally adjusted for sm
oking, education, hypertension, diabetes, prevalent stroke, M
M
SE and anti-depressants use.  
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1a: Depressive symptoms and risk of incident dementia per follow-up interval
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1b: Depressive symptoms and risk of incident dementia with cummulatively increasing follow-up
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Figure 1. Depressive symptoms and risk of incident dementia-Effect estimates per 100 
consecutive incident dementia cases. 
Fully adjusted hazard ratios for risk of dementia at different time points in depressed individuals (N=4,393). Total 
number of dementia cases (N=582) were split into groups of 100 patients according to dementia incidence, and 
hazard ratios were calculated for each group of 100 cases. The circles represent the hazard ratios and the lines 
represent the 95 % confidence intervals.
 
 
 Table 2. Clinically relevant depressive sym
ptom
s and risk of incident dem
entia-overall and gender stratified analysis, N
=4,393. 
Depressive sym
ptom
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Follow
-up tim
e in years 
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=4,393) 
O
verall 
follow
-up 
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 confidence intervals) 
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=1,794) 
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=2,599) 
 
Cases/N
 
406/2,599 
160/2,599 
167/2,113 
79/1,569 
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Depressive score, (per SD) b 
1.09 (1.00, 1.18) 
1.10 (0.96, 1.26) 
1.15 (1.01, 1.31) 
0.92 (0.73, 1.15) 
 Depression score is taken as a continuous standardized variable, and cases refer to incident dem
entia cases. 
a M
odel 1: age and gender adjusted. 
b M
odel 2: additionally adjusted for sm
oking, education, hypertension, diabetes, prevalent stroke, M
M
SE and anti-depressants use.  
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During a shorter follow-up time i.e. 5 years from baseline, depressive symptoms were 
associated with a high risk of incident dementia, fully adjusted HR 1.13 (95% CI: 1.01, 
1.27). The same was true for the period of 5 to 10 years follow-up, HR 1.14 (95% CI: 1.01, 
1.29). In contrast, we did not find any relationship in the third follow-up period in the fully 
adjusted model, HR 0.83 (95% CI: 0.66, 1.04).  
After additional adjustments for marital status, APOE-ɛ4 carrier status, cognitive 
complaints at baseline and use of psychotropic drug use, our results remained unchanged. 
In a secondary gender split analysis, we found a more pronounced effect in men than in 
women, though the overall pattern in both sexes was similar to the main analysis (Table 
2). In depressed men however, the risk of dementia in the 10-13.7 year interval was 
reduced by 60%, HR 0.38 (95% CI: 0.16, 0.93). The interaction for gender was statistically 
significant (p<0.001). Interaction for age was not significant, hence not shown. 
Repeating all analyses using Alzheimer’s disease as outcome yielded similar results and 
patterns (Supplement table 1). Results using depressive symptoms as a dichotomized 
variable showed similar pattern and are shown in Supplement table 2. 
In the sensitivity analysis, after excluding individuals who had been screened positive for 
clinically relevant depressive symptoms 4 years prior to baseline, the presence of 
depressive symptoms showed a 16 % higher risk of incident dementia in the 0-5 year 
follow-up, HR 1.16 (95% CI: 1.02, 1.32). 
Using depressive symptoms assessed at the 2002-2004 examination round, we found a 
similar pattern of results as the main analysis (data not shown). 
 
DISCUSSION  
We found that persons with depressive symptoms had a higher risk of incident dementia, 
including Alzheimer disease. These associations were strongest for short follow-up time 
and attenuated with incrementally longer follow-up periods. Furthermore, the association 
was more pronounced in men than in women.  
Prevalence of depressive symptoms is relatively low in this cohort. However it falls within 
the variable range of 2.8% to 35% reported in a review of depressive symptoms in the 
elderly.26 In addition, the SHARE study has reported the Netherlands to be one of the 
lower depression prevalence countries in Europe.27 
 
 
 
Strengths of the study include the large population-based cohort followed for over 13 
years. However, certain methodological considerations need to be mentioned. First, we 
included clinically relevant depressive symptoms (assessed by CES-D) as the determinant 
rather than diagnosed depression. Therefore, we cannot be certain about the 
generalizability of our results to clinical depressive syndromes as well. Second, some 
residual confounding due to unknown or unmeasured confounders such as physical 
activity and diet cannot be completely ruled out. Third, there is a possibility that some 
selection through depressive symptoms and/or cognitive function in the previous 
examination round may have influenced the results. Fourth, depressive symptoms were 
related to death of participants in the first ten years of follow-up, so there is a possibility 
of some selection by death in the 10-13.7 year interval. 
There are a few possible explanations for our observation that the association of 
depression with incident dementia was strongest with short follow-up and attenuated 
with longer follow-up. First, late-onset depressive symptoms preceding dementia could be 
merely a reactive phenomenon. It is possible that depression is a psychological response 
to the ongoing cognitive decline.28 Second, late onset depressive symptoms may represent 
a prodrome of dementia. The prodrome can be defined as a pre-dementia syndrome in 
which the underlying subclinical dementing process manifests itself by depression or 
altered behavior, thus marking the onset of clinical dementia in the near future. Where a 
depression in adult life or a lifetime history of depression would be considered a risk 
factor for dementia, a very recent history of late-onset depressive symptoms may be an 
early clinical manifestation of the underlying neurodegenerative condition. This implies 
that both depression and dementia are the result of a common underlying process(es) but 
that symptoms of depression manifest earlier than dementia. It has been shown that 
patients experiencing cognitive decline together with late onset depression develop 
dementia within a few years after the onset of depression.28 This prodromal hypothesis is 
in line with recent findings from large cohort studies suggesting that late-onset depression 
is a prodrome of dementia onset.21,29 Studies have reported a positive association 
between depression and dementia over a shorter follow-up period of at most 5 years.4-7 
Previously in a subset of the Rotterdam Study, we reported a null association between 
depressive symptoms and dementia; however, differences in sample size, follow-up, age 
and cognition at baseline could explain the difference in results.30 
Third, depression may increase the risk of dementia over a short term period only. Some 
individuals with depressive symptoms may be more vulnerable for incident dementia 
because of certain genetic or environmental risk factors although a shared etiology would 
typically convey a constant risk over time.3,31 Several potential biological mechanisms 
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could be a common intermediate between depression and dementia such as hippocampal 
atrophy.2 It has also been shown that depressed individuals have low levels of adrenaline32 
and serotonin33, and deficits of these monoamines are also associated with increased 
severity of dementia. The underlying neurodegenerative process, might get accelerated 
due to depression, by the activation of hippocampal pituitary axis leading to increased 
cortisol levels, hence precipitating dementia.28  
We also found that the association of depressive symptoms and dementia in the short 
term period was stronger in men than in women. This finding concurs with two 
prospective cohort studies which reported a stronger association of depressive symptoms 
and risk of incident dementia in men compared with women.34,35 There is limited literature 
available in this context, and further epidemiological and etiological studies are highly 
recommended to better understand the gender differences in association between 
depression and dementia.  
We observed a protective association between depression and dementia in the 10-13.7 
year interval in men. However, since this period has a fewer number of cases (n=43) the 
estimates may not be very precise. It is also possible, that reduced effect estimates are a 
result of other competing risks in this period and deaths occurring due to other causes 
such as cardiovascular causes or cancers. Additionally, we speculate that perhaps 
depressed persons who survive ten years or more, become resilient against subsequent 
dementia.  
In conclusion, late-onset depressive symptoms represent a part of the prodromal stage of 
dementia, rather than being a risk factor for dementia. Depressive symptoms posed a 
much higher risk of incident dementia in men compared with women in a short follow-up. 
 
 
 
SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Clinically relevant depressive symptoms and risk of Alzheimer’s 
disease, N=4,393. 
 
Depressive symptoms Follow-up time in years 
Total population (N-4,393) Overall 0-5 years 5-10 years 10-13.7 years 
 Hazard ratios (95% confidence intervals) 
Cases/N 489/4,393 194/4,393 199/3,529 96/2,554 
Depressive score, (per SD)a 1.08 (0.99, 1.17) 1.16 (1.03, 1.31) 1.11 (0.98, 1.27) 0.79 (0.61, 1.03) 
Depressive score, (per SD)b 1.05 (0.96, 1.15) 1.11 (0.98, 1.26) 1.09 (0.95, 1.25) 0.79 (0.60, 1.04) 
Males (N=1,794)  
Cases/N 131/1,794 43/1,794 55/1,416 33/985 
Depressive score, (per SD)a 1.16 (0.95, 1.41) 1.38 (1.04, 1.82) 1.30 (0.98, 1.73) 0.43 (0.17, 1.06) 
Depressive score, (per SD)b 1.02 (0.83, 1.25) 1.16 (0.83, 1.60) 1.13 (0.83, 1.53) 0.48 (0.19, 1.22) 
Females (N=2,599)  
Cases/N 358/2,599 151/2,599 144/2,113 63/1,569 
Depressive score, (per SD)a 1.07 (0.97, 1.17) 1.13 (0.99, 1.28) 1.08 (0.93, 1.24) 1.08 (0.93, 1.24) 
Depressive score, (per SD)b 1.06 (0.96, 1.16) 1.11 (0.97, 1.27) 1.07 (0.92, 1.25) 1.07 (0.92, 1.25) 
 
Depression score is taken as a continuous standardized variable, and cases refer to incident Alzheimer’s disease 
cases. 
a Model 1: age and gender adjusted. 
b Model 2: additionally adjusted for smoking, education, hypertension, diabetes, prevalent stroke, MMSE and 
anti-depressants use. 
 
Supplementary Table 2. Clinically relevant depressive symptoms and risk of incident 
dementia, N=4,393. 
 
Depressive symptoms Follow-up time in years 
 Overall 0-5 years 5-10 years 10-13.7 years 
 Hazard ratios (95% confidence intervals) 
Cases/N 582/4,393 222/4,393 238/3,529 122/2,554 
Depressive symptomsa 1.46 (1.13, 1.89) 1.43 (0.96, 2.15) 1.94 (1.33, 2.82) 0.74 (0.34, 1.59) 
Depressive symptomsb 1.38 (1.06, 1.80) 1.26 (0.83, 1.91) 1.94 (1.31, 2.87) 0.74 (0.34, 1.60) 
 
Depression is used as dichotomized (cut-off CES-D score ≥ 16 taken as positive for depressive symptoms), and 
cases refer to incident dementia cases. 
a Model 1: age and gender adjusted. 
b Model 2: additionally adjusted for smoking, education, hypertension, diabetes, prevalent stroke, MMSE and 
anti-depressants  use. 
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ABSTRACT 
Background: Late life depressive symptoms have been extensively studied for their role in 
incident dementia, but were typically assessed at a single time-point. Such an approach 
neglects the course of depression, which, given its remitting and relapsing nature, might 
reveal more subtle associations with dementia.  
Methods: In 5,300 dementia-free participants (mean age: 69.4 ±8, 58% women), we used 
depressive symptoms assessments at three examinations over an 11-year period (1993-
2004), to identify trajectories of depression by latent class trajectory modelling. Dementia 
incidence by latent trajectory over a subsequent 10-year period (2004-2014) was 
computed using Cox proportional hazards models. We repeated the analyses censoring 
incident stroke, and for Alzheimer’s disease only as outcome.  
Results: We identified five trajectories characterized by low (75.1%), decreasing (10.1%), 
remitting (5.3%), increasing (7.8%), and high (1.8%) depressive symptoms. During 25,434 
person-years, 417 participants had incident dementia. Only the trajectory with increasing 
depressive symptoms was associated with a higher risk of dementia, relative to the low 
depressive symptoms trajectory (reference): HR before censoring stroke 1.51 (95% 
CI:1.10,2.09), HR after censoring stroke 1.76 (95% CI: 1.27, 2.45) and Alzheimer’s disease, 
HR 1.59 (95%CI: 1.12, 2.26).  
Conclusions: Risk of dementia differed with different courses of depression which could 
not be captured by a single assessment of depressive symptoms. The higher risk of 
dementia only in the increasing trajectory suggests depression to be a prodrome of 
dementia.  
 
 
 
INTRODUCTION 
Clinical depression, particularly clinically-relevant depressive symptoms are not only highly 
prevalent in dementia but are also highly predictive of incident dementia.1  
The course of depression and depressive symptoms over the lifetime varies across 
individuals.2 For instance, persons might suffer from clinically relevant depressive 
symptoms only transiently, followed by full remission. Others might have a consistent 
remitting and relapsing depression, whereas some may become chronically depressed. 
Such different courses may reflect different etiology and may consequently predict 
dementia risk differentially. For instance, depressive symptoms as a physiologic response 
to an adverse life event or diagnosis of a chronic illness may have different impact on the 
risk of dementia compared to depression with more severe biologic basis, such as brain 
pathology, or dysregulation of neurotransmitters. However, existing studies on the 
association of depression and dementia have assessed depression only once, which 
neglects the course of depression.3-5 Assessment of depressive symptoms in a remitting 
phase could lead to an underestimation of the risk of dementia associated with chronic 
depression. This remitting and relapsing nature of depression necessitates to study the 
course of depression in relation to risk of dementia. 
Therefore, we used repeated measures of depressive symptoms over a 10-year period to 
study different trajectories of depression, and their subsequent risk of dementia in a 
population-based setting. This approach might also identify high risk groups from a 
population-based perspective to facilitate effective prevention and treatment targeted at 
the persons at risk. 
 
METHODS 
Setting  
This study was embedded in the Rotterdam Study, a population-based study of adults 
aged ≥55 years, ongoing since 1990. Follow-up examinations including home interviews 
and physical exams at a research center take place every three to four years. In addition, 
the cohort is continuously monitored for all major events by a highly efficient data linkage 
system between the study database and the general practitioners (GPs).6 The Rotterdam 
Study has been approved by the medical ethics committee according to the Population 
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Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the 
Netherlands. Written informed consent was obtained from all participants.  
Study population  
This study utilized data on depressive symptoms from three examination rounds of the 
Rotterdam Study (1993-1995, 1997-1999, and 2002-2004). The examination round in 
1993-1995 was defined as the baseline for this study because the assessment of 
depressive symptoms was introduced in the Rotterdam Study in this examination round. 
Incidence of dementia was investigated from last round of depressive symptoms 
assessment onward, i.e. from 2002-2004 until 2014 in those who were dementia-free or 
“at-risk” for dementia. 
Identification of trajectories: At baseline (1993-1995), data for depressive symptoms were 
available for 4,597 dementia-free participants. In the examination rounds in 1997-1999 
and 2002-2004, depressive symptoms were assessed in 4,294 and 3,251 participants 
respectively. In total, 5,300 participants had depressive symptoms data at at-least one 
examination round, 4,385 at more than one examination rounds, and 2,689 for all three 
examination rounds. 703 participants did not respond at the first round, but did so at later 
rounds. From 1993-1995 to 2002-2004, 512 participants had incident dementia. Any 
depressive symptoms scores available after the diagnosis of dementia (n=95 had 
depressive symptoms score available at one or two rounds) were not used to assign 
trajectories because of unreliability of these scores. 
Survival cohort for dementia: From the study entry in 1993-1995 to the last round of 
depressive symptoms assessment in 2002-2004, 1,734 participants died. Of the 3,342 
surviving persons who attended the examination round in 2002-2004, 139 had prevalent 
dementia and were excluded. Therefore, 3,203 (95.8%) dementia-free participants were 
included in the survival analysis. Follow-up for dementia was complete until January 2014. 
Survival analyses were performed beyond the date of last depressive symptoms 
assessment to avoid the problem of non-proportionality of hazards, and selective survival 
of participants during the period of depressive symptoms assessments. In addition, the 
concomitant events of incident dementia and deaths occurring during the period of 
depression assessments made it difficult to assess the true risks associated with each 
trajectory.  
 
 
 
 
 
Assessment of depressive symptoms 
In the first examination round, we measured depressive symptoms using two different 
instruments: the validated Dutch version of the Center for Epidemiology Depression Scale 
(CES-D),7 and the Hospital Anxiety and Depression Scale-Depression (HADS-D).8 At this 
round, a random half of participants received the CES-D questionnaire, while the other 
half received the HADS-D questionnaire. For all subsequent rounds, CES-D was used. The 
CES-D comprises 20 items, each with a possible score of 0-3, and the score ranges from 0-
60.7 HADS-D comprises of 7 items each with a possible score of 0-3, and the score ranges 
from 0-21.8 Both scales have been validated for assessment of depression and can 
indicate clinically-relevant depressive symptoms. We checked for evidence whether this 
introduces information bias but we found the same percentage of screen positives (10%) 
using validated pre-defined cut-offs.9 For analyses, depressive symptoms scores were 
weighted for missing items, only if missing items did not exceed 25%. Scores with missing 
values exceeding 25% were excluded. Depressive symptoms scores were then used as a 
standardized continuous variable, calculated as weighted individual CES-D/HADS-D score 
minus mean score, divided by the standard deviation. 
Assessment of dementia  
Participants were screened for dementia at study entry and all follow-up examinations 
using a three-step protocol.10 First, screening was done using the Mini Mental State 
Examination (MMSE) and the Geriatric Mental Schedule (GMS) organic level. Second, 
screen-positives (MMSE<26 or GMS organic level>0) subsequently underwent an 
examination and informant interview with the Cambridge Examination for Mental 
Disorders in the Elderly (CAMDEX). Participants who were suspected of having dementia, 
if necessary had further neuropsychological testing. Third, a consensus panel led by a 
neurologist, decided on the final diagnosis in accordance with the standards using the 
DSM-III-R criteria for dementia and the NINCDS-ADRDA for Alzheimer’s disease. 
Additionally, the total cohort was continuously monitored for dementia through 
computerized linkage between the study database and digitized medical records from 
general practitioners and the Regional Institute for Outpatient Mental Health Care. This 
data linkage system is highly efficient in the Dutch situation and the possibility of 
underestimation of cases is very low. In this setting, the GPs receive all medical 
information about their patients if they contact any medical care-giver or professional 
including specialists. We calculated the potential and observed person-years to calculate 
the completeness of dementia follow-up,11 which was 93.7% complete until January 1st, 
2014. 
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Covariates 
Age, sex, APOE-ɛ4 carrier status, educational level, body mass index (BMI), smoking habits, 
alcohol consumption, MMSE score, use of anti-depressant medication, and prevalent 
hypertension, diabetes mellitus 2, myocardial infarction (MI) and stroke were assessed at 
baseline (1993-1995) and considered potential confounders for the association between 
depression and dementia as they are associated with depression, and are independent 
risk factors for dementia.12,13 For APOE-ɛ4 carrier status, participants were classified into 
non-carriers of ɛ4 allele or carriers of one or two ɛ4 alleles. For educational level, 
participants were classified as having primary (primary only or unfinished secondary) or 
higher than primary education (secondary, vocational or university). BMI was calculated as 
weight in kilograms/height in meters squared. For smoking habits, participants were 
classified into never, past, or current smokers. Weekly reported alcohol consumption was 
categorized into beer, wine, liquor, and moderately strong alcohol types. These were 
converted to grams of alcohol by taking the average amount of ethanol in a drink. By 
adding the amount of ethanol in all four groups, total amount of alcohol in g/day was 
calculated.14 Information on the use of anti-depressants (ATC code n06) was obtained by 
interview. As this information was not present for the baseline round (1993-1995), we 
utilized information available from the previous examination round (1990-1992) and the 
next (1995-1997). Participants using antidepressants at any of these two rounds were 
labelled positive for anti-depressant use. Hypertension was defined as systolic blood 
pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive 
medication assessed by interview and pharmacy records. Diabetes mellitus 2 was 
diagnosed as fasting blood glucose ≥ 7.0 mmol/l, or use of anti-diabetic medication 
evaluated by interview and pharmacy records. Previous MI and strokes were determined 
by reported events on interview and confirmed by medical records.6  
Statistical analyses 
Identification of trajectories: We used latent class trajectory models (LCTM) to identify 
trajectories of depressive symptoms over time. This is a specialized form of finite mixture 
modelling, and is designed to identify trajectories, which are latent classes of individuals 
following similar progression of an outcome over time or with age.15 One of the key 
assumptions in this model is that, a population comprises multiple trajectories. We used 
the censored normal distribution (cnorm) in trajectory modelling which is intended for the 
analysis of repeatedly measured continuous scales. For every subject, the posterior 
probabilities for each trajectory were computed, taking into account their age, sex and 
educational level, and subjects were assigned post-hoc to the trajectory with the highest 
 
 
 
probability. The final model was chosen, based on minimizing the Bayesian Information 
Criterion (BIC)16 Mean probabilities per trajectory ranged from 0.78 to 0.95. To facilitate 
interpretability, we assigned labels to the trajectories based on their graphical patterns.  
Risk of dementia: We computed hazard ratios for dementia by assigned trajectory using 
Cox proportional hazards models. Adherence to proportional hazards assumption was 
tested by plotting smoothed Schoenfeld residuals against time; no violations of the 
assumption were identified. We also investigated the risk of dementia across trajectories 
after censoring incident strokes occurring during follow-up. For these analyses, all 
participants with prevalent stroke were excluded. Additionally, we investigated the risk of 
Alzheimer’s disease across trajectories. To assess the possibility of reverse causality, we 
stratified the follow-up time arbitrarily at 3 years into a short-term stratum of 0-3 years 
and a long-term stratum of >3 years. We tested several cut-offs namely 2, 3, 4, and 5 
years, but results for stratification at 3 years only are shown. Finally, to test the influence 
of mortality as a competing risk for dementia, we performed a competing risk analysis. For 
all analyses, two models were fitted. Model 1 was adjusted for age and sex only. Model 2 
was additionally adjusted for APOE-ε4 carrier status, educational level, BMI, smoking, 
alcohol consumption, cognitive score at baseline, use of anti-depressant medication, and 
prevalent disease status at baseline, including hypertension, diabetes mellitus 2, MI, and 
stroke (where applicable).  
All analyses were performed using the Stata Software Version 13 (StataCorp, College 
Station, TX, USA). 
RESULTS 
This study included 5,300 non-demented participants (mean±SD age: 69.4±8.0, 58% 
women) with up to 3 assessments of depressive symptoms during 11 years, to identify 
different trajectories of depressive symptoms. We identified five distinct trajectories of 
depressive symptoms (Figure 1): 75.1% of participants were in a trajectory defined by 
maintaining a low CES-D score throughout the follow-up (T1: low, n=3,826), 10.1% started 
moderately high but remitted (T2: decreasing, n=673), 5.3% started low, increased but 
remitted (T3: remitting, n=278), 7.8% started low on the CES-D but steadily increased 
throughout follow-up (T4: increasing, n=394), whereas 1.8% maintained a high score 
throughout (T5: high, n=129). Baseline characteristics of participants across trajectories 
are summarized in Table 1. As compared to persons in the other trajectories, T1 had equal 
proportions of men and women, and participants were likely to be younger and more 
educated. 
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Covariates 
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calculated.14 Information on the use of anti-depressants (ATC code n06) was obtained by 
interview. As this information was not present for the baseline round (1993-1995), we 
utilized information available from the previous examination round (1990-1992) and the 
next (1995-1997). Participants using antidepressants at any of these two rounds were 
labelled positive for anti-depressant use. Hypertension was defined as systolic blood 
pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive 
medication assessed by interview and pharmacy records. Diabetes mellitus 2 was 
diagnosed as fasting blood glucose ≥ 7.0 mmol/l, or use of anti-diabetic medication 
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prevalent disease status at baseline, including hypertension, diabetes mellitus 2, MI, and 
stroke (where applicable).  
All analyses were performed using the Stata Software Version 13 (StataCorp, College 
Station, TX, USA). 
RESULTS 
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moderately high but remitted (T2: decreasing, n=673), 5.3% started low, increased but 
remitted (T3: remitting, n=278), 7.8% started low on the CES-D but steadily increased 
throughout follow-up (T4: increasing, n=394), whereas 1.8% maintained a high score 
throughout (T5: high, n=129). Baseline characteristics of participants across trajectories 
are summarized in Table 1. As compared to persons in the other trajectories, T1 had equal 
proportions of men and women, and participants were likely to be younger and more 
educated. 
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Numbers of incident dementia cases and deaths per trajectory before the survival 
analyses are shown in Supplement table 1. 
Of the 3,203 participants included in the survival analyses, 417 developed dementia during 
25,435 person-years. Of these, 332 had Alzheimer’s disease, and 25 had vascular 
dementia. Using T1 as the reference trajectory, we found that only those within the  
 
Figure 1. Trajectories of depressive symptoms, N=5,300. 
The figure shows trajectories of standardized depressive symptoms scores over 11 years, using three measures 
of depressive symptoms. The plot uses mean follow-up time of 9 years. 
 
increasing trajectory had a higher risk of dementia, HR 1.51 (95% CI: 1.10, 2.09) (Table 2 
and Figure 2). Results remained consistent after censoring for incident stroke with only 
the increasing trajectory associated with a higher risk of dementia, HR 1.76 (95% CI: 1.27, 
2.45) (Table 3). Both before and after censoring for incident stroke, estimates for the high 
trajectory were also suggestive of a higher incidence of dementia, although non-
significant, uncensored HR 1.46 (95% CI: 0.80, 2.69). In the analyses for Alzheimer’s 
disease as outcome, again, the increasing trajectory was the only trajectory associated 
with a higher risk of dementia, HR 1.59 (95% CI: 1.12, 2.26) (Supplement table 2). 
However, as opposed to the risk of all-cause dementia, risk estimates for the high 
trajectory were not suggestive of a higher risk of Alzheimer’s disease, HR 1.00 (95% CI: 
 
 
 
0.46, 2.18). The remitting trajectory was not associated with a higher risk of dementia, HR 
1.04 (95% CI: 0.68, 1.60), or Alzheimer’s disease, HR 1.08 (95% CI: 0.67, 1.75).  
In the short-term follow-up of 0-3 years, estimates for the remitting trajectory, HR 1.50 
(95% CI: 0.66, 3.33), and the increasing trajectory, HR 1.47 (95% CI: 0.74, 2.95) were 
suggestive of a higher risk of dementia (Table 4). However, after excluding the first 3 years 
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 Table 1. Baseline characteristics of the study population betw
een 1993 and 1995, N
=5,300. 
Characteristics 
Low
, n=3,826 
Decreasing, n=673 
Rem
itting, n=278 
Increasing, n=394 
High, n=129 
P-value 
Trajectory num
ber on Figure 1 
T1 
T2 
T3 
T4 
T5 
 
Age at baseline, years 
68.3 (7.5) 
72.2 (8.3) 
70.4 (7.5) 
73.5 (9.0) 
72.8 (8.5) 
<0.001 
W
om
en 
2,006 (52.4) 
445 (66.1) 
213 (76.6) 
328 (83.2) 
98 (76.0) 
<0.001 
APOE-ε4 carrier status 
1,021 (27.9) 
177 (28.3) 
63 (23.8) 
95 (25.6) 
37 (30.1) 
0.49 
Prim
ary education  
601 (15.7) 
188 (30.0) 
58 (21.0) 
118 (30.0) 
44 (34.1) 
<0.001 
Body m
ass index, kg/m
2 
26.3 (3.4) 
26.7 (3.8) 
26.8 (3.6) 
27.0 (3.7) 
26.6 (3.6) 
0.001 
Current sm
oking  
779 (20.4) 
139 (20.6) 
52 (18.7) 
71 (18.0) 
28 (21.7) 
<0.001 
M
M
SE, points 
28.0 (1.6) 
27.5 (1.9) 
27.7 (1.5) 
27.4 (1.8) 
27.1 (1.8) 
<0.001 
A
lcohol consum
ption, g/day 
11.5 (14.3) 
8.8 (14.3) 
9.4 (13.3) 
7.2 (11.7) 
6.0 (8.9) 
<0.001 
Antidepressants’ use 
95 (2.5) 
38 (5.6) 
34 (12.2) 
25 (6.3) 
23 (17.8) 
<0.001 
Hypertension 
2,611 (68.2) 
500 (74.3) 
183 (65.8) 
293 (74.4) 
97 (75.2) 
0.001 
Diabetes m
ellitus 2 
200 (5.2) 
50 (7.4) 
22 (7.9) 
25 (6.3) 
12 (9.3) 
0.03 
M
yocardial infarction 
300 (7.8) 
39 (6.0) 
18 (6.5) 
25 (6.3) 
15 (11.6) 
0.10 
Stroke 
113 (2.9) 
43 (6.4) 
15 (5.4) 
29 (7.4) 
12 (9.3) 
<0.001 
Abbreviations: M
M
SE M
ini-M
ental State Exam
ination. 
Values are m
eans (standard deviation).or counts (percentage). 
P-values are based on Analysis O
f Variance (AN
O
VA) for continuous, and Chi2 test for categorical variables. 
 
 
 
of follow-up, the remitting trajectory was no longer associated with a higher risk, but the 
increasing trajectory remained associated with a higher risk of dementia, HR 1.51 (95% CI: 
1.05, 2.17). Estimates for the high trajectory were also suggestive of a higher risk, HR 1.42 
(95% CI: 0.71, 2.86). In the competing risk analyses, the overall pattern of results remained 
consistent: the increasing trajectory showed a higher risk of dementia, HR 1.41 (95% CI: 
1.02, 1.96) (Data not shown).  
Of the 3,300 participants included in the survival analyses, 513 developed dementia during 
25,469 person-years. Of the total 513, 417 had Alzheimer’s disease, and 29 had vascular 
dementia. We found that only those within the increasing trajectory had a higher risk of 
dementia, HR 1.56 (95% CI: 1.17, 2.08) (Table 2 and Figure 2).  
 
Table 2. Trajectories of depressive symptoms and risk of dementia, N=3,203. 
Trajectories Cases/n Risk of dementia, hazard ratios (95% confidence intervals) 
  Model 1a P-value Model 2b P-value 
T1: Low 283/2,420 1.00 (ref)  1.00 (ref)  
T2: Decreasing  48/319 1.10 (0.81, 1.50) 0.53 1.04 (0.68, 1.62) 0.71 
T3: Remitting 23/163 1.04 (0.68, 1.60) 0.85 1.51 (1.10, 2.09) 0.84 
T4: Increasing 52/244 1.66 (1.23, 2.24) 0.001 1.20 (0.62, 2.32) 0.01 
T5: High  11/57 1.46 (0.80, 2.69) 0.22 1.06 (0.77, 1.45) 0.58 
a Model 1: adjusted for age (time varying covariate) and sex. 
b Model 2: additionally adjusted for APOE-ε4 carrier status, educational level, BMI, smoking, alcohol 
consumption, cognition at baseline, use of anti-depressant medication, hypertension, diabetes type 2, prevalent 
stroke and myocardial infarction. 
 
 
Results remained consistent after censoring for incident stroke with only the increasing 
trajectory associated with a higher risk of dementia, HR 1.76 (95% CI: 1.31, 2.38) (Table 3). 
After censoring for incident stroke, estimates for the high trajectory were also suggestive 
of a higher risk of dementia, although non-significant, HR 1.40 (95% CI: 0.75, 2.62). In the 
analyses for Alzheimer’s disease as outcome, again, the increasing trajectory was the only 
trajectory associated with a higher risk of dementia, HR 1.58 (95% CI: 1.15, 2.16) 
(Supplement table 1). However, as opposed to the risk of all-cause dementia, risk 
estimates for the high trajectory were not suggestive of a higher risk of Alzheimer’s 
disease, HR 1.00 (95% CI: 0.48, 2.04). The remitting trajectory was not associated with a 
higher risk of dementia, HR 1.29 (95% CI: 0.90, 1.86), or Alzheimer’s disease, HR 1.18 (95% 
CI: 0.77, 1.80).  
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of follow-up, the remitting trajectory was no longer associated with a higher risk, but the 
increasing trajectory remained associated with a higher risk of dementia, HR 1.51 (95% CI: 
1.05, 2.17). Estimates for the high trajectory were also suggestive of a higher risk, HR 1.42 
(95% CI: 0.71, 2.86). In the competing risk analyses, the overall pattern of results remained 
consistent: the increasing trajectory showed a higher risk of dementia, HR 1.41 (95% CI: 
1.02, 1.96) (Data not shown).  
Of the 3,300 participants included in the survival analyses, 513 developed dementia during 
25,469 person-years. Of the total 513, 417 had Alzheimer’s disease, and 29 had vascular 
dementia. We found that only those within the increasing trajectory had a higher risk of 
dementia, HR 1.56 (95% CI: 1.17, 2.08) (Table 2 and Figure 2).  
 
Table 2. Trajectories of depressive symptoms and risk of dementia, N=3,203. 
Trajectories Cases/n Risk of dementia, hazard ratios (95% confidence intervals) 
  Model 1a P-value Model 2b P-value 
T1: Low 283/2,420 1.00 (ref)  1.00 (ref)  
T2: Decreasing  48/319 1.10 (0.81, 1.50) 0.53 1.04 (0.68, 1.62) 0.71 
T3: Remitting 23/163 1.04 (0.68, 1.60) 0.85 1.51 (1.10, 2.09) 0.84 
T4: Increasing 52/244 1.66 (1.23, 2.24) 0.001 1.20 (0.62, 2.32) 0.01 
T5: High  11/57 1.46 (0.80, 2.69) 0.22 1.06 (0.77, 1.45) 0.58 
a Model 1: adjusted for age (time varying covariate) and sex. 
b Model 2: additionally adjusted for APOE-ε4 carrier status, educational level, BMI, smoking, alcohol 
consumption, cognition at baseline, use of anti-depressant medication, hypertension, diabetes type 2, prevalent 
stroke and myocardial infarction. 
 
 
Results remained consistent after censoring for incident stroke with only the increasing 
trajectory associated with a higher risk of dementia, HR 1.76 (95% CI: 1.31, 2.38) (Table 3). 
After censoring for incident stroke, estimates for the high trajectory were also suggestive 
of a higher risk of dementia, although non-significant, HR 1.40 (95% CI: 0.75, 2.62). In the 
analyses for Alzheimer’s disease as outcome, again, the increasing trajectory was the only 
trajectory associated with a higher risk of dementia, HR 1.58 (95% CI: 1.15, 2.16) 
(Supplement table 1). However, as opposed to the risk of all-cause dementia, risk 
estimates for the high trajectory were not suggestive of a higher risk of Alzheimer’s 
disease, HR 1.00 (95% CI: 0.48, 2.04). The remitting trajectory was not associated with a 
higher risk of dementia, HR 1.29 (95% CI: 0.90, 1.86), or Alzheimer’s disease, HR 1.18 (95% 
CI: 0.77, 1.80).  
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Figure 2. Figure 2. Dementia-free survival across different trajectories of depresive 
symptoms, N=3,300. 
The figure shows Kaplan-Meier survival curves for dementia for different trajectories of standardized depressive 
symptoms’scores. 
 
Table 3. Trajectories of depressive symptoms and risk of dementia after censoring 
incident stroke, N=3,028. 
Trajectories Cases/n Risk of dementia, hazard ratios (95% confidence intervals) 
  Model 1a P-value Model 2b P-value 
T1: Low 257/2,290 1.00 (ref)  1.00 (ref)  
T2: Decreasing  45/306 1.12 (0.81, 1.54) 0.49 1.08 (0.78, 1.50) 0.64 
T3: Remitting 22/156 1.08 (0.70, 1.68) 0.72 1.12 (0.72, 1.76) 0.60 
T4: Increasing 50/226 1.84 (1.34, 2.51) <0.001 1.76 (1.27, 2.44) 0.001 
T5: High  10/50 1.47 (0.78, 2.77) 0.24 1.29 (0.64, 2.58) 0.47 
 
175 cases of prevalent stroke were excluded at baseline; 234 participants suffered an incident stroke during 
follow-up. 
aModel 1: adjusted for age (time varying covariate) and sex. 
bModel 2: additionally adjusted for APOE-ε4 carrier status, educational level, BMI, smoking, alcohol consumption, 
cognition at baseline, use of anti-depressant medication, hypertension, diabetes type 2, and myocardial 
infarction. 
 
 
 
In the short-term follow-up of 0-3 years, the highest risk of dementia was observed in 
persons within the remitting trajectory, HR 1.91 (95% CI: 1.13, 3.22), followed by those 
within the increasing trajectory, HR 1.59 (95% CI: 0.99, 2.55) which was borderline 
significant (Table 4). However, after excluding the first 3 years of follow-up, the remitting 
trajectory was no longer associated with a higher risk, but the increasing trajectory 
remained associated with a higher risk of dementia, HR 1.53 (95% CI: 1.07, 2.21). 
Estimates for the high trajectory were also suggestive of a higher risk, HR 1.46 (95% CI: 
0.73, 2.94). In the competing risk analyses, although the risk estimates attenuated slightly, 
the overall pattern of results remained consistent; the increasing trajectory showed a 
higher risk of dementia, HR 1.52 (95% CI: 1.13, 2.05) (Data not shown).  
Number of incident dementia cases and deaths per trajectory before the survival analyses 
is shown in Supplement table 2. 
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 Table 4. Trajectories of depressive sym
ptom
s and risk of dem
entia w
ith follow
-up tim
e stratified at 3 years. 
Trajectories 
 
Risk of dem
entia, hazard ratios (95%
 confidence intervals) 
 
 
0-3 years of follow
-up 
 
>3 years of follow
-up 
 
 
Cases/n 
 
Fully adjusted m
odel 
 
P-value 
 
Cases/n 
 
Fully adjusted m
odel 
 
P-value 
T1: Low
 
 
53/2,420 
 
1.00 (ref) 
 
 
 
230/2,154 
 
1.00 (ref) 
 
 
T2: Decreasing  
 
8/319 
 
0.71 (0.32, 1.58) 
 
0.40 
 
40/277 
 
1.15 (0.81, 1.62) 
 
0.42 
T3: Rem
itting 
 
7/163 
 
1.48 (0.66, 3.33) 
 
0.34 
 
16/142 
 
0.91 (0.54, 1.53) 
 
0.73 
T4: Increasing 
 
12/244 
 
1.47 (0.73, 2.95) 
 
0.27 
 
40/194 
 
1.51 (1.05, 2.17) 
 
0.03 
T5: High  
 
1/57 
 
0.47 (0.06, 3.48) 
 
0.46 
 
10/44 
 
1.42 (0.71, 2.86) 
 
0.32 
Hazard ratios are adjusted for age as a tim
e varying covariate, sex, APO
E-ε4 carrier status, educational level, B
M
I, sm
oking, alcohol consum
ption, cognition at baseline, 
use of anti-depressant m
edication, hypertension, diabetes type 2, prevalent stroke, and m
yocardial infarction.
 
 
 
DISCUSSION  
In this study of community-dwelling older adults, we identified 5 distinct trajectories of 
depressive symptoms, characterized by low, decreasing, remitting, increasing and high 
depressive symptoms. The trajectory with increasing depressive symptoms was 
consistently associated with a higher risk of dementia. The trajectory typical of remitting 
depression was only associated with a higher risk of dementia in the short term. 
We found that persons with steadily increasing symptoms of depression had a significantly 
higher incidence of dementia. This finding is consistent with the prodromal hypothesis, 
which suggests that depressive symptoms in older age possibly represent a prodrome or 
an early stage of dementia.1,17,18 This implies that depressive symptoms appear as a 
“reaction” to the underlying subclinical cognitive impairment, and lie in a continuum 
between subclinical cognitive impairment and overt dementia. Where the available 
literature supporting the prodromal hypothesis is largely based on a single assessment of 
depression, we studied the course of depressive symptoms, and could demonstrate the 
gradual escalation of symptoms which started several years before the onset of clinical 
dementia.  
These findings suggest that depression and dementia both are manifestations of a 
common etiology, where symptoms of depression precede the onset of clinical dementia. 
On a molecular level, the biological underpinnings of depression and neurodegenerative 
diseases overlap considerably, including insufficient antioxidant defense and 
neurogenesis, increased apoptosis, and immune system dysregulation.19 Several potential 
biological mechanisms or their interplay can account for the observed association. First, 
vascular disease, is implicated in the development of depression, formulating the 
“vascular depression hypothesis”,20 as well as in the development of dementia, including 
Alzheimer’s disease.21,22 Second, studies suggest that hippocampal atrophy might also give 
rise to symptoms of depression, besides resulting in cognitive dysfunction.1,23 Third, 
dysregulation of neurotransmitters could be the common pathway underlying the 
observed association. Studies have shown that altered serotonin activity and low 
adrenergic activity is observed in both depression and cognitive impairment.24-26 Recently, 
lower levels of melatonin, which itself a serotonin derivative, have been implicated in 
cognitive impairment and depression in population-based settings.27 Fourth, in recent 
studies low serum folate levels are suggested to be associated with both depression and 
dementia syndromes.28 Finally, inflammation has been suggested as a possible link 
between depression and cognitive decline.29  
Chapter 2.2
50
Trajectories of depression and risk of dementia
51
 
 
 Table 4. Trajectories of depressive sym
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Risk estimates for the trajectory with sustained high depressive symptoms in our study 
were also suggestive of a higher risk of dementia, but lack of sufficient power in this group 
might explain why these results did not reach statistical significance. However, the high 
trajectory was not associated with a higher risk of Alzheimer’s disease. It can be 
speculated that the risk in this group was largely explained by vascular dementia, as 
persons within this trajectory had the highest prevalence of cardiovascular risk factors and 
events. 
In our study, although the remitting trajectory was substantially high on depressive 
symptoms at around the second round of assessment, persons in this trajectory did not 
have a higher risk of dementia than those with no depressive symptoms. On one hand, 
this finding might suggest that having severe symptoms of depression at one point in time 
does not have any lasting influence, and does not imply a higher risk of dementia. It is 
likely that this peak of symptoms merely represent a normal reaction to adverse life 
events, such as loss of a partner or a loved one, or diagnoses of chronic debilitating 
illnesses, which might cause a transitory increase in depressive symptoms. On the other 
hand, we observed that the remitting trajectory showed a higher risk of dementia during 
the short-term. It is possible that the remitting trajectory is a reflection of the increasing 
trajectory except for the time lag between their peaks, and the rise of depressive 
symptoms in the remitting trajectory also represents a prodrome of incident dementia 
which occurred in the first few years of follow-up. 
The main strengths of this study are the use of repeated measures of depressive 
symptoms, and the trajectory approach that allowed to study different courses of 
depression in relation to incidence of dementia. Other strengths include a population-
based setting, large sample size, long follow-up, robust dementia follow-up, and 
adjustment for pertinent covariates. There are some limitations as well. Our analyses were 
fit based on assigned trajectories, and do not take into account the uncertainty in class-
membership of each individual. As such, our confidence intervals may be anti-
conservative. However, given that the posterior probabilities of class-membership were 
universally high (mean=, maximum=), and the robustness of our findings for the increasing 
symptoms trajectory across several analyses, it is unlikely that this would affect the 
general conclusions. There is a possibility of selection on health. Since depression is 
related to a higher risk of mortality, participants with most severe depression might have 
died before the survival analyses. This might have led to an underestimation of results, 
and is particularly true for the high trajectory, in which 49.8% of participants died before 
the survival analyses. Further, estimates for the high symptoms trajectory might not be 
precise because of insufficient power. Incidence of dementia during the trajectories (i.e. 
 
 
 
before the start of the at-risk period for dementia used in survival analysis) was highest in 
the remitting, followed by the decreasing and high trajectories, possibly leading to an 
underestimation of risks due to selection. Additionally, we had insufficient power to 
compare the risks of vascular dementia.  
In conclusion, different trajectories of depression, identified by repeated measures of 
depressive symptoms, were associated with different risks of dementia. Increasing 
depressive symptoms were associated with a higher risk of dementia. Future studies are 
warranted to unravel the biological underpinnings of these associations.  
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SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Trajectories of depressive symptoms and risk of Alzheimer’s 
disease, N=3,203. 
Trajectories Cases/n  Risk of dementia, hazard ratios (95% confidence intervals) 
   Model 1a  P-value  Model 2b  p-value 
T1: Low 283/2,420  1.00 (ref)    1.00 (ref)   
T2: Decreasing  48/319  1.10 (0.78, 1.55)  0.59  1.05 (0.74, 1.50)  0.77 
T3: Remitting 23/163  1.06 (0.66, 1.70)  0.80  1.08 (0.67, 1.74)  0.75 
T4: Increasing 52/244  1.69 (1.21, 2.35)  0.002  1.59 (1.12, 2.26)  0.009 
T5: High  11/57  1.12 (0.53, 2.40)  0.76  1.00 (0.46, 2.18)  0.99 
a Model 1: adjusted for age (time varying covariate) and sex. 
b Model 2: additionally adjusted for APOE-ε4 carrier status, educational level, BMI, smoking, alcohol 
consumption, cognition at baseline, use of anti-depressant medication, hypertension, diabetes type 2, prevalent 
stroke, and myocardial infarction. 
Supplementary Table 2. Incident dementia and deaths before the survival analysis. 
Trajectory of depressive 
symptoms 
 Total number of 
participants  Dementia  Deaths 
T1: Low  3,826  310 (8.1)  1,145 (30) 
T2: Decreasing   673  92 (13.7)  307 (45.6) 
T3: Remitting  278  46 (16.6)  91 (32.7) 
T4: Increasing  394  47 (11.9)  128 (35.5) 
T5: High   129  17 (13.2)  63 (49.0) 
Values are counts (percentage). 
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ABSTRACT 
Background: Clinical depression and depressive symptoms have consistently been shown 
to be associated with excess mortality. However, populations of depressed persons are 
typically comprised of individuals that follow different courses of depression and thus 
might carry different risks of mortality.  
Methods: In the population-based Rotterdam Study, we examined depressive symptoms 
trajectories of 5,754 participants (aged ≥ 55) over 17 years, and related them to the risk of 
mortality. Depressive symptoms were assessed by the Center for Epidemiological Studies 
Depression scale (CES-D), and follow-up for mortality was complete until March 2015 
(mean follow-up 14±6 years, max=21.7 years). Joint-latent-class trajectory modelling was 
used to identify trajectories of depressive symptoms over time, and model mortality risk 
over time across trajectories, adjusting for relevant confounders.  
Results: Six trajectories of depressive symptoms were identified, characterized by low, 
chronic-mild, decreasing, remitting, increasing, and high depressive symptoms. 
Trajectories with increasing or chronic high depressive symptoms had a high risk of 
mortality (>30% by six years), while the trajectories with chronic-mild and remitting 
depressive symptoms had a low risk (<10% by six years).  
Conclusions: The chronicity and course of depressive symptoms predicted mortality better 
than the severity at one time point. Chronic high or consistently increasing  symptoms 
were strongly related to mortality, whereas persons with a trajectory typical of remitting 
depression did not show excess mortality. Our results open avenues for etiological and 
prognostic research to focus upon risk factors key to a particular trajectory. 
 
 
 
 
 
 
INTRODUCTION 
Clinical depression or clinically relevant depressive symptoms are highly prevalent among 
community-dwelling older adults.1 Clinically relevant depressive symptoms, which gauge 
sub-threshold depression, are not only more prevalent but are associated with 
impairment similar to major depression.2 Both clinical depression and depressive 
symptoms have been repeatedly shown to be associated with a higher risk of mortality in 
patient and community samples.3,4 
Depressive symptoms may root from diverse biologic and psychosocial factors including 
genetic predisposition and gene-environment interactions, chronic diseases or disability, 
life events and daily hassles, social disadvantage, personality attributes, and 
bereavement.2 In every individual with depressive symptoms, depression follows a unique 
course dependent upon a combination of such risk and perpetuating factors, which 
typically interact. In large populations, these individuals can be combined into unique 
groups with distinct trajectories of depressive symptoms course.5 For instance, persons 
with clinically relevant depressive symptoms may experience them transiently and 
undergo full remission. Other persons may undergo partial remission only. Yet other 
persons may experience several repeated recurrences of symptoms throughout life with 
intermittent periods of health, while a minority may become chronically depressed. 
However, it remains largely unknown how these different courses of depressive symptoms 
relate to mortality, as the existing studies mainly focus on prevalent depression or 
depressive symptoms. Thus the course of depression is largely neglected, which is an 
important gap considering the relapsing and remitting nature of depression.6-10 This issue 
can be addressed by utilizing repeated measures of depressive symptoms to study the 
course of depression, identify different trajectories of depression in a population, and 
then study the risk of mortality across these trajectories. Such an approach can help 
unravel high risk groups, and “filter out” the effects of any group in which depressive 
symptoms may have little or no effect on long-term health outcomes. Understanding the 
possibly differential risks associated with the course of depressive symptoms upon 
mortality and other outcomes opens avenues for efficient preventive and therapeutic 
strategies. 
The aims of this study were to identify different trajectories of depressive symptoms in 
community-dwelling older adults using repeated measures of depressive symptoms, and 
study the risk of mortality across these trajectories over a maximum follow-up of 22 years. 
We were especially interested to investigate how the remitting and relapsing course of 
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depressive symptoms relate to mortality, as many persons suffer from depression during 
the life time, but revert back to the non-depressed state.  
 
METHODS  
Setting  
This study was embedded in a large population-based cohort of persons aged 55 and 
older, ongoing since 1990. Follow-up examinations including home interviews and physical 
exams at a research center take place every three to four years. In addition, the cohort is 
continuously monitored for all major events by a highly efficient data linkage system 
between the study database and the general practitioners.11 This study is approved by the 
medical ethics committee according to the Population Study Act, executed by the Ministry 
of Health of the Netherlands. A written informed consent was obtained from all 
participants.  
Study population 
This study utilized depressive symptoms data from four examination rounds between 
1993 and 2011, and included 5,754 participants with at least one assessment of 
depressive symptoms at any of the four rounds. Number of participants that had 
depressive symptoms data available at more than one examination round was 4,385, and 
1,639 participants had depressive symptoms data for all four examination rounds. At 
baseline (1993-1995), depressive symptoms data were available for 4,874 participants. In 
the subsequent rounds in 1997-1999, 2002-2004, and 2009-2011, data for depressive 
symptoms were available for 4,500, 3,434, and 2,107 participants respectively. 
Assessment of depressive symptoms 
In the first examination round, we measured depressive symptoms using two different 
instruments: the validated Dutch version of the Center for Epidemiological Studies 
Depression Scale (CES-D),12 and the Hospital Anxiety and Depression Scale-Depression 
(HADS-D).13 In this round, assessment of depressive symptoms was introduced in the 
study protocol, and as a pilot project, a random half of participants received the CES-D 
questionnaire, while the other half received the HADS-D questionnaire. For all subsequent 
rounds, only CES-D was used. The CES-D comprises 20 items, each with a possible score of 
0-3, and the score ranges from 0-60.12 HADS-D comprises of 7 items each with a possible 
score of 0-3, and the score ranges from 0-21.13 Both scales are valid and reliable 
 
 
 
 
instruments for assessment of depression and can indicate clinically relevant depressive 
symptoms. We checked for evidence whether this introduces information bias but we 
found the same percentage of screen positives (10%) using validated, pre-defined cut-
offs.14 For analyses, depressive symptoms scores were used as a standardized variable, 
calculated as weighted individual score minus mean score, divided by the standard 
deviation. Scores were weighted for missing items only if missing items did not exceed 
25%; scores with missing items >25% were excluded.  
Vital Status 
Information on vital status was obtained continuously via computerized linkages from 
municipal authorities. Mortality follow-up was complete until March 2015.  
Other measurements  
Covariates 
All covariates were measured at baseline, and were considered potential confounders 
because they are associated with depression and are independent predictors of mortality. 
Socio-demographic: Age, sex, educational level,15 partner status,16 and loss of a partner 
were considered potential confounders. Educational level was categorized as primary 
(primary only or unfinished secondary) or higher than primary education (secondary, 
vocational or university). For partner-status, participants were classified as living or not 
living with a partner. Participants were inquired if they had experienced loss of a partner 
and categorized into two groups accordingly. 
Health-indicators: Body mass index (BMI) was calculated as weight in kilograms/height in 
meters.2 Smoking habits were inquired during the home interview and participants were 
classified into never, past, and current smokers. Cognition 17 was assessed by the Mini-
Mental State examination (MMSE).18 Disability index was derived from the Activities of 
Daily Living from the Stanford Health Assessment Questionnaire Disability Index (HAQ-
DI).19 
Prevalent disease and medication: Hypertension was defined as systolic blood pressure ≥ 
140 mmHg, or diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive medication 
assessed by interview and pharmacy records.20 Diabetes Mellitus type 2 (DM) was 
diagnosed as fasting blood glucose ≥ 7.0 mmol/l, or use of anti-diabetic medication 
evaluated by interview and pharmacy records.21 Previous stroke, myocardial infarction 
(MI), and hip fractures were determined by reported events on interview and confirmed 
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by medical records.11 For cancers, linkage of the regional pathology databases to the 
Rotterdam Study identified cancer patients in more than 95% of persons. Use of anti-
depressant medication was assessed by interview and confirmed by pharmacy records.22 
Dementia 
Dementia was diagnosed according to DSM-III-R criteria for dementia, NINCDS-ADRDA for 
Alzheimer’s disease, NINCDS-AIREN criteria for vascular dementia following a standard 
protocol, and through continuous monitoring as described previously.23 
Statistical analyses  
Main analyses 
Participants entered the study at the examination round in 1993-1995 and were followed 
for all-cause mortality until 2015. We used the joint latent class mixed model (Jointlcmm-
R-package) 24 to study the effect of longitudinal course of depressive symptoms over time 
on the risk of mortality. This model, which is a form of linear mixed model, identifies 
distinct trajectories, which are latent classes of individuals following similar progression of 
an outcome over time or with age.25-27 For every subject, the posterior probabilities to 
belong to each trajectory were computed, taking into account their age, sex and 
educational level, and subjects were assigned to the trajectory with the highest 
probability. We tested different numbers and forms of possible trajectories starting with 1 
trajectory, till the Bayesian Information Criterion (BIC) minimized.26 The criteria for the 
final number of trajectories were based on minimizing the BIC while maintaining the 
posterior probabilities by class (>0.70), and class size (at least 2% of the population). 
Analyses were repeated using different random starting values to prevent convergence to 
a local maximum. We included random intercepts and random slopes over time. The joint 
survival model was defined by a two parameter Weibull distribution with a class-specific 
baseline risk function for mortality. In a basic survival model (Model 1), we adjusted for 
age and sex only, and in an extended model (Model 2), we additionally adjusted for 
educational level, partner-status, loss of partner, BMI, smoking, cognitive score, disability 
index, prevalent disease at baseline, including hypertension, DM, MI, stroke, cancer, hip 
fractures, and use of anti-depressant medication. Survival curves were plotted for the 
mean of the covariates. Analyses were conducted using the lcmm package in R version 
3.1.2.  
During the period of depressive symptoms assessments (1993-2011), 814 participants 
were diagnosed of incident dementia. In a sensitivity analyses, we did not use the 
 
 
 
 
depressive symptoms scores after the diagnoses of dementia, however, since the results 
did not change meaningfully, we used all the depressive symptoms assessments available. 
Alternative statistical approach 
We performed the latent-class trajectory modelling using the Stata Software Version 13,28 
which uses the same methodology to assign trajectories as the Jointlcmm. However, it has 
the limitation of unavailability of a joint survival model with trajectory classification. 
Detailed methods for this analysis are provided in the supplement text (Supplement 
methods). In a further step, we used the trajectory classifications as indicator variables to 
calculate hazard ratios for mortality using Cox proportional hazards (PH) models, using the 
low depressive symptoms trajectory as reference. Adherence to the PH assumption was 
tested by plotting smoothed Schoenfeld residuals against time. For these analyses also, 
two models were fitted. Model 1 was adjusted for age and sex, and Model 2 was adjusted 
for all aforementioned covariates. Analyses were performed using the Stata Software 
Version 13 (StataCorp, College Station, TX, USA).  
Finally, for comparability with other studies, we also tested the association of clinically 
relevant depressive symptoms measured continuously at baseline with mortality, using 
Cox PH models. 
Differences in baseline characteristics across trajectories 
To test whether baseline characteristics of persons differ across trajectories, we used 
Analysis of Variance (ANOVA) test with post-hoc Bonferroni for continuous variables, and 
logistic regression for categorical variables. This was performed for both main and 
alternative statistical analyses. 
 
RESULTS 
Main analyses 
5,754 participants (mean age 70±8.1 years, 59% women), who were dementia-free at 
baseline, were followed for a mean of 14±6 years (maximum follow-up= 21.7 years), 
during which 3,716 participants died. For the trajectory classification, the model with six 
latent classes of depressive symptoms had the best fit with the lowest BIC (Table 1). Mean 
posterior probabilities of class-membership were at least 0.71 (lowest average of any 
class). In contrast, the seven-class model had lower mean posterior probabilities for class-
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membership (0.57). Further, this model only added a small class (n=111) with a pattern 
largely overlapping the low symptoms trajectory in the six-class model, thus added little 
extra information. 
The six trajectories of depressive symptoms are shown in Figure 1A. They were named 
according to their graphical pattern to facilitate interpretability. 76% of participants were 
assigned to a trajectory which had low depressive symptoms throughout the study period 
(Low, n=4,386). The more symptomatic classes were characterized by the following 
trajectories: mild symptoms throughout the follow-up with little fluctuation up till 19 
years (Chronic-mild, n=298, 5.2%); high depressive symptoms at baseline, remitted and 
then remained low (Decreasing, n=247, 4.3%); a transient increase in depressive 
symptoms but remitted (Remitting, n=293, 5.1%); increasing symptoms throughout the 
follow-up (Increasing, n=395, 6.9%); and chronic high depressive symptoms throughout 
(High, n=135, 2.3%).  
Table 2 shows a comparison of baseline characteristics of participants by trajectories. 
Those assigned to the increasing or high depressive symptoms trajectory had a higher 
prevalence of chronic disease and health events. 
In the survival model adjusted for age and sex only (Model 1), those in the high depressive 
symptoms trajectory had a high cumulative incidence of mortality (predicted risk of death 
over 35% by 6 years and 80% by 12 years) (Table 3, Figure 1B). Those in the increasing 
trajectory had a similar high mortality (predicted risk of death 33% by 6 years and over 
75% by 12 years). These risks were substantially higher than the risks in the chronic-mild 
trajectory (predicted risk of death 0.6% by 6 years and 12% by 12 years). The low, 
decreasing, and remitting trajectories of depressive symptoms, all had similar risks of 
mortality (e.g. ~30% by 12 years). 
 
  
 
 
 
 Table 1. Sum
m
ary of joint m
odel fits. 
N
 classes 
Log-likelihood 
N
 param
eters 
BIC 
Score test (p-value) 
Latent class proportion (%
) 
1 Class 
-33056.31 
16 
66251.14 
76.71 (0) 
100 
2 Classes 
-32228.41 
26 
64681.91 
29.51 (0) 
93.97, 6.03 
3 Classes 
-31678.28 
36 
63668.25 
22.98 (0) 
88.58, 6.78, 4.64 
4 Classes 
-31330.15 
46 
63058.56 
17.86 (<0.001) 
5.72, 82.55, 6.71, 5.02 
5 Classes 
-30971.22 
56 
62427.27 
12.84 (0.002) 
7.7, 7.79, 76.82, 5.11, 2.59 
6 Classes 
-30735.53 
66 
62042.46 
10.43 (0.005) 
6.86, 4.29, 76.23, 5.09, 2.35, 5.18 
7 Classes 
-30687.38 
76 
62032.75 
10.16 (0.006) 
6.73, 4.17, 73.71, 5.13, 2.29, 6.05, 1.93 
 Abbreviations: N
 = num
ber, BIC = Bayesian inform
ation criterion. 
M
inim
um
 posterior probability for six-class m
odel w
as 0.71 
M
inim
um
 posterior probability for 7 class m
odel w
as 0.57; the seventh class in this m
odel com
prised 111 participants w
ith a pattern largely overlapping the low
 
sym
ptom
s trajectory. 
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1A 
1B 
Figure 1. Trajectories of depressive symptoms and risk of mortality. 1A: Predicted evolution of 
depressive symptoms over time. Trajectory classification is adjusted for age, sex and education. 1B: Class-specific 
survival. Survival curves adjusted for age and sex. 
 
 
 
 
 Table 2. Baseline characteristics of study population betw
een 1993-1995, N
=5,754. 
Characteristics 
Increasing 
N
=395 
Decreasing 
N
=247 
Low
 
N
=4368 
Rem
itting 
N
=293 
High 
N
=135 
Chronic-m
ild 
N
=298 
Socio-dem
ographics 
Age 
71.5 (7.9) 
69.6 (8.4) 
69.4 (8.2) a 
69.9 (7.8) 
71.1 (8.0) 
69.1 (7.5) a 
W
om
en 
248 (62.8) 
154 (62.3) 
2503 (57.1) a 
212 (72.3) a, b, c 
81 (60.0) d 
204 (68.5) c 
Prim
ary education 
84 (21.3) 
57 (23.1) 
835 (19.0) 
54 (18.4) 
36 (26.7) c 
60 (20.1) 
Living w
ith a partner 
245 (62.7) 
146 (59.8) 
2958 (68.3) a, b 
191 (65.4) 
76 (58.0) c 
196 (66.0) 
Loss of a partner 
30 (10.1) 
32 (16.7) a 
283 (9.8) b 
22 (10.4) 
16 (14.0) 
24 (11.6) 
Health indicators 
Body m
ass index 
26.8 (3.6) 
26.6 (3.4) 
26.4 (3.3) 
26.5 (3.4) 
26.3 (3.4) 
26.9 (3.5) 
Current sm
oking 
108 (27.3) 
56 (22.7) 
84 (19.3) a 
52 (17.7) a 
39 (28.9) c, d 
42 (14.1) a, b, c, e 
M
M
SE score 
27.5 (1.7) 
27.5 (2.1) 
27.9 (1.6) 
27.7 (1.5) 
27.2 (2.0) 
27.9 (1.5) 
Disability index 
0.5 (0.6) 
0.4 (0.5) 
0.3 (0.4) a, b 
0.4 (0.5) c 
0.7 (0.7) a, b, c, d 
0.4 (0.5) a, c, e 
M
edical history 
Hypertension 
312 (79.0) 
163 (66.0) a 
3138 (71.5) a 
197 (67.2) a 
98 (72.6) 
209 (70.1) a 
Diabetes M
ellitus 2 
31 (7.8) 
15 (6.1) 
242 (5.5) 
23 (7.8) 
13 (9.6) c 
14 (4.7) e 
M
yocardial infarction 
42 (10.6) 
15 (6.1) a 
323 (7.4) a 
23 (7.8) 
15 (11.1) 
14 (4.7) a, e 
Stroke 
33 (8.3) 
9 (3.6) a 
150 (3.4) a 
15 (5.1) 
15 (11.1) b, c, d 
5 (1.7) a, d, e 
Cancer 
36 (9.1) 
10 (4.0) a 
217 (4.9) a 
15 (5.1) a 
12 (8.9) c 
8 (2.7) a, e 
Hip fractures 
10 (2.5) 
0 
40 (0.9) a 
0 
3 (2.2) 
1 (0.3)a 
Anti-depressants use 
11 (3.4) 
7 (3.5) 
58 (2.0) a 
16 (6.8) c 
15 (12.6) a, b, c, d 
10 (4.7) c, e 
 Values are counts (percentage) or m
eans (standard deviation).  
a If a trajectory is different from
 increasing Trajectory; b If a trajectory is different from
 decreasing trajectory; c If a trajectory is different from
 low
 trajectory; d If a 
trajectory is different from
 rem
itting trajectory; e If a trajectory is different from
 high trajectory. 
Com
parisons are based on Analysis of Variance (AN
O
VA) for continuous and logistic regression for categorical variables. 
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In the fully adjusted survival model (Model 2), somewhat different results were obtained 
suggesting that covariates accounted for some of the observed effects. The increasing 
trajectory was still characterized by a very high cumulative incidence of mortality 
(predicted risk of death 85% by 6 years), like the decreasing depressive symptoms 
trajectory (predicted risk of death 59% by 6 years) (Figure 2). The high, low and remitting 
trajectories only showed a moderate risk in this model (predicted risk of death <25% by 6 
years). The chronic-mild trajectory again showed low risk of <2 % by 6 years. 
Alternative statistical approach 
Results for these analyses are shown as a supplement (Supplement Figure 1 & 2, 
Supplement Table 1). The main setback of this approach was that the hazard ratios (HRs) 
were calculated without accounting for the uncertainty in class-membership and does not 
fit a joint survival model of depressive symptoms trajectories and mortality. However, the 
probabilities of the class-membership in these analyses ranged from 0.7 to 0.9, and both 
the obtained classes and the association with mortality were largely similar to those 
obtained in the joint survival model. The differences observed were that we identified two 
trajectories with a remitting pattern in this analysis, and did not find the chronic-mild 
trajectory. Additionally, the HRs suggested a much higher risk of mortality in those with 
high depressive symptoms, than observed in the joint survival model. We show these 
trajectories and HRs for illustration only, but can only be very cautiously interpreted. This 
was also reflected in the non-proportionality of hazards for the remitting and the 
increasing trajectories in these analysis. 
When we tested the association of clinically relevant depressive symptoms at baseline for 
comparability with other studies, depression was associated with a higher risk of mortality 
in the basic model, HR per SD 1.15 (95% CI: 1.05, 1.25), but this attenuated after adjusting 
for all confounders, HR per SD 1.03 (95% CI: 0.99, 1.07).  
 
 
 
 
Table 3. Cumulative incidences of death for trajectories of depressive symptoms. 
 Cumulative incidences of mortality per class, (%) 
Follow-up  Increasing n=395 
Decreasing 
n=247 
Low 
n=4,386 
Remitting 
n=293  
High 
n=135  
Chronic-mild 
n=298  
3 years 14.1 1.6 1.5 1.4 17.5 0.03 
6 years 33.1 7.1 6.6 7.1 37.9 0.6 
9 years 54.4 17.4 15.9 18.3 59.7 3.6 
12 years 75.9 31.6 28.5 34.7 80.7 11.9 
 
 Cumulative incidence adjusted for age and sex. 
 
 
 
 
Figure 2. Survival across different trajectories of depressive symptoms. 
Survival curves are adjusted for age, sex educational-level, partner-status, smoking status, body mass index, 
cognitive score, disability index, prevalent disease (hypertension, diabetes mellitus type 2, hip fractures, 
myocardial infarction, stroke, and cancer), and use of anti-depressant medication.  
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DISCUSSION 
This population-based prospective study of 5754 older adults suggests that different 
trajectories of depressive symptoms have different risks of mortality during a long-follow-
up. Incidence of mortality was most substantial in persons with increasing, decreasing, or 
high depressive symptoms trajectories. In contrast, persons with low or remitting 
depressive symptoms had a low incidence of mortality.  
Individuals in the high and increasing depression trajectories in our study were more likely 
to be older, single or widowed, less educated, or have a higher prevalence of physical 
disability and chronic diseases. These findings concur with the well-documented evidence 
suggesting that depression is associated with increasing age, lower education, having no 
partner, and chronic diseases including diabetes mellitus, coronary heart disease, stroke, 
cancers, and fractures, particularly of the hip joint.29-33 
Previously, three distinct patterns of depressive symptoms severity in relation to 
differential mortality risk have been reported over a 12-month period in primary-care 
older adults.5 In our study, the trajectories with increasing and high depressive symptoms 
were associated with a higher risk of mortality. This suggests that increasing or chronic 
symptoms predict mortality, and not high symptoms at only one point in time. However, 
the excess mortality in persons in the chronic high symptoms trajectory could be largely 
explained by pre-existing comorbidities, such as hypertension, diabetes, myocardial 
infarction, and stroke. In the other trajectories, such as with increasing and decreasing 
symptoms, arguably, more subclinical physiologic mechanisms underlie the association 
with mortality rather than clinically apparent disorders. For example, the hypothalamic-
pituitary-axis (HPA), which is often hyperactive in depressed patients,34 hyperactivity of 
the autonomic nervous system and enhanced platelet aggregation in depressed patients, 
all are common causes of cardiovascular disease and thus may contribute to mortality.35,36 
Also, lifestyle factors, such as non-compliance to medication, unhealthy life-style with 
poor diet or lack of exercise could underlie our observations. 
Interestingly, the remitting trajectory, although being high on the depressive symptoms 
scale at at-least one point, did not have excess mortality. Perhaps high depressive 
symptoms in these persons indicate a “normal reaction” to life stressors followed by full 
recovery and had no lasting adverse influence on health. It is also possible that after 
getting diagnosed with chronic illnesses such as diabetes or hypertension, individuals 
react with a transient increase in depressive symptoms, but at the same time become 
more conscious about health and thus might have a better survival. These results suggest 
 
 
 
 
that a remitting course of depressive symptoms has no worse survival than a trajectory 
characterized by few or no depressive symptoms. In some persons, the poor prognosis of 
depressive symptoms would certainly have to be modified if depressive symptoms were 
measured repeatedly. Hence, other studies observing a higher mortality risk associated 
with prevalent depression 6-10 might be under-estimating the risk of those with more 
chronic depression, and at the same time over-estimating the risk for those with remitting 
symptoms.  
An interesting finding consistent across both analyses, is the higher risk of mortality 
observed for the decreasing trajectory, although the remission after round 2 was quite 
stable. One reason could be the partner loss at baseline. It is known that lack of partner 
support and social engagement can adversely affect health in general,16,29,37 which might 
explain this finding. Additionally, the chronicity of symptoms prior to the study 
observation period might explain this higher risk, but, we did not have that information.  
Finally, depression assessment at baseline only modestly predicted mortality. Perhaps in 
our study, more depressive symptoms at a single assessment possibly did little effect and 
the association was largely explained by the presence of unfavorable socio-demographic 
factors, poor health, and chronic diseases.  
The novelty of this study is to study different trajectories of depressive symptoms over 17 
years in relation to mortality. Other strengths include a large population-based sample, a 
long and thorough mortality follow-up, and consideration of several potential 
confounders. The main limitation of the study is that we could not calculate confidence 
intervals for the survival model which a limitation of the statistical software. Although we 
calculated hazard ratios with confidence intervals in the alternative approach (Stata), they 
might not be precise as the uncertainty associated with class-membership could not be 
accounted for in this method. Further in this method, the proportionality of hazard 
assumption was not met for two trajectories. Moreover, we did not exclude participants 
with incident dementia during trajectory assignment, and they remained at-risk for 
mortality in our analyses, as excluding them could have introduced selection bias. We also 
repeated analyses by excluding the depressive symptoms scores after dementia diagnosis, 
as it might have introduced some information bias. However, the trajectories were largely 
similar, and thus all available scores were used. Another limitation is that while we could 
model the course of depressive symptoms over a 17 year period, we did not have 
information on how depressed the participants were previously. Finally, although we 
assessed the association between depressive symptoms trajectories and mortality in a 
number of ways, each analysis had inherent limitations that restrict causal interpretation. 
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Nonetheless, the current analyses represent an important first step toward describing the 
potential role of chronicity and late-life course of depressive symptoms in excess 
mortality. Future research may build upon these observed patterns to address refined 
etiological questions. 
 
 
 
 
 
SUPPLEMENTARY INFORMATION 
Methods 
Identification of trajectories using Stata Software Version 13 (StataCorp, College Station, 
TX, USA):  
We used the Traj Stata command for the latent class trajectory modelling of depressive 
symptoms data over time. This is a specialized form of finite mixture modelling, and is 
designed to identify distinct trajectories, which are latent classes of individuals following 
similar progression of an outcome over time or with age.(Jones BL, 2013) One of the key 
assumptions of the model is that a population comprises multiple trajectories. We used 
the censored normal distribution (cnorm) in trajectory modelling which is intended for the 
analysis of repeatedly measured continuous scales. For every subject, the posterior 
probabilities for each trajectory were computed, taking into account their age, sex and 
educational level, and subjects were assigned to the trajectory with the highest 
probability. We tested different numbers and forms of possible trajectories starting with 1 
trajectory, till the Bayesian Information Criterion (BIC) minimized. Thus the final number 
of trajectories was determined using the BIC(Proust-Lima C, 2015) and by assessing the 
mean posterior probabilities of belonging to each trajectory according to final 
classification. After identification, we assigned names to the trajectories based on their 
graphical patterns to facilitate comprehension and interpretation of results.  
Assessment of risk of mortality: 
Subsequently, we studied the risk of mortality in the identified trajectories of depressive 
symptoms using Cox proportional hazards model. Adherence to the proportional hazards 
(PH) assumption was tested by plotting smoothed Schoenfeld residuals against time. The 
trajectory classifications were used as indicator variables only, to calculate hazard ratios of 
depressive symptoms for mortality in survival analyses. Two models were fitted: Model 1 
was adjusted for age and sex only, and Model 2 was additionally adjusted for educational 
level, partner-status, loss of partner, BMI, smoking, cognitive score, disability index, 
prevalent disease at baseline, including hypertension, DM, MI, stroke, cancer, hip 
fractures, and use of anti-depressant medication. 
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Supplementary Table 1. Risk of mortality across trajectories of depressive symptoms.  
Trajectories Deaths/N Risk of mortality, Hazard ratios (95% Confidence intervals 
Model 1a P-value Model 2b P-value 
T1: Low  2,226/3,812 1.00 (ref)  1.00 (ref)  
T2: Decreasing  444/580 1.46 (1.32, 1.62) <0.001 1.24 (1.11, 1.37) <0.001 
T3: Remitting I 219/310 1.11 (0.97, 1.28) 0.13 0.94 (0.81, 1.08) 0.36 
T4: Remitting IIc   104/164 0.98 (0.80, 1.19) 0.83 0.78 (0.64, 0.95) 0.01 
T5: Increasingc 622/762 1.30 (1.18, 1.43) <0.001 1.15 (1.05, 1.27) 0.003 
T6: High  101/126 1.90 (1.55, 2.32) <0.001 1.38 (1.12, 1.69) 0.002 
 
a Model 1: adjusted for age and sex. 
b Model 2: additionally adjusted for educational-level, partner-status, smoking status, body mass index, cognitive 
score, disability index, prevalent disease (hypertension, diabetes mellitus type 2, hip fractures, myocardial 
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Figure 2. Survival across different trajectories of depressive symptoms. 
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scores over 20 years of follow-up.  
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Supplementary Table 1. Risk of mortality across trajectories of depressive symptoms.  
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ABSTRACT 
Background: Anxiety and depression frequently co-occur in the elderly and in patients 
with dementia. Prior research has shown that depression is related to the risk of 
dementia, but the effect of anxiety on dementia remains unclear. We studied whether 
anxiety symptoms and anxiety disorders are associated with the risk of dementia and 
cognition. In the population-based Rotterdam Study. 
Methods: In 1993-1995, anxiety symptoms were assessed in 2,708 non-demented 
participants with the Hospital Anxiety and Depression Scale (HADS) (sample I). In 2002-
2004, anxiety disorders were assessed using the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, in 3,069 non-demented participants (sample II). In both 
study samples, participants were continuously monitored for dementia until January 1, 
2011. Cognition was tested in 2002-2004 and at a follow-up visit in 2009-2011 in sample II 
only.  
Results: In sample I, 358 persons developed dementia and in sample II, 248 persons 
developed dementia. We did not find an association with the risk of dementia for anxiety 
symptoms (hazard ratio (HR) 1.05, 95%-confidence interval (CI) 0.77; 1.43, Wald-statistic 
0.08, p-value 0.77, degrees of freedom (df) 1) or for anxiety disorders (HR 0.92, 95%-CI: 
0.58; 1.45, Wald-statistic 0.14, p-value 0.71, df 1). We could demonstrate an association of 
anxiety disorders with poor cognition cross-sectionally, but this attenuated after 
additional adjustments. 
Conclusions: Our findings do not offer evidence for an association between anxiety 
symptoms or anxiety disorders with the risk of dementia or with cognition. This suggests 
that anxiety is not a risk factor nor a prodrome of dementia in an elderly, community-
dwelling population. 
 
 
 
 
INTRODUCTION 
Psychiatric disorders, such as anxiety and depression, are common co-manifestations in 
dementia.1-4 Not only are anxiety and depression often diagnosed in demented persons, 
but anxiety and depression may be one of the presenting symptoms of dementia.2 Studies 
demonstrating a longitudinal association between depression and incident dementia 
suggest that depression might be a risk factor of dementia or alternatively an early clinical 
marker of incipient dementia.5,6 Since anxiety shares both symptoms and risk factors with 
depression,7 it is often thought that anxiety is also associated with the risk of dementia. 
Here too, the underlying hypothesis is based on either a shared etiology between anxiety 
and dementia, or on anxiety as early symptom of incipient and yet to be diagnosed 
dementia.7-9 
Previous studies examining the association between anxiety and dementia or cognition 
remain inconclusive.8-23 Methodological differences, such as assessment of anxiety or 
selection of study participants might explain inconsistencies. Moreover, in some studies 
reporting an association between anxiety and increased risk of dementia, the influence of 
depression on these associations remains unclear.8,23 
In the prospective, population-based Rotterdam Study we studied the association of 
anxiety symptoms and anxiety disorders with the risk of incident dementia. To further 
explore the effect of anxiety, we also related anxiety disorders to cognition, both cross-
sectionally and longitudinally, in persons without dementia. 
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METHODS  
Setting  
The Rotterdam Study is a prospective, population-based cohort that started in 1990 and is 
conducted among inhabitants, aged 55 years and older, of Ommoord, a district of 
Rotterdam, The Netherlands. Of the 10,215 invited inhabitants, 7,983 (78%) agreed to 
participate in the baseline examination. Up until 2013, there have been 5 examination 
rounds. Details of the study have been described elsewhere.24 For this study, two 
baselines were chosen because information on anxiety symptoms and anxiety disorders 
was collected at different examination  rounds.  
Anxiety symptoms were assessed in 1993-1995 and this examination was constituted as 
baseline for sample I. Of the 6,315 subjects that participated at baseline, a random half 
(N=3,060) was invited to undergo screening for anxiety symptoms using the Hospital 
Anxiety and Depression Scale (HADS). Of these, 83 participants were excluded because 
they were not sufficiently screened for anxiety symptoms. Furthermore, 44 persons were 
excluded because they had prevalent dementia, 215 because they did not agree to 
undergo screening for dementia, and 10 participants were excluded due to lack of follow-
up data. Eventually, sample I comprised 2,708 non-demented subjects that underwent 
both screening for anxiety symptoms and had follow-up information on dementia 
diagnosis.  
Anxiety disorders were assessed in 2002-2004 and this examination was constituted as 
baseline for sample II. Of the 3,550 participants that were eligible, a total of 3,259 persons 
underwent screening for anxiety disorders. Of this sample, 124 persons were excluded 
because they were prevalent demented, 56 because they did not agree to undergo 
screening for dementia, and 10 participants were excluded for lack of follow-up data. 
Finally, sample II comprised 3,069 non-demented subjects that underwent screening for 
anxiety disorders and had follow-up information on dementia diagnosis. Of the 3,069 
subjects that were included in sample II, 1,506 subjects were also included in sample I. 
Follow-up for dementia for both samples was complete until January 1, 2011 (for 98.3% of 
potential person-years in sample I and for 96.9% of potential persons-years in sample II). 
Sample II was also used to assess the association between anxiety disorders and cognition. 
Cognition was assessed at baseline in 2002-2004 and at follow-up in 2009-2011. Of the 
3,069 subjects in sample II, 2,351 subjects had information on cognitive performance 
cross-sectionally and 1,115 subjects had information on cognitive decline longitudinally. 
 
 
 
 
The medical ethics committee at Erasmus University of Rotterdam approved the study and 
written informed consent was obtained from all subjects. 
Anxiety symptoms 
Anxiety symptoms were assessed in 1993-1995 in a random half of the study population 
using the HADS.25 The HADS is a brief questionnaire that is used often in the Netherlands 
for the assessment of anxiety symptoms and depressive symptoms. It consists of two 
subscales, the HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A), each including 7-
items. Total scores range from 0-21 with higher scores indicating more symptoms of 
depression or anxiety. A score of 8 or higher on the HADS-A scale was considered positive 
for anxiety symptoms.  
Anxiety disorders 
Anxiety disorders were diagnosed in 2002-2004 using a slightly adapted version of the 
Munich version of the Composite International Diagnostic Interview (M-CIDI).26 We 
assessed the 12-month prevalence of anxiety disorders. The following anxiety disorders 
were assessed with a computerized diagnostic algorithm according to Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria: generalized 
anxiety disorder, panic disorder, agoraphobia, social phobia, and specific phobia.27 These 
results were converted into a binary variable that stated whether a participant had at least 
one of the above-mentioned anxiety disorders or was free of any anxiety disorders. This 
variable was used in the analysis. 
Dementia 
Participants were screened for dementia at every examination round using a three-step 
protocol. Screening was done using the Mini-Mental State Examination (MMSE) and the 
Geriatric Mental Schedule (GMS) organic level.28,29 Screen-positives (MMSE <26 or GMS 
organic level >0) subsequently underwent an examination and informant interview with 
the Cambridge Examination for Mental Disorders in the Elderly (CAMDEX).30 Participants 
who were suspected of having dementia, underwent, if necessary, further 
neuropsychological testing. Additionally, the total cohort was continuously monitored for 
dementia through computerized linkage between the study database and digitized 
medical records from general practitioners and the Regional Institute for Outpatient 
Mental Health Care. When information on neuro-imaging was required and available, it 
was used for decision making on the diagnosis. In the end, a consensus panel, led by a 
neurologist, decided on the final diagnosis in accordance with standard criteria for 
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dementia (Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised 
(DSM-III-R)) and Alzheimer Disease (National Institute of Neurological and Communicative 
Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA)).31,32 
Cognition 
In sample II, cognitive performance was assessed at baseline in 2002-2004 and  at follow-
up in 2009-2011 with a cognitive test battery comprising Letter-Digit Substitution Task 
(LDST)33. Stroop test,34 Verbal Fluency Test (VFT),35 and 15-Word verbal Learning Test 
based on Rey’s recall of words (15-WLT).36 These tests tap into several cognitive domains: 
executive function, information processing, and memory function.37 Higher test scores 
indicate better cognitive performance in all tests, except for the Stroop test, in which 
lower test scores indicate better cognitive performance. To calculate cognitive decline, we 
subtracted the test scores at the baseline examination from the test scores at the follow-
up examination.  
Other measurements 
In sample I, depressive symptoms were assessed at baseline using the HADS-D subscale of 
the HADS.25 A score of 9 or higher on the HADS-D scale was considered positive for 
depressive symptoms.38 In sample II, depressive disorders were assessed at baseline in 
two steps. First, all participants were screened for depressive symptoms using the Center 
for Epidemiological Studies-Depression scale (CES-D).39 Second, the participants with 
clinically significant depressive symptoms (CES-D ≥16) were invited for a semi-structured 
interview using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN).40 
Subsequently, depression was defined according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR).41 The category of clinical 
depressive disorders included the DSM-IV-TR-defined major depressive disorder, 
dysthymia, and depressive disorder not otherwise specified (including the former category 
of minor depression). Low educational level was defined as less than 12 years of 
education. Information on apolipoprotein E (APOE) genotype was obtained using 
polymerase chain reaction on coded DNA samples without knowledge of the dementia 
diagnosis.42 Missing values in covariates (for every variable less than 6.5%) were imputed 
based on age and sex. 
 
 
 
 
 
 
Statistical analyses 
We used Cox proportional hazards models to assess the associations between anxiety 
symptoms and anxiety disorders with incident dementia. We also investigated the relation 
between the various subtypes of anxiety disorders and incident dementia. Plotting the 
Kaplan Meier curves did not reveal any overt violations of the proportional hazards 
assumption (see supplementary figures I and II, Supplemental Digital Content 1, which 
show the dementia free survival curves of persons with and without anxiety symptoms or 
disorders). The underlying time-scale in these models was the follow-up time. Follow-up 
time for both analyses was defined from time at assessment of anxiety symptoms or 
anxiety disorders until January 1, 2011. Subjects were censored within this time period 
when they were diagnosed with dementia, died, or decided to terminate their 
participation in the study. All models were adjusted for age and sex (basic model). In 
sample I, we adjusted subsequently for low educational level, APOE-ε4 carrier status, and 
depressive symptoms (fully adjusted model) for being potential confounders. In sample II 
we adjusted for the same potential confounders but instead of depressive symptoms now 
adjusted for depressive disorders. The same set of analyses was repeated for Alzheimer 
disease separately. To compare the results of samples I and II, we conducted a sensitivity 
analysis stratifying the follow-up time of sample I. A cut-off of 5.8 years was chosen 
because this was the mean follow-up time of sample II. We used linear regression models 
to examine the effect of anxiety disorders on cognition. These models were adjusted for 
age and sex (basic model), and subsequently for low educational level, APOE-ε4 carrier 
status, and depressive disorders (fully adjusted model). In the analyses with cognitive 
decline, all models were additionally adjusted for time between the baseline and follow-
up assessment of cognition.  
All analyses were performed using IBM SPSS statistics for Windows, Version 20.0 (IBM 
Corp, Armonk, NY).  
 
RESULTS  
The baseline characteristics of our study samples are presented in Table 1. In sample I, 
361 participants had anxiety symptoms. The mean follow-up in sample I was 11.8 years 
(standard deviation (SD) 5.0, total follow-up 32,047 person-years) during which 358 
persons were diagnosed with incident dementia, of whom 291 with incident Alzheimer 
disease. In sample II, 258 participants had anxiety disorders. Of these, 9 persons had panic 
disorder, 51 specific phobia, 27 social phobia, 80 generalized anxiety disorder, and 127 
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persons suffered from agoraphobia. The mean follow-up in sample II was 5.8 years (SD 
1.9, total follow-up 17,778 person-years) during which 248 persons were diagnosed with 
incident dementia, of whom 207 with incident Alzheimer disease. 
 
Table 1. Population characteristics. 
 Sample I, Anxiety symptoms Sample II, Anxiety disorders 
 N=2,708 N=3,069 
Age, years  68.6 (8.5) 75.5 (6.2) 
Women 1,495 (55.2) 1,810 (59.0) 
APOE-ε4 carrier 712 (28.1) 786 (26.8) 
Low educational level 797 (29.4) 850 (27.7) 
Anxiety symptoms 361 (13.3) NA 
Anxiety disorders NA 258 (8.4) 
Depressive symptoms 236 (8.7) NA 
Depressive disorders NA 81 (2.6) 
 
Abbreviations: N number of persons in sample, SD standard deviation, APOE apolipoprotein E, NA not applicable 
Data are presented as means (standard deviation) or counts (percentage).  
Percentages are calculated without missing data. For all reported variables, missing numbers occurred in 6.5% or 
less of all participants. 
 
We did not find an association between anxiety symptoms and incident dementia (Table 
2). The HADS-anxiety and HADS-depression subscales were moderately correlated within 
our population (Spearman’s rank correlation coefficient 0.62, p-value <0.001). However, 
additional adjustments for depressive symptoms and other potential confounders only 
slightly altered the associations.  
 
 
 
 Table 2. Associations betw
een anxiety and incident dem
entia. 
Anxiety 
 
Dem
entia 
 
Alzheim
er’s disease 
 
 
n/N
 
Hazard Ratio 
(95%
 CI) 
W
ald-
statistic 
p-value 
n/N
 
Hazard Ratio 
(95%
 CI) 
W
ald-
statistic 
p-value 
Anxiety sym
ptom
s 
 
Basic m
odel a 
358/2,708 
1.05 (0.77, 1.43) 
0.08 
0.77 
291/2,708 
1.01 (0.71, 1.43) 
0.00 
0.97 
 
Fully adjusted m
odel b 
358/2,708 
0.99 (0.69, 1.41) 
0.01 
0.94 
291/2708 
1.07 (0.73, 1.59) 
0.13 
0.72 
Anxiety disorders 
 
Basic m
odel a 
248/3,069 
0.92 (0.58, 1.45) 
0.14 
0.71 
207/3,069 
0.98 (0.60, 1.59) 
0.01 
0.92 
 
Fully adjusted m
odel b 
248/3,069 
0.81 (0.50, 1.30) 
0.80 
0.37 
207/3,069 
0.87 (0.53, 1.45) 
0.28 
0.60 
 Abbreviations: n num
ber of cases, N
 num
ber of persons at risk, CI confidence interval. 
Com
parisons betw
een groups are based on W
ald tests, degrees of freedom
=1. 
a Basic m
odel: Adjusted for age and sex. 
b Fully adjusted m
odel: Adjusted for age, sex, low
 educational level, apolipoprotein E-ε4 carrier status, and depressive sym
ptom
s in anxiety sym
ptom
s or depressive 
disorders in anxiety disorders. 
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Persons with anxiety disorders did not have an increased risk of dementia (Table 2). 
Consistent with these findings, no associations were found between subtypes of anxiety 
disorders and incident dementia. The corresponding hazard ratios (HR) were: generalized 
anxiety disorder (HR 0.46, 95%-confidence interval (CI): 0.15, 1.44, Wald-statistic 1.78, p-
value 0.18, degrees of freedom (df) 1), agoraphobia (HR 0.81, 95%-CI: 0.41, 1.58, Wald-
statistic 0.39, p-value 0.53, df 1), and  specific phobia (HR 1.20, 95%-CI: 0.50, 2.92, Wald-
statistic 0.17, p-value 0.68, df 1). Associations remained stable after additional 
adjustments. Unfortunately, small sample size prevented us to investigate the relation 
between panic disorder or social phobia and dementia. Results were similar for Alzheimer 
disease (Table 2) and after stratification of follow-up time (Table 3). 
Participants with anxiety disorders performed poorer at baseline on the LDST (difference 
in cognitive performance -1.21, 95%-CI -2.14; -0.29, t-statistic -2.57, df 2,347, p-value 0.01) 
and 15-WLT delayed recall (difference in cognitive performance -0.43, 95%-CI: -0.83, -0.04, 
t-statistic -2.18, df 2,347, p-value 0.03). These associations attenuated after adjusting for 
low educational level, APOE-ε4 carrier status, and depressive disorders (Table 4). We did 
not observe any associations between anxiety disorders and cognitive decline, except for 
the interference subtask of the Stroop test (fully adjusted difference in cognitive decline 
5.05; 95% CI: 0.98, 9.11, t-statistic 2.43, df 1,107). However, the p-value of this association 
(p-value 0.02) would not have survived correction for multiple testing for seven cognitive 
tests. Additional information on mean cognitive test scores and mean cognitive decline is 
provided as supplementary material (see supplementary information, which provides the 
mean test scores and mean cognitive decline of our study sample). 
 
 
 
 Table 3. Associations betw
een anxiety sym
ptom
s and incident dem
entia w
ith stratified follow
-up tim
e. 
 
Dem
entia 
 
Follow
-up ≤ 5.8 years 
n/N
=103/2,708 
Follow
-up > 5.8 years 
n/N
=255/2,243 
 
HR (95%
 CI) 
W
ald-statistic 
p-value 
HR (95%
 CI) 
W
ald-statistic 
p-value 
Basic m
odel a 
1.08 (0.63, 1.85) 
0.09 
0.77 
1.02 (0.70, 1.50) 
0.02 
0.90 
Fully adjusted m
odel b 
0.95 (0.52, 1.74) 
0.03 
0.87 
1.00 (0.64, 1.55) 
0.00 
0.99 
 
Alzheim
er’s disease 
 
Follow
-up ≤ 5.8 years 
n/N
=80/2,708 
Follow
-up > 5.8 years 
n/N
=211/2,243 
 
HR (95%
 CI) 
W
ald-statistic 
p-value 
HR (95%
 CI) 
W
ald-statistic 
p-value 
Basic m
odel a 
1.02 (0.55, 1.89) 
0.00 
0.95 
1.00 (0.66, 1.52) 
0.00 
0.99 
Fully adjusted m
odel b 
1.01 (0.51, 1.99) 
0.00 
0.99 
1.11 (0.69, 1.79) 
0.19 
0.66 
 Abbreviations: n=num
ber of cases, N
=num
ber of persons at risk, HR=hazard ratio, CI=confidence interval 
Com
parisons betw
een groups are based on W
ald tests, degrees of freedom
=1. 
a Basic m
odel: Adjusted for age and sex 
b Fully adjusted m
odel: Additionally adjusted for age, sex, low
 educational level, apolipoprotein E-ε4 carrier status, and depressive sym
ptom
s  
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 Table 4. Anxiety disorders and cognition. 
  
LDST 
(correct answ
ers) 
Stroop 1 
(seconds) 
Stroop 2 
(seconds) 
Stroop 3 
(seconds) 
VFT 
(anim
al nam
es) 
Im
m
ediate recall 
(correct answ
ers) 
Delayed recall 
(correct answ
ers) 
Cross-sectional (N
=2,351) 
Basic 
m
odel a 
-1.21 (-2.14, -0.29) 
0.41 (-0.20, 1.02) 
0.53 (-0.20, 1.25) 
1.76 (-1.31, 4.84) 
-0.73 (-1.47, 0.01) 
-0.83 (-1.67, 0.01) 
-0.43 (-0.83, -0.04) 
Fully 
adjusted 
m
odel b 
-0.66 (-1.57, 0.25) 
0.37 (-0.24, 0.99) 
0.43 (-0.30, 1.17) 
0.97 (-2.14, 4.09) 
-0.57 (-1.32, 0.17) 
-0.44 (-1.28, 0.40) 
-0.30 (-0.69, 0.10) 
Longitudinal (N
=1,115) 
Basic 
m
odel a 
-0.17 (-1.16, 0.83) 
0.48 (-0.29, 1.25) 
0.73 (-0.04, 1.50) 
4.74 (0.73, 8.76) 
0.26 (-0.76, 1.29) 
-0.28 (-1.47, 0.91) 
0.00 (-0.53, 0.53) 
Fully 
adjusted 
m
odel b 
-0.27 (-1.27, 0.74) 
0.45 (-0.34, 1.23) 
0.74 (-0.05, 1.52) 
5.05 (0.98, 9.11) 
0.33 (-0.71, 1.37) 
-0.36 (-1.56, 0.85) 
-0.05 (-0.59, 0.49) 
 Abbreviations: LDST Letter-Digit Substitution Task, Stroop 1 reading subtask of Stroop test, Stroop 2 color nam
ing subtask of Stroop test, Stroop 3 interference subtask of 
Stroop test, VFT Verbal Fluency Test, Im
m
ediate recall 15-W
ord Learning Test im
m
ediate recall, Delayed recall 15-W
ord Learning Test delayed recall, N
 num
ber of 
persons included in analysis  
Values are the differences in cognitive perform
ance (95%
 confidence interval) betw
een persons w
ith anxiety disorders and those w
ithout anxiety disorders. Com
parisons 
betw
een groups are based on t-tests. For cross-sectional analyses the values are differences in test scores. Degrees of freedom
 in the cross-sectional analyses: 2,347 in 
the basic m
odel and 2,344 in the fully adjusted m
odel. For longitudinal analyses, the values are differences in change of test scores betw
een the betw
een baseline and 
follow
-up 
assessm
ent 
of 
cognition. 
Degrees 
of 
freedom
 
in 
the 
longitudinal 
analyses: 
1,110 
in 
the 
basic 
m
odel 
and 
1,107 
in 
the 
fully 
adjusted 
m
odel. 
Higher test scores indicate better cognitive perform
ance in all tests, except for the Stroop test.  
a Basic m
odel: Adjusted for age, sex, and tim
e betw
een m
easurem
ents (if applicable). 
b Fully adjusted m
odel: Adjusted for age, sex, low
 educational level, apolipoprotein E -ε4 carrier status, depressive disorders, and tim
e betw
een m
easurem
ents (if 
applicable).
 
 
 
 
DISCUSSION  
In this study, we found that persons with anxiety symptoms or anxiety disorders did not 
have an increased risk of dementia. Persons with anxiety disorders performed poorer in 
several cognitive tests at baseline, but these associations attenuated after additional 
adjustments. Moreover, we did not find an association between anxiety disorders and 
cognitive decline.  
Strengths of this study are its prospective, population-based design and nearly complete 
dementia case finding. We thoroughly examined the association between anxiety and 
dementia using both anxiety symptoms and anxiety disorders. Furthermore, we assessed 
the association between anxiety disorders with cognitive performance cross-sectionally 
and cognitive decline longitudinally. This study also has limitations. Since we used two 
samples with different baselines, the subjects of sample I were younger than those of 
sample II, which may limit direct comparison of results. Moreover, there might be some 
survivor effect, because only the more healthy subjects survived up until the baseline of 
sample II. This effect was especially present when we examined the association between 
anxiety disorders and cognition, as a relatively small sample underwent the complete 
cognitive test battery. Unfortunately, we did not have information on duration of anxiety 
disorders and were not able to study the importance of duration of anxiety disorders on 
the risk of dementia. Furthermore, small sample size prevented us to examine the 
associations between some of the subtypes of anxiety disorders and dementia, which 
would be an interesting topic for further research. Finally, we studied a relatively 
homogeneous sample mainly of white, middle class persons. This limits generalizability of 
our results to other populations. 
The results of this study do not provide evidence for an association between anxiety 
symptoms or anxiety disorders and incident dementia. This suggests that anxiety is not a 
risk factor of dementia. Given that anxiety often occurs in dementia, there is a possibility 
that anxiety presents as a very early symptom, or prodrome, of dementia. However, when 
we stratified follow-up time in the association between anxiety symptoms and dementia, 
results remained similar. An explanation for our findings could be that anxiety occurs in a 
later phase of the dementia syndrome as a reaction to declining cognitive abilities.  
As for cognition, we only found marginal effects of anxiety disorders on cognitive 
performance at baseline, which attenuated after additional adjustments. For longitudinal 
cognitive performance, we found an association between anxiety disorders and decline in 
performance on the interference subtask of the Stroop test. This effect estimate was also 
relatively small (only one third of the SD of the study sample, please see supplementary 
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the risk of dementia. Furthermore, small sample size prevented us to examine the 
associations between some of the subtypes of anxiety disorders and dementia, which 
would be an interesting topic for further research. Finally, we studied a relatively 
homogeneous sample mainly of white, middle class persons. This limits generalizability of 
our results to other populations. 
The results of this study do not provide evidence for an association between anxiety 
symptoms or anxiety disorders and incident dementia. This suggests that anxiety is not a 
risk factor of dementia. Given that anxiety often occurs in dementia, there is a possibility 
that anxiety presents as a very early symptom, or prodrome, of dementia. However, when 
we stratified follow-up time in the association between anxiety symptoms and dementia, 
results remained similar. An explanation for our findings could be that anxiety occurs in a 
later phase of the dementia syndrome as a reaction to declining cognitive abilities.  
As for cognition, we only found marginal effects of anxiety disorders on cognitive 
performance at baseline, which attenuated after additional adjustments. For longitudinal 
cognitive performance, we found an association between anxiety disorders and decline in 
performance on the interference subtask of the Stroop test. This effect estimate was also 
relatively small (only one third of the SD of the study sample, please see supplementary 
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table I) and the association was not statistically significant after correction for multiple 
testing. However, it is possible that anxiety disorders are associated with cognitive decline 
on a specific domain, such as executive function.43-45 Further studies are needed to clarify 
this association. 
Several studies have reported on the association between anxiety and dementia or 
cognitive decline, but results have been inconclusive.8-23 There are various explanations 
for these inconsistent findings. Firstly, there was a large variation across studies regarding 
the assessment of anxiety; different questionnaires were used and anxiety was defined in 
various ways. Although we found similar results when we examined the association 
between anxiety symptoms and anxiety disorders with dementia, it is likely that some 
discrepancies between studies are due to methodological variability.  
Secondly, there was also variability in selection of study participants. Whereas our study 
sample was a community-dwelling population, several other studies selected participants 
with mild cognitive impairment (MCI). One study found that among subjects with MCI, 
anxiety was a predictor for conversion to dementia, while for cognitively healthy subjects 
it was not.17 Since MCI is an intermediate phase between normal aging and dementia, 
there is a possibility that anxiety appears as a presenting symptom in subjects, who are 
already on the verge of developing dementia. It is conceivable that persons become more 
anxious as they notice a decline in cognitive performance and everyday functioning. 
Support for this hypothesis comes from a study, which found that among MCI patients 
anxiety symptoms increased with increasing cognitive and functional impairment 
according to the Clinical Dementia Rating score (CDR).9 Another study found that MCI 
patients with anxiety had more abnormal cerebrospinal fluid (CSF) concentrations of 
amyloid-β42 and tau compared to MCI patients without anxiety symptoms.46 These results 
could imply a shared etiology between anxiety and dementia. Although there was no 
difference in cognitive performance at baseline between the two groups of MCI subjects, 
this was a cross-sectional study and unable to detect cognitive decline. Therefore, it is 
possible that the MCI subjects with abnormal CSF concentrations were on the verge of 
developing dementia and were anxious because they had been noticing a decline in their 
cognitive performance. 
Thirdly, when selecting participants from a memory clinic, there might be referral bias. For 
instance, persons with an anxious personality are often more worried and might be more 
prone to visit a memory clinic when they notice only the slightest memory complaint. 
These persons may be less likely to convert to dementia compared to non-anxious persons 
who might visit a memory clinic only after experiencing more advanced  memory 
 
 
 
 
complaints.14 This could explain why some studies found a protective effect of anxiety on 
the risk of dementia in participants with MCI.14,22 Finally, an important consideration when 
examining the effect of anxiety on dementia is the overlap with depression.7 One study, 
that assessed the association between several facets of neuroticism and dementia, 
observed an association between anxiety and increased risk of dementia.23 However, 
there was a moderate correlation with depression (correlation=0.68) for which models 
were not adjusted. Another large population-based study also found anxiety symptoms to 
be associated with dementia and Cognitive Impairment No Dementia (CIND) over a follow-
up of 17 years.8 However, models were only adjusted for psychological distress, and not 
specifically for depressive symptoms or depressive disorder. In both studies it therefore 
remained unclear to what extent the associations were independent of depression.  
In conclusion, our data do not offer evidence for an association between anxiety 
symptoms or anxiety disorders and dementia. Persons with anxiety disorders had a worse 
cognitive performance at baseline,  but these associations attenuated after additional 
adjustments. Moreover, anxiety disorders were not related to cognitive decline. These 
results suggest that anxiety is not a risk factor nor a prodrome of dementia in an elderly, 
community-dwelling population. 
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SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Cross-sectional test scores and longitudinal decline in test 
scores. 
Cognitive tests Cross-sectional test scores 
Longitudinal decline in test 
scores 
 N=2,351 N=1,115 
LDST, correct answers, mean (SD) 25.93 (6.70) -2.82 (4.41) 
Stroop 1, seconds, mean (SD) 19.00 (4.29) 0.49 (3.42) 
Stroop 2, seconds, mean (SD) 25.07 (5.09) 1.60 (3.43) 
Stroop 3, seconds, mean (SD) 59.41 (22.45) 7.00 (17.91) 
VFT, animal names, mean (SD) 20.60 (5.15) -1.46 (4.56) 
Immediate recall, correct answers, mean (SD) 20.29 (5.89) -1.15 (5.26) 
Delayed recall, correct answers, mean (SD) 6.43 (2.71) -0.55 (2.35) 
 
Abbreviations: N number of persons, LDST Letter-Digit Substitution Task, SD standard deviation, Stroop 1 reading 
subtask of Stroop test, Stroop 2 color naming subtask of Stroop test, Stroop 3 interference subtask of Stroop test, 
VFT Verbal Fluency Test, Immediate recall 15-Word Learning Test immediate recall, Delayed recall 15-Word 
Learning Test delayed recall.  
Data represent means (standard deviations). Decline in test scores was the change of test scores between the 
between baseline and follow-up assessment of cognition. Higher test scores indicate better cognitive 
performance in all tests, except for the Stroop test. 
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Figure 1. Dementia free survival of anxiety symptoms versus no anxiety symptoms. 
The figure shows Kaplan-Meier curve of dementia free survival of anxiety symptoms versus no anxiety 
symptoms. 
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Figure 2. Dementia free survival of anxiety disorders versus no anxiety disorders. 
The figure shows Kaplan-Meier curve of dementia free survival of anxiety disorders versus no anxiety disorders. 
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ABSTRACT 
Background: The association of anxiety and excess mortality in community-dwelling 
persons is debated.  
Methods: In the population-based Rotterdam Study, we followed 2,716 non-demented 
participants assessed for anxiety symptoms in 1993-1995 (Sample I), and 3,079 non-
demented participants assessed for anxiety disorders in 2002-2004 (Sample II), for all-
cause mortality till 2013. We assessed anxiety symptoms by the Hospital Anxiety and 
Depression Scale, and anxiety disorders by the composite International Diagnostic 
Interview. Anxiety disorders were diagnosed according to the DSM-IV TR criteria. Cox 
proportional hazards models were used to study associations between anxiety and 
mortality.  
Results: In sample I, 1,451 participants died during 19.3 years, whereas in sample II, 1,138 
participants died during 11.3 years. Anxiety symptoms but not disorders showed an 
increased risk of mortality (HR 1.10, 95% CI: 1.02, 1.14) which attenuated after adjusting 
for cardiovascular confounders (HR 1.04, 95% CI: 1.00, 1.10). Neither anxiety symptoms 
(HR 0.99, 95% CI: 0.92, 1.07), nor anxiety disorders (HR 0.99, 95% CI: 0.77, 1.29) were 
associated with an increased risk of mortality after additionally adjusting for depression. 
No gender-differences were observed.  
Conclusions: Anxiety is not independently associated with excess mortality in a 
community-dwelling elderly population; any observed association was largely explained by 
cardiovascular risk factors or depression. 
 
 
 
 
INTRODUCTION 
Anxiety and depression frequently co-occur with a high degree of overlap of both 
symptoms and diagnosed disorders.1 The association between depressive symptoms and 
diagnosed depressive disorders with increased risk of mortality is well documented, 
particularly in the elderly.2,3 However, literature on association between anxiety and 
excess mortality is relatively sparse and inconsistent. In a review in 2004, Dewey et al 
concluded that anxiety was not associated with a significant increase in mortality.4 Since 
then, some studies have shown an excess mortality in persons with anxiety,5-9 but others 
have failed to confirm this association.10,11 One study reported a lower risk of mortality in 
people with anxiety aged 80 or older only,12 while another observed a lower risk of 
mortality only in those with co-morbid depression.10,13 The HUNT study reported a U-
shaped association between anxiety and mortality during 6 years of follow-up.13  
Most of these studies studied anxiety symptoms as risk factor for mortality6,8,12-15, few 
tested diagnosed anxiety disorders,10,11,16,17 and only one study tested both symptoms and 
disorders in relation to mortality5 Although the significant overlap of symptoms between 
anxiety and depression makes it imperative to examine confounding or effect modification 
by depression, not all studies have considered depression as a covariate in their study of 
mortality. In addition, most studies followed participants for short periods only, and rarely 
did the follow-up exceed 10 years. In a short follow-up, the issue of reverse causality 
cannot be completely ruled out.  
There are a few studies reporting gender-specific associations between anxiety and 
mortality. Recent findings from the ESPRIT study suggested an association of anxiety and 
mortality only in women and that anxiety disorders, but not symptoms, were associated 
with  excess mortality.5 Previously, Denolet et al also reported an association in middle-
age Dutch women,6 but data from the LASA study suggested that anxiety disorders predict 
higher mortality only in men.17 These inconsistencies in results can partly be attributed to 
methodological variation including use of varying instruments for anxiety assessment, 
difference in sample sizes, age of participants, number of deaths, follow-up time, and 
controlling for confounders, particularly depression.  
This paper aims to investigate the association of anxiety with risk of all-cause mortality in 
a large population-based setting. Importantly, we investigated both anxiety symptoms and 
DSM-anxiety disorders and examined the difference in association of anxiety and mortality 
between men and women. 
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METHODS 
Setting 
This study was embedded in the Rotterdam Study, an ongoing population-based 
prospective study of the elderly that started in a suburb of Rotterdam (Ommoord) in 1990 
and studies the incidence and determinants of chronic diseases in late life.18 In 1990, 
7,983 participants were enrolled in the Rotterdam Study, and every 3 to 4 years, all 
participants undergo an extensive home interview and a physical examination at the 
research center. In addition, all participants are continuously monitored for the 
occurrence of all major events during follow-up by linkage of the study database with 
medical files from general practitioners. The second (1993-1995) and fourth (2002-2004) 
examination rounds of Rotterdam study formed the two baselines of this study. The 
Rotterdam Study is approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and 
Sports of the Netherlands. A written informed consent was obtained from all participants. 
Study Population 
We defined two samples in the Rotterdam Study; Sample I which was assessed for anxiety 
symptoms’, and sample II which was assessed  for DSM-anxiety disorders.  
Sample I-Anxiety symptoms 
In the second examination round of the Rotterdam Study in 1993-1995, we assessed 
anxiety symptoms in 2,977 individuals by the Hospital Anxiety and Depression Scale 
(HADS), which is a valid and reliable instrument for anxiety and depression assessment.19 
HADS incorporates two subscales with 7 items for assessment of each anxiety (HADS-A) 
and depression (HADS-D). Score ranges from 0-21 for each HADS-A and HADS-D; more 
score indicating higher anxiety. Anxiety scores were weighted by missing values only if 
missing values did not exceed 25%. For analysis, anxiety symptoms’ score was used as a 
standardized continuous variable. Z-scores were calculated as (anxiety scores-mean 
anxiety score) / standard deviation of anxiety score. After excluding 259 participants with 
prevalent dementia, and 2 individuals who were lost to follow-up, a total of 2,716 
individuals were available for analysis.  
Sample II-DSM-Anxiety disorders 
In the fourth examination round of the Rotterdam Study in 2002-2004, assessment of 
DSM-anxiety disorders was added to the data collection protocol in the Rotterdam Study. 
 
 
 
 
In 3,430 individuals, as part of the home interview, an adapted version of the Munich 
version of the Composite International Diagnostic Interview (M-CIDI)20 was administered 
to assess 1-year prevalence of the following anxiety disorders according to the DSM-IV-TR 
criteria.21 generalized anxiety disorder, panic disorder, agoraphobia, social phobia, and 
specific phobia as described previously by Hek et al.22 For analysis, we categorized 
participants into two groups on basis of being free of any anxiety disorder or having at 
least one of the above mentioned anxiety disorders. After excluding 348 participants with 
prevalent dementia, and 3 who were lost to follow-up, a total of 3,079 individuals were 
available for analysis. 
Of these 3,079, 1512 (49.1 %) participants were also included in the analyses of anxiety 
symptoms. Persons with prevalent dementia were excluded to ensure the reliability of 
anxiety assessments. Follow-up for mortality for both anxiety symptoms and anxiety 
disorders was complete till January 2013. 
Vital Status 
Information on vital status was obtained continuously via computerized linkages from 
municipal authorities in Rotterdam, notifications from the general practitioners (GPs) or 
nursing homes, or notification from family. Cardiovascular deaths were ascertained by a 
research physician by weighing all available clinical information in each potential 
cardiovascular death according to predefined criteria23 to adjudicate the underlying cause 
of death as being cardiovascular or non-cardiovascular. All cases were verified by a 
physician specializing in cardiology, whose judgment was considered final. 
Covariates 
Education level was assessed during the interview and people were classified into low 
(primary only or primary and unfinished secondary), intermediate (secondary or 
vocational) or high education (higher vocational or university). Participants were 
categorized into current, former and never-smokers based on interview. Diabetes mellitus 
type 2 was diagnosed as fasting blood glucose ≥ 126.13 mg/dl, or use of anti-diabetic 
medication evaluated by interview and pharmacy records.24 Myocardial Infarction (MI) 
was confirmed by interview, and hospital, GP and medical specialists’ records. Previous 
stroke was determined by reported events on interview and confirmed by medical 
records. In addition, participants were continuously monitored for all major events 
through automated linkage of study database with GP files. A low level of education,25 
smoking, prevalent diabetes, MI, and stroke are well established risk factors for mortality. 
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Cognition was assessed by the Mini-Mental State Examination (MMSE) at baseline26 as 
cognition might influence the response of participants to the anxiety assessment 
questionnaires. Living situation, which might influence the level of anxiety in participants, 
was defined as living independently or in a nursing home. Beer, wine, liquor and other 
strong alcohol consumption was converted to grams of alcohol by taking the average 
amount of ethanol in a drink. By summing the amount of ethanol in all four groups, total 
amount of alcohol in g/day was calculated.27 All covariates were measured at the time of 
anxiety symptoms’ assessment or anxiety disorders’ assessment. 
Depression as a covariate 
In the cohort with assessment of anxiety symptoms, depressive symptoms were assessed 
by the HADS-D questionnaire.19 In the cohort with assessment of DSM-anxiety disorders, 
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview,28 a semi-
standardized clinical interview was administered to assess the depressive disorders 
according to the DSM-IV-TR criteria.21  
Statistical analysis  
We used Cox proportional-hazards models to evaluate the relation of anxiety symptoms 
and DSM-anxiety disorders with risk of all-cause mortality. The underlying time-scale in 
these analyses was the follow-up time. For both samples, effect modification by gender 
was explored using stratification by gender and use of interaction terms. Anxiety 
symptoms’ score was used as a standardized continuous variable. A quadratic term for 
anxiety score was also included to explore a non-linear relation between anxiety symptom 
scores and mortality. Three models were fitted for each analysis. Model 1 was adjusted 
only for age and sex. Model 2 was  additionally adjusted for smoking, education, cognition 
status at baseline, living situation, alcohol intake, and prevalent diabetes, myocardial 
infarction, and stroke. Model 3 was additionally adjusted for depression. In the cohort 
with assessment of anxiety symptoms, we adjusted for depressive symptoms, and in the 
cohort with assessment of anxiety disorders, we adjusted for depressive disorders.  
We repeated our analyses using cardiovascular mortality as outcome instead of all-cause 
mortality. We also repeated our analyses excluding the positively-worded items from 
HADS-Anxiety scale in the anxiety symptom analyses, and excluding specific phobias from 
anxiety disorder definition, in the anxiety disorder analyses. As studies with short follow-
up8,14 have reported that anxiety is associated with excess mortality, we also investigated 
the association of anxiety symptoms and disorders with risk of mortality in shorter follow-
up periods of 3 and 5 years.  
 
 
 
 
Results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). Data were 
analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, USA).  
 
RESULTS 
Baseline characteristics of all persons in the study are described in Table 1. In sample I 
with assessment of anxiety symptoms, 1,451 participants died during 19.3 years (mean 
13.2 years, SD 5.5). Pearson correlation coefficient for anxiety and depression scores as 
assessed by HADS was 0.66 and did not differ between men and women.  
Anxiety symptoms showed an increased risk of mortality in models adjusted for age and 
gender, HR 1.10 (95% CI: 1.02, 1.14, Score-test 2.91, p-value 0.004) which attenuated to 
marginal significance after adjusting for education, cardiovascular risk factors, baseline 
cognition and prevalent disease, HR 1.04 (95% CI: 1.00, 1.10, Score-test 1.54, p-value 
0.12), and further attenuated to non-significant, after additional adjustment for 
depressive symptoms, HR 0.99 (95% CI: 0.92, 1.07, Score-test -0.25, p-value 0.80) (Table 
2). Men but not women with anxiety, had a higher risk of mortality in multivariable model, 
however the association became non-significant after additionally adjusting for depressive 
symptoms. 
 
Table 1. Baseline characteristics of cohorts with anxiety symptoms’ and anxiety 
disorders’ assessments followed till 2013 for mortality. 
Characteristics  Anxiety symptoms, N=2,716 
(1993-1995) 
Anxiety disorders, N=3,079 
(2002-2004) 
Women  1,502 (55.3) 1,820 (59.1) 
Age, years  68.7 (8.5) 75.5 (6.2) 
Body mass index, kg/m2  26.3 (3.6) 27.5 (4.1) 
Education     
Low  799 (29.8) 856 (28.1) 
Intermediate to high  1,882 (70.2) 2,189 (71.9) 
Smoking     
Never  885 (32.6) 929 (30.2) 
Former  1,245 (45.8) 1,707 (55.4) 
Current  586 (21.6) 443 (14.4) 
Hypertension  1,212 (44.6) 2,006 (65.1) 
Diabetes mellitus 2  136 (5.1) 360 (11.7) 
Myocardial infarction  188 (7.0) 304 (9.9) 
Stroke  79 (3.0) 160 (5.2) 
 
Values are means (standard deviation), or counts (percentage).  
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Table 2. Anxiety symptoms and risk of mortality from 1993-2013. 
Anxiety score (HADS-A) Deaths/N Risk of Mortality, hazard Ratios  
(95 % confidence intervals) 
  Model 1a Model 2b Model 3c 
All participants     
Anxiety symptoms, per SD 1,451/2,716 1.10 (1.02, 1.14) 1.04 (1.00, 1.10) 0.99 (0.92, 1.07) 
Men     
Anxiety symptoms, per SD 702/1,214 1.13 (1.04, 1.22) 1.09 (1.00, 1.19) 1.03 (0.91, 1.16) 
Women     
Anxiety symptoms, per SD 749/1,502 1.04 (0.98, 1.11) 1.01 (0.94, 1.09) 0.97 (0.88, 1.06) 
 
Abbreviations: HADS-A Hospital Anxiety and Depression Scale-Anxiety; SD standard deviation. 
a Model 1: adjusted for age and sex (if applicable). 
b Model 2: additionally adjusted for education, smoking, living situation, cognition at baseline, alcohol intake, and 
prevalent diabetes mellitus 2, myocardial infarction and stroke. 
c Model 3: additionally adjusted for depressive symptoms.  
 
We did not observe any evidence of effect modification by gender through testing 
interaction between anxiety symptoms and gender (P-value=0.23). There was no 
indication of a curvilinear relation between anxiety and mortality (P-value=0.29).  
In sample II assessed for anxiety disorders,1,138 participants died during 11.3 years (mean 
7.4 years, SD 2.5). Anxiety disorders were not associated with the risk of mortality, HR 
0.99 (95% CI: 0.77-1.29, Score-test -0.03, p-value 0.98) in the fully adjusted model (Table 
3). Stratification by gender also showed no association between anxiety disorders and risk 
of mortality. 
Analyses of anxiety symptoms and anxiety disorders in relation to cardiovascular 
mortality, showed similar results as all-cause mortality (Supplement table 1). Repeating 
the analyses with anxiety symptoms after excluding the positively-worded items from 
HADS-A, results remained unchanged, HR 1.00 (95% CI: 0.98, 1.03, Score-test 0.37, p-value 
0.71) in fully adjusted model. Results also remained unchanged when we repeated the 
anxiety disorder analyses after excluding specific phobias from the anxiety definition, HR 
1.04 (95% CI: 0.79, 1.37, Score-test 0.31, p-value 0.76) in fully adjusted model. There was 
some evidence of effect of anxiety symptoms on short-term mortality (Supplement table 
2). Men but not women with anxiety symptoms at baseline showed a significantly higher 
risk of mortality only during first three years of follow-up in fully adjusted models. In the 
analyses with anxiety disorders and risk of mortality during short follow-up, again men 
with anxiety disorders showed a higher risk of mortality than controls during 3 years only, 
however non-significant. 
 
 
 
 
Table 3. DSM-Anxiety disorders and risk of mortality from 2002-2013. 
Anxiety disorders Deaths/N Risk of Mortality, hazard Ratios (95 % confidence intervals) 
  Model 1a Model 2b Model 3c 
All participants     
Anxiety disorders 1,138/3,079 0.98 (0.78, 1.23) 1.03 (0.81, 1.33) 0.99 (0.77, 1.29) 
Men     
Anxiety disorders 548/1,259 1.23 (0.81, 1.87) 1.11 (0.69, 1.79) 1.09 (0.68, 1.77) 
Women     
Anxiety disorders 590/1,820 0.91 (0.70, 1.18) 0.98 (0.73, 1.32) 0.96 (0.70, 1.30) 
 
a Model 1: adjusted for age and sex (if applicable). 
b Model 2: additionally adjusted for education, smoking, living situation, cognition at baseline, alcohol intake, and 
prevalent diabetes mellitus 2, myocardial infarction and stroke. 
c Model 3: additionally adjusted for depressive disorders. 
DISCUSSION  
In this population-based study with a long follow-up, we examined the association of 
anxiety symptoms and DSM-anxiety disorders with risk of mortality. Anxiety disorders 
were not associated with excess mortality. Anxiety symptoms showed a marginally 
increased risk of mortality which disappeared after adjustment for cardiovascular risk 
factors, co-morbidity, and depressive symptoms. 
Strengths of the study include the population-based design, large sample size, assessment 
of both anxiety symptoms and anxiety disorders, and a long follow-up. A methodological 
consideration is that the anxiety symptoms and anxiety disorders were not assessed at the 
same time, as anxiety disorder assessment was added in the fourth examination round in 
the Rotterdam Study. In addition, he possibility of some survivor bias, with a selective 
survival of individuals at the fourth examination round, cannot be ruled out.  
Anxiety symptoms were associated with a marginally increased risk of mortality 
particularly in men. However, this association was largely explained by the presence of 
cardiovascular risk factors, prevalent stroke, MI, and diabetes, and comorbid depressive 
symptoms. This finding is in line with recent findings from the ESPRIT Study. However, this 
study also reported that anxiety disorders but not symptoms are related to excess 
mortality, only in women even after adjustment for depressive symptomatology.5 It is 
plausible that persons with chronic disease can develop anxiety or have more severe 
anxiety. In our study, many individuals who were depressed and therefore had a high risk 
of mortality, also exhibited symptoms of anxiety; correlation between HADS sub-scales for 
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c Model 3: additionally adjusted for depressive symptoms.  
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Analyses of anxiety symptoms and anxiety disorders in relation to cardiovascular 
mortality, showed similar results as all-cause mortality (Supplement table 1). Repeating 
the analyses with anxiety symptoms after excluding the positively-worded items from 
HADS-A, results remained unchanged, HR 1.00 (95% CI: 0.98, 1.03, Score-test 0.37, p-value 
0.71) in fully adjusted model. Results also remained unchanged when we repeated the 
anxiety disorder analyses after excluding specific phobias from the anxiety definition, HR 
1.04 (95% CI: 0.79, 1.37, Score-test 0.31, p-value 0.76) in fully adjusted model. There was 
some evidence of effect of anxiety symptoms on short-term mortality (Supplement table 
2). Men but not women with anxiety symptoms at baseline showed a significantly higher 
risk of mortality only during first three years of follow-up in fully adjusted models. In the 
analyses with anxiety disorders and risk of mortality during short follow-up, again men 
with anxiety disorders showed a higher risk of mortality than controls during 3 years only, 
however non-significant. 
 
 
 
 
Table 3. DSM-Anxiety disorders and risk of mortality from 2002-2013. 
Anxiety disorders Deaths/N Risk of Mortality, hazard Ratios (95 % confidence intervals) 
  Model 1a Model 2b Model 3c 
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Anxiety disorders 1,138/3,079 0.98 (0.78, 1.23) 1.03 (0.81, 1.33) 0.99 (0.77, 1.29) 
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b Model 2: additionally adjusted for education, smoking, living situation, cognition at baseline, alcohol intake, and 
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c Model 3: additionally adjusted for depressive disorders. 
DISCUSSION  
In this population-based study with a long follow-up, we examined the association of 
anxiety symptoms and DSM-anxiety disorders with risk of mortality. Anxiety disorders 
were not associated with excess mortality. Anxiety symptoms showed a marginally 
increased risk of mortality which disappeared after adjustment for cardiovascular risk 
factors, co-morbidity, and depressive symptoms. 
Strengths of the study include the population-based design, large sample size, assessment 
of both anxiety symptoms and anxiety disorders, and a long follow-up. A methodological 
consideration is that the anxiety symptoms and anxiety disorders were not assessed at the 
same time, as anxiety disorder assessment was added in the fourth examination round in 
the Rotterdam Study. In addition, he possibility of some survivor bias, with a selective 
survival of individuals at the fourth examination round, cannot be ruled out.  
Anxiety symptoms were associated with a marginally increased risk of mortality 
particularly in men. However, this association was largely explained by the presence of 
cardiovascular risk factors, prevalent stroke, MI, and diabetes, and comorbid depressive 
symptoms. This finding is in line with recent findings from the ESPRIT Study. However, this 
study also reported that anxiety disorders but not symptoms are related to excess 
mortality, only in women even after adjustment for depressive symptomatology.5 It is 
plausible that persons with chronic disease can develop anxiety or have more severe 
anxiety. In our study, many individuals who were depressed and therefore had a high risk 
of mortality, also exhibited symptoms of anxiety; correlation between HADS sub-scales for 
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anxiety and depression was 0.66. Given the considerable comorbidity between anxiety 
and depression, a  substantial correlation  is expected on the symptom level. Of the 362 
(13.3 %) participants who had anxiety symptoms, and the 238 (8.8 %) who had depressive 
symptoms, 151 (5.6%) participants had comorbid depression and anxiety, applying the 
accepted cut-offs.19 This suggests that the items on the anxiety sub-scale inherently tap 
depressive symptoms. In addition, as the symptoms of anxiety and depression overlap, it 
is difficult to distinguish between the two mood disorders by questionnaires. Moreover, 
such a substantial correlation may not only reflect the symptoms shared between anxiety 
and depression, but also point towards a common disorder. Nevertheless, others may 
argue that, given this overlap of symptomatology, there is a possibility of overcorrection 
of the actual association between anxiety and mortality, when we additionally adjusted 
for depressive symptoms. However, after adjusting for cardiovascular risk factors and  
prevalent disease in the second model, the association was left only marginally significant.  
When we investigated the association between anxiety symptoms and mortality during 
shorter follow-up of 3 years, a significantly increased risk was observed in men. This may 
indicate reverse causality in our study in a short follow-up. In this case, the underlying 
cause of death was not anxiety; rather anxiety was possibly secondary to existent 
morbidities which caused mortality in a short follow-up. 
Our analyses of DSM-anxiety disorders and risk of mortality are very consistent with those 
of anxiety symptoms and mortality, although the overlap between anxiety disorders and 
depressive disorders was small. Of the 252 (8.2 %) participants with anxiety disorders and 
81 (2.6 %) with depressive disorders, only 36 (1.2 %) had both anxiety and depression. This 
low co-morbidity reflects the fact that interviews of depressive disorders and those to 
diagnose anxiety disorders were conducted with different instruments, SCAN and CIDI and 
on different days, but less than one month apart. We did not find an association in 
univariable or multivariable analyses, and no difference between men and women. Similar 
results have been previously reported.10,11  
Conclusively, anxiety symptoms or anxiety disorders were not associated with excess 
mortality. Observed associations between anxiety symptoms and increased mortality 
were largely explained by the presence of cardiovascular risk factors, prevalent disease, 
and comorbid depression. This reflects the substantial overlap in symptoms between 
anxiety and depression. In addition, the observed association between anxiety symptoms 
and short-term mortality was probably explained by existing morbidity. 
 
 
 
SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Anxiety and risk of cardiovascular mortality. 
Anxiety measure Deaths/N Risk of mortality, hazard ratios 
(95% confidence intervals) 
  Model 1a Model 2b Model 3c 
Anxiety symptoms, per SD 458/2,716 1.13 (1.03, 1.23) 1.07 (0.98, 1.18) 1.01 (0.88, 1.14) 
DSM-Anxiety disorders 313/3,079 0.83 (0.52, 1.33) 0.81 (0.47, 1.40) 0.76 (0.44, 1.34) 
 
Abbreviation: SD standard deviation. 
Mortality follow-up complete until 2013. 
a Model 1: adjusted for age and sex (if applicable). 
b Model 2: additionally adjusted for education, smoking, living situation, cognition at baseline, alcohol intake, and 
prevalent diabetes mellitus 2, myocardial infarction and stroke. 
c Model 3: additionally adjusted for depression (adjusted for depressive symptoms in cohort assessed for anxiety 
symptoms, and adjusted for depressive disorders in cohort assessed for anxiety disorders). 
 
Supplement Table 2. Anxiety and risk of mortality in short follow-up of 3 years. 
Anxiety score (HADS-A) Deaths/N Risk of mortality, hazard ratios (95% confidence intervals) 
  Model 1a Model 2b Model 3c 
All participants     
Anxiety symptoms, per SD 181/2,716 1.21 (1.06, 1.38) 1.16 (0.99, 1.36) 1.12 (0.90, 1.39) 
Men     
Anxiety symptoms, per SD 92/1,214 1.55 (1.31, 1.85) 1.61 (1.32, 1.96) 1.77 (1.28, 2.44) 
Women     
Anxiety symptoms, per SD 89/1,502 0.96 (0.79, 1.16) 0.83 (0.65, 1.07) 0.79 (0.57, 1.09) 
DSM-Anxiety disorders Deaths/N Risk of mortality, hazard ratios (95% confidence intervals) 
  Model 1a Model 2b Model 3c 
All participants     
Anxiety disorders 259/3,079 1.01 (0.61, 1.66) 0.98 (0.53, 1.81) 0.80 (0.42, 1.52) 
Men     
Anxiety disorders 148/1,259 2.26 (1.22, 4.17) 1.57 (0.68, 3.62) 1.37 (0.59, 3.21) 
Women     
Anxiety disorders 111/1,820 0.49 (0.21, 1.11) 0.67 (0.27, 1.67) 0.54 (0.21, 1.41) 
 
Abbreviations: HADS-A Hospital Anxiety and Depression Scale-Anxiety; SD standard deviation. 
a Model 1: adjusted for age and sex (if applicable). 
b Model 2: additionally adjusted for education, smoking, living situation, cognition at baseline, alcohol intake, and 
prevalent diabetes mellitus 2, myocardial infarction and stroke. 
c Model 3: additionally adjusted for depression (adjusted for depressive symptoms in cohort assessed for anxiety 
symptoms, and adjusted for depressive disorders in cohort assessed for anxiety disorders). 
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ABSTRACT 
Background: Many people with Mild Cognitive Impairment (MCI), a transitional stage 
between healthy aging and dementia, suffer from concomitant depression or anxiety 
disorders. Whether MCI also increases the risk of future depression or anxiety is not 
known. 
Methods: MCI was assessed in 4,198 participants (mean age 72 years; women 58%) 
between 2002 and 2005, in the population-based Rotterdam Study. Criteria for MCI 
assessment included presence of subjective memory complaints and objective cognitive 
impairment, and absence of dementia. Depressive and anxiety disorders were assessed at 
baseline, and reassessed between 2009 and 2012, using Schedules for Clinical Assessment 
of Neuropsychiatry interviews, and the Composite International Diagnostic Interview 
respectively. Associations of MCI with prevalent and incident DSM depressive and anxiety 
disorders were assessed by multiple logistic regression.  
Results: Of the 4,168 participants eligible for analyses, 413 had MCI at baseline, of which 
22 had comorbid depression, and 46 had comorbid anxiety. Participants with MCI were 
more likely to have depressive disorders, OR 1.94 (95% CI:1.20,3.15) as well as anxiety 
disorders, OR 1.70 (95% CI:1.19,2.42). During the study period, 6 non-depressed/anxious 
participants with MCI at baseline developed incident depression, and 11 developed 
incident anxiety. Persons with MCI had a higher risk of developing both depressive, OR 
3.13 (95% CI:1.26,7.77) and anxiety disorders, OR 2.59 (95% CI:1.31,5.12). 
Conclusions: MCI is not only a risk factor for dementia but also a harbinger of depressive 
and anxiety disorders. Our results suggest that common pathological pathways underlie 
cognitive and psychiatric outcomes, thus opening avenues for joint etiological research. 
  
 
 
 
INTRODUCTION  
Dementia poses a high burden on society and health care, both in terms of suffering for 
patients and care-givers as well as financial costs.1 Since brain pathology is thought to 
accumulate for years before the onset of dementia, much research has been dedicated to 
study this preclinical phase of dementia. In this context, mild cognitive impairment (MCI) 
has been conceptualized as a transitional stage between normal cognition and dementia, 
and serves as a clinical construct in which meaningful interventions are possible.2 
Another important manifestation thought to be a part of dementia prodrome is the 
occurrence of affective disorders, namely depression and anxiety.3 Indeed, there is ample 
evidence suggesting that depression in late life is associated with a 2-fold increased risk of 
dementia.4,5 Extending these findings, some recent studies have also shown that 
depression is a risk factor for MCI.6-8 These studies imply that depression precedes MCI in 
the chronological order of events. However, given that both MCI and affective symptoms 
are considered to manifest during the preclinical stage of dementia, it is also not unlikely 
that MCI precedes depression and anxiety. However, the association of MCI in relation to 
risk of depression or anxiety has never been investigated. Therefore, we investigated the 
cross-sectional and longitudinal associations of MCI with depression and anxiety in a 
population-based cohort of older adults. 
 
METHODS 
Setting  
This study was part of the Rotterdam Study, a population-based cohort ongoing since 
1990 in Ommoord, a district of Rotterdam.9 In 1990, 7,983 participants aged 55 years or 
older were enrolled. In 2000, the original cohort was expanded by additionally enrolling 
3,011 participants who had become 55 years of age or moved to the district since the start 
of the study. Follow-up examinations including home interviews and physical exams at a 
research center take place every 3 to 4 years. The Rotterdam Study is approved by the 
Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and 
Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO (Population 
Studies Act: Rotterdam Study)”. A written informed consent was obtained from all 
participants. 
 
Chapter 2.6
114
MCI and risk of depression or anxiety
115
 
 
 
ABSTRACT 
Background: Many people with Mild Cognitive Impairment (MCI), a transitional stage 
between healthy aging and dementia, suffer from concomitant depression or anxiety 
disorders. Whether MCI also increases the risk of future depression or anxiety is not 
known. 
Methods: MCI was assessed in 4,198 participants (mean age 72 years; women 58%) 
between 2002 and 2005, in the population-based Rotterdam Study. Criteria for MCI 
assessment included presence of subjective memory complaints and objective cognitive 
impairment, and absence of dementia. Depressive and anxiety disorders were assessed at 
baseline, and reassessed between 2009 and 2012, using Schedules for Clinical Assessment 
of Neuropsychiatry interviews, and the Composite International Diagnostic Interview 
respectively. Associations of MCI with prevalent and incident DSM depressive and anxiety 
disorders were assessed by multiple logistic regression.  
Results: Of the 4,168 participants eligible for analyses, 413 had MCI at baseline, of which 
22 had comorbid depression, and 46 had comorbid anxiety. Participants with MCI were 
more likely to have depressive disorders, OR 1.94 (95% CI:1.20,3.15) as well as anxiety 
disorders, OR 1.70 (95% CI:1.19,2.42). During the study period, 6 non-depressed/anxious 
participants with MCI at baseline developed incident depression, and 11 developed 
incident anxiety. Persons with MCI had a higher risk of developing both depressive, OR 
3.13 (95% CI:1.26,7.77) and anxiety disorders, OR 2.59 (95% CI:1.31,5.12). 
Conclusions: MCI is not only a risk factor for dementia but also a harbinger of depressive 
and anxiety disorders. Our results suggest that common pathological pathways underlie 
cognitive and psychiatric outcomes, thus opening avenues for joint etiological research. 
  
 
 
 
INTRODUCTION  
Dementia poses a high burden on society and health care, both in terms of suffering for 
patients and care-givers as well as financial costs.1 Since brain pathology is thought to 
accumulate for years before the onset of dementia, much research has been dedicated to 
study this preclinical phase of dementia. In this context, mild cognitive impairment (MCI) 
has been conceptualized as a transitional stage between normal cognition and dementia, 
and serves as a clinical construct in which meaningful interventions are possible.2 
Another important manifestation thought to be a part of dementia prodrome is the 
occurrence of affective disorders, namely depression and anxiety.3 Indeed, there is ample 
evidence suggesting that depression in late life is associated with a 2-fold increased risk of 
dementia.4,5 Extending these findings, some recent studies have also shown that 
depression is a risk factor for MCI.6-8 These studies imply that depression precedes MCI in 
the chronological order of events. However, given that both MCI and affective symptoms 
are considered to manifest during the preclinical stage of dementia, it is also not unlikely 
that MCI precedes depression and anxiety. However, the association of MCI in relation to 
risk of depression or anxiety has never been investigated. Therefore, we investigated the 
cross-sectional and longitudinal associations of MCI with depression and anxiety in a 
population-based cohort of older adults. 
 
METHODS 
Setting  
This study was part of the Rotterdam Study, a population-based cohort ongoing since 
1990 in Ommoord, a district of Rotterdam.9 In 1990, 7,983 participants aged 55 years or 
older were enrolled. In 2000, the original cohort was expanded by additionally enrolling 
3,011 participants who had become 55 years of age or moved to the district since the start 
of the study. Follow-up examinations including home interviews and physical exams at a 
research center take place every 3 to 4 years. The Rotterdam Study is approved by the 
Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and 
Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO (Population 
Studies Act: Rotterdam Study)”. A written informed consent was obtained from all 
participants. 
 
Chapter 2.6
116
MCI and risk of depression or anxiety
117
 
 
 
Study population 
Between 2002 and 2005, the original cohort and the expanded cohort were re-examined, 
and an extensive neuropsychological test battery was implemented. Given that extensive 
neuropsychological testing is required to determine MCI, 2002-2005 was set as baseline 
for MCI screening in our study. Of the 6,061 study participants who underwent 
examinations between 2002 and 2005, 192 participants were excluded because they were 
demented, 67 because they were not sufficiently screened for dementia, and another 250 
participants because they did not answer the questions regarding subjective cognitive 
complaints. An additional 1,354 participants were excluded because they missed one or 
more cognitive test scores or had unreliable test scores. Consequently, MCI was validly 
assessed in 4,198 participants.  
Between 2002 and 2005, depression and anxiety disorders were assessed in the 
Rotterdam Study. Of the 4,198 participants with available MCI data, depression data were 
available for 4,168 participants, while anxiety data were available for 4,060 participants. 
At baseline, 125 participants fulfilled the criteria for depressive disorders, while 330 
participants met the criteria for anxiety disorders.  
Between 2009 and 2012, depressive disorders were reassessed in 3,117 participants of the 
3,370 participants attending the examination round (798 participants died during follow-
up, 4,168-798=3,370). After excluding 125 depression cases at baseline, and 25 persons 
who were diagnosed of incident dementia during the study period, depressive disorders 
data were available for 2,967 persons for the analyses of MCI and incident depressive 
disorders (response rate= 92%).  
Between 2009-2012, anxiety disorders were reassessed in 2,714 participants of the 3,293 
participants attending the examination round (767 participants died during follow-up, 
4,060-767=3,239). We excluded 330 anxiety cases at baseline, and 9 persons who were 
diagnosed with incident dementia during the study period. Therefore, 2,375 participants 
were available for the analyses of MCI and incident anxiety disorders (response 
rate=82%.).  
Assessment of MCI 
MCI was assessed using the following criteria: 1) presence of subjective memory 
complaints, 2) presence of objective cognitive impairment, and 3) absence of dementia.10 
 
 
 
Subjective memory complaints were assessed by interview, which included three 
questions on memory (difficulty remembering, forgetting what one had planned to, and 
difficulty finding words), and three questions on everyday functioning (difficulty managing 
financing, problems using a telephone, and difficulty getting dressed). Persons answering 
“yes” to at least one of these questions were scored positive on subjective memory 
complaints. Objective cognitive impairment was assessed using a cognitive test battery 
that comprised Letter-digit substitution task, Stroop test, Verbal fluency test, and 15-Word 
verbal learning test based on Rey’s recall of words. To obtain more robust measures, we 
calculated different compound scores for various cognitive domains including memory 
function, information processing speed, and executive function. Briefly, compound score 
for memory was calculated as the mean Z-score for the immediate and delayed recall of 
the 15-Word verbal learning test. For information processing speed, average Z-scores for 
the Stroop reading and Stroop colour-naming sub tasks and the Letter-digit substitution 
task were used. For calculating compound score of executive function, Z-scores of Stroop 
interference subtask, the Letter-digit substitution task, and the verbal fluency task were 
used. Persons were classified as cognitively impaired if they scored below 1.5 standard 
deviations of the age and education adjusted means of the study population.  
Subsequently, we sub-classified MCI into amnestic and non-amnestic MCI. Amnestic MCI 
was defined as persons with MCI who had an impaired test score on memory irrespective 
of other domains. Non-amnestic MCI was defined as persons with MCI having normal 
memory function, but an impaired test score on executive function or information 
processing speed.  
Assessment of depressive disorders 
Depressive disorders were diagnosed during home interview.11 Participants were screened 
for symptoms of depression with the Center for Epidemiological Studies Depression (CES-
D) scale. Screen-positive persons (CES-D-score≥16) were invited for a semi-structured 
clinical interview with the Schedules for Clinical Assessment of Neuropsychiatry (SCAN).12 
This interview was conducted by a trained clinician at the participant's home one week to 
two months (median time interval: three weeks) after the screening procedure and the 
anxiety interview done simultaneously. We were able to use the SCAN in this population-
based setting, because depression can be screened for with high sensitivity.13 With a 
computerized DSM-IV based diagnostic algorithm, major depression, minor depression 
and dysthymia during the past month were diagnosed.  
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Assessment of anxiety disorders 
During the home interview, an adapted version of the Munich version of the Composite 
International Diagnostic Interview (M-CIDI) 14 was administered to all participants, to 
assess 1-year prevalence of the following anxiety disorders according to the DSM-IV-TR 
criteria:15 generalized anxiety disorder, panic disorder, agoraphobia, social phobia, and 
specific phobia as described previously.16 Participants were classified as positive for 
anxiety disorders if they had at least one of the above mentioned anxiety disorders. The 
M-CIDI was specifically designed to obtain DSM-IV diagnoses of mental disorders, and the 
test–retest reliability for the anxiety disorders is satisfactory.14  
Other assessments 
Assessment of dementia for exclusion during the study period  
Participants were first screened for dementia at baseline and follow-up examinations 
using a three-step protocol.17 Screening was done using the Mini Mental State 
Examination (MMSE)18 and the Geriatric Mental Schedule (GMS) organic level.19 Second, 
screen-positives (MMSE<26 or GMS organic level>0) subsequently underwent an 
examination and informant interview with the Cambridge Examination for Mental 
Disorders in the Elderly (CAMDEX).20 Participants who were suspected of having dementia, 
if necessary, had further neuropsychological testing. Additionally, the total cohort was 
continuously monitored for dementia through computerized linkage between the study 
database and digitized medical records from general practitioners and the Regional 
Institute for Outpatient Mental Health Care. Third, a consensus panel led by a neurologist, 
decided on the final diagnosis in accordance with the standards using the DSM-III-R 
criteria for dementia and the NINCDS-ADRDA for Alzheimer’s disease.21  
Covariates 
Age, sex, educational level, body mass index, smoking status, total serum cholesterol, 
high-density lipoprotein (HDL) cholesterol, prevalent disease including hypertension and 
diabetes mellitus type 2, and cardiovascular events including myocardial infarction and 
stroke were considered potential confounders for the association of MCI with depression 
and anxiety. Education, vascular factors and cardiovascular events are implicated as risk 
factors for MCI and are also associated with depression and anxiety.  
Education was assessed during the home interview and participants were classified into 
three groups: low educational level (primary or unfinished secondary, or lower vocational 
 
 
 
training), intermediate (secondary, or intermediate or higher vocational training), and high 
(completed college or university). Body mass index was calculated as weight in 
kilograms/height in meters squared. We defined smokers as never, former or current. 
Serum total cholesterol and HDL cholesterol (mmol/L) were measured by an automated 
enzymatic procedure (Boehringer Mannheim System). Hypertension was defined as a 
blood pressure ≥140/90mmHg or use of blood pressure lowering medication, prescribed 
for the indication of hypertension.22 Diabetes mellitus was defined as a fasting serum 
glucose level ≥7.0 mmol/L, non-fasting serum glucose level ≥11.1 mmol/L, or use of anti-
diabetic medication.23 At study entry, history of myocardial infarction and stroke was 
assessed using home interviews and confirmed by reviewing medical records.24,25 
Statistical Analyses 
We first assessed the cross-sectional associations of MCI with depressive disorders and 
anxiety disorders using logistic regression. In secondary analyses, we also assessed the 
association of subtypes of MCI (amnestic and non-amnestic) with depressive and anxiety 
disorders. 
Subsequently, we examined the longitudinal associations of MCI with depressive and 
anxiety disorders using logistic regression. For these analyses, cases of depression at 
baseline were excluded for the depression analyses, and similarly, cases of anxiety at 
baseline were excluded before performing the anxiety analyses. We also excluded persons 
with incident dementia diagnosed during the study period. Further, we examined the 
longitudinal associations of subtypes of MCI with incident depressive and anxiety 
disorders.  
For all analyses, two models were fitted. In both cross-sectional and longitudinal analyses, 
model 1 was adjusted for age and sex only. Model 2 was additionally adjusted for 
educational level, body mass index, smoking status, serum total cholesterol, HDL 
cholesterol, hypertension, diabetes mellitus 2, myocardial infarction, stroke, and cohort. 
The longitudinal analyses were additionally adjusted for time interval between the two 
assessments of depression and anxiety.  
The following covariates had missing values, which were dealt with using multiple 
imputations and chained equations (ICE command Stata): education level (1.5%), BMI 
(1.5%), total cholesterol (1.7%), HDL cholesterol (1.7%), and myocardial infarction (0.6%). 
For all tests, a significance level of 0.05 was used. All analyses were performed using Stata 
Software Version 13 (Stata Corp, College Station, TX, USA). 
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Assessment of anxiety disorders 
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For all tests, a significance level of 0.05 was used. All analyses were performed using Stata 
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RESULTS 
Characteristics of participants included in the analyses of depressive disorders are 
summarized in Table 1. Numbers for the analyses of anxiety disorders were similar but 
slightly less, as shown in the Supplement Table. 
 
Table 1. Baseline characteristics of the study population included in the analyses of MCI 
and depressive disorders. 
Characteristics Cross-sectional analysis of 
depressive disorders, N=4,168 
Longitudinal analysis of 
depressive disorders, N=2,796 
 No MCI n=3,755 
MCI 
n=413 
No MCI 
n=2,755  
MCI 
n=212 
Age, years 71.4 (7.1) 73.3 (7.5) 70.0 (6.4) 70.0 (6.2) 
Women 2,183 (58.1) 215 (52.1) 1,608 (58.4) 108 (50.9) 
Body mass index, kg/m2 27.6 (4.1) 27.7 (4.1) 27.7 (4.0) 27.7 (4.0) 
Educational level 
Low  341 (9.2) 71 (17.3) 197 (7.3) 30 (14.3) 
Intermediate 2,826 (76.5) 284 (69.3) 2,100 (77.5) 147 (70.0) 
High 528 (14.3) 55 (13.4) 412 (15.2) 33 (15.7) 
Smoking 
Never 1120 (29.8) 111 (26.9) 838 (30.4) 58 (27.4) 
Former 2,067 (55.0) 230 (55.7) 1,536 (55.7) 126 (59.4) 
Current 568 (15.1) 72 (17.4) 381 (13.8) 28 (13.2) 
Total, cholesterol, mmol/L 5.6 (1.0) 5.4 (0.9) 5.7 (1.0) 5.5 (1.0) 
HDL cholesterol, mmol/L 1.5 (0.4) 1.4 (0.4) 1.5 (0.4) 1.4 (0.4) 
Hypertension 3,024 (80.5) 344 (83.3) 2,156 (78.3) 161 (75.9) 
Diabetes mellitus 508 (13.5) 74 (17.9) 316 (11.5) 31 (14.6) 
Myocardial infarction 252 (6.7) 50 (12.3) 157 (5.7) 22 (10.5) 
Stroke 112 (3.0) 22 (5.3) 53 (1.9) 11 (5.2) 
 
Values are means (standard deviation) or counts (percentage). 
 
Table 2 presents the results for the cross-sectional associations of MCI and its subtypes, 
with depressive and anxiety disorders. Participants with MCI were more likely to suffer 
from depressive disorders than persons without MCI, OR 1.94 (95% CI: 1.20, 3.15). In 
secondary analyses, we found similar associations for both amnestic and non-amnestic 
MCI with depressive disorders, compared to those without MCI: amnestic, OR 2.02 (95% 
CI: 0.95, 4.29), and non-amnestic, OR 1.90 (95% CI: 1.05, 3.40). 
In the cross-sectional analyses of MCI and anxiety disorders, participants with MCI were 
more likely to suffer from anxiety disorders than persons without MCI, OR 1.70 (95% CI: 
 
 
 
1.19, 2.42). In analyses with subtypes of MCI, participants with non-amnestic MCI were 
more likely to have an anxiety disorder, OR 2.00 (95% CI: 1.30, 3.04), but not those with 
amnestic MCI, OR 1.28 (95% CI: 0.69, 2.38).  
Results for the longitudinal analyses of MCI with depressive and anxiety disorders are 
presented in Table 3. For the analyses of MCI and incident depression, we found that MCI 
at baseline was associated with a higher relative risk of incident depressive disorders, OR 
3.13 (95% CI: 1.26, 7.77). In secondary analyses, we found that non-amnestic MCI was 
associated with a higher relative risk of depressive disorders, OR 3.77 (95% CI: 1.40, 
10.13).  
MCI at baseline was also associated with a higher relative risk of anxiety disorders, OR 
2.59 (95% CI: 1.31, 5.12). Both amnestic MCI, OR 3.22 (95% CI: 1.21, 8.55), and non-
amnestic MCI, OR 2.24 (95% CI: 0.90, 5.56), predicted the risk of anxiety after adjusting for 
all potential confounders. 
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 Table 2. Cross-sectional association of M
CI w
ith depressive and anxiety disorders. 
M
CI 
Analyses of depressive disorders, N
=4,168 
Analyses of anxiety disorders, N
=4,060 
 
Cases/N
a 
O
dds ratios (95%
 confidence intervals) 
Cases/N
a 
O
dds ratios (95%
 confidence intervals) 
 
 
M
odel 1
b 
p 
M
odel 2
c 
p 
 
M
odel 1
b 
p 
M
odel 2
c 
p 
N
o M
CI 
103/3,755 
Reference 
 
Reference 
 
284/3,662 
Reference 
 
Reference 
 
M
CI 
22/413 
2.02 (1.25, 3.26) 
0.004 
1.94 (1.20, 3.15) 
0.007 
46/398 
1.74 (1.24, 2.44) 
0.001 
1.70 (1.19,2.42) 
0.004 
Am
nestic 
8/161 
2.11 (1.00, 4.44) 
0.05 
2.02 (0.95, 4.29) 
0.07 
14/160 
1.35 (0.76, 2.39) 
0.30 
1.28 (0.69,2.38) 
0.42 
N
on-Am
nestic 
14/252 
1.97 (1.10, 3.53) 
0.02 
1.90 (1.05, 3.40) 
0.03 
32/238 
2.00 (1.34, 2.98) 
0.001 
2.00 (1.30,3.04) 
0.001 
 a Cases/N
: num
ber of depression or anxiety cases/total num
ber of participants in respective groups; p: p-values. 
b M
odel 1: adjusted for age and sex. 
c M
odel 2: additionally adjusted for educational level, BM
I, sm
oking, total cholesterol, HDL cholesterol, hypertension, diabetes m
ellitus 2, m
yocardial infarction, stroke, 
and cohort. 
 
 
 
 
 Table 3. Longitudinal association of M
CI w
ith incident depressive and anxiety disorders. 
M
CI 
Analyses of depressive disorders, N
=2,967 
Analyses of anxiety disorders, N
=2,375 
 
Cases/N
a 
O
dds ratios (95%
 confidence intervals) 
Cases/N
a 
O
dds ratios (95%
 confidence intervals) 
 
 
M
odel 1
b 
p 
 
M
odel 2
c 
p 
 
M
odel 1
b 
p 
 
M
odel 2
c 
p 
N
o M
CI 
29/2,755 
Reference 
 
 
Reference 
 
75/2,224 
Reference 
 
 
Reference 
 
M
CI 
6/212 
2.96 (1.21,7.25) 
0.02 
 
3.13 (1.26,7.77) 
0.01 
11/151 
2.54 (1.31,4.94) 
0.006 
 
2.59 (1.31,5.12) 
0.006 
Am
nestic 
1/80 
1.58 (0.21,11.9) 
0.66 
 
1.79 (0.23,13.70) 
0.57 
5/67 
2.92 (1.12,7.62) 
0.03 
 
3.22 (1.21,8.55) 
0.02 
N
on-Am
nestic 
5/132 
3.66 (1.39,9.65) 
0.009 
 
3.77 (1.40,10.13) 
0.008 
6/84 
2.31 (0.97,5.52) 
0.06 
 
2.24 (0.90,5.56) 
0.08 
 For these analyses, cases of dem
entia w
hich occurred during the study period w
ere excluded. These w
ere 25 cases in the analyses of depressive disorders, and 9 for the 
analyses of anxiety disorders. 
The odds ratios represent the relative risk of any depressive disorder (m
ajor depressive disorder, M
DD, dysthym
ia, or m
inor depression), or anxiety disorder (generalized 
anxiety disorder, GAD, panic disorder, or phobias) over 9 years.  
a Cases/N
: num
ber of depression or anxiety cases/total num
ber of participants in respective groups; p: p-values. 
b M
odel 1: adjusted for age and sex. 
c M
odel 2: additionally adjusted for educational level, BM
I, sm
oking, total cholesterol, HDL cholesterol, hypertension, diabetes m
ellitus 2, m
yocardial infarction, stroke, 
cohort, and tim
e interval betw
een tw
o assessm
ents. 
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DISCUSSION 
In this population-based study, persons with MCI were more likely to have prevalent 
depressive and anxiety disorders as compared to those without MCI. Moreover, MCI was 
associated with a higher relative risk of incidence of each depressive and anxiety disorder. 
Non-amnestic MCI was associated with a higher relative risk of incident depressive 
disorders, whereas both subtypes of MCI were associated with a higher relative risk of 
incident anxiety disorders. 
We found that persons with MCI had a higher prevalence of depressive and anxiety 
disorders compared to those without MCI, which is in line with the existing literature.26-30 
There are no prospective  studies to investigate the association of MCI with depressive or 
anxiety disorders. The only evidence about an association of MCI with depression and 
anxiety is either derived from cross-sectional studies, or a few short follow-up studies 
which reported depression a risk factor for MCI, i.e. depression precedes the development 
of MCI.6,7,29  
We found that MCI increased the risk of incident depression and anxiety. A lack of 
longitudinal studies on this subject hampered comparison of our results. However, several 
potential explanations gave rise to our hypothesis and can account for the observed 
associations. First, both depression and anxiety could occur as a “reactive” response to the 
underlying cognitive impairment, and symptoms could worsen with the increasing 
cognitive impairment. Experiencing forgetfulness, gradual inability to perform everyday 
tasks, and a fear of developing dementia could be intimidating enough to trigger severe 
symptoms of anxiety or depression in vulnerable individuals with MCI. Possibly, psychiatric 
symptoms would affect those persons with MCI more, who are more “aware” of their 
condition, and are able to quantitate the decline in their cognitive abilities. This might be 
particularly true for symptoms of anxiety, and could explain the finding of the prominent 
association between non-amnestic MCI with prevalent anxiety disorders in our study. 
Previously, an equally high prevalence of anxiety in both subtypes of MCI has been 
reported, but only in small clinical sample.29 Nevertheless, the results regarding subtypes 
of MCI in our study should be interpreted with caution, as these comparative analyses 
lacked sufficient power. Second, depressive or anxiety disorders might affect those 
individuals who are genetically or environmentally more vulnerable to develop these 
conditions. Perhaps in vulnerable persons, depressive or anxiety disorders precipitate 
earlier, or their risk is amplified by having MCI. Third, the incidence of depression or 
anxiety in persons with MCI might represent an early stage of dementia. This implies that 
depression or anxiety appear as an intermediate stage between MCI and dementia. 
 
 
 
Studies have shown that depression in late life is a prodrome of dementia.31 Fourth, both 
MCI and psychiatric symptoms can result from a common etiological factor where 
cognitive symptoms precede emotional symptoms. One such pathway could be the 
vascular damage.32 In this regard, the vascular depression hypothesis had been put 
forward, which implicates vascular pathology as a link between cognitive disorders, 
namely dementia, and depression, as the two entities frequently co-occur.32 Some studies 
have also suggested that the atrophy of hippocampus results in both cognitive impairment 
and depression.33 There is limited evidence as to the pathophysiology of anxiety disorders 
in context of early stages of neurodegeneration, but some studies have highlighted the 
role of caudate nucleus pathology as a possible link between MCI and anxiety.29 The 
caudate nucleus plays a vital role in executive function, and shows typical pathological 
features in early stages of dementia,34 and has been implicated in anxiety disorders.35,36 In 
Alzheimer’s disease patients with comorbid anxiety, the role of bilateral entorhinal cortex, 
amygdala, anterior parahippocampal gyri, left superior temporal gyrus, and insula has 
been implicated.37,38 However, pathological changes in both the hippocampus and the 
caudate nucleus could very well be the consequences of underlying vascular pathology. 
Another common pathway could be the dysregulation of neurotransmitters. Both altered 
serotonergic activity observed in anxiety and depression, and the low adrenergic activity 
observed in depression, are also associated with cognitive disorders.39-41 Further, 
inflammation has also been implicated by some studies as a common pathway between 
cognitive impairment and depression.42  
Studies have also argued that MCI is a psychiatric entity. This hypothesis proposes that in 
MCI, although the underlying pathology is neurodegenerative, the manifestation is largely 
in the form of psychiatric symptoms.43,44 Persons experiencing a decline in their cognitive 
abilities and being aware of this decline are likely to react with an alteration in mood or 
behavior, and sleeping or eating habits.  
There are several strengths of this study. To our knowledge, this is the first study to 
investigate MCI in relation to incident anxiety and depression. Other strengths include a 
large population-based sample, adjusting for several potential confounders, and a robust 
continuous monitoring of dementia which enabled to exclude incident cases occurring 
during the study period. However, there are certain limitations. We did not measure 
visuospatial ability, and therefore could not include this component in our diagnostic 
criteria for MCI. We did not have sufficient number of cases to test the association 
between amnestic MCI and incident depression and therefore the estimates might not be 
precise. Finally, residual confounding due to unknown or unmeasured confounders might 
be present. 
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of MCI.6,7,29  
We found that MCI increased the risk of incident depression and anxiety. A lack of 
longitudinal studies on this subject hampered comparison of our results. However, several 
potential explanations gave rise to our hypothesis and can account for the observed 
associations. First, both depression and anxiety could occur as a “reactive” response to the 
underlying cognitive impairment, and symptoms could worsen with the increasing 
cognitive impairment. Experiencing forgetfulness, gradual inability to perform everyday 
tasks, and a fear of developing dementia could be intimidating enough to trigger severe 
symptoms of anxiety or depression in vulnerable individuals with MCI. Possibly, psychiatric 
symptoms would affect those persons with MCI more, who are more “aware” of their 
condition, and are able to quantitate the decline in their cognitive abilities. This might be 
particularly true for symptoms of anxiety, and could explain the finding of the prominent 
association between non-amnestic MCI with prevalent anxiety disorders in our study. 
Previously, an equally high prevalence of anxiety in both subtypes of MCI has been 
reported, but only in small clinical sample.29 Nevertheless, the results regarding subtypes 
of MCI in our study should be interpreted with caution, as these comparative analyses 
lacked sufficient power. Second, depressive or anxiety disorders might affect those 
individuals who are genetically or environmentally more vulnerable to develop these 
conditions. Perhaps in vulnerable persons, depressive or anxiety disorders precipitate 
earlier, or their risk is amplified by having MCI. Third, the incidence of depression or 
anxiety in persons with MCI might represent an early stage of dementia. This implies that 
depression or anxiety appear as an intermediate stage between MCI and dementia. 
 
 
 
Studies have shown that depression in late life is a prodrome of dementia.31 Fourth, both 
MCI and psychiatric symptoms can result from a common etiological factor where 
cognitive symptoms precede emotional symptoms. One such pathway could be the 
vascular damage.32 In this regard, the vascular depression hypothesis had been put 
forward, which implicates vascular pathology as a link between cognitive disorders, 
namely dementia, and depression, as the two entities frequently co-occur.32 Some studies 
have also suggested that the atrophy of hippocampus results in both cognitive impairment 
and depression.33 There is limited evidence as to the pathophysiology of anxiety disorders 
in context of early stages of neurodegeneration, but some studies have highlighted the 
role of caudate nucleus pathology as a possible link between MCI and anxiety.29 The 
caudate nucleus plays a vital role in executive function, and shows typical pathological 
features in early stages of dementia,34 and has been implicated in anxiety disorders.35,36 In 
Alzheimer’s disease patients with comorbid anxiety, the role of bilateral entorhinal cortex, 
amygdala, anterior parahippocampal gyri, left superior temporal gyrus, and insula has 
been implicated.37,38 However, pathological changes in both the hippocampus and the 
caudate nucleus could very well be the consequences of underlying vascular pathology. 
Another common pathway could be the dysregulation of neurotransmitters. Both altered 
serotonergic activity observed in anxiety and depression, and the low adrenergic activity 
observed in depression, are also associated with cognitive disorders.39-41 Further, 
inflammation has also been implicated by some studies as a common pathway between 
cognitive impairment and depression.42  
Studies have also argued that MCI is a psychiatric entity. This hypothesis proposes that in 
MCI, although the underlying pathology is neurodegenerative, the manifestation is largely 
in the form of psychiatric symptoms.43,44 Persons experiencing a decline in their cognitive 
abilities and being aware of this decline are likely to react with an alteration in mood or 
behavior, and sleeping or eating habits.  
There are several strengths of this study. To our knowledge, this is the first study to 
investigate MCI in relation to incident anxiety and depression. Other strengths include a 
large population-based sample, adjusting for several potential confounders, and a robust 
continuous monitoring of dementia which enabled to exclude incident cases occurring 
during the study period. However, there are certain limitations. We did not measure 
visuospatial ability, and therefore could not include this component in our diagnostic 
criteria for MCI. We did not have sufficient number of cases to test the association 
between amnestic MCI and incident depression and therefore the estimates might not be 
precise. Finally, residual confounding due to unknown or unmeasured confounders might 
be present. 
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In conclusion, MCI is a possible precursor of psychiatric outcomes, such as depressive and 
anxiety disorders. Therefore, MCI should not just be regarded as a potential transition 
stage between normal aging and dementia, but a forerunner of both cognitive and 
psychiatric outcomes. Our results suggest a shared etiology between neurodegenerative 
and psychiatric disorders and opens avenues for etiological research to unravel the 
common biological pathways underlying cognitive and psychiatric disorders. 
 
 
 
SUPPLEMENTARY INFORMATION 
Supplementary Table. Baseline characteristics of the study population included in the 
analyses of MCI and anxiety disorders. 
 
Characteristics Cross-sectional analysis of 
anxiety disorders, N=4,060 
Longitudinal analysis of 
anxiety disorders, N=2,384 
 No MCI n=3,662 
MCI 
n=398 
No MCI 
n=2,230 
MCI 
n=154 
Age, years 71.4 (7.1) 73.3 (7.5) 69.4 (6..2) 69.1 (5.8) 
Women  2,339 (57.7) 202 (50.9) 1,261 (56.6) 67 (43.5) 
Body mass index, kg/m2 27.6 (4.1) 27.6 (4.1) 27.7 (4.0) 27.5 (4.0) 
Educational level 
Low  375 (9.4) 69 (17.5) 142 (6.5) 17 (11.2) 
Intermediate 3,028 (75.9) 271 (68.8) 1,701 (77.8) 106 (69.7) 
High 585 (14.7) 54 (13.7) 344 (15.7) 29 (19.1) 
Smoking 
Never 1,214 (29.9) 105 (26.4) 680 (30.5) 38 (24.7) 
Former 2,207 (54.4) 221 (55.7) 1,238 (55.5) 96 (62.3) 
Current 634 (15.6) 71 (17.9) 312 (14.0) 20 (13.0) 
Total, cholesterol, mmol/L 5.6 (1.0) 5.4 (1.0) 5.7 (0.9) 5.5 (1.0) 
HDL cholesterol, mmol/L 1.4 (0.4) 1.4 (0.4) 1.5 (0.4) 1.4 (0.4) 
Hypertension 3,254 (80.2) 330 (83.1) 1,715 (77.0) 109 (70.8) 
Diabetes mellitus 559 (13.8) 71 (17.9) 253 (11.3) 22 (14.3) 
Myocardial infarction 286 (7.1) 49 (12.6) 119 (5.3) 14 (9.2) 
Stroke  120 (3.0) 22 (5.5) 37 (1.7) 9 (5.8) 
 
Values are means (standard deviation) or counts (percentage). 
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ABSTRACT 
Background: Coffee consumption has been frequently reported for its protective 
association with incident dementia. However, this association has mostly been reported in 
studies with short follow-up periods, and it remains unclear to what extent reverse 
causality influences this association. Studying the long-term effect of coffee consumption 
on dementia with stratified follow-up time may help resolve this issue.  
Methods: In the population-based Rotterdam Study, coffee consumption was assessed in 
1989-1991 (N=5,408), and reassessed in 1997-1999 (N=4,368). Follow-up for dementia 
was complete until 2011. We investigated the association of coffee consumption and 
incident dementia for the two examination rounds separately using flexible parametric 
survival models. We studied the entire follow-up period as well as stratified follow-up 
time at 4 years.  
Results: For both examination rounds, we did not find an association between coffee 
consumption and dementia over the entire follow-up. In contrast, for both examination 
rounds, a protective association was observed only in the follow-up stratum of 0 to 4 
years.  
Conclusions: Our data suggest that coffee consumption is not associated with incident 
dementia during long-term. The protective association observed in the short-term might 
be driven by reverse causality.
 
 
 
INTRODUCTION 
Coffee is one of the most popular beverages throughout the world and has been 
frequently reported for its protective association with incident dementia1-3 and cognitive 
decline.4-6 Coffee contains a diverse group of biologically active compounds namely 
caffeine, phytochemicals, and minerals, which have considerable metabolic, physiological, 
cellular, and molecular influence.7 The beneficial effect of coffee on dementia has been 
attributed mainly to caffeine, a neuro-stimulatory compound.8 Coffee also prevents 
endothelial damage9 by reducing the risk of hypertension and diabetes mellitus type 21 
which is partly attributed to its anti-oxidant properties. Therefore coffee-intake might also 
reduce the risk of dementia indirectly.  
To date, most studies reporting a protective association between coffee and dementia 
have examined the association over relatively short follow-up periods, mostly ranging 
from 1 to 5 years.3,6,10,11 In contrast, studies with longer follow-up time have produced 
inconsistent results.1,5,12,13 An advantage of studies with short follow-up, particularly those 
with younger populations, is that less attrition occurs and therefore there is less 
opportunity for bias from differential attrition. However, in short follow-up studies, it is 
challenging to disentangle the independent influence of coffee consumption on dementia 
from the effects of lifestyle factors which may indicate general well-being of individuals. 
Thus, protective associations observed in short follow-ups might represent reverse 
causality. Stratification of follow-up time into short and long follow-up may elucidate this 
issue, but was not performed in previous studies. 
In a population-based cohort study with repeated assessments of coffee consumption, we 
investigated the association of coffee with dementia. Specifically, we examined this 
association over the entire follow-up as well as stratified follow-up time to address 
reverse causality. 
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METHODS 
Setting 
This study was embedded in the Rotterdam Study, an ongoing population-based cohort of 
the elderly that started in 1989-1990 and studies the incidence and determinants of 
chronic diseases in late life.14 The Rotterdam Study has been approved by the medical 
ethics committee according to the Population Study Act Rotterdam Study, executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. A written informed consent 
was obtained from all participants.  
Every 3 to 4 years, all participants undergo an extensive home interview and a physical 
examination at the research center. In addition, all participants are continuously 
monitored for the occurrence of all major events by linkage of the study database with 
medical files from general practitioners. Coffee consumption was assessed in 1989-1991 
and in1997-1999. Follow-up started from the day of study entry, till the date of incident 
dementia, date of death, or the censor date January 1st, 2011, whichever occurred first.  
Study population  
Of the original cohort of 7,983 participants, 482 with prevalent dementia, and 455 who 
were not sufficiently screened for dementia, were excluded. Of the remaining 7,046 
participants, 1,638 who did not have coffee consumption data available at baseline were 
also excluded. This yielded a total of 5,408 participants available for analysis, followed for 
a maximum of 20.7 years, (mean 13.2, standard deviation (SD) 5.4years) for incident 
dementia. The missing data for coffee consumption was completely at random , and 
occurred mainly because the food frequency questionnaires were not offered to all 
participants due to unavailability of trained interviewers at certain times. It was not 
related to any participant characteristics and therefore, was not likely to be a source of 
bias in our study. 
From the 5,408 persons  assessed in 1989-1991, 4,797 individuals participated in the 
follow-up examination round in 1997-1999 (major lost to follow-up was because of 
deaths). We excluded 347 participants with prevalent dementia, 7 who were lost to 
follow-up, and 75 for whom coffee data were not available at this repeated assessment. 
This yielded a total of 4,368 individuals for analysis, followed for a maximum of 13.8 years, 
(mean 8.7, (SD) 3.5 years) for incident dementia.  
 
 
 
 
Assessment of coffee consumption 
Daily coffee consumption was assessed as part of the home interview. In addition, types of 
coffee consumed, such as regular, decaffeinated, instant, or a combination of these was 
also inquired. Coffee consumption was categorized into three categories for main 
analyses; no coffee to low coffee consumption (0-1 cup/day) which was used as the 
reference category, moderate consumption (>1-3 cups/day) and high coffee consumption 
(>3 cups/day). Similar cut-offs have been used in studies investigating the association 
between coffee consumption and dementia.1,13 Coffee consumption was not dichotomized 
as non-drinkers and drinkers, as the percentage of non-drinkers in our sample was very 
small (<3.1%). 
Assessment of dementia 
Participants were screened for dementia at baseline and follow-up examinations using a 
three-step protocol.15 Screening was done using the Mini Mental State Examination 
(MMSE) 16 and the Geriatric Mental Schedule (GMS) organic level.17 Screen-positives 
(MMSE<26 or GMS organic level>0) subsequently underwent an examination and 
informant interview with the Cambridge Examination for Mental Disorders in the Elderly 
(CAMDEX).18 Participants who were suspected of having dementia, if necessary, had 
further neuropsychological testing. Additionally, the total cohort was continuously 
monitored for dementia through computerized linkage between the study database and 
digitized medical records from general practitioners (GPs)and the Regional Institute for 
Outpatient Mental Health Care. This data linkage system is highly efficient in the Dutch 
situation, where the GPs receive all medical information about the patients if they contact 
any medical care-giver or professional including specialists. In case of death of a patient, 
GPs also receive information about the cause of death. Finally, a consensus panel led by a 
neurologist, decided on the final diagnosis in accordance with the standards using the 
DSM-III-R criteria for dementia and the NINCDS-ADRDA for Alzheimer’s disease19 If 
required for differential diagnosis, neuro-imaging was used. We calculated the potential 
and observed person-years to calculate the completeness of follow-up.20 Follow-up for 
incident dementia was complete (98.2 % for cohort followed from baseline and 97.6% for 
cohort followed from repeated assessment of coffee consumption) till January 1st, 2011.  
Covariates 
In addition to age and gender, education level, family history of dementia, working status, 
body mass index (BMI), smoking, diabetes, hypertension, and alcohol use were considered 
as potential confounders. Smoking, hypertension and diabetes are well documented risk 
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factors for dementia. Low education level has been found to be associated with increased 
risk of dementia.21 BMI was used as a covariate as a measure overall dietary intake. 
Working status was used as a measure of social engagement in participants. Smoking and 
alcohol intake are important lifestyle factors as is coffee consumption. 
Level of education was assessed during the interview and participants were classified into 
eight categories; primary education , primary with unfinished secondary education, lower 
vocational, lower secondary, intermediate vocational, general secondary, higher 
vocational, and university education. BMI was calculated as weight in kilograms/height in 
meters-squared. For family history, participants were asked if their parents, siblings or 
children suffer from dementia. Participants were asked if they are engaged in any paid or 
volunteer work versus retired or unemployed. Smoking habits were also assessed during 
the interview and participants were classified as current, former or never smokers. 
Diabetes mellitus type 2 was defined as non-fasting serum glucose level exceeding 198 
mg/dl or the use of anti-diabetic medication or insulin.22 Blood pressure was measured 
twice at the right arm in sitting position at the research center; average of two blood 
pressure readings was used. Hypertension was defined as systolic blood pressure ≥ 140 
mmHg, diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive medication 
assessed by interview and pharmacy records.23 Alcohol consumption was assessed as part 
of the home interview. Weekly reported alcohol consumption was categorized into beer, 
wine, liquor, and moderately strong alcohol types. These were converted to grams of 
alcohol by taking the average amount of ethanol in a drink. “A drink” was defined as 200 
ml of beer (8.0 g ethanol), 100 ml of wine (10.0 g ethanol), 50 ml of liquor (14.0 g ethanol), 
or 75 ml of moderately strong alcohol (10.5 g ethanol). By adding the amount of ethanol in 
all four groups, total amount of alcohol in g/day was calculated.24 
Statistical analyses 
Coffee consumption was assessed at two examination rounds (1989-1991 and 1997-1999), 
which formed the baseline for two respective analyses. Using these baselines, we assessed 
coffee consumption and risk of dementia using flexible parametric models for survival 
analyses. We studied the entire follow-up period, and subsequently stratified follow-up 
time at 4 years into a stratum of short follow-up of 0-4 years, and a longer follow-up of >4 
years.  
In order to obtain more robust effect estimates, we meta-analyzed the hazard ratios from 
the 0-4 year intervals from both analyses, based on the martingale properties of survival 
data, which state that the time increments in a survival analysis are independent of each 
 
 
 
other. Since the hazard at any given time instant is not influenced by the hazards at the 
previous instant of time in a survival data of the same persons, it is justified to pool the 
hazard ratios from these two sets of same persons, assessed at different time points, 
assuming that they are independent.25 We performed simulations to further verify the 
independence of the hazard ratios of the two subsequent time epochs. 
Several sensitivity analyses were performed. The 4-year cut-off was arbitrary and was 
used to ensure comparability with other studies. Therefore, analyses were repeated 
examining intervals of 2, 3 and 5 years. Analyses were also repeated using 0-2 cups of 
coffee per day as reference: 0-2 cups/day, >2-3 cups/day, and >3 cups/day. In addition, all 
analyses were repeated after excluding persons drinking decaffeinated coffee only (n= 660 
from baseline, and n=429 from repeated assessment of coffee), excluding non-coffee-
drinkers (n=156 from baseline, and n=134 from repeated assessment of coffee), and by 
using Alzheimer’s disease as outcome instead of all-cause dementia. Effect modification of 
the association between high coffee consumption and dementia by smoking and diabetes 
mellitus 2 was assessed by stratification and use of interaction terms. We also repeated 
our analyses stratified on baseline age. Finally, change in coffee consumption from 
baseline to repeated assessment was investigated in relation to incident dementia.  
Results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). All 
analyses were adjusted for age, sex, and additionally for education, family history of 
dementia, working status, BMI, smoking, diabetes mellitus 2, hypertension, and alcohol 
intake. Data were analyzed using the Stata Software Version 13 (StataCorp, College 
Station, TX, USA).  
 
RESULTS 
In our data, persons in the >3 cups category at both coffee consumption assessments 
were younger, more involved in work, more educated, and had a lower prevalence of 
hypertension and diabetes. However, they had more prevalence of current smoking  and 
lower HDL cholesterol as compared to those in the lower coffee consumption categories. 
Table 1 summarizes the baseline characteristics of persons in the analyses.  
From 1989-1991 to end of follow-up, 814 persons developed incident dementia during 
71,629 person-years. From 1997-1999 onwards, 578 persons developed dementia during 
38,002 person-years. We found no evidence of a protective association between higher 
coffee consumption and incidence of dementia over the entire follow-up for both  
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 Table 1. Characteristics of participants at baseline exam
 in 1989-1991 and at repeated exam
 in 1997-1999. 
 
At Baseline, N
=5,408 
At Follow
-up, N
=4,368 
Characteristics 
0-1 cup/day 
>1-3 cups/day 
>3 cups/day 
P-value 
0-1 cup/day 
>1-3 cups/day 
>3 cups/day 
P-value 
Age, years 
70.3 (8.6) 
69.5 (7.8) 
66.3 (7.3) 
<0.001 
75.1 (8.0) 
74.3 (7.5) 
70.9(6.5) 
<0.001 
W
om
en 
230 (63.9) 
1,160 (64.7) 
1,802 (55.3) 
<0.001 
323 (65.6) 
1,090 (64.2) 
1,164 (53.4) 
<0.001 
Education Level 
Low
 
133 (37.0) 
631 (35.4) 
1,104 (34.1) 
0.02 
164 (34.2) 
569 (34.0) 
613 (28.5) 
0.002 
Interm
ediate 
182 (50.7) 
991 (55.6) 
1,876 (57.9) 
 
262 (54.6) 
948 (56.7) 
1,317 (61.3) 
 
High 
44 (12.3) 
161 (9.0) 
259 (8.0) 
 
54 (11.2) 
156 (9.3) 
218 (10.1) 
 
Fam
ily history of dem
entia 
72 (20.1) 
426 (23.8) 
813 (25.0) 
0.10 
96 (20.2) 
400 (24.1) 
511 (23.9) 
0.18 
W
orking (volunteering incl.) 
42 (11.7) 
235(13.2) 
559 (17.3) 
<0.001 
93 (18.9) 
386 (22.7) 
541 (24.8) 
0.014 
Sm
oking 
N
ever 
174 (48.5) 
731 (41.1) 
909 (28.1) 
<0.001 
220 (44.7) 
654 (38.5) 
633 (29.0) 
<0.001 
Form
er 
153 (42.6) 
774 (43.5) 
1,378 (42.6) 
 
234 (47.6) 
840 (49.5) 
1,069 (49.1) 
 
Current 
32 (8.9) 
275 (15.4) 
950 (29.4) 
 
38 (7.7) 
204 (12.0) 
476 (21.9) 
 
Body m
ass index, kg/m
2 
25.9 (3.8) 
26.1 (3.6) 
26.5 (3.6) 
<0.001 
26.7 (3.7) 
26.8 (3.6) 
26.9 (3.8) 
0.2 
Hypertension 
218 (60.6) 
1,065 (59.4) 
1,662 (51.0) 
<0.001 
354 (71.9) 
1,201 (70.7) 
1,415 (64.6) 
<0.001 
Diabetes m
ellitus 2 
33 (9.2) 
189 (10.5) 
283 (8.7) 
0.09 
143 (29.1) 
478 (28.1) 
466 (21.3) 
<0.001 
Total cholesterol, m
g/100 m
l 
255.2(46.4) 
259.1(46.4) 
259.1 (46.4) 
0.1 
224.3 (39.4) 
228.1 (38.2) 
224.3 (34.8) 
0.06 
HDL cholesterol, m
g/100 m
l 
50.3 (14.3) 
54.1 (13.9) 
50.3 (15.5) 
0.01 
54.5 (18.6) 
54.5 (15.5) 
50.3 (15.5) 
<0.001 
 Abbreviations: HDL High Density Lipoprotein. 
Values are m
eans (standard deviation) or counts (percentage). 
P-values indicate differences in characteristics across coffee consum
ption categories, as estim
ated by T-tests for continuous variables and Chi-square test for categorical 
variable.  
 
 
 
analyses: HR 1.09 (95% CI: 0.94, 1.25) for the first coffee assessment, and HR 1.11 (95% CI: 
0.94, 1.32) for the second assessment (Table 2). 
 
Table 2. Hazard ratios (95% confidence intervals) for incident dementia during the entire 
follow-up period. 
Coffee consumption Risk of dementia, hazard ratios (95% confidence intervals) 
 n/N  Model 1a  Model 2b 
Coffee consumption at baseline exam (1989-1991) 
Continuous 814/5,408  1.02 (0.98, 1.07)  1.02 (0.98, 1.06) 
      
Categorical      
0-1 cup/day 67/360  1 (ref)  1 (ref) 
>1-3 cups/day 296/1,792  0.92 (0.70, 1.20)  0.88 (0.67, 1.16) 
>3 cups/day 451/3,256  1.04 (0.80, 1.35)  1.00 (0.76, 1.30) 
      
Coffee consumption at repeated exam (1997-1999) 
Continuous 578/4,368  1.04 (0.99, 1.10)  1.05 (0.99, 1.11) 
      
Categorical      
0-1 cup/day 80/492  1 (ref)  1 (ref) 
>1-3 cups/day 235/1,698  0.87 (0.67, 1.12)  0.86 (0.66, 1.12) 
>3 cups/day 263/2,178  1.01 (0.78, 1.31)  1.03 (0.79, 1.34) 
 
a Model 1: Hazard ratios adjusted for age and sex. 
b Model 2: Hazard ratios additionally adjusted for education level, body mass index, smoking, hypertension, 
diabetes mellitus 2, alcohol use, family history of dementia, and working status. 
 
Table 3 shows hazard ratios after stratifying follow-up time at 4 years. At both assessment 
rounds of coffee consumption, we found a protective association between higher coffee 
consumption and incident dementia during the first 4 years of follow-up, comparing 
individuals drinking 3 or more cups of coffee per day with individuals drinking no coffee or 
up to 1 cup per day. Meta-analysis of hazard ratios for >3 cups category in the 0-4 year 
interval from the two assessment rounds showed a statistically significant association 
between coffee consumption of >3 cups/day and dementia, HR 0.70 (95% CI: 0.51, 0.96).  
In contrast, during the follow-up period from 4 years onwards, we found an increased risk 
of incident dementia in persons drinking 3 or more cups of coffee per day compared with 
individuals drinking no coffee or up to 1 cup per day (Table 3).  
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 Table 1. Characteristics of participants at baseline exam
 in 1989-1991 and at repeated exam
 in 1997-1999. 
 
At Baseline, N
=5,408 
At Follow
-up, N
=4,368 
Characteristics 
0-1 cup/day 
>1-3 cups/day 
>3 cups/day 
P-value 
0-1 cup/day 
>1-3 cups/day 
>3 cups/day 
P-value 
Age, years 
70.3 (8.6) 
69.5 (7.8) 
66.3 (7.3) 
<0.001 
75.1 (8.0) 
74.3 (7.5) 
70.9(6.5) 
<0.001 
W
om
en 
230 (63.9) 
1,160 (64.7) 
1,802 (55.3) 
<0.001 
323 (65.6) 
1,090 (64.2) 
1,164 (53.4) 
<0.001 
Education Level 
Low
 
133 (37.0) 
631 (35.4) 
1,104 (34.1) 
0.02 
164 (34.2) 
569 (34.0) 
613 (28.5) 
0.002 
Interm
ediate 
182 (50.7) 
991 (55.6) 
1,876 (57.9) 
 
262 (54.6) 
948 (56.7) 
1,317 (61.3) 
 
High 
44 (12.3) 
161 (9.0) 
259 (8.0) 
 
54 (11.2) 
156 (9.3) 
218 (10.1) 
 
Fam
ily history of dem
entia 
72 (20.1) 
426 (23.8) 
813 (25.0) 
0.10 
96 (20.2) 
400 (24.1) 
511 (23.9) 
0.18 
W
orking (volunteering incl.) 
42 (11.7) 
235(13.2) 
559 (17.3) 
<0.001 
93 (18.9) 
386 (22.7) 
541 (24.8) 
0.014 
Sm
oking 
N
ever 
174 (48.5) 
731 (41.1) 
909 (28.1) 
<0.001 
220 (44.7) 
654 (38.5) 
633 (29.0) 
<0.001 
Form
er 
153 (42.6) 
774 (43.5) 
1,378 (42.6) 
 
234 (47.6) 
840 (49.5) 
1,069 (49.1) 
 
Current 
32 (8.9) 
275 (15.4) 
950 (29.4) 
 
38 (7.7) 
204 (12.0) 
476 (21.9) 
 
Body m
ass index, kg/m
2 
25.9 (3.8) 
26.1 (3.6) 
26.5 (3.6) 
<0.001 
26.7 (3.7) 
26.8 (3.6) 
26.9 (3.8) 
0.2 
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218 (60.6) 
1,065 (59.4) 
1,662 (51.0) 
<0.001 
354 (71.9) 
1,201 (70.7) 
1,415 (64.6) 
<0.001 
Diabetes m
ellitus 2 
33 (9.2) 
189 (10.5) 
283 (8.7) 
0.09 
143 (29.1) 
478 (28.1) 
466 (21.3) 
<0.001 
Total cholesterol, m
g/100 m
l 
255.2(46.4) 
259.1(46.4) 
259.1 (46.4) 
0.1 
224.3 (39.4) 
228.1 (38.2) 
224.3 (34.8) 
0.06 
HDL cholesterol, m
g/100 m
l 
50.3 (14.3) 
54.1 (13.9) 
50.3 (15.5) 
0.01 
54.5 (18.6) 
54.5 (15.5) 
50.3 (15.5) 
<0.001 
 Abbreviations: HDL High Density Lipoprotein. 
Values are m
eans (standard deviation) or counts (percentage). 
P-values indicate differences in characteristics across coffee consum
ption categories, as estim
ated by T-tests for continuous variables and Chi-square test for categorical 
variable.  
 
 
 
analyses: HR 1.09 (95% CI: 0.94, 1.25) for the first coffee assessment, and HR 1.11 (95% CI: 
0.94, 1.32) for the second assessment (Table 2). 
 
Table 2. Hazard ratios (95% confidence intervals) for incident dementia during the entire 
follow-up period. 
Coffee consumption Risk of dementia, hazard ratios (95% confidence intervals) 
 n/N  Model 1a  Model 2b 
Coffee consumption at baseline exam (1989-1991) 
Continuous 814/5,408  1.02 (0.98, 1.07)  1.02 (0.98, 1.06) 
      
Categorical      
0-1 cup/day 67/360  1 (ref)  1 (ref) 
>1-3 cups/day 296/1,792  0.92 (0.70, 1.20)  0.88 (0.67, 1.16) 
>3 cups/day 451/3,256  1.04 (0.80, 1.35)  1.00 (0.76, 1.30) 
      
Coffee consumption at repeated exam (1997-1999) 
Continuous 578/4,368  1.04 (0.99, 1.10)  1.05 (0.99, 1.11) 
      
Categorical      
0-1 cup/day 80/492  1 (ref)  1 (ref) 
>1-3 cups/day 235/1,698  0.87 (0.67, 1.12)  0.86 (0.66, 1.12) 
>3 cups/day 263/2,178  1.01 (0.78, 1.31)  1.03 (0.79, 1.34) 
 
a Model 1: Hazard ratios adjusted for age and sex. 
b Model 2: Hazard ratios additionally adjusted for education level, body mass index, smoking, hypertension, 
diabetes mellitus 2, alcohol use, family history of dementia, and working status. 
 
Table 3 shows hazard ratios after stratifying follow-up time at 4 years. At both assessment 
rounds of coffee consumption, we found a protective association between higher coffee 
consumption and incident dementia during the first 4 years of follow-up, comparing 
individuals drinking 3 or more cups of coffee per day with individuals drinking no coffee or 
up to 1 cup per day. Meta-analysis of hazard ratios for >3 cups category in the 0-4 year 
interval from the two assessment rounds showed a statistically significant association 
between coffee consumption of >3 cups/day and dementia, HR 0.70 (95% CI: 0.51, 0.96).  
In contrast, during the follow-up period from 4 years onwards, we found an increased risk 
of incident dementia in persons drinking 3 or more cups of coffee per day compared with 
individuals drinking no coffee or up to 1 cup per day (Table 3).  
Chapter 3.1
142
Coffee and dementia
143
 
 
 Table 3. Hazard ratios (95%
 confidence intervals) for incident dem
entia after stratifying follow
-up tim
e at 4 years. 
Coffee consum
ption 
Risk of dem
entia, hazard ratios (95%
 confidence intervals) 
 
Stratum
 0-4 years 
Stratum
 >4 years 
 
n/N
a 
M
odel 1
b 
M
odel 2
c 
n/N
 
M
odel 1
b 
M
odel 2
c 
Coffee consum
ption at baseline exam
 (1989-1991) 
Continuous 
112/5,408 
0.94 (0.83, 1.05) 
0.94 (0.83, 1.06) 
702/4,935 
1.04 (0.99, 1.08) 
1.04 (0.99, 1.08) 
Categorical 
0-1 cup/day 
13/360 
1 (ref) 
1 (ref) 
54/318 
1 (ref) 
1 (ref) 
>1-3 cups/day 
50/1,792 
0.92 (0.50, 1.70) 
0.88 (0.47, 1.63) 
246/1,596 
0.92 (0.69, 1.24) 
0.90 (0.67, 1.21) 
>3 cups/day 
49/3,256 
0.75 (0.40, 1.40) 
0.74 (0.39, 1.39) 
402/3,021 
1.10 (0.83, 1.47) 
1.05 (0.78, 1.41) 
Coffee consum
ption at repeated exam
 (1997-1999) 
Continuous 
152/4,368 
0.97 (0.83, 1.08) 
0.96 (0.86, 1.07) 
426/3,727 
1.06 (1.02, 1.13) 
1.07 (1.01, 1.15) 
Categorical 
0-1 cup/day 
27/492 
1 (ref) 
1 (ref) 
53/387 
1 (ref) 
1 (ref) 
>1-3 cups/day 
75/1,698 
0.87 (0.56, 1.34) 
0.87 (0.55, 1.37) 
160/1,405 
0.88 (0.64, 1.20) 
0.85 (0.62, 1.17) 
>3 cups/day 
50/2,178 
0.74 (0.46, 1.19) 
0.69 (0.42, 1.15) 
213/1,935 
1.13 (0.83, 1.53) 
1.14 (0.83, 1.56) 
 a n/N
: dem
entia cases/num
ber of persons at risk for dem
entia. 
b M
odel 1: adjusted for age and sex. 
c M
odel 2: additionally adjusted for education level, body m
ass index, sm
oking, hypertension, diabetes, m
ellitus 2, alcohol use, fam
ily history of dem
entia, and w
orking 
status. 
  
 
 
Results did not change meaningfully on repeating our analysis using 2, 3 and 5 years as 
cut-offs of follow-up (Supplement table 1), and using 0-2 cups of coffee consumption as 
reference (data not shown). Results also did not change after excluding persons drinking 
decaffeinated coffee, excluding non-coffee-drinkers, and using Alzheimer’s disease as 
outcome (data not shown).  
Interaction terms were non-significant for both smoking (p-value 0.185) and diabetes (p-
value 0.697). In addition, no significant change in results was observed after stratification 
on smoking and diabetes (data not shown). Results also remained unchanged after 
stratification on 75 years of age and are shown in supplement table 2. 
Finally, we investigated change in coffee consumption from baseline assessment to 
reassessment of coffee consumption in relation with dementia. Persons who maintained 
drinking >3 cups/day (1,755) showed a statistically significantly lower risk of incident 
dementia over 4 years of follow-up compared to participants who reduced their intake, HR 
0.59 (95% CI: 0.35, 0.98).  
 
DISCUSSION 
In this population-based study using coffee assessment of the same persons at two time 
points, we found no protective association between coffee consumption and the risk of 
dementia during the entire follow-up period. Instead, we found a protective association 
between coffee consumption and incident dementia with short follow-up, which reversed 
with long follow-up.  
Strengths of the study include a population-based design, the long follow-up period 
including stratification, repeated assessment of coffee consumption, and intensive 
dementia case-ascertainment. There are certain methodological considerations which 
should be discussed. Coffee consumption was self-reported in our study. The methods of 
brewing coffee as filtering or boiling were not registered. Possibility of some residual 
confounding due to unknown or unmeasured confounders, such as physical activity, 
depression, and dietary patterns cannot be completely ruled out. We however adjusted 
for many potential confounders and the results remained unchanged. Another 
methodological consideration is that we assume no interaction with time and aging in our 
study. 
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brewing coffee as filtering or boiling were not registered. Possibility of some residual 
confounding due to unknown or unmeasured confounders, such as physical activity, 
depression, and dietary patterns cannot be completely ruled out. We however adjusted 
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study. 
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Coffee drinking, similar to other lifestyle factors, is associated with a number of socio-
demographic variables and health in general,13 but it did not independently predict 
dementia in our study during long follow-up. The Finnish twin study13 and the Honolulu-
Asia Aging Study12 also reported similar findings; the former used cognitive performance 
as outcome, measured by a telephonic interview and the latter included only men. In 
contrast, the CAIDE study reported a protective association of midlife coffee consumption 
and dementia over 21 years in 1409 participants. It is possible that a long-term protective 
association is present only for continued coffee consumption from midlife onwards, but 
note that the study included relatively young individuals which led to relatively small 
number of incident dementia cases.1  
The novelty of our study is that we stratified follow-up time at 4 years, and found a 
protective association between coffee consumption and incident dementia during the 
short follow-up of 0-4 years. Importantly, this observation was made for both coffee 
assessments. 
A possible explanation for our finding of a short-term protective association is reverse 
causality. Elderly drinking more cups of coffee per day are likely to be engaged in physical 
and social activities and are healthier in general. Coffee drinking therefore, like alcohol 
drinking or socializing, or any other lifestyle factor, could be a proxy of good health and 
general wellbeing. In contrast, persons experiencing cognitive decline or even with 
subclinical dementia, modify their dietary habits which includes reducing coffee 
consumption. This would therefore result in a protective association of high coffee 
consumption with incident dementia. This view is supported by our data, as we observed 
that the persons in >3 cups category were younger, more involved in work, more 
educated, and had a lower prevalence of hypertension and diabetes as compared to 
persons in the lower consumption categories at both rounds of coffee consumption 
assessment. Further evidence in support of this explanation comes from the observation 
in our study that persons who maintained their coffee consumption between the two 
assessments had a lower risk of dementia compared to those who reduced coffee 
consumption. Such healthy-worker effect leading to reverse causality may also explain 
similar short-term associations reported in previous studies as well as the lack of 
associations in studies with long follow-up.3,6,10,11  
An alternate explanation for short-term association is that there is actually only a short-
term beneficial association of coffee and incident dementia. Being a short-acting neuro-
stimulant, caffeine may exert its beneficial effect on cognition in the beginning which 
subsequently wanes away with prolonged use. The beneficial effects of coffee on 
 
 
 
hypertension might also explain this association.26,27 Also, a short-term protective 
association might be a chance finding. This is however unlikely because a protective 
association was observed in 0-4 year periods after both coffee assessments: at baseline 
and at the follow-up round.  
Interestingly, we found a harmful association between coffee consumption and incident 
dementia after excluding the first four years of follow-up. With these data, however, it is 
early to comment whether the increased risk after 4 years is driven by coffee consumption 
or by other confounding risk factors, or both. Coffee consumption especially of boiled 
coffee,8 may increase the risk of dementia via hypercholesterolemia1 with prolonged use. 
There is a possibility that high coffee consumption delays symptoms of cognitive decline 
and therefore diagnosis, which leads to more case detection later during follow-up. In the 
same vein, an increased risk of dementia after excluding first 4 years of follow-up could be 
a reactive phenomenon, which manifests because of the reduction in coffee consumption, 
removing its beneficial effects.  
In conclusion, our data suggest that coffee consumption is not associated with incident 
dementia over a long follow-up. The observed short-term protective association likely 
represents reverse causality. Coffee consumption like other lifestyle factors is likely a 
proxy of good health and general well-being.  
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SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Hazard ratios (95% confidence intervals) for incident dementia 
by coffee consumption categories, stratifying follow-up time at cut-offs of 2, 3 and 5 
years. 
Coffee consumption  Risk of dementia 
  Strata of short follow-up Strata beyond short follow-up 
 Cut-off point of follow-up n/N 
Hazard ratio 
(95% CI) n/N 
Hazard ratio 
(95% CI) 
Coffee consumption at baseline exam (1989-1991) 
 2 years 51/5,408 0.93 (0.31, 2.81) 763/5,213 0.99 (0.76, 1.31) 
 3 years 77/5,408 0.58 (0.28, 1.22) 737/5,093 1.06 (0.80, 1.41) 
 5 years 167/5,408 0.86 (0.51, 1.43) 647/4,777 1.05 (0.77, 1.44) 
Coffee consumption at repeated exam (1997-1999) 
 2 years 76/4,368 0.61 (0.31, 1.20) 502/4,055 1.10 (0.82, 1.47) 
 3 years 138/4,368 0.73 (0.44, 1.24) 440/3,885 1.11 (0.81, 1.52) 
 5 years 220/4,368 0.97 (0.63, 1.49) 358/3,505 1.03 (0.73, 1.44) 
 
Hazard ratios for dementia are for >3cups of coffee/day versus 0-1 cup of coffee/day. 
Hazard ratios are adjusted for age, sex, education level, body mass index, smoking, hypertension, diabetes 
mellitus 2, alcohol use, family history of dementia, and working status. 
Supplementary Table 2. Hazard ratios (95% confidence intervals) for incident dementia 
stratified by age. 
 ≤ 75 years ˃ 75 years 
 0-4 years ˃ 4 years 0-4 years ˃ 4 years 
n/N 37/4,360 486/4,119 75/1,048 216/816 
Coffee consumption at baseline exam (1989-1991) 
0-1 cup/day 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>1-3 cups/day 0.54 (0.17, 1.72) 1.11 (0.72, 1.71) 1.04 (0.50, 2.17) 0.72 (0.47, 1.10) 
>3 cups/day 0.56 (0.18, 1.69) 1.26 (0.83, 1.93) 0.82 (0.38, 1.76) 0.93 (0.61, 1.42) 
     
n/N 31/2,804 199/2,582 121/1,564 227/1,145 
Coffee consumption at repeated exam (1997-1999) 
0-1 cup/day 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>1-3 cups/day 0.38 (0.14, 1.06) 0.92 (0.53, 1.60) 1.04 (0.62, 1.74) 0.81 (0.55, 1.21) 
>3 cups/day 0.38 (0.14, 1.01) 1.31 (0.78, 2.23) 0.81 (0.46, 1.46) 1.03 (0.69, 1.53) 
 
Hazard ratios are adjusted for age, sex, education level, body mass index, smoking, hypertension, diabetes 
mellitus 2, alcohol use, family history of dementia, and working status. 
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SUPPLEMENTARY INFORMATION 
Supplementary Table 1. Hazard ratios (95% confidence intervals) for incident dementia 
by coffee consumption categories, stratifying follow-up time at cut-offs of 2, 3 and 5 
years. 
Coffee consumption  Risk of dementia 
  Strata of short follow-up Strata beyond short follow-up 
 Cut-off point of follow-up n/N 
Hazard ratio 
(95% CI) n/N 
Hazard ratio 
(95% CI) 
Coffee consumption at baseline exam (1989-1991) 
 2 years 51/5,408 0.93 (0.31, 2.81) 763/5,213 0.99 (0.76, 1.31) 
 3 years 77/5,408 0.58 (0.28, 1.22) 737/5,093 1.06 (0.80, 1.41) 
 5 years 167/5,408 0.86 (0.51, 1.43) 647/4,777 1.05 (0.77, 1.44) 
Coffee consumption at repeated exam (1997-1999) 
 2 years 76/4,368 0.61 (0.31, 1.20) 502/4,055 1.10 (0.82, 1.47) 
 3 years 138/4,368 0.73 (0.44, 1.24) 440/3,885 1.11 (0.81, 1.52) 
 5 years 220/4,368 0.97 (0.63, 1.49) 358/3,505 1.03 (0.73, 1.44) 
 
Hazard ratios for dementia are for >3cups of coffee/day versus 0-1 cup of coffee/day. 
Hazard ratios are adjusted for age, sex, education level, body mass index, smoking, hypertension, diabetes 
mellitus 2, alcohol use, family history of dementia, and working status. 
Supplementary Table 2. Hazard ratios (95% confidence intervals) for incident dementia 
stratified by age. 
 ≤ 75 years ˃ 75 years 
 0-4 years ˃ 4 years 0-4 years ˃ 4 years 
n/N 37/4,360 486/4,119 75/1,048 216/816 
Coffee consumption at baseline exam (1989-1991) 
0-1 cup/day 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>1-3 cups/day 0.54 (0.17, 1.72) 1.11 (0.72, 1.71) 1.04 (0.50, 2.17) 0.72 (0.47, 1.10) 
>3 cups/day 0.56 (0.18, 1.69) 1.26 (0.83, 1.93) 0.82 (0.38, 1.76) 0.93 (0.61, 1.42) 
     
n/N 31/2,804 199/2,582 121/1,564 227/1,145 
Coffee consumption at repeated exam (1997-1999) 
0-1 cup/day 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>1-3 cups/day 0.38 (0.14, 1.06) 0.92 (0.53, 1.60) 1.04 (0.62, 1.74) 0.81 (0.55, 1.21) 
>3 cups/day 0.38 (0.14, 1.01) 1.31 (0.78, 2.23) 0.81 (0.46, 1.46) 1.03 (0.69, 1.53) 
 
Hazard ratios are adjusted for age, sex, education level, body mass index, smoking, hypertension, diabetes 
mellitus 2, alcohol use, family history of dementia, and working status. 
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ABSTRACT 
Background: Coffee is one of the mostly consumed beverages worldwide, and has been of 
considerable interest in cognitive and dementia research due to its neuro-stimulatory 
effects. However, the associations of coffee consumption with MRI biomarkers of 
dementia, and pre-morbid cognitive performance have rarely been investigated.  
Methods: In a community-dwelling sample of 2,914 older adults, we assessed coffee 
consumption habits. Moreover, these participants underwent brain MRI to quantify brain 
volume, hippocampal volume, and white matter lesion volume and to assess the presence 
of lacunar infarct. Finally, we examined cognitive function in these participants using a 
standardized neuropsychological test battery. We investigated associations of coffee 
consumption with MRI-markers and cognitive function using multiple linear and logistic 
regression models, and explored if MRI-markers affected the association between coffee 
consumption and cognition.  
Results: We found that per cup increase in coffee consumption was associated with a 
lower prevalence of lacunar infarcts, Odds Ratio (OR) 0.88 (95% confidence interval (CI): 
0.80,  0.97), and with smaller hippocampal volume, difference of the mean in hippocampal 
volume (mL): -0.01 (95% CI: -0.02, -0.00)]. Regarding cognitive function, we found that the 
consumption of >3 cups of coffee per day was associated with better performance on the 
Letter-Digit Substitution Task, difference of the mean: 1.20 (95% CI: 0.46, 1.94)], but worse 
performance on the Stroop color naming subtask, difference of the mean: 0.74 ( 95% CI: 
0.22, 1.26), Stroop interference subtask, difference 1.81 (95% CI: 0.22, 3.40), and the 15-
word verbal learning delayed recall, difference of the mean:-0.38 (95% CI:-0.74, -0.03)]. 
These associations were independent of the MRI findings. 
Conclusions: Habitual coffee consumption was associated with a smaller hippocampal 
volume, and worse information processing speed and delayed memory. However, habitual 
coffee consumption seemed to be protective against lacunar infarcts, and was associated 
with better executive function. 
  
 
 
 
INTRODUCTION 
Coffee is one of the mostly consumed beverages worldwide and has therefore been of 
considerable interest regarding its potential effects on health.1-4 Coffee is a complex 
mixture consisting of more than 1,000 different compounds with different physiological 
effects.5 Compounds that are thought to be beneficial for health are caffeine, which is the 
major constituent of coffee and a strong neurostimulant, polyphenols, which have 
antioxidant properties.5,6 Several studies have shown that the overall effect of coffee 
consumption is beneficial for various diseases, including diabetes,2 and cardiovascular 
disease,1,3 and all-cause and cerebrovascular, mainly stroke related mortality.7-9 More 
recent evidence also links coffee consumption to a lower risk of dementia.4,10-12  
Dementia is multifactorial disease with a long pre-clinical phase during which various 
pathologies steadily accumulate. Amyloid deposition and vascular brain disease are the 
two major pathologic processes involved in the development of dementia.13,14 Clinically, 
these pathologies lead to subtle cognitive deficits that can be detected using cognitive 
testing, whilst structural magnetic resonance imaging (MRI) allows for in vivo visualization 
of markers of these pathologies, including brain atrophy, hippocampal atrophy, white 
matter lesions, and lacunar infarcts.15 Elucidating the link between coffee consumption 
and these pre-clinical markers is essential to further disentangle the exact effect of coffee 
consumption on the brain. Preliminary evidence indeed links coffee consumption to 
cognition or brain MRI-markers, but these studies consisted of small samples, focused only 
one or two cognitive domains, or included persons not at risk of dementia (e.g. health 
young volunteers).4,10,12,15,16 Therefore, it remains largely unknown how coffee 
consumption affects pre-clinical markers of dementia. 
In a population-based setting of community-dwelling older adults, we investigated the 
association of habitual coffee consumption with several structural brain-MRI-markers and 
cognitive function. 
 
METHODS 
Setting  
This study was embedded within the Rotterdam Study,17 a population-based cohort study, 
aimed at investigating determinants of chronic diseases in the middle aged and elderly. 
The study started in 1990 with 7,893 persons, aged 55 years and older. In 2000, the cohort 
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was expanded with 3,011 participants, with the same inclusion criteria. In 2006, the cohort 
was again expanded with 3,932 participants aged 45 years or older. From 2005 onwards, 
all participants that came to the research center were invited for an MRI examination of 
the brain. For the current study, we included all participants that visited the research 
center from the first expansion between 2004 and 2006 and second expansion between 
2006 and 2008, and who underwent MRI between 2005 and 2009. The Rotterdam Study 
has been approved by the medical ethics committee according to the Population Screening 
Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the 
Netherlands. All participants provided written informed consent. A written informed 
consent was obtained from all participants.  
Study population 
A total of 3,871 persons underwent MRI between 2005 and 2009. Of these MRI 
examinations, 13 were excluded due to image artefacts. Moreover, we excluded all persons 
with prevalent dementia (n=16), cortical infarcts (n=99), and prevalent clinical stroke 
(n=55). Coffee consumption data was not available for 774 participants because not all 
participants received a food frequency questionnaire due to unavailability of trained 
personnel at times to administer the questionnaire. Therefore, information on coffee 
consumption was available for 2,914 persons, constituting the total sample available for 
analyses. Not all persons underwent all cognitive tests, resulting in slightly different totals 
for each separate cognitive test (Figure 1). 
Assessment of coffee consumption 
Coffee consumption was assessed as part of a validated semi-quantitative food frequency 
questionnaire indicating all foods and drinks consumed more than once a month during 
the preceding year.18 The questionnaire comprised food items and all relevant beverages, 
including coffee, and was administered by a trained dietician. Participants reported their 
habitual coffee intake as number of cups per day, week, or month. The dietary coffee 
consumption was converted into miligrams (mg) of coffee per day, and then into cups of 
coffee per day.  
Brain MRI and post-processing 
Brain MRI-scanning was performed on a 1.5T-scanner with an eight-channel head coil (GE 
Healthcare, Milwaukee, Wisconsin, USA), and included a T1-weighted (T1w) sequence, a 
proton-density (PDw) weighted sequence, and a fluid-attenuated-inversion-recovery 
(FLAIR) sequence.19 Automated brain tissue classification based on a k-nearest-neighbor-
 
 
 
classifier algorithm extended with white matter lesion segmentation was used to quantify 
brain volume, grey matter volume, white matter volume, white matter lesion volume, (in 
milliliters).20,21 We also quantified left and right hippocampal volume (in millilitres) using a 
validated, custom atlas-based method.22 Total hippocampal volume was defined as the 
sum of the left and right hippocampal volumes. Lacunar and cortical infarcts were rated on 
the FLAIR, PDw and T1w sequences.23 Lacunar infarcts were dichotomized into present 
versus absent.  
Figure 1. Flowchart demonstrating the selection of the study population. 
The figure shows sequential exclusions of participants due to missing information on MRI markers, coffee 
consumption, or cognitive tests.
Brain MRI data from the second and third cohort of the 
Rotterdam Study between 2005 and 2009, N=3,871  
 
Participants eligible to participate: N=3,688 participate in this 
study. 
 
Participants with coffee consumption data, N= 2,914 composing 
the sample in this study. 
 
2,699 persons had data on Stoop reading, color naming and 
interference subtask. 
2,847 persons had data on Letter-Digit Substitution Task.  
2,871 persons had data on Verbal fluency test. 
2,681 persons had data on 15- word learning test (immediate 
and delayed recall).  
2,817 persons had data on Purdue Pegboard test.  
 
13 persons were excluded because 
the MRI images did not meet the 
quality standards. 
16 persons were excluded due to 
prevalent dementia; 
99 persons were excluded because 
of cortical infarcts. 
     
 
Missing coffee consumption  
information. Not all participants 
received a food frequency 
questionnaire because of 
unavailability of trained personnel 
at times to administer the 
questionnaire. 
Missing data on cognitive function 
tests. 
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Assessment of cognitive function 
All participant underwent a standardized neuropsychological test battery which included 
the following tests: Stroop tests24 (which were used to evaluate speed of reading, color 
naming, and interference of automated processing and attention; Letter-Digit Substitution 
Task (LDST) to evaluate processing speed and executive function,25 verbal fluency test to 
evaluate efficiency of long term memory,26 15-Word verbal immediate and delay recall 
tests to evaluate retrieval from verbal memory and recognition of verbal memory,27 and 
Purdue Pegboard test to evaluate dexterity and fine motor skill.28 Higher scores indicate a 
better performance on all cognitive tests, except for the Stroop tests in which a higher 
score indicates a worse performance as it measures time taken to complete the task. 
Accordingly, scores for the Stroop test were inverted for comparison to other tests.29 
Other measurements 
Information on educational level and cardiovascular risk factors was gathered by interview, 
physical examination and laboratory tests. We assessed the highest educational 
attainment of each participant (university degree, higher vocational education, general 
secondary education, intermediate vocational education, lower secondary education, 
lower vocational education, primary education). Body mass index was calculated as weight 
in kilograms/height in meters-squared (Kg/m2). We measured systolic and diastolic blood 
pressures twice at the right arm and used the mean of the two measurements. 
Hypertension was defined as a blood pressure ≥140/90mmHg or use of blood pressure 
lowering medication prescribed for the indication of hypertension. Fasting blood samples 
were obtained and serum total cholesterol and high-density lipoprotein (HDL) cholesterol 
were measured using an automatic enzymatic procedure (Hitachi analyzer, Roche 
Diagnostics). Glucose was determined enzymatically by the Hexokinase method. Diabetes 
mellitus 2 was defined as a fasting serum glucose level ≥7.0 mmol/L, or use of anti-diabetic 
medication. A history of coronary heart disease was defined as myocardial 
revascularization and/or myocardial infarction. Alcohol consumption and smoking status 
were assessed by interview. For alcohol consumption, participants were categorized as 
users or nonusers, for smoking, participants were categorized as current, former, or never 
smokers.  
Statistical analysis 
We compared characteristics between the participants included and excluded from the 
analyses using Analysis Of Variance (ANOVA) for continuous variables, and chi-square tests 
for categorical variables adjusting for age and sex where applicable. We analyzed habitual 
 
 
 
coffee consumption  as cups per day. White matter lesion volume was natural log-
transformed due to right-skewness of its distribution. 
We used linear regression to investigate the relationship of coffee consumption with 
continuous MRI-markers (i.e. total brain volume, hippocampal volume and white matter 
lesion volume), and with cognitive tests. We used logistic regression to assess the 
association between coffee consumption and the presence of lacunar infarcts. Analyses 
were adjusted for age, sex and educational attainment in model 1. In a second model we 
additionally adjusted for body mass index, hypertension, diabetes mellitus 2, total 
cholesterol levels, HDL-cholesterol levels, previous coronary heart disease , alcohol 
consumption, and smoking (model 2). Analyses which included MRI-based brain volumes 
as outcome were additionally adjusted for intracranial volume (as measure of head size). 
For analyses with cognition as outcome, we constructed a third model, in which we 
included the MRI-markers that associated with coffee consumption to test whether the 
association between coffee consumption and cognitive performance was independent on 
these markers. 
Finally, we repeated all analyses after categorizing coffee consumption into three groups: 
0–1 cup/day, >1–3 cups/ day, and >3 cups/day.30 Analyses were conducted using the Stata 
12.0 (Stata Corporation, College Station, USA). 
 
RESULTS 
Characteristics of the study population are presented in Table 1. The mean age of the 
study population was 59.3 years, and 55% were women. Participants excluded due to 
missing data for coffee consumption were more likely to be younger, less educated, 
current smokers, non-users of alcohol, and had lower HDL-cholesterol levels and higher 
BMI than participants included in our analyses (Table 1).  
  
Chapter 3.2
154
Coffee and cognition
155
 
 
 
Assessment of cognitive function 
All participant underwent a standardized neuropsychological test battery which included 
the following tests: Stroop tests24 (which were used to evaluate speed of reading, color 
naming, and interference of automated processing and attention; Letter-Digit Substitution 
Task (LDST) to evaluate processing speed and executive function,25 verbal fluency test to 
evaluate efficiency of long term memory,26 15-Word verbal immediate and delay recall 
tests to evaluate retrieval from verbal memory and recognition of verbal memory,27 and 
Purdue Pegboard test to evaluate dexterity and fine motor skill.28 Higher scores indicate a 
better performance on all cognitive tests, except for the Stroop tests in which a higher 
score indicates a worse performance as it measures time taken to complete the task. 
Accordingly, scores for the Stroop test were inverted for comparison to other tests.29 
Other measurements 
Information on educational level and cardiovascular risk factors was gathered by interview, 
physical examination and laboratory tests. We assessed the highest educational 
attainment of each participant (university degree, higher vocational education, general 
secondary education, intermediate vocational education, lower secondary education, 
lower vocational education, primary education). Body mass index was calculated as weight 
in kilograms/height in meters-squared (Kg/m2). We measured systolic and diastolic blood 
pressures twice at the right arm and used the mean of the two measurements. 
Hypertension was defined as a blood pressure ≥140/90mmHg or use of blood pressure 
lowering medication prescribed for the indication of hypertension. Fasting blood samples 
were obtained and serum total cholesterol and high-density lipoprotein (HDL) cholesterol 
were measured using an automatic enzymatic procedure (Hitachi analyzer, Roche 
Diagnostics). Glucose was determined enzymatically by the Hexokinase method. Diabetes 
mellitus 2 was defined as a fasting serum glucose level ≥7.0 mmol/L, or use of anti-diabetic 
medication. A history of coronary heart disease was defined as myocardial 
revascularization and/or myocardial infarction. Alcohol consumption and smoking status 
were assessed by interview. For alcohol consumption, participants were categorized as 
users or nonusers, for smoking, participants were categorized as current, former, or never 
smokers.  
Statistical analysis 
We compared characteristics between the participants included and excluded from the 
analyses using Analysis Of Variance (ANOVA) for continuous variables, and chi-square tests 
for categorical variables adjusting for age and sex where applicable. We analyzed habitual 
 
 
 
coffee consumption  as cups per day. White matter lesion volume was natural log-
transformed due to right-skewness of its distribution. 
We used linear regression to investigate the relationship of coffee consumption with 
continuous MRI-markers (i.e. total brain volume, hippocampal volume and white matter 
lesion volume), and with cognitive tests. We used logistic regression to assess the 
association between coffee consumption and the presence of lacunar infarcts. Analyses 
were adjusted for age, sex and educational attainment in model 1. In a second model we 
additionally adjusted for body mass index, hypertension, diabetes mellitus 2, total 
cholesterol levels, HDL-cholesterol levels, previous coronary heart disease , alcohol 
consumption, and smoking (model 2). Analyses which included MRI-based brain volumes 
as outcome were additionally adjusted for intracranial volume (as measure of head size). 
For analyses with cognition as outcome, we constructed a third model, in which we 
included the MRI-markers that associated with coffee consumption to test whether the 
association between coffee consumption and cognitive performance was independent on 
these markers. 
Finally, we repeated all analyses after categorizing coffee consumption into three groups: 
0–1 cup/day, >1–3 cups/ day, and >3 cups/day.30 Analyses were conducted using the Stata 
12.0 (Stata Corporation, College Station, USA). 
 
RESULTS 
Characteristics of the study population are presented in Table 1. The mean age of the 
study population was 59.3 years, and 55% were women. Participants excluded due to 
missing data for coffee consumption were more likely to be younger, less educated, 
current smokers, non-users of alcohol, and had lower HDL-cholesterol levels and higher 
BMI than participants included in our analyses (Table 1).  
  
Chapter 3.2
156
Coffee and cognition
157
 
 
 
Table 1. Characteristics of the included and excluded study population. 
Characteristics Included in analysis 
n=2,914 
Excluded from analysis 
n=774 
Women  1,608 (55.2) 415 (53.6) 
Age, years 59.28 (7.2) 56.6 (7.2)a 
Educational attainment   
University degree 166 (5.7) 40 (5.2)a 
Higher Vocational Education 610 (20.9) 132 (17.1) 
General Secondary Education 160 (5.5) 42 (5.4) 
Intermediate Vocational Education 673 (23.1) 182 (23.5) 
Lower Secondary Education 559 (19.2) 120 (15.5) 
Lower Vocational Education 485 (16.6) 161 (20.8) 
Primary Education 224 (7.7) 87 (11.2) 
Missing 37 (1.3) 10 (1.3) 
Body mass index (kg/m2) 27.42 (4.1) 27.98 (4.4)a 
Hypertension 1,559 (53.8) 351 (45.8) 
Diabetes Mellitus type 2 62 (9.0) 76 (9.8) 
Total cholesterol, (mmol/l) 5.63 (1.0) 5.60 (1.1) 
HDL-cholestero,l (mmol/l) 1.45 (0.4) 1.37 (0.4)a 
Previous coronary heart disease 181 (6.3) 36 (4.7) 
Alcohol consumption 2,639 (90.7) 659 (86.9)a 
Smoking   
Never 896 (30.8) 205 (27.0)a 
Former 1,373 (47.2) 323 (42.6) 
Current 643 (22.0) 231 (30.4) 
 
Values are means (standard deviation) or counts (percentage). 
a Significant difference (p<0.05) between included participants and excluded participants adjusting for age and 
gender where applicable. 
 
Table 2 shows the associations between habitual coffee consumption as number of cups 
per day with structural brain MRI-markers. We found that coffee consumption was 
associated with a lower prevalence of lacunar infarcts, odds ratio (OR) per cup increase in 
coffee consumption 0.88 (95% confidence interval (CI): 0.80, 0.97). This association 
remained significant after additional adjustment for cardiovascular risk factors, OR 0.88 
(95% CI: 0.78, 0.97). We also found coffee consumption to be associated with lower 
hippocampal volume but only in model 2, difference of the mean in hippocampal volume 
per cup increase in coffee consumption: -0.01 (95% CI:-0.02, -0.00). 
 
  
 
 
 
Table 2. Association of coffee consumption and structural MRI-markers (45 to 89 years of 
age). 
Coffee consumption  
(per cup increase per day) 
Model 1d Model 2e 
Difference (95%CI) p-value Difference (95%CI) p-value 
Total Brain Volumea -0.16 (-0.93, 0.61) 0.677 -0.39 (-1.14, 0.37) 0.318 
White Matter Volumea 0.08 (-0.68, 0.83) 0.845 0.13 (-0.65, 0.91) 0.747 
Grey Matter Volumea -0.50 (-1.19, 0.18) 0.159 -0.51 (-1.21, 0.18) 0.150 
Total Hippocampal Volumea -0.01 (-0.02, 0.00) 0.108 -0.01 (-0.02, -0.00) 0.033 
White Matter Lesionsa,b -0.00 (-0.02, 0.01) 0.531 -0.00 (-0.01, 0.00) 0.423 
 Odds ratio (95%CI) p-value Odds ratio (95%CI) p-value 
Lacunar Infarctsc 0.88 (0.80, 0.97) 0.014 0.88 (0.78, 0.97) 0.012 
 
a Volumes measures were also adjusted for intracranial volume.  
b White Matter Lesions values were log transformed.  
c Performed by logistic regression  
d Model 1: Adjusted for age, sex, and educational attainment. 
e Model 2: Additionally adjusted for alcohol consumption, smoking, cholesterol total, HDL-
cholesterol, hypertension, diabetes mellitus 2, body mass index, and coronary heart disease. 
Table 3 shows the associations between coffee consumption and cognitive tests. We found 
that coffee consumption was associated with better performance on the LDST, but also 
with worse performance on immediate and delayed recall tests. Interestingly, these 
associations remained statistically significant even after adjustment for total hippocampal 
volume and lacunar infarcts, difference of the mean in LDST: 0.12 (95% CI: 0.02, 0.22); 
immediate recall -0.04 (95% CI:-0.07, -0.00), and delayed recall -0.06 (95% CI:-0.11, -0.01). 
Coffee consumption (cups/per day) was not associated with performance on the verbal 
fluency test, the Purdue pegboard test or any of the Stroop subtasks (Table 3). 
In analyses with categories of coffee consumption, there were 296 persons (10.2%) in the 
0-1 cup/day category, 703 persons (24.1%) in the >1-3 cups/day category, and 1,915 
(65.7%) persons in the >3 cups/day category. We observed a lower prevalence of lacunar 
infarcts, when comparing the >1-3 cups/day and >3 cups/day categories to 0-1 cup/day. In 
contrast, the associations with hippocampal volume, LDST, and delayed recall were only 
found when comparing the >3 cups/day category to 0-1 cup/day. Additionally, we found 
significant associations between coffee consumption and worse performance on Stroop 
color, difference in test score when comparing >3cups/day to 0-1 cup/day: 0.74 (95% CI: 
0.22, 1.26) and interference subtask, difference in test score when comparing >3cups/day 
to 0-1 cup/day: 1.81 (95% CI: 0.22, 3.39) (Figure 2). No significant associations were 
present anymore with immediate recall and hippocampus volume (data not shown).  
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 Table 3. Association of coffee consum
ption and cognitive function tests (45 to 89 years of age). 
Coffee consum
ption (per cup increase per day) 
M
odel 1
a 
M
odel 2
b 
M
odel 3
c 
Difference (95%
CI) 
p-value 
Difference (95%
CI) 
p-value 
Difference (95%
CI) 
p-value 
Stroop reading subtask (seconds) 
0.02 (-0.04, 0.07) 
0.554 
0.00 (-0.05, 0.06) 
0.807 
0.00 (-0.05, 0.06) 
0.883 
Stroop color nam
ing subtask (seconds) 
0.07 (-0.00, 0.14) 
0.065 
0.07 (-0.00, 0.14) 
0.067 
0.06 (-0.01, 0.13) 
0.092 
Stroop interference subtask (seconds) 
-0.02 (-0.23, 0.19) 
0.827 
-0.02 (-0.23, 0.20) 
0.862 
-0.03(-0.25, 0.19) 
0.790 
LDST (num
ber of correct digits) 
0.09 (-0.01, 0.19) 
0.065 
0.12 (0.02, 0.22) 
0.021 
0.12 (0.02, 0.22) 
0.021 
Verbal fluency test (num
ber of anim
als listed) 
0.06 (-0.04, 0.15) 
0.216 
0.03 (-0.06, 0.13) 
0.491 
0.03(-0.07, 0.12) 
0.580 
15- W
LT, im
m
ediate recall (num
ber of correct answ
ers) 
-0.04 (-0.07, -0.00) 
0.037 
-0.03 (-0.07, -0.00) 
0.049 
-0.04 (-0.07, -0.00) 
0.034 
15-W
LT, delayed recall (num
ber of correct answ
ers) 
-0.05 (-0.10, -0.01) 
0.025 
-0.05 (-0.10, -0.01) 
0.027 
-0.06 (-0.11, -0.01) 
0.018 
Purdue Pegboard test (num
ber of pins placed) 
-0.02 (-0.05, 0.00) 
0.128 
-0.01 (-0.04, 0.02) 
0.362 
-0.02 (-0.05, 0.01) 
0.221 
 Abbreviations: LDST Letter-Digit substitution task; W
LT W
ord Learning Test 
a M
odel 1: Adjusted for age, sex and educational attainm
ent. 
b M
odel 2: Additionally adjusted for alcohol consum
ption, sm
oking, cholesterol total, HDL-cholesterol, hypertension, diabetes m
ellitus 2, body m
ass index, and coronary 
heart disease status.  
c M
odel 3: Additionally adjusted for total hippocam
pal volum
e and lacunar infarcts.  
 
 
 
Figure 2. Association of coffee consumption categories with lacunar infarcts and 
cognitive function tests (45 to 89 years of age). 
LDST= Letter-Digit Substitution Task; WLT= Word Learning Test  
The upper figure shows odds ratios for the presence of lacunar infarcts for each category of coffee consumption as 
compared to the reference category (0-1 cups/day). 
The lower four figures show differences in cognitive test scores for each category of coffee consumption as compared to 
the reference category (0-1 cups/day). 
Chapter 3.2
158
Coffee and cognition
159
 
 
 Table 3. Association of coffee consum
ption and cognitive function tests (45 to 89 years of age). 
Coffee consum
ption (per cup increase per day) 
M
odel 1
a 
M
odel 2
b 
M
odel 3
c 
Difference (95%
CI) 
p-value 
Difference (95%
CI) 
p-value 
Difference (95%
CI) 
p-value 
Stroop reading subtask (seconds) 
0.02 (-0.04, 0.07) 
0.554 
0.00 (-0.05, 0.06) 
0.807 
0.00 (-0.05, 0.06) 
0.883 
Stroop color nam
ing subtask (seconds) 
0.07 (-0.00, 0.14) 
0.065 
0.07 (-0.00, 0.14) 
0.067 
0.06 (-0.01, 0.13) 
0.092 
Stroop interference subtask (seconds) 
-0.02 (-0.23, 0.19) 
0.827 
-0.02 (-0.23, 0.20) 
0.862 
-0.03(-0.25, 0.19) 
0.790 
LDST (num
ber of correct digits) 
0.09 (-0.01, 0.19) 
0.065 
0.12 (0.02, 0.22) 
0.021 
0.12 (0.02, 0.22) 
0.021 
Verbal fluency test (num
ber of anim
als listed) 
0.06 (-0.04, 0.15) 
0.216 
0.03 (-0.06, 0.13) 
0.491 
0.03(-0.07, 0.12) 
0.580 
15- W
LT, im
m
ediate recall (num
ber of correct answ
ers) 
-0.04 (-0.07, -0.00) 
0.037 
-0.03 (-0.07, -0.00) 
0.049 
-0.04 (-0.07, -0.00) 
0.034 
15-W
LT, delayed recall (num
ber of correct answ
ers) 
-0.05 (-0.10, -0.01) 
0.025 
-0.05 (-0.10, -0.01) 
0.027 
-0.06 (-0.11, -0.01) 
0.018 
Purdue Pegboard test (num
ber of pins placed) 
-0.02 (-0.05, 0.00) 
0.128 
-0.01 (-0.04, 0.02) 
0.362 
-0.02 (-0.05, 0.01) 
0.221 
 Abbreviations: LDST Letter-Digit substitution task; W
LT W
ord Learning Test 
a M
odel 1: Adjusted for age, sex and educational attainm
ent. 
b M
odel 2: Additionally adjusted for alcohol consum
ption, sm
oking, cholesterol total, HDL-cholesterol, hypertension, diabetes m
ellitus 2, body m
ass index, and coronary 
heart disease status.  
c M
odel 3: Additionally adjusted for total hippocam
pal volum
e and lacunar infarcts.  
 
 
 
Figure 2. Association of coffee consumption categories with lacunar infarcts and 
cognitive function tests (45 to 89 years of age). 
LDST= Letter-Digit Substitution Task; WLT= Word Learning Test  
The upper figure shows odds ratios for the presence of lacunar infarcts for each category of coffee consumption as 
compared to the reference category (0-1 cups/day). 
The lower four figures show differences in cognitive test scores for each category of coffee consumption as compared to 
the reference category (0-1 cups/day). 
Chapter 3.2
160
Coffee and cognition
161
 
 
 
DISCUSSION 
In this large sample of community-dwelling middle-age and older adults, we found that 
habitual coffee consumption was associated with a lower prevalence of lacunar infarcts, 
but also with a smaller hippocampal volume on structural MRI. Additionally, coffee 
consumption was related to better performance on LDST, but worse performance on the 
Stroop and memory tests, independent of MRI findings.  
Coffee is a complex mixture of chemicals including caffeine, chlorogenic acid, polyphenols, 
melanoidins and diterpenes,31,32 some of which have shown to have beneficial effects on 
neurodegeneration, as assessed in neuronal cell cultures,6 or on cognition in aged rats.14 
Yet, diterpenes from the lipid fraction, such as cafestol, kahweol and especially 16-O-
methylcafestol, if present in high amounts as in unfiltered or Turkish coffee, might impact 
circulating cholesterol levels.32 However, at doses found in filtered coffee and espresso, 
these compounds largely have anti-inflammatory and anti-carcinogenic effects.33,34  
We found that persons with higher consumption of coffee (>3 cups/day) had lower 
likelihood of having lacunar infarcts. Given the strong vascular origin of lacunar infarcts, it 
is likely that the beneficial effect of coffee on cardiovascular health might also underlie this 
association.35,36 More specifically, studies have shown that coffee consumption is 
associated with a decreased risk of clinical stroke, probably due to its preventive effect on 
inflammation in the cascade of atherosclerosis.3,12,35,36 Given the similarities between the 
pathophysiology of clinical stroke and lacunar infarcts, similar processes might underlie 
part of our observations. 
Extending on our findings for lacunar infarcts, we also found coffee consumption to be 
associated with better performance on the LDST, which is a test of executive function. This 
is particularly noteworthy because of all cognitive domains executive function is thought 
to be primarily affected by vascular brain disease, including white matter lesions and 
lacunar infarcts.15,37 Interestingly, the association of coffee with LDST was independent 
from lacunar infarcts, suggesting that other processes might also be involved. Future 
research should therefore focus on further unraveling the link between coffee, vascular 
health, lacunar infarcts, and executive function. 
In contrast, we found coffee consumption to be associated with smaller hippocampal 
volume and poorer memory function. This finding is at odds with previous studies that 
suggest coffee to act as neurostimulant, improving memory function.12,38 It is possible that 
the neurostimulatory effect of coffee might be short-acting, whereas in our study cognitive 
tests were administered as part of our study protocol and participants had not consumed 
 
 
 
coffee for at least the preceding 60 minutes. Similarly, our MRI studies were not designed 
to find any short-acting effect of coffee, since hippocampus atrophy is a slow, protracted 
process. Alternatively, as indicated above, coffee contains numerous compounds, some of 
which might actually be detrimental at higher doses.15,31 In our study, it was not possible to 
disentangle the potential consequences of different ways of coffee preparation (e.g. 
decaffeinate coffee, coffee with or without milk or sugar etc) to further unravel these 
associations. 
From a practical point of view, the overall effect of coffee on brain needs further 
clarification. Indeed, the opposing effects we found for lacunar infarcts and hippocampus – 
and by extension LDST and delayed recall, are intriguing. In this regard, it is important to 
note that most studies investigating clinical neurological outcomes, have found protective 
effects of coffee consumption on clinical stroke, dementia, including Alzheimer’s disease, 
and Parkinson’s.10,12,16,35,38-41 It seems thus that the net effect of coffee consumption is 
beneficial. Still, some caution is warranted, since most human studies have been 
observational by design, thereby thus being prone to methodological issues, such as recall 
bias and reverse causality. 
Strengths of our study include the population-based design, large sample size, extensive 
phenotyping, and the focus on both cognitive function and brain MRI-biomarkers in the 
same population. There are also some limitations. Although we adjusted for known 
potential confounding factors in our study, there is a possibility of residual confounding 
due to other not measured factors, such as use of neuroleptics, anticonvulsants, 
anticholinesterase and antiparkinsonian drugs, or included confounders not being 
measured entirely accurately, such as alcohol or smoking. Also, there is the possibility of 
measurement error, which is especially true for questionnaire-based dietary exposures. 
We also did not take into account the method of brewing coffee such as filtering or boiling. 
Most importantly, our study was cross-sectional, which limits any causal inference. 
Nevertheless, the finding that associations with objective quantifiable structural MRI-
markers correspond to those found for cognitive tests does add to the robustness of our 
findings.  
In conclusion, habitual coffee consumption was associated with a lower prevalence of 
lacunar infarcts as well as better performance on executive function. At the same time, 
habitual coffee consumption was related to smaller hippocampal volumes and worse 
performance on speed tests and delayed memory. More studies are needed to further 
disentangle the subtle effects of coffee drinking on brain health, especially with respect to 
pre-clinical biomarkers. 
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Abstract 
Background: Cognitive reserve may increase the tolerance to subclinical 
neurodegenerative pathology before it manifests clinically as dementia. However, it 
remains unclear if cognitive reserve also protects against dementia after clinical 
cerebrovascular events, such as stroke or transient ischemic attack (TIA). 
Methods: Within the population-based Rotterdam Study, 12,561 participants (58.3% 
women, age-range 45-106 years) free of stroke, TIA, and dementia were followed for 
occurrence of stroke, TIA and dementia. Educational level was used as measure of 
cognitive reserve. We investigated associations of incident stroke or TIA with subsequent 
development of dementia across educational levels, using time-dependent Cox 
proportional hazard models. Additionally, we examined differences in cognitive decline 
across educational levels following stroke or TIA using linear regression.  
Results: During 124,862 person-years, 1,463 persons suffered a stroke or TIA, 1,158 
persons developed dementia, and 186 persons developed dementia after stroke or TIA. 
The risk of dementia in persons with stroke or TIA compared to persons without was 
highest in individuals with low education, HR 1.46 (95% CI: 1.18, 1.81), followed by those 
with intermediate education, HR 1.38 (95% CI: 1.04, 1.83). No significant association was 
observed in individuals with high education, HR 0.61 (95% CI: 0.25, 1.50). Additionally, 
persons with high education declined less in cognition following stroke or TIA compared to 
persons with low education.  
Conclusions: Stroke or TIA increased the risk of subsequent development of dementia in 
persons with low and intermediate education, but not in persons with high education. Our 
results suggest a role of cognitive reserve in protection against dementia after stroke or 
TIA. 
  
 
 
 
INTRODUCTION 
The cognitive reserve hypothesis postulates that people with a higher reserve can tolerate 
more neurodegenerative pathology and maintain brain function for longer than people 
with low reserve, before the damage  manifests clinically as dementia.1-3 In the context of 
Alzheimer’s disease, people with higher cognitive reserve can have more senile plaques 
and amyloid-β deposits before the disease manifests clinically.4-7 
Although vascular disease is also an important risk factor for dementia including 
Alzheimer’s disease,8 it is less known if people with higher education, and thus more 
cognitive reserve, can also tolerate more cerebrovascular damage before dementia 
occurs. Evidence does suggest, however, that subclinical vascular lesions such as white 
matter lesions9 or silent brain infarcts10 result in less cognitive decline in people with 
higher education. Since clinical cerebrovascular events such as stroke and transient 
ischemic attack (TIA) are related to more tissue damage than silent lesions,11 it remains to 
be established whether cognitive reserve also protects against dementia after clinical 
events. More importantly, stroke and TIA have a high clinical impact and may lead to 
considerable morbidity, which is further aggravated by sequelae like dementia.12,13 Hence, 
identification of (modifiable) factors that act as protectors against dementia following a 
stroke or TIA is of major public health and clinical importance.  
Therefore, in this population-based study we investigated whether cognitive reserve, 
operationalized using education, protects against dementia after a stroke or TIA. We also 
examined differences in cognitive decline after a stroke or TIA across levels of education. 
 
METHODS 
Setting and study population 
This study was part of the population-based Rotterdam Study.14 In 1990, 7,983 persons 
aged 55 years and older were recruited. In 2000, the cohort was expanded by 3,011 
persons aged 55 and older, and in 2006 in a second expansion wave, an additional 3,932 
persons aged 45 and older were added. Of these total 14,926 participants, 527 with 
prevalent dementia, and 902 with insufficient baseline information for dementia or no 
consent for the follow-up of stroke, TIA or dementia were excluded. We also excluded 354 
persons with prevalent stroke, 324 with prevalent TIA, and 258 with missing education 
information, resulting in 12,561 participants eligible for the analyses of incident dementia. 
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INTRODUCTION 
The cognitive reserve hypothesis postulates that people with a higher reserve can tolerate 
more neurodegenerative pathology and maintain brain function for longer than people 
with low reserve, before the damage  manifests clinically as dementia.1-3 In the context of 
Alzheimer’s disease, people with higher cognitive reserve can have more senile plaques 
and amyloid-β deposits before the disease manifests clinically.4-7 
Although vascular disease is also an important risk factor for dementia including 
Alzheimer’s disease,8 it is less known if people with higher education, and thus more 
cognitive reserve, can also tolerate more cerebrovascular damage before dementia 
occurs. Evidence does suggest, however, that subclinical vascular lesions such as white 
matter lesions9 or silent brain infarcts10 result in less cognitive decline in people with 
higher education. Since clinical cerebrovascular events such as stroke and transient 
ischemic attack (TIA) are related to more tissue damage than silent lesions,11 it remains to 
be established whether cognitive reserve also protects against dementia after clinical 
events. More importantly, stroke and TIA have a high clinical impact and may lead to 
considerable morbidity, which is further aggravated by sequelae like dementia.12,13 Hence, 
identification of (modifiable) factors that act as protectors against dementia following a 
stroke or TIA is of major public health and clinical importance.  
Therefore, in this population-based study we investigated whether cognitive reserve, 
operationalized using education, protects against dementia after a stroke or TIA. We also 
examined differences in cognitive decline after a stroke or TIA across levels of education. 
 
METHODS 
Setting and study population 
This study was part of the population-based Rotterdam Study.14 In 1990, 7,983 persons 
aged 55 years and older were recruited. In 2000, the cohort was expanded by 3,011 
persons aged 55 and older, and in 2006 in a second expansion wave, an additional 3,932 
persons aged 45 and older were added. Of these total 14,926 participants, 527 with 
prevalent dementia, and 902 with insufficient baseline information for dementia or no 
consent for the follow-up of stroke, TIA or dementia were excluded. We also excluded 354 
persons with prevalent stroke, 324 with prevalent TIA, and 258 with missing education 
information, resulting in 12,561 participants eligible for the analyses of incident dementia. 
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The Rotterdam Study is approved by the Medical Ethics Committee of the Erasmus MC 
and by the Ministry of Health, Welfare and Sport of the Netherlands , implementing the 
“Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. Written 
informed consent was obtained from all participants. 
For the analyses of cognition, only participants who suffered a stroke or TIA between the 
two follow-up rounds in 2004-2008 and 2009-2013 were eligible, as these rounds 
comprised the most comprehensive cognitive test battery. In these examination rounds, 
7,039 persons participated, of which 34 participants with no consent for collection of 
follow-up data, 435 participants with prevalent stroke or TIA at the first test date, 83 
participants with prevalent dementia or insufficient information for dementia at the first 
test date, and 83 with missing data on education were excluded. Of the remaining 6,404 
participants, 261 actually suffered a stroke or TIA between the two follow-up rounds. 205 
of these participants had at least one cognitive test and were therefore eligible for 
analyses. 
Educational level as a measure of cognitive reserve  
We used educational level as a measure of cognitive reserve which was inquired during 
the home interview and participants were classified as having low (primary, unfinished 
secondary, and lower vocational), intermediate (secondary or intermediate vocational), or 
high education (higher vocational or university).  
Assessment of stroke and TIA 
At baseline, history of stroke and TIA was assessed using home interviews and verified 
using medical records. From baseline onwards, participants were continuously followed-
up for occurrence of stroke and TIA through a computerized linkage between the study 
database and medical records of general practitioners (GPs). This data linkage system is 
highly efficient in the Dutch situation where the GPs receive all medical information about 
their patients if they contact any medical caregiver or professional, including specialists. 
Additionally, nursing home physicians’ files and files from GPs of participants that moved 
out of the study area were checked on a regular basis. Information from GPs and hospital 
records was collected from participants with a potential stroke or TIA. Research physicians 
reviewed the information and an experienced vascular neurologist verified the strokes 
according to World Health Organization criteria.15,16 We defined TIAs as temporary attacks 
with presence of focal symptoms, which are attributable to dysfunction of one arterial 
territory of the brain.17 Follow-up for stroke and TIA was complete until 2013 for 98.5% of 
potential person-years.18 
 
 
 
Assessment of dementia 
Participants were screened for dementia at baseline and follow-up examinations using a 
three-step protocol.19 First, screening was done using the Mini-Mental State Examination 
(MMSE)20 and the Geriatric Mental Schedule (GMS) organic level. Second, screen-positives 
(MMSE < 26 or GMS organic level > 0) subsequently underwent an examination and 
informant interview with the Cambridge Examination for Mental Disorders in the Elderly 
(CAMDEX). Participants who were suspected of having dementia, underwent if necessary, 
further neuropsychological testing. Additionally, the total cohort was continuously 
monitored for dementia through computerized linkage between the study database and 
digitized medical records from GPs and the Regional Institute for Outpatient Mental 
Health Care. Third, a consensus panel led by a neurologist decided on the final diagnosis in 
accordance with standard criteria using the DSM-III-R criteria for dementia, the NINCDS-
ADRDA for Alzheimer disease,21 and the NINCDS-AIREN criteria for vascular dementia.22 
Follow-up for dementia was complete until 2013 for 98.4% of potential person-years.  
Cognitive tests 
From 2004-2008 and 2009-2013, participants underwent extensive cognitive testing. 
Executive function was assessed by the Stroop test (interference task) which tests 
attention and concentration, Letter-Digit Substitution Task which tests processing speed, 
and Verbal Fluency Test which assesses verbal fluency. Memory was assessed by the 15-
Word verbal Learning test including both immediate and delayed recall. Fine motor skills 
and coordination was assessed by the Purdue pegboard test for both hands.23 A higher 
score indicates a better cognitive performance for all tests, except the Stroop test in which 
a higher score indicates a worse performance as it measures time to complete the task. 
Covariates 
Smoking habits and medication use were assessed during the home interview. Participants 
were categorized into current, former and never smokers. Body mass index was calculated 
as weight in kilograms/height in meters squared. Total cholesterol and high-density 
lipoprotein cholesterol were measured in serum in mmol/L. Blood pressure was measured 
twice at the right arm in sitting position at the research center and average of two blood 
pressure readings was used. Diabetes mellitus type 2 was diagnosed as fasting blood 
glucose ≥ 7.00 mmol/L, or use of anti-diabetic medication evaluated by interview and 
pharmacy records.24 Cognitive score was assessed using the Mini-Mental State 
Examination.20 
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Statistical analyses 
We examined the risk of dementia in people with stroke or TIA as compared to people 
without stroke or TIA using Cox proportional hazard models. Adherence to the 
proportional hazards assumption was tested by plotting smoothed Schoenfeld residuals 
against time; no violations of the assumption were identified. Stroke or TIA was used as 
time varying exposure, which took into account the incident cases of stroke or TIA as they 
occurred during follow-up. Participants were censored at date of dementia, date of death, 
or last date of follow-up, whichever came first. Subsequently, we examined this 
association across levels of education by stratifying on educational level as well as by 
including an interaction term. In secondary analyses, we examined this association in men 
and women separately since levels of education differ between older men and women, as 
well as their risk factors for stroke.25  
Subsequently, we tested whether education is associated with change in cognitive test 
scores after a stroke or TIA using linear regression models. This was conducted in a 
subgroup of participants with stroke or TIA, for which cognitive test scores were available 
both before and after the stroke or TIA. Using low education level as the reference, we 
first examined the association of education with cognitive test scores before stroke or TIA. 
Second, we examined the association of education with cognitive test scores after stroke 
or TIA. Finally, the association of education with the change in cognitive tests scores after 
stroke or TIA was examined. This was tested by performing linear regression of education 
with cognitive test scores after stroke or TIA, adjusting for the test score before stroke or 
TIA.  
For all analyses, two models were fitted. Model 1 was adjusted for age and sex only 
(where applicable). Model 2 was additionally adjusted for education level (where 
applicable), body mass index, smoking, total and high-density lipoprotein cholesterol, 
systolic and diastolic blood pressure, lipid- and blood pressure-lowering medication, 
diabetes mellitus type 2, and MMSE. The analyses of change in cognition were additionally 
adjusted for time between the two cognitive examinations. The dementia analyses were 
adjusted for covariates using their baseline values, while cognition analyses were adjusted 
using the values of covariates from the first visit of cognition assessment. Missing values 
on covariates (< 6%) were handled by multiple imputations. 
Data were analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, 
USA) and IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
 
 
 
RESULTS 
This study included 12,561 dementia-, TIA-, and stroke-free participants at baseline. Table 
1 summarizes baseline characteristics of the study population. People with higher 
education were younger and more frequently men. During a mean follow-up of 9.9 ± 5.2 
years, 1,463 persons suffered a stroke or TIA and 1,158 persons were diagnosed with 
dementia; 186 persons developed dementia after a stroke or TIA. 
 
Table 1. Baseline characteristics of the study population, N=12,561. 
Characteristics Levels of education 
 Low Intermediate High 
 N=5,299 N=5,342 N=1,920 
Age, years 67.8 (9.9) 63.3 (8.8) 60.0 (8.2) 
Women 3754 (70.8) 2838 (53.1) 735 (38.3) 
Body mass index, kg/m2 27.2 (4.2) 26.8 (4.1) 26.5 (3.9) 
Smoking    
Never 1,993 (37.9) 1,558 (29.3) 539 (28.1) 
Former 2,018 (38.4) 2,459 (46.2) 950 (49.6) 
Current  1,247 (23.7) 1,301 (24.5) 428 (22.3) 
Total cholesterol, mmol/L 6.4 (1.3) 6.1 (1.2) 5.8 (1.2) 
HDL cholesterol, mmol/L 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 
Lipid lowering medication 409 (7.7) 556 (10.4) 222 (11.6) 
Systolic blood pressure, mmHg 139.8 (22.2) 137.3 (20.9) 135.3 (21.1) 
Diastolic blood pressure, mmHg 76.0 (12.0) 78.0 (11.6) 79.8 (11.7) 
Blood pressure lowering medication 1,313 (24.8) 1,131 (21.2) 350 (18.3) 
Mini Mental State Examination, points 27.2 (2.1) 28.2 (1.5) 28.6 (1.4) 
Diabetes mellitus type 2 417 (8.6) 390 (7.7) 107 (5.8) 
 
Abbreviations: HDL high density lipoprotein; N number of persons included in study. 
Values are means (standard deviation) or counts (percentage). 
 
People with a stroke or TIA had an increased risk of dementia compared to participants 
without stroke or TIA (multivariable adjusted hazard ratio (HR) 1.42 (95% CI: 1.20, 1.67)). 
In analyses stratified for education, this risk was highest in persons with low education, HR 
1.46 (95% CI: 1.18, 1.81), followed by those with intermediate education, HR 1.38 (95% CI: 
1.04, 1.83).In the high education group, people with a stroke or TIA did not have an 
increased risk of dementia compared to people without a stroke or TIA, HR 0.61 (95% CI: 
0.25, 1.50) (Table 2). 
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Stratification by gender showed a similar pattern of associations, which was more 
pronounced in men than in women (Table 3). Interaction testing of educational level with 
stroke or TIA on the risk of dementia yielded p-value 0.71 in the overall population, 0.05 in 
men, and 0.79 in women. 
 
Table 2. Risk of dementia after stroke or TIA by levels of education. 
 Risk of dementia, hazard ratios (95% confidence intervals) 
 n/Na n/Nb Model 1c Model 2d 
Total population 1,158/12,561 186/1,463 1.40 (1.19, 1.65) 1.42 (1.20, 1.67) 
Strata of education     
Low education 732/5,299 112/749 1.47 (1.19, 1.81) 1.46 (1.18, 1.81) 
Intermediate 
education 364/5,342 68/576 1.38 (1.04, 1.82) 1.38 (1.04, 1.83) 
High education 62/1,920 6/138 0.74 (0.31, 1.77) 0.61 (0.25, 1.50) 
 
Abbreviations: TIA transient ischemic attack 
a n/N: number of dementia cases/total number of participants at risk for dementia. 
b n/N: number of dementia cases after stroke or TIA/total number of stroke or TIA. 
c Model 1: adjusted for age and sex. 
d Model 2: additionally adjusted for age, sex, education (where applicable), Mini-Mental state Examination score, 
body mass index, smoking, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication use, 
systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication use, and diabetes mellitus 
type 2. 
 
People with high education scored better on 15-Word verbal learning test (both 
immediate and delayed recall), Verbal fluency test, and Letter Digit Substitution task both 
before and after stroke or TIA (Table 4). When we studied the change in cognitive test 
scores from before to after stroke or TIA, we found that that people with high education 
declined less in delayed recall compared to people with low education, β 1.42 (95% CI: 
0.34, 2.50). Effect sizes of the Stroop interference task and Verbal fluency test also 
suggested a lower decline in the higher education group, although only borderline 
significant. 
 
 
 Table 3. Risk of dem
entia after a stroke or TIA by levels of education in m
en and w
om
en. 
 
Risk of dem
entia, hazard ratios (95%
 confidence intervals) 
 
M
en 
W
om
en 
 
n/N
a 
n/N
b 
M
odel 1
c 
M
odel 2
d 
n/N
a 
n/N
b 
M
odel 1
c 
M
odel 2
d 
Total population 
360/5,234 
70/618 
1.56 (1.18; 2.06) 
1.67 (1.26; 2.21) 
798/7327 
116/845 
1.33 (1.08; 1.63) 
1.32 (1.07; 1.62) 
Strata of education 
 
 
 
 
 
 
 
 
Low
 education 
147/1,545 
29/202 
2.10 (1.36, 3.23) 
2.20 (1.42, 3.42) 
585/3,754 
83/547 
1.33 (1.04, 1.70) 
1.32 (1.03, 1.68) 
Interm
ediate education 
172/2,504 
36/320 
1.36 (0.91, 2.03) 
1.47 (0.98, 2.20) 
192/2838 
32/256 
1.41 (0.95, 2.09) 
1.40 (0.94, 2.08) 
High education 
41/1,185 
5/96 
0.87 (0.33, 2.30) 
0.68 (0.24, 1.95) 
21/735 
1/42 
0.33 (0.04, 2.61) 
0.21 (0.02, 1.95) 
 Abbreviations: TIA transient ischem
ic attack. 
an/N
: num
ber of dem
entia cases/total num
ber of participants at risk for dem
entia. 
bn/N
: num
ber of dem
entia cases after stroke or TIA
/total num
ber of stroke or TIA
. 
M
odel 1: adjusted for age. 
M
odel 2: adjusted for age, education (w
here applicable), M
ini-M
ental state Exam
ination score, body m
ass index, sm
oking, total cholesterol, high-density lipoprotein 
cholesterol, lipid-low
ering m
edication use, systolic blood pressure, diastolic blood pressure, blood pressure-low
ering m
edication use, and diabetes m
ellitus type 2. 
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1.41 (0.95, 2.09) 
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0.87 (0.33, 2.30) 
0.68 (0.24, 1.95) 
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0.33 (0.04, 2.61) 
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 Abbreviations: TIA transient ischem
ic attack. 
an/N
: num
ber of dem
entia cases/total num
ber of participants at risk for dem
entia. 
bn/N
: num
ber of dem
entia cases after stroke or TIA
/total num
ber of stroke or TIA
. 
M
odel 1: adjusted for age. 
M
odel 2: adjusted for age, education (w
here applicable), M
ini-M
ental state Exam
ination score, body m
ass index, sm
oking, total cholesterol, high-density lipoprotein 
cholesterol, lipid-low
ering m
edication use, systolic blood pressure, diastolic blood pressure, blood pressure-low
ering m
edication use, and diabetes m
ellitus type 2. 
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 Table 4. Change in cognitive test scores after stroke or TIA by levels of education. 
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(correct answ
ers) 
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(anim
al nam
es listed) 
15-W
LT-Im
m
ediate 
recall (correct answ
ers) 
15-W
LT-Delayed recall 
(correct answ
ers) 
Purdue Pegboard 
(num
ber of pins placed) 
 
Difference (95%
 confidence intervals) 
Before stroke or TIA 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-0.46 (-6.83; 5.92) 
4.04 (1.79; 6.29) 
1.32 (-0.39; 3.03) 
2.55 (0.45; 4.65) 
1.32 (0.31; 2.33) 
0.56 (0.03; 1.08) 
High-education 
43 
-4.29 (-12.15; 3.57) 
6.01 (3.24; 8.78) 
5.11 (3.03; 7.20) 
4.77 (2.25; 7.30) 
2.09 (0.87; 3.31) 
0.36 (-0.28; 1.00) 
After stroke or TIA 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-3.24 (-11.32; 4.85) 
3.35 (1.16; 5.53) 
1.64 (-0.16; 3.44) 
3.41 (1.29; 5.52) 
1.32 (0.33; 2.31) 
0.20 (-0.39; 0.79) 
High-education 
43 
-11.31 (-21.29; -1.33) 
4.86 (2.17; 7.56) 
4.66 (2.46; 6.85) 
4.86(2.31; 7.40) 
2.44 (1.25; 3.63) 
-0.06 (-0.78; 0.65) 
Decline after 
stroke or TIA 
Difference in change in cognition (95%
 confidence intervals) 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-2.87 (-9.58; 3.85) 
0.60 (-1.04; 2.25) 
0.91 (-0.65; 2.47) 
2.09 (0.24; 3.93) 
0.68 (-0.20; 1.56) 
0.02 (-0.55; 0.60) 
High-education 
43 
-8.44 (-16.77; -0.11) 
0.80 (-1.25; 2.84) 
1.87 (-0.13; 3.88) 
2.21 (-0.07; 4.49) 
1.42 (0.34; 2.50) 
-0.18 (-0.88; 0.51) 
 Abbreviations: Int. Interm
ediate; LDST Letter-Digit Substitution Task; VFT Verbal Fluency Test; 15-W
LT 15-W
ord Learning Test; N
 num
ber of persons w
ith at least one 
cognitive test 
Estim
ates represent differences in test score, and differences in change in cognitive test scores as com
pared to the low
 education category, w
ith 95%
 confidence 
intervals. A higher score indicates a better cognitive perform
ance for all tests (scores), except the Stroop test (tim
e taken to finish the task, in seconds) in w
hich a higher 
score indicates a w
orse perform
ance.Change in cognition is defined as cognition after stroke or TIA, adjusted for cognition before stroke or TIA.  
Estim
ates are adjusted for age, sex, body m
ass index, sm
oking, total cholesterol, high-density lipoprotein cholesterol, lipid-low
ering m
edication use, systolic blood 
pressure, diastolic blood pressure, blood pressure-low
ering m
edication use, and diabetes m
ellitus type 2. Estim
ates for change in cognition are additionally adjusted for 
tim
e betw
een the tw
o exam
ination dates.  
 
 
 
DISCUSSION 
This population-based study showed that stroke or TIA increased the risk of subsequent 
dementia in persons with low and intermediate education, but not in persons with high 
education. Additionally, as compared to people with low education, those with high 
education not only scored better on cognitive tests both before and after stroke or TIA, 
but also declined less on cognitive test scores after a stroke or TIA. 
It is known that people with stroke or TIA have an increased risk of dementia compared to 
those without stroke or TIA,17,26 but we showed that this effect was dependent upon the 
level of education. This differing effect across levels of education, points towards a 
protective role for cognitive reserve. Cognitive reserve is an established concept and has 
been shown to protect against Alzheimer pathology. A major novelty of our study is that 
we demonstrated the protective role of cognitive reserve against clinical cerebrovascular 
pathology. 
Here we point out that clinical studies have previously identified low education as a risk 
factor for dementia in patients with stroke, but because of the clinical setting, a 
comparison to risk of dementia in persons without stroke was lacking.13,27-29 It is 
specifically this comparison with persons without stroke that provides evidence for 
cognitive reserve as a protective factor against post-stroke dementia. Therefore, the 
second major novelty of our study is that we were able to make this comparison and 
importantly showed that in persons with high education, stroke or TIA did not increase the 
risk of dementia. This suggests that people with higher education, and hence higher 
cognitive reserve can bear more cerebrovascular damage before it becomes clinically 
apparent as dementia. 
The question remains what the underlying neural substrate is of cognitive reserve. One 
explanation is that people with higher cognitive reserve might be more resilient to the 
damage caused by a stroke or TIA, either due to better efficiency, capacity, or flexibility of 
brain networks already present before the damage occurred (neural reserve), or because 
of better compensation for the damage (neural compensation). Neural compensation 
pertains to the ability of persons with higher cognitive reserve, to form collateral networks 
in the brain, when the usual neuronal networks are compromised by the vascular 
damage.2,30,31 Studies have suggested that cognitively stimulating activities, which are 
mostly experienced during education, not only promote neurogenesis, but also upregulate 
Brain Derived Neurotrophic Factor (BDNF) which in turn promotes plasticity.1,31 However, 
an alternative explanation is that people with higher education have a more favorable 
Chapter 3.3
174
Cognitive reserve after stroke or TIA
175
 
 
 Table 4. Change in cognitive test scores after stroke or TIA by levels of education. 
 
N
 
Stroop interference 
task (seconds) 
LDST 
(correct answ
ers) 
VFT 
(anim
al nam
es listed) 
15-W
LT-Im
m
ediate 
recall (correct answ
ers) 
15-W
LT-Delayed recall 
(correct answ
ers) 
Purdue Pegboard 
(num
ber of pins placed) 
 
Difference (95%
 confidence intervals) 
Before stroke or TIA 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-0.46 (-6.83; 5.92) 
4.04 (1.79; 6.29) 
1.32 (-0.39; 3.03) 
2.55 (0.45; 4.65) 
1.32 (0.31; 2.33) 
0.56 (0.03; 1.08) 
High-education 
43 
-4.29 (-12.15; 3.57) 
6.01 (3.24; 8.78) 
5.11 (3.03; 7.20) 
4.77 (2.25; 7.30) 
2.09 (0.87; 3.31) 
0.36 (-0.28; 1.00) 
After stroke or TIA 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-3.24 (-11.32; 4.85) 
3.35 (1.16; 5.53) 
1.64 (-0.16; 3.44) 
3.41 (1.29; 5.52) 
1.32 (0.33; 2.31) 
0.20 (-0.39; 0.79) 
High-education 
43 
-11.31 (-21.29; -1.33) 
4.86 (2.17; 7.56) 
4.66 (2.46; 6.85) 
4.86(2.31; 7.40) 
2.44 (1.25; 3.63) 
-0.06 (-0.78; 0.65) 
Decline after 
stroke or TIA 
Difference in change in cognition (95%
 confidence intervals) 
Low
-education 
73 
Ref 
Ref 
Ref 
Ref 
Ref 
Ref 
Int-education 
89 
-2.87 (-9.58; 3.85) 
0.60 (-1.04; 2.25) 
0.91 (-0.65; 2.47) 
2.09 (0.24; 3.93) 
0.68 (-0.20; 1.56) 
0.02 (-0.55; 0.60) 
High-education 
43 
-8.44 (-16.77; -0.11) 
0.80 (-1.25; 2.84) 
1.87 (-0.13; 3.88) 
2.21 (-0.07; 4.49) 
1.42 (0.34; 2.50) 
-0.18 (-0.88; 0.51) 
 Abbreviations: Int. Interm
ediate; LDST Letter-Digit Substitution Task; VFT Verbal Fluency Test; 15-W
LT 15-W
ord Learning Test; N
 num
ber of persons w
ith at least one 
cognitive test 
Estim
ates represent differences in test score, and differences in change in cognitive test scores as com
pared to the low
 education category, w
ith 95%
 confidence 
intervals. A higher score indicates a better cognitive perform
ance for all tests (scores), except the Stroop test (tim
e taken to finish the task, in seconds) in w
hich a higher 
score indicates a w
orse perform
ance.Change in cognition is defined as cognition after stroke or TIA, adjusted for cognition before stroke or TIA.  
Estim
ates are adjusted for age, sex, body m
ass index, sm
oking, total cholesterol, high-density lipoprotein cholesterol, lipid-low
ering m
edication use, systolic blood 
pressure, diastolic blood pressure, blood pressure-low
ering m
edication use, and diabetes m
ellitus type 2. Estim
ates for change in cognition are additionally adjusted for 
tim
e betw
een the tw
o exam
ination dates.  
 
 
 
DISCUSSION 
This population-based study showed that stroke or TIA increased the risk of subsequent 
dementia in persons with low and intermediate education, but not in persons with high 
education. Additionally, as compared to people with low education, those with high 
education not only scored better on cognitive tests both before and after stroke or TIA, 
but also declined less on cognitive test scores after a stroke or TIA. 
It is known that people with stroke or TIA have an increased risk of dementia compared to 
those without stroke or TIA,17,26 but we showed that this effect was dependent upon the 
level of education. This differing effect across levels of education, points towards a 
protective role for cognitive reserve. Cognitive reserve is an established concept and has 
been shown to protect against Alzheimer pathology. A major novelty of our study is that 
we demonstrated the protective role of cognitive reserve against clinical cerebrovascular 
pathology. 
Here we point out that clinical studies have previously identified low education as a risk 
factor for dementia in patients with stroke, but because of the clinical setting, a 
comparison to risk of dementia in persons without stroke was lacking.13,27-29 It is 
specifically this comparison with persons without stroke that provides evidence for 
cognitive reserve as a protective factor against post-stroke dementia. Therefore, the 
second major novelty of our study is that we were able to make this comparison and 
importantly showed that in persons with high education, stroke or TIA did not increase the 
risk of dementia. This suggests that people with higher education, and hence higher 
cognitive reserve can bear more cerebrovascular damage before it becomes clinically 
apparent as dementia. 
The question remains what the underlying neural substrate is of cognitive reserve. One 
explanation is that people with higher cognitive reserve might be more resilient to the 
damage caused by a stroke or TIA, either due to better efficiency, capacity, or flexibility of 
brain networks already present before the damage occurred (neural reserve), or because 
of better compensation for the damage (neural compensation). Neural compensation 
pertains to the ability of persons with higher cognitive reserve, to form collateral networks 
in the brain, when the usual neuronal networks are compromised by the vascular 
damage.2,30,31 Studies have suggested that cognitively stimulating activities, which are 
mostly experienced during education, not only promote neurogenesis, but also upregulate 
Brain Derived Neurotrophic Factor (BDNF) which in turn promotes plasticity.1,31 However, 
an alternative explanation is that people with higher education have a more favorable 
Chapter 3.3
176
Cognitive reserve after stroke or TIA
177
 
 
 
environment including a healthier lifestyle and better access to healthcare. This might lead 
to less severe strokes, perhaps better detection of less severe strokes, and more 
importantly, early hospitalization and thus fewer complications after stroke.  
In analyses stratified on gender, we found that the pattern of associations was more 
pronounced in men than in women. This suggests a stronger protective effect of cognitive 
reserve against dementia following stroke in men. One explanation could be that only few 
women had dementia after a stroke or TIA in the high education group, which could have 
affected our power. For low and intermediate education groups, for which we had larger 
numbers, results were similar for men and women. Another explanation could be that 
perhaps in women from older generation birth cohorts, education is less representative of 
their cognitive reserve than in men, particularly for West-European populations. In our 
study, many women were born in a period when girls were not equally encouraged for 
education as boys, and often only completed limited years of education, which was not 
reflective of their potential. Instead, they quit school to work at home. Therefore, in this 
group, educational level might not be the best proxy for cognitive reserve and thus 
obscured any associations in women. The time spent on leisure activities including social, 
physical and recreational activities might have been a better proxy for cognitive reserve, 
but we did not have that information in our study. 
The finding in our study of less cognitive decline in the high education category in people 
with stroke or TIA further supports the role of cognitive reserve. Unlike previous studies 
which only had information on cognitive decline after stroke or TIA,28,29 we had cognition 
assessments both before and after the stroke or TIA. This allowed to demonstrate that the 
impact of a stroke or TIA on cognition was smaller in people with high education, 
suggesting that persons with higher education not only have a better cognition in the first 
place, they can also adapt better to the cerebrovascular damage, indicating cognitive 
reserve.  
Strengths of this study include a large population-based sample representative of different 
levels of education, a long and robust follow-up of incident TIA, stroke, and dementia, and 
the availability of cognitive tests before and after stroke or TIA. However there are certain 
limitations. Only education as a measure of cognitive reserve was available. Activities in 
later life, such as occupation or leisure activities including recreation, physical and social 
engagements could not be taken into account, which might be important particularly in 
older adults. However, education is the most used measure of cognitive reserve in existing 
literature.30,32 Furthermore, we could not adjust for brain reserve in our study, since brain 
volumes were not available in this population. This might have led to an overestimation of 
 
 
 
results, as the observed associations could partly be explained by brain reserve. Another 
limitation is that we did not have information about the severity of stroke. It is possible 
that people with higher education had less severe strokes leading to less brain damage 
and therefore a smaller risk of dementia. Moreover, we did not have enough cases of 
dementia in the high education category for women and therefore the effect estimates 
might be underpowered. Finally, complete cognitive testing was available in a subgroup of 
our study population only, therefore the results might be influenced by selection. 
In conclusion, our study shows that cognitive reserve protects against dementia after 
cerebrovascular events. Future studies should explore the exact mechanism of this 
protective effect as well as investigate whether improvement of cognitive reserve later in 
life, for instance using cognitively stimulating activities, might delay or prevent dementia 
in stroke patients.
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ABSTRACT 
Background: The Amino-terminal pro B-type natriuretic peptide (NT-proBNP) has a well-
documented prognostic value for cardiovascular disease (CVD) and higher levels have 
been associated with cognitive dysfunction in CVD patients. However, how NT-proBNP 
relates to incident dementia and cognitive-decline in community-dwelling persons is 
unknown.  
Methods: Between 1997-2001, serum NT-proBNP was measured in 6,040 participants 
(mean age 69 years, 57% women) free of heart-failure and dementia from the population-
based Rotterdam Study. Persons were continuously followed-up for incident dementia till 
2012, for 56,616 person-years. Cognition was assessed at baseline and reassessed 
between 2002-2006 by Letter-Digit-Substitution-task, Stroop test, and Word-Fluency test. 
Associations of NT-proBNP with dementia (555 cases), Alzheimer’s disease (357 cases), 
and vascular dementia (32 cases) were assessed linearly and in quartiles using Cox 
regression. Associations of NT-proBNP with cognitive-decline were assessed using multiple 
linear regression. All analyses were repeated after excluding persons with any CVD.  
Results: Higher NT-proBNP was associated with a higher risk of dementia, even after 
excluding persons with CVD and adjusting for cardiovascular risk factors, HR per SD 1.27 
(95%CI: 1.13, 1.44). Associations were particularly strong for vascular dementia, HR per SD 
2.04 (95%CI: 1.18, 3.55), but also for Alzheimer’s disease when comparing the second and 
third quartile with the first. Higher NT-proBNP was cross-sectionally associated with 
poorer performance in multiple cognitive tests but longitudinally only in Letter-Digit-
Substitution-task.  
Conclusions: NT-proBNP reflecting subclinical CVD is associated with dementia, 
particularly vascular dementia. NT-proBNP can be a useful marker of imminent cognitive-
decline and dementia in the absence of clinical CVD. 
  
 
 
 
INTRODUCTION 
Dementia is a major public health concern, with a prevalence of 35.6 million patients, and 
7.7 million new cases every year worldwide.1 Dementia, including Alzheimer’s disease, has 
a multifactorial etiology with a substantial vascular component.2-5 Amino-terminal pro B-
type natriuretic peptide (NT-proBNP) is an emerging serum marker for cardiovascular 
diseases.6,7 NT-proBNP is the inactive amino terminal of proBNP, which is synthesized and 
released from the ventricular myocardium in response to stretch of cardiomyocytes due to 
volume or pressure overload, and higher levels mark the presence of cardiovascular 
disease, particularly heart failure (HF).8 It has been shown that after adjustment for the 
classical cardiovascular risk factors, higher levels of NT-proBNP were associated with up to 
two-fold increased risk of coronary heart disease and ischemic stroke,9-11and 3-fold 
increase in the risk of HF as compared to those with lower levels.9 Importantly, it has been 
suggested that NT-proBNP indicates vascular disease even in the absence of overt clinical 
cardiovascular disease.12 Moreover, in absence of clinical cardiovascular disease, arterial 
stiffness was found to be independently associated with higher levels of NT-proBNP.13  
Previously, associations of NT-proBNP and BNP with dementia and cognition have been 
reported in relatively small studies or in clinical settings, precluding generalizability of the 
findings.14-18 Therefore, two important knowledge gaps remain. First, it remains largely 
unknown how NT-proBNP relates to dementia and Alzheimer’s disease in community-
dwelling persons, which is important to assess its public health impact. Second, the role of 
clinical cardiovascular disease in the association of NT-proBNP with dementia is unclear. It 
is conceivable that many persons with subclinical vascular disease, as reflected by 
increased NT-proBNP, would first experience clinical cardiovascular disease and 
subsequently develop dementia. This issue can be addressed in a longitudinal design that 
censors for onset of clinical cardiovascular disease. 
This paper aims to assess the association of NT-proBNP with incident dementia, 
Alzheimer’s disease, vascular dementia, and cognitive decline in a large population-based 
cohort study. Importantly, we also studied these associations in persons without clinical 
cardiovascular disease to elucidate the role of NT-proBNP as a marker of subclinical 
cardiovascular disease and its association with dementia. 
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METHODS 
Setting 
This study was part of the Rotterdam Study, a population-based cohort ongoing since 
1990, which studies chronic diseases in the elderly. In 1990, 7,983 participants were 
enrolled. In 2000, the original cohort was extended by additionally recruiting 3,011 
participants. Follow-up examinations including home interviews and physical exams at the 
research center take place every 3 to 4 years.19 The Rotterdam Study has been approved 
by the medical ethics committee according to the Population Study Act Rotterdam Study, 
executed by the Ministry of Health, Welfare and Sports of the Netherlands. A written 
informed consent was obtained from all participants. 
Study population 
NT-proBNP was assessed between 1997 and 2001 in 3,930 participants of the original 
cohort, and 2,580 participants recruited in the second cohort. Of these 6,510 participants, 
12 with an unreliable NT-proBNP test measure, and 47 not consenting to undergo 
dementia screening were excluded. In addition, 112 persons with prevalent dementia, 243 
with prevalent HF, 24 with incomplete HF follow-up, and 32 persons not consenting for HF 
follow-up were excluded. This yielded a total of 6,040 participants eligible for analyses. 
Cognition was assessed at baseline (1997-2001) in 5,693 participants, and at a follow-up 
examination (2002-2006) in 4,509 participants. 
Participants were censored if died or lost to follow-up. If participants were lost to follow-
up, they were censored on the date they were last seen/contacted. 
Assessment of NT-pro-BNP 
Blood samples for NT-proBNP measurement were collected in glass tubes containing clot 
activator and gel for serum separation. After collection, samples were allowed to stand for 
30 minutes for clotting and then centrifuged for 20 minutes at 3000 rpm at 4ºC. 
Subsequently, serum was stored at -80ºC. NT-proBNP was measured using commercially 
available electrochemiluminescense immunoassay (Elecsys proBNP, F.Hoffman-La Roche 
Ltd. Basel, Switzerland) on an Elecsys 2010 analyser.13 The precision, analytic sensitivity 
and stability features of the system have been described previously.20 NT-proBNP levels 
are reported in pmol/L.  
 
 
 
 
Assessment of dementia 
Participants were screened for dementia at baseline and follow-up examinations using a 
three-step protocol.21 Screening was done using the Mini-Mental State Examination 
(MMSE) and the Geriatric Mental Schedule (GMS) organic level. Screen-positives (MMSE < 
26 or GMS organic level > 0) subsequently underwent an examination and informant 
interview with the Cambridge Examination for Mental Disorders in the Elderly (CAMDEX). 
Participants who were suspected of having dementia, underwent if necessary, further 
neuropsychological testing. Additionally, the total cohort was continuously monitored for 
dementia through computerized linkage between the study database and digitized 
medical records from general practitioners (GPs) and the Regional Institute for Outpatient 
Mental Health Care. Finally, a consensus panel led by a neurologist, decided on the final 
diagnosis in accordance with standard criteria using the DSM-III-R criteria for dementia, 
the NINCDS-ADRDA for Alzheimer disease,22 and the NINCDS-AIREN criteria for vascular 
dementia.23 If required for differential diagnosis, neuroimaging was used. Cases of 
Alzheimer’s disease that also showed evidence of cerebrovascular disease, were classified 
as Alzheimer’s disease+cerebrovascular disease, which in all analyses is included as 
Alzheimer’s disease (5% of all cases). The data linkage system mentioned above is highly 
efficient in the Dutch situation and the possibility of underestimation is very low. In this 
setting, the GPs receive all medical information about their patients if they contact any 
medical care-giver or professional including specialists. Although, it is difficult to ascertain 
the exact number of cases that could have been missed by the system, we calculated the 
potential and observed person-years to calculate the completeness of dementia follow-
up24 which was complete (97.92 %) till January 2012. 
Assessment of cognition 
The cognitive test battery comprised the Letter-Digit-Substitution task (LDST) which tests 
processing speed, Stroop test (including reading, colour-naming, and interference 
subtasks) which tests attention and concentration, and the Word-Fluency test (WFT) 
which assesses verbal fluency and executive function.25 Cognition was assessed at baseline 
in 1997-2001, and reassessed at the follow-up examination round in 2002-2006. 
Other measurements 
NT-proBNP reflects cardiovascular health; body mass index, serum lipid levels, 
hypertension, diabetes mellitus type 2, level of education of individuals, APOE genotype, 
life-style habits such as alcohol intake and smoking, inflammatory markers such as C-
reactive protein (CRP), atherosclerotic markers such as carotid intima-media thickness 
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(IMT), and cardio- and cerebrovascular events such as myocardial infarction (MI) and 
stroke are associated with cardiovascular disease.26-29 All these factors are also 
independent predictors of dementia,30-33 and therefore were considered as potential 
confounders in addition to age and sex. Body mass index (BMI) was calculated as weight in 
kilograms/height in meters squared. Total cholesterol and high density lipoprotein (HDL) 
cholesterol were measured in serum in mmol/L. Blood pressure was measured twice at 
the right arm in sitting position at the research center and average of two blood pressure 
readings was used. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, or 
diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive medication assessed by 
interview and pharmacy records.34 Diabetes mellitus type 2 (DM) was diagnosed as fasting 
blood glucose ≥ 7.00 mmol/L, or use of anti-diabetic medication evaluated by interview 
and pharmacy records.35  Educational level was assessed during the home interview and 
people were classified into two categories: low level of education (primary only or 
unfinished secondary), and intermediate to high (secondary, vocational, or university). For 
APOE-ɛ4 carrier status, persons were classified in two categories; non-carriers of APOE-ɛ4 
allele, or carriers of one or two APOE-ɛ4 alleles. Alcohol intake was inquired during the 
home interview and participants were dichotomized as consumers versus non-consumers. 
Smoking habits were also assessed during the home interview and participants were 
categorized into current, former and never smokers. High-sensitivity CRP was measured in 
serum in nmol/L.36  An average of 3 measures of carotid IMT by ultrasonography on both 
sides was used to calculate a mean measure for analyses.37 All covariates were measured 
at baseline and were modelled as fixed at baseline. Cardiovascular disease was defined as 
prevalent or incident HF, stroke, MI, or any coronary revascularization procedure, as 
described previously14 and participants were continuously monitored for all major 
cardiovascular events through automated linkage of study database with GP files.38 HF 
was assessed by a validated score similar to the definition of heart failure of the European 
society of Cardiology.39 This score was based on the presence of at least two signs of 
symptoms of heart failure (shortness of breath, ankle swelling and pulmonary 
crepitations) confirmed by chest X-ray and echocardiography or use of medication for the 
indication of HF in combination with objective evidence of cardiovascular diseases.40 
Previous stroke and MI were determined by reported events on interview and confirmed 
by medical records. Stroke was defined according to the WHO criteria as a syndrome of 
rapidly developing clinical signs of focal or global disturbance of cerebral function with 
symptoms lasting 24 hours or longer or leading to death, with no apparent cause other 
than of vascular origin.41 MI was diagnosed by a cardiologist or an internist and is defined 
as pathology findings of an acute MI within 28 days of death, or a rise/fall in cardiac 
biomarkers and/or objective indicative ECG changes, and preferably the presence of signs 
 
 
 
and symptoms of MI. Revascularization procedures included coronary artery bypass 
grafting (CABG) and percutaneous coronary interventions (PCIs).42 
Statistical Analyses 
We log-transformed the NT-proBNP data to achieve a normal distribution, and then 
standardized the values by creating z-scores (log-transformed NT-proBNP minus mean of 
log-transformed NT-proBNP, divided by standard deviation of log-transformed NT-
proBNP). In addition, we classified persons into quartiles on basis of NT-proBNP levels.  
Risk of dementia, Alzheimer’s disease, and vascular dementia was assessed using Cox 
proportional hazards models both linearly and in quartiles. Adherence to the proportional 
hazards assumption was tested by plotting smoothed schoenfeld residuals against time; 
no violations of the assumption were identified. In addition, analyses were repeated with 
tertiles and quintiles to test the dose effect. As sensitivity analyses, a competing risk 
analysis was also performed to account for death as a competing risk for the incidence of 
dementia, Alzheimer’s and vascular dementia. Cross-sectional associations between NT-
proBNP and cognitive function tested by LDST, Stroop1, Stroop2, Stroop3, and WFT were 
assessed by multiple linear regression models. Decline in the scores of all cognitive tests 
from the baseline assessment to the end of follow-up was studied using multiple linear 
regression models which were adjusted for baseline test scores. 
All analyses were repeated after excluding persons with cardiovascular disease. For Cox 
regression analyses, this meant that persons with prevalent cardiovascular disease were 
excluded, whereas all incident cases of cardiovascular disease were censored. 
Two models were fitted for all analyses. Model 1 was adjusted for age and sex only. Model 
2 was additionally adjusted for APOE-ɛ4 carrier status, education level, alcohol intake, 
BMI, smoking, hypertension, total cholesterol, HDL, CRP, carotid IMT, and DM. BMI was 
also tested as a quadratic term, BMI2, but was not included in the final model as there was 
no evidence of a U-shaped association between BMI and dementia.  
The following variables had missing values which were dealt with, using multiple 
imputations using all covariates of interest as predictors:  APOE-ɛ4 carrier status (3%), 
education level (1.3%), alcohol intake (0.8%), BMI (0.9%), smoking (0.2%), hypertension 
(0.1 %), total cholesterol (0.6%), HDL (1.4%), CRP (4.2%), and carotid IMT (8.2%). Data 
were analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, USA). 
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rapidly developing clinical signs of focal or global disturbance of cerebral function with 
symptoms lasting 24 hours or longer or leading to death, with no apparent cause other 
than of vascular origin.41 MI was diagnosed by a cardiologist or an internist and is defined 
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and symptoms of MI. Revascularization procedures included coronary artery bypass 
grafting (CABG) and percutaneous coronary interventions (PCIs).42 
Statistical Analyses 
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RESULTS 
Table 1 summarizes baseline characteristics of the 6,040 persons followed-up for 
dementia for a mean follow-up of 9.4 years.  
 
Table 1. Baseline Characteristics of the study population, N=6,040. 
Characteristics Descriptives 
Age, years 69.0 (8.2) 
Women 3,502 (56.9) 
APOE-ɛ4 carriers* 1,643 (27.6) 
Education  
Primary or below 1,889 (31.1) 
Intermediate to high 4,177 (68.9) 
Body mass index, kg/m2 26.8 (3.9) 
Smoking  
Never 1,970 (32.1) 
Former 2,960 (48.2) 
Current  1,212 (19.7) 
Alcohol drinking 5,043 (83.6) 
Total cholesterol, mmol/L 5.8 (0.9) 
High-density lipoprotein, mmol/L 1.4 (0.4) 
NT-proBNP*, pmol/L 9.5 (5.1-18.3) 
C-reactive protein, nmol/L 17.4 (6.7-36.2) 
Carotid intima-media thickness, mm 1.0 (0.2) 
Prevalent disease  
Hypertension 3,536 (57.5) 
Myocardial infarction 391 (6.4) 
Diabetes mellitus type 2  557 (9.0) 
Stroke 286 (4.5) 
 
Values are means (standard deviations) or counts (percentages). 
Abbreviations: APOE-ɛ4: Apolipoprotein E-allele 4; NT-proBNP: N-terminal pro B-type natriuretic peptide and C-
reactive protein are presented as medians (inter-quartile ranges) because of skewed distribution. 
 
A total of 555 persons developed dementia during 56,616 person-years, of whom 357 
developed Alzheimer’s disease and 32 developed vascular dementia. 697 persons had 
prevalent cardiovascular disease at baseline, and 935 suffered incident cardiovascular 
disease during follow-up. Participants who died or were lost to follow-up (N=1,545+13) 
were more likely to be older, male, smokers, hypertensive, diabetic, and more likely to 
have suffered from an MI or stroke (supplement table 1). 
Higher levels of NT-proBNP were associated with an increased risk of dementia, HR per SD 
1.17 (95%CI: 1.05,1.30), which was particularly driven by vascular dementia, though 
statistically non-significant (Table 2). 
 
 
 
The risk estimates for dementia showed a gradual increase over the quartiles (Table 2 and 
Figure 1). 
 
 
 
 
Figure 1. Kaplan-Meier survival curves for dementia across quartiles of NT-proBNP. 
The curves show cumulative dementia-free survival across quartiles of NT-proBNP. 
 
Persons in the second and third quartiles of NT-proBNP also showed a significantly 
increased risk of Alzheimer’s disease compared to those in the lowest quartile. For 
vascular dementia, the number of cases was not sufficient to perform quartile analyses. 
Adjusting for cardiovascular risk factors did not materially change these results. A 
significant p-trend was observed when assessing the dose effect for NT-proBNP (p-trend 
0.02), and similar results were obtained in the analyses with tertiles and quintiles (data 
not shown). 
In the competing risk analyses, we still found an increased risk of dementia per SD 
increase of NT-proBNP, HR per SD 1.05 (95% CI: 1.01, 1.09). In contrast, the risk for 
Alzheimer’s disease in the continuous analyses inverted, HR per SD 0.92 (95% CI: 0.87, 
0.97), possibly because the pattern across quartiles showed a very strongly increased risk 
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in quartile 2 and less strongly increased risks in quartiles 3 and 4, which were substantially 
increased nevertheless. Overall, results of these analyses did not reveal a substantial, but 
only a minor effect of competing risks on our main findings. (Supplement table 2) 
After excluding persons with cardiovascular disease, NT-pro-BNP remained significantly 
associated linearly with dementia, HR per SD 1.27 (95%CI: 1.13,1.44), but now also with 
vascular dementia, HR per SD 2.04 (95%CI: 1.18,3.55) (Table 3). 
Associations over the quartiles attenuated slightly, but remained statistically significant 
with dementia over all quartiles, and with Alzheimer’s disease for the second quartile 
(Table 3). However, in a post-hoc power analyses, analyses for Alzheimer’s disease lacked 
sufficient power both in analyses with and without excluding CVD. In the competing risk 
analysis after excluding persons with CVD, effect estimates slightly changed, but the 
pattern of results remained the same. (Supplement table 2) 
Higher levels of NT-proBNP were associated with a poorer performance on LDST, and 
Stroop test cross-sectionally (Table 4). After excluding persons with cardiovascular 
disease, the association of NT-proBNP with LDST persisted (Table 4). 
 
Longitudinally, higher NT-proBNP was only associated with a significant decline in 
performance on LDST, which remained significant after excluding persons with 
cardiovascular disease (difference in decline per SD -0.21, 95%CI: -0.37,-0.04) (Table 5).  
 
 
 
 Table 2. Hazard ratios and 95 %
 confidence intervals for risk of incident dem
entia, per standard deviation increase, and across 
quartiles of N
T-proBN
P. 
N
T-proBN
P 
Dem
entia 
Alzheim
er's disease 
Vascular dem
entia 
 
n/N
a 
M
odel 1
b 
M
odel 2
c 
n/N
a 
M
odel 1
b 
M
odel 2
c 
n/N
a 
M
odel 1
b 
M
odel 2
c 
Per SD 
555/6,040 
1.19(1.07,1.32) 
1.17(1.05,1.30) 
357/6,040 
1.03(0.91,1.18) 
1.03(0.90,1.18) 
32/6,040 
1.34(0.90,2.01) 
1.27(0.85,1.91) 
Q
uartile 1 
57/1,511 
1.00 (ref) 
1.00 (ref) 
32/1,511 
1.00 (ref) 
1.00 (ref) 
2/1,511 
 
 
Q
uartile 2 
117/1,510 
1.45(1.05,2.00) 
1.39(1.01,1.92) 
86/1,510 
1.76(1.17,2.65) 
1.68(1.11,2.53) 
7/1,510 
—
 
—
 
Q
uartile 3 
176/1,509 
1.53(1.12,2.09) 
1.45(1.06,1.99) 
121/1,509 
1.62(1.08,2.43) 
1.54(1.02,2.32) 
8/1,509 
—
 
—
 
Q
uartile 4 
205/1,510 
1.59(1.16,2.18) 
1.52(1.10,2.09) 
118/1,510 
1.34(0.89,2.04) 
1.30(0.85,1.99) 
15/1,510 
—
 
—
 
 a D
em
entia cases/total num
ber of participants. 
b M
odel 1: Adjusted for age and sex. 
c M
odel 2: Additionally adjusted for APO
E-ɛ4 carrier status, education, alcohol intake, body m
ass index, sm
oking, hypertension, total cholesterol, high density lipoprotein, 
C-reactive protein, carotid intim
a-m
edia thickness, and diabetes m
ellitus 2. 
Hazard ratios for vascular dem
entia w
ere not calculated across quartiles of N
T-proBN
P because of sm
all num
ber of cases per quartile. 
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entia cases/total num
ber of participants. 
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E-ɛ4 carrier status, education, alcohol intake, body m
ass index, sm
oking, hypertension, total cholesterol, high density lipoprotein, 
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Hazard ratios for vascular dem
entia w
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all num
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 Table 3. Hazard ratios and 95 %
 confidence intervals for risk of incident dem
entia, per standard deviation increase, and across quartiles 
of N
T-proBN
P, in persons w
ithout cardiovascular disease. 
N
T-proBN
P 
Dem
entia 
Alzheim
er's disease 
Vascular dem
entia 
 
n/N
a 
M
odel 1
b 
M
odel 2
c 
n/N
a 
M
odel 1
b 
M
odel 2
c 
n/N
a 
M
odel 1
b 
M
odel 2
c 
Per SD 
461/5,343 
1.29(1.14,1.46) 
1.27(1.13,1.44) 
308/5,343 
1.14(0.98,1.33) 
1.13(0.96,1.31) 
19/5,343 
2.09(1.22,3.59) 
2.04(1.18,3.55) 
Q
uartile 1 
46/1,336 
1.00 (ref) 
1.00 (ref) 
32/1,336 
1.00 (ref) 
1.00 (ref) 
1/1,336 
 
 
Q
uartile 2 
94/1,337 
1.38(0.97,1.97) 
1.34(0.93,1.92) 
71/1,337 
1.63(1.04,2.55) 
1.58(1.00,2.47) 
2/1,337 
—
 
—
 
Q
uartile 3 
135/1,336 
1.49(1.05,2.12) 
1.42(1.00,2.01) 
97/1,336 
1.58(1.01,2.46) 
1.49(0.95,2.33) 
5/1,336 
—
 
—
 
Q
uartile 4 
191/1,334 
1.68(1.18,2.39) 
1.56(1.09,2.24) 
115/1,334 
1.38(0.87,2.18) 
1.28(0.80,2.04) 
11/1,334 
—
 
—
 
 a dem
entia cases/total num
ber of participants. 
b Adjusted for age and sex. 
c Additionally adjusted for APO
E-ɛ4 carrier status, education, alcohol intake, body m
ass index, sm
oking, hypertension, total cholesterol, high density lipoprotein, C-
reactive protein, carotid intim
a-m
edia thickness, and diabetes m
ellitus 2. 
Hazard ratios for vascular dem
entia w
ere not calculated across quartiles of N
T-proBN
P because of sm
all num
ber of cases per quartile. 
 
 
 
 
Table 4. Cross-sectional association between per SD increase in NT-proBNP and 
cognition in non-demented persons. 
Cognitive Tests All participants Participants without CVD 
 Difference (95% CI) Difference (95% CI) 
 Model 1a Model 2b Model 1a Model 2b 
LDST, number of 
correct answers -0.43 (-0.63, -0.23) -0.35(-0.55,-0.16) -0.40 (-0.61, -0.18) -0.31(-0.53,-0.10) 
Stroop 1, 
seconds 0.20 (0.07, 0.31) 0.19(0.07,0.31) 0.12 (-0.01, 0.25) 0.13(-0.01,0.26) 
Stroop 2, 
seconds 0.27 (0.11, 0.44) 0.25(0.08,0.42) 0.19 (0.01, 0.36) 0.17(-0.02,0.35) 
Stroop 3, 
seconds 0.72 (0.16, 1.29) 0.57(-0.01,1.14) 0.48 (-0.14, 1.10) 0.36(-0.25,0.98) 
WFT*, number of 
animals listed -0.12 (-0.28, 0.03) -0.07(-0.23,0.10) -0.07 (-0.24, 0.11) -0.07(-0.25,0.11) 
 
Abbreviations: CVD cardiovascular disease; LDST Letter-Digit Substitution task; WFT Word Fluency test 
a Adjusted for age and sex 
b Additionally adjusted for APOE-ɛ4 carrier status, education, alcohol intake, body mass index, smoking, 
hypertension, total cholesterol, high density lipoprotein, C-reactive protein, carotid intima-media thickness, and 
diabetes mellitus 2. 
 
Table 5. Longitudinal association between per SD increase in NT-proBNP and cognitive 
decline in non-demented persons. 
Cognitive Tests All participants Participants without CVD 
 Difference in decline (95 % CI) Difference in decline (95 % CI) 
 Model 1a Model 2b Model 1a Model 2b 
LDST, number of 
correct answers -0.22 (-0.36, -0.08) -0.22 (-0.36, -0.08) -0.19 (-0.35, -0.02) -0.21 (-0.37, -0.04) 
Stroop 1, 
seconds 0.08 (-0.05, 0.22) 0.07 (-0.07, 0.21) -0.02 (-0.17, 0.12) -0.02 (-0.17, 0.13) 
Stroop 2, 
seconds 0.06 (-0.08, 0.21) 0.05 (-0.10, 0.21) 0.11 (-0.05, 0.28) 0.11 (-0.06, 0.28) 
Stroop 3, 
seconds -0.63 (-1.30, 0.02) -0.72 (-1.40, -0.04) -0.91 (-1.69, -0.14) -0.84 (-1.62,-0.06) 
WFT*, number of 
animals listed -0.05 (-0.20, 0.10) -0.03 (-0.18, 0.12) 0.01 (-0,18, 0.18) 0.01 (-0.18, 0.19) 
 
Abbreviations: CVD cardiovascular disease; LDST Letter-Digit Substitution task WFT: Word Fluency test. 
a Adjusted for age and sex. 
b Additionally adjusted for APOE-ɛ4 carrier status, education, alcohol intake, body mass index, smoking, 
hypertension, total cholesterol, high density lipoprotein, C-reactive protein, carotid intima-media thickness, and 
diabetes mellitus 2. 
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correct answers -0.22 (-0.36, -0.08) -0.22 (-0.36, -0.08) -0.19 (-0.35, -0.02) -0.21 (-0.37, -0.04) 
Stroop 1, 
seconds 0.08 (-0.05, 0.22) 0.07 (-0.07, 0.21) -0.02 (-0.17, 0.12) -0.02 (-0.17, 0.13) 
Stroop 2, 
seconds 0.06 (-0.08, 0.21) 0.05 (-0.10, 0.21) 0.11 (-0.05, 0.28) 0.11 (-0.06, 0.28) 
Stroop 3, 
seconds -0.63 (-1.30, 0.02) -0.72 (-1.40, -0.04) -0.91 (-1.69, -0.14) -0.84 (-1.62,-0.06) 
WFT*, number of 
animals listed -0.05 (-0.20, 0.10) -0.03 (-0.18, 0.12) 0.01 (-0,18, 0.18) 0.01 (-0.18, 0.19) 
 
Abbreviations: CVD cardiovascular disease; LDST Letter-Digit Substitution task WFT: Word Fluency test. 
a Adjusted for age and sex. 
b Additionally adjusted for APOE-ɛ4 carrier status, education, alcohol intake, body mass index, smoking, 
hypertension, total cholesterol, high density lipoprotein, C-reactive protein, carotid intima-media thickness, and 
diabetes mellitus 2. 
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DISCUSSION 
In this prospective population-based study, higher levels of NT-proBNP were associated 
with a higher risk of dementia, including vascular dementia, and to a lesser extent with 
Alzheimer’s disease. Moreover, higher levels of NT-proBNP were associated with poorer 
performance on multiple cognitive domains cross-sectionally, but only with poorer 
information processing speed longitudinally. All associations persisted after excluding 
persons with cardiovascular disease and after adjustment for sociodemographic and 
cardiovascular risk factors. 
Strengths of this study are accounting for lifestyle and cardiovascular confounders, 
censoring for incident cardiovascular disease, and a long and robust follow-up for 
dementia. However, there are certain limitations. We did not have a specific test for 
memory at baseline, and therefore, the association of NT-proBNP and decline in memory 
could not be tested. Some selection based on NT-proBNP levels cannot be ruled out, as 
persons with severe cardiovascular disease, thus highest NT-pro-BNP levels, were less 
likely to attend the examination rounds. In addition, risk estimates for vascular dementia 
across quartiles of NT-proBNP could not be calculated due to small number of cases per 
quartile.  
We found that higher levels of NT-proBNP were associated with increased risk of 
dementia, particularly vascular dementia. There are no longitudinal studies to show an 
association of NT-proBNP with risk of dementia, but previously, one study showed the 
association of BNP with incident dementia and decline on MMSE scores in 464 persons 
over a follow-up of 5 years.17 The link between NT-proBNP and dementia can be explained 
in several ways. First, it is possible that persons with high NT-proBNP first suffer from a 
clinical cardiovascular event which subsequently leads to development of dementia. 
However, this is unlikely because we observed an association even after censoring persons 
with clinical cardiovascular disease during follow-up. Second, shared risk factors such as 
body mass index, smoking, or blood lipid levels could also explain the association between 
NT-proBNP and dementia. However, we observed that after adjusting for many potential 
confounders in this respect, associations attenuated only slightly, although some residual 
confounding cannot be fully ruled out. The third and most likely explanation is that NT-
proBNP reflects the presence of subclinical cardiovascular disease. Even though in clinical 
practice NT-proBNP is used as a marker of HF, studies have increasingly shown a role of 
NT-proBNP to reflect subclinical disease, especially poor cardiac function and volume 
overload in relation with hypertension.12 There is indeed evidence suggesting a role for 
subclinical cardiovascular disease in dementia, which is further supported by our data. The 
 
 
 
 
association of NT-proBNP with dementia in a cardiovascular disease free population 
controlled for cardiovascular risk factors indicates that neurodegenerative changes 
commence very early in the course of cardiovascular disease even when it is below the 
diagnostic threshold. Given the strong association of NT-proBNP with HF, information on 
cardiac function such as ejection fraction could be further informative to identify HF which 
has not been diagnosed. Interestingly, we found associations not only with vascular 
dementia, but with Alzheimer’s disease as well in the second and third quartiles of NT-
proBNP, which further advocates the role of vascular pathology in development of 
Alzheimer’s disease. Given the insidious onset of dementia through a long pre-clinical 
phase of cognitive decline, we also showed an important link of NT-proBNP with cognition 
cross-sectionally and to a lesser extent longitudinally. This suggests that subclinical 
cardiovascular disease already leads to subtle cognitive deficits without overt dementia 
and therefore pinpoints a potential window of opportunity for developing preventive 
strategies. Higher NT-proBNP was not associated with a significant decline in multiple 
domains because these analyses might be underpowered and changes would become 
detectable with increasing follow-up. In addition, there could be a selective attrition of 
persons with major cognitive deficits during follow-up. Further, it is possible that NT-
proBNP associates more with changes in memory rather than these domains, but we did 
not have memory tests to assess this association in this study. 
We did not observe statistical significance for the highest quartile of NT-proBNP in relation 
with Alzheimer’s disease in contrast to dementia. However, since we lacked sufficient 
power for Alzheimer’s disease analyses, definitive conclusions cannot be drawn from 
these estimates. Moreover, since dementia might represent multiple brain pathologies 
especially cerebrovascular, these findings possibly indicate that the higher risk for 
dementia was driven by the vascular component of dementia and NT-proBNP may be a 
marker of cerebrovascular pathology and associated cognitive deficits independent of 
Alzheimer’s disease pathology Additionally, results of the competing risk analyses did not 
reveal a substantial, but only a minor effect of competing risks on our main findings.  
The exact mechanism underlying the association between subclinical cardiovascular 
disease and brain damage remains unknown, but it is possible that a compromised 
systemic perfusion and vascular deterioration may affect cerebral homeostasis. It is 
known that autoregulation of cerebral vasculature augments the blood flow to the brain, 
during periods of reduced cardiac function. However, studies have suggested that these 
autoregulatory mechanisms are less effective when systemic flow reductions are 
subclinical or chronic.43,44 Another possibility is that impairment in contractility of atria or 
ventricles leads to formation of thrombi. 45,46 Finally, it is also possible that a separate 
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mechanism, such as inflammation or oxidative stress, links cardiovascular disease and 
neurodegenerative changes. 
Our data suggest that subclinical cardiovascular disease as reflected by serum NT-proBNP 
levels is associated with dementia. Since NT-proBNP marks the presence of subclinical 
cardiovascular disease in absence of overt cardiovascular disease, it can indicate persons 
at a higher risk of  dementia. This provides a window of opportunity for timely preventive 
and treatment strategies for the subtle neurodegenerative changes caused by subclinical 
cardiovascular disease, leading to a delay in dementia onset or even prevention. However, 
certain prerequisites such as testing for the predictive accuracy of the marker and cost-
effectiveness should be assessed. In addition, the risk factors which require intervention 
should be identified. In conclusion, NT-proBNP is a potential marker of subclinical 
cardiovascular disease that may cause neurodegenerative changes.
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ABSTRACT 
Background: Several cardiovascular, metabolic, and renal biomarkers, are associated with 
depression. However, it is not known if these biomarkers also predict depression.  
Methods: In the Rotterdam Study, 5,813 participants with a mean age of 69±8 years were 
followed from 1997 to 2011 for ‘incident major depressive disorder (MDD)’ and ‘clinically 
relevant depressive symptoms’ (mean follow-up:9±4 years). The following biomarkers 
were tested: NT-proBNP, CRP, glucose, total cholesterol, HDL, cystatin C, uric acid, 
creatinine, and homocysteine. To assess the joint effects of biomarkers, Principal 
Component Analysis was conducted, and four groups of renal, metabolic, cardiovascular, 
and lipid biomarkers were extracted. Data on incident MDD and incident depressive 
symptoms were obtained through repeated screening by a validated questionnaire, with 
subsequent semi-structured psychiatric interview, as well as continuous monitoring of 
general practitioners’ records. Cox proportional hazards models adjusted for socio-
demographics, cardiovascular risk factors, health markers, and prevalent chronic diseases 
were used to analyze the association of biomarkers with incident depression. 
Results: Higher levels of NT-proBNP and CRP were each related to a higher relative risk of 
incident depressive symptoms, HR per SD 1.08 (95% CI: 1.00, 1.16), and 1.09 (95% CI: 1.02, 
1.17) respectively. Higher levels of NT-proBNP were also associated with a higher risk of 
incident MDD, HR per SD 1.27 (95% CI: 1.05, 1.54). In joint analysis, cardiovascular (HR 
1.14 (95% CI: 1.05, 1.23)), and metabolic biomarkers (HR 1.08 (95% CI: 1.00, 1.18)) were 
associated with incident depressive symptoms. 
Conclusions: Cardiovascular, inflammatory, and metabolic pathways have a possible role 
in the etiology of depressive disorders and depressive symptoms in older adults. 
  
 
 
 
 
INTRODUCTION 
Major depressive disorder (MDD) and clinically relevant depressive symptoms are 
common in older age, and are associated with a poor quality of life and excess mortality.1-3 
The etiology of depression in older adults is poorly understood, and may differ from their 
younger counterparts. In older adults, depression is less related to family history of 
depression, presents with more cognitive symptoms, has a worse response to treatment 
than in younger adults,3 and is highly prevalent in many chronic disorders, for instance 
diabetes mellitus or heart failure.  
Many clinical studies tested biomarkers of cardiovascular, metabolic, or renal diseases, in 
relation to prevalent depression, and found positive associations.4-7 Extending the findings 
from clinical studies, many population based studies also reported associations between 
biomarkers of cardiovascular, metabolic, and renal diseases, with prevalent depression in 
older adults. 8-11 However, these studies were largely cross-sectional. Given these 
associations in both clinical and population-based studies, it is possible that such 
biomarkers or the biological pathways they represent, are also involved in the etiology of 
depression in the general population. However, there are no prospective studies to 
investigate the associations of such biomarkers with incident depression in population-
based studies. Although there are studies which suggest that depression is associated with 
vascular impairment, and shares risk factors with cardiovascular diseases such as smoking 
behavior and diabetes mellitus,12,13 it remains largely unknown if biomarkers of these 
diseases are also longitudinally associated with incident depression.  
Identifying biomarkers of cardiovascular, metabolic, and renal pathways that predict 
depression may help elucidate its pathophysiology in older adults. However, it should be 
noted that these pathways are interrelated. For instance, vascular impairment or diabetes 
mellitus can give rise to impairment renal function, and impaired renal function can lead 
to cardiovascular dysfunction. Therefore, biomarkers of these biological systems are also 
dependent on each other to some extent. However, the correlations between these 
biomarkers in relation to depression have not been taken into account by previous 
studies. Findings from studies, which have investigated individual biomarkers in relation to 
depression, are also inconsistent.8-11,14 Understanding these correlations between 
biomarkers might be a beginning step to understand the interrelated pathways leading to 
depression in older adults. Further, testing biomarkers jointly may help tease out the true 
independent associations and thus improve precision. 
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Therefore, we aimed to investigate the associations of novel and traditional biomarkers, 
namely amino-terminal pro–B-type natriuretic peptide (NT-proBNP), C-reactive protein 
(CRP), glucose, total cholesterol, high-density lipoprotein cholesterol (HDL), cystatin C, uric 
acid, creatinine, and homocysteine, individually and jointly, with incident MDD and 
clinically relevant depressive symptoms in a population-based setting. 
 
METHODS 
Setting 
This study was embedded in the Rotterdam Study, an ongoing population-based cohort 
addressing the incidence and determinants of chronic diseases in late life.15 Every 3 to 4 
years, all participants undergo an extensive home interview and physical examination at 
the research center. In addition, the study database is linked to medical files from general 
practitioners, ensuring continuous surveillance for all major events. Depressive disorders 
and symptoms were assessed for the first time in the examination round in 1997-2001 
(response rate: 79%), which formed the baseline for this study.  
Study population 
In total, 7,808 participants attended the baseline assessment. Of these, 148 individuals 
who had prevalent dementia, 354 with no assessment for dementia or depression at 
baseline, and 5 persons with bipolar disorder, were excluded. We further excluded 975 
participants who did not have data for any of the following biomarkers: cystatin C, uric 
acid, creatinine, homocysteine, glucose, total cholesterol, HDL-C, CRP and NT-proBNP. Of 
the 6,326 remaining participants, 513 had clinically relevant depressive symptoms at 
baseline, and were excluded. Thus, 5,813 participants were eligible for analyses. 
Assessment of biomarkers 
At baseline, fasting blood samples were collected to determine serum or plasma levels of 
biomarkers. NT-proBNP was measured using a commercially available 
electrochemiluminescence immunoassay (Elecsys proBNP; F Hoffman-La Roche Ltd., Basel, 
Switzerland).16,17 High-sensitivity CRP measurement was performed using rate near-
infrared particle immunoassay (Immage Immunochemistry System; Beckman Coulter, San 
Diego, CA).18 Glucose was enzymatically determined using the Hexokinase method 
(Boehringer Mannheim, Mannheim, Germany).19 Total and HDL cholesterol were 
determined using an automatic enzymatic procedure (Boehringer Mannheim).19 Cystatin C 
 
 
 
 
levels were attained using a BNII nephelometer (Dade Behring Inc., Deerfield, IL).20 Uric 
acid was measured with Kone Diagnostica reagent kit and Kone autoanalyzer.21 Creatinine 
level was assessed by a nonkinetic alkaline picrate (Jaffé) method (Kone Autoanalyzer; 
Kone Corp, Espoo, Finland, and Elan; Merck, Darmstadt, Germany).22 Total homocysteine 
levels were measured using the Architect i2000 RS analyzer (VUmc), HPLC-method (WUR) 
and LC–MS/MS (EMC).23  
Biomarker measurements were not available for all participants due to insufficient 
quantity of blood for some participants. This was not likely to introduce bias as the 
missings were completely at random.  
Assessment of depression  
Depressive disorders and depressive symptoms and were each determined from two 
sources of information as described previously.24 The first source had two steps. In step 1, 
all participants were screened for depressive symptoms during the examination rounds 
with the Dutch version of the Centre for Epidemiologic Studies Depression (CES-D) scale25 
which consists of 20 items, each with a possible score of 0-3 scale. Maximum score is 60, 
and participants with a score of 16 or above are considered to have clinically relevant 
depressive symptoms (categorically defined). In the next step, all screen positives were 
interviewed by a clinician using the Dutch version of the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN).26 MDD was diagnosed according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th revised edition (DSM-IV). The second source 
was the medical records of general practitioners, which were continuously monitored for 
occurrence of episodes of depressive disorders and depressive symptoms from baseline 
onward. All available information from these two sources was used to define the incident 
MDD episodes and incident depressive symptoms episodes that occurred first 
chronologically in any of the two data sources.  
Assessment of covariates 
Age, sex, education, civil status, home status, alcohol intake, smoking behavior, body mass 
index (BMI), hypertension and prevalent type 2 diabetes mellitus, myocardial infarction 
(MI) and stroke were considered possible confounders as these are known risk factors for 
depression in the elderly.13,27,28 In addition, depressive symptoms score at baseline was 
also used as a covariate for the analyses of MDD. 
Education was assessed during interview and people were classified into two categories, 
low level of education (primary only or unfinished secondary) and intermediate to high 
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(secondary, vocational or university). Civil status was defined as married (or cohabiting 
with a partner) or not married (single). Home status was defined as living independently 
or not living independently (including nursing homes). Alcohol intake was measured in 
grams of ethanol intake per week.29 Participants were categorized into current, former 
and never smokers. BMI was assessed as weight in kilograms/height in meters squared. 
Hypertension was defined as systolic blood pressure ≥ 140 mmHg, or diastolic blood 
pressure ≥ 90 mmHg, or use of antihypertensive medication assessed by interview and 
pharmacy records.30 Diabetes Mellitus type 2 was diagnosed as fasting blood glucose ≥ 
7.00 mmol/l or use of anti-diabetic medication evaluated by interview and pharmacy 
records.31 Previous MI and stroke were determined by reported events in interview and 
confirmed by medical records. In addition, participants were continuously monitored for 
all major events through automated linkage of study database with general practitioners 
files.  
Statistical analysis 
We tested the associations of NT-proBNP, CRP, glucose, total cholesterol, HDL, cystatin C, 
uric acid, creatinine, and homocysteine, with incident MDD and clinically relevant 
depressive symptoms using Cox proportional hazards models. First, each biomarker was 
analyzed individually for MDD and depressive symptoms. Later, the biomarkers were 
tested jointly to improve precision and explore their interrelated effects, using the 
components derived from the PCA. All biomarkers were log-transformed to achieve a 
normal distribution, and standardized. In addition, we performed multiple imputations to 
handle missing values in the covariates, and winsorized the outliers at three standard 
deviations. As mentioned above, all analyses were conducted in a population (N=5,813), 
free of clinically relevant depressive symptoms at baseline (CES-D ≥ 16). 
Principal Component Analyses (PCA): This technique allowed the highly correlated 
biomarkers to be interpreted as one domain. Additionally, PCA reduced the problem of 
multiple testing, as the number of tests was reduced from 9 to 4. Therefore, the analysis 
could be reasonably exempted from the requirement of adjustment for multiple testing. 
PCA were conducted using oblique rotation (direct oblimin), and the analyses were 
adequate ( Kaiser-Meyer-Olkin score for the overall analysis: 0.725, all individual marker 
scores: >0.5). Correlations between the variables were sufficiently large to perform PCA ( 
Bartlett`s test of sphericity, p-value <0.001). Given the large sample size and the average 
communality > 0.6, Kaiser’s criterion was used to retain components with eigenvalues 
over 1, and the scree plot was in concordance with this criteria.32 Therefore four 
components were retained, explaining, in total, 69% of the variation in biomarker levels.  
 
 
 
 
Biomarker loadings of an absolute value > 0.4 on a factor were considered to have a 
strong association. Factors were described and labelled as follows, according to the 
principal biomarker loadings: ‘Cardiovascular’ (NT-proBNP and cystatin C), ‘metabolic’ 
(glucose, HDL and CRP), ‘renal’ (cystatin C, uric acid, creatinine, and homocysteine), and 
‘lipid’ (total cholesterol). Each participant received an individual score of the four 
biomarker components based on levels of biomarkers and factor loadings.  
For all analysis, two models were fitted: Model 1 was adjusted for age and sex only. Model 
2 was additionally controlled for education, civil status, home status, BMI, hypertension, 
smoking status, alcohol intake, type 2 diabetes mellitus, previous MI and stroke. Data 
were analyzed using the Stata Software Version 13 (StataCorp, College Station, TX, USA). 
 
RESULTS 
The present study included 5,813 persons. Mean age at baseline was 69 years and 55% of 
the participants were women. During 52,536 person-years, 1,058 (18%) persons 
developed clinically relevant depressive symptoms, including 152 (3%) persons that 
developed MDD. Baseline characteristics of the study population are described in Table 1. 
In the analyses of individual biomarkers, higher levels of NT-proBNP were associated with 
a higher relative risk of MDD, and remained associated with MDD after adjusting for 
potential confounders, HR per SD 1.27 (95% CI: 1.05, 1.54) (Table 2). None of the other 
biomarkers was related to incident MDD. For depressive symptoms, higher levels of NT-
proBNP, CRP, and glucose were associated with a higher risk of incident depressive 
symptoms when adjusted for age and sex. After additional adjustment for all possible 
confounders, NT-proBNP and CRP remained associated to a higher risk of incident 
depressive symptoms, HR per SD 1.08 (95% CI: 1.00, 1.16) and 1.09 (95% CI: 1.02, 1.17) 
respectively (Table 2). 
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Table 1. Baseline characteristics of study population, N=5,813. 
Characteristics Descriptives 
Social demographics  
Age, years  69.0 (8.1) 
Women  3,198 (55.0) 
Education – Intermediary or high  4,588 (79.7) 
Civil Status – married or cohabiting  4,119 (70.9) 
Home Status – Dependent  761(13.1) 
Alcohol Intake, g/week  82.3 (108.1) 
Smoking behavior   
Never 1,793 (30.8) 
Past 2,885 (49.6) 
Current 1,135 (19.5) 
Health markers and diseases 
Body Mass Index, kg/m²  27.0 (4.0) 
Hypertension  4,039 (70.3) 
Prevalent type 2 diabetes mellitus  494 (8.5) 
Prevalent myocardial infarction  368 (6.4) 
Prevalent stroke  474 (8.1) 
Blood measurements 
NT-proBNP, pmol/l  23.6 (75.8) 
CRP, mmol/ml  32.3 (57.3) 
Glucose, mmol/l  6.5 (7.1) 
Total cholesterol, mmol/l  5.8 (1.0) 
HDL cholesterol, mmol/l  1.4 (0.4) 
Cystatin C, nmol/l  77.9 (20.0) 
Uric Acid, moml/l  0.3 (0.1) 
Creatinine, umol/l  79 (24.0) 
Homocysteine, umol/l  14.7 (5.6) 
 
Values are means (standard deviation)s or counts (percentage). 
 
 
 
 
 
Table 2. Association of individual  biomarkers with incident major depression and 
clinically relevant depressive symptoms. 
 
a Number of cases/population at risk. 
b Model 1: Adjusted for age and sex. 
c Model 2: Additionally adjusted for education, civil status, home status, alcohol intake, smoking behavior, BMI, 
hypertension and prevalent type 2 diabetes. 
 
In joint analyses of biomarkers, we tested the components derived from PCA in relation to 
incident MDD. None of the cardiovascular, metabolic, renal, or lipid components was 
associated to incident MDD (Table 3). However, higher scores in the cardiovascular and 
metabolic factors were associated with an increased risk of incident depressive symptoms. 
These associations remained after adjusting for all potential confounders, cardiovascular: 
HR 1.14 (95% CI: 1.05, 1.23), and metabolic: 1.08 (95% CI: 1.00, 1.18). No associations 
were observed for the renal and lipid components with incident depressive symptoms 
(Table 3). Pattern matrix, eigenvalue and percentage of variance explained by each 
extracted PCA component are shown in Table 4. 
  
Biomarkers Incident Major depressive disorder, hazard ratios 
(95% confidence intervals) 
 n/N a Model 1 b P-value Model 2 c P-value 
NT-proBNP 149/5,682 1.28 (1.06,1.55) 0.009 1.27 (1.05,1.54) 0.01 
CRP 146/5,583 1.07 (0.91,1.27) 0.41 1.00 (0.83,1.20) 0.97 
Glucose 151/5,777 1.11 (0.93,1.33) 0.24 1.10 (0.87,1.38) 0.44 
Total cholesterol 151/5,777 1.00 (0.83,1.18) 0.93 1.01 (0.85,1.20) 0.90 
HDL-C 149/5,713 0.85 (0.75,1.01) 0.07 0.90 (0.75,1.08) 0.26 
Cystatin C 148/5,613 1.17 (0.96,1.42) 0.12 1.11 (0.90,1.35) 0.33 
Uric Acid 149/5,682 1.11 (0.94,1.33) 0.21 1.07 (0.88,1.29) 0.50 
Creatinine 149/5,682 0.92 (0.74,1.14) 0.46 0.92 (0.74,1.14) 0.46 
Homocysteine 130/4,929 1.01 (0.83,1.23) 0.63 0.97 (0.79,1.19) 0.79 
Biomarkers Incident clinically relevant depressive symptoms, hazard ratios 
(95% confidence intervals) 
 n/N a Model 1 b P-value Model 2 c P-value 
NT-proBNP 1,035/5,682 1.09 (1.01,1.17) 0.02 1.08 (1.00,1.16) 0.04 
CRP 1,019/5,583 1.11 (1.05,1.18) 0.001 1.09 (1.02,1.17) 0.009 
Glucose 1,055/5,777 1.07 (1.02,1.17) 0.01 1.08 (0.99,1.18) 0.09 
Total cholesterol 1,055/5,777 1.00 (0.93,1.06) 0.79 1.00 (0.94,1.07) 0.92 
HDL-C 1,043/5,713 0.92 (0.86,0.98) 0.01 0.95 (0.88,1.02) 0.14 
Cystatin C 1,027/5,613 1.06 (0.98,1.15) 0.12 1.03 (0.95,1.12) 0.44 
Uric Acid 1,035/5,682 0.97 (0.91,1.04) 0.45 0.95 (0.88,1.02) 0.13 
Creatinine 1,035/5,682 0.95 (0.88,1.03) 0.25 0.95 (0.88,1.04) 0.26 
Homocysteine 909/4,929 1.01 (0.93,1.08) 0.93 0.99 (0.92,1.07) 0.85 
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Table 3. Association of PCA derived components of biomarkers with incident major 
depression and clinically relevant depressive symptoms. 
 
Abbreviations: CI confidence intervals. 
a Number of cases/population at risk. 
b Adjusted for age and sex. 
c Additionally adjusted for education, civil status, home status, alcohol intake, smoking behavior, BMI, 
hypertension and prevalent type 2 diabetes. 
Table 4. Pattern Matrix ( Principal Component Analysis). 
 
Loadings over 0.4 are in bold letters. 
a Metabolic component was multiplied by (-1) to represent a risk factor. 
  
Components Incident Major depressive disorder, hazard ratios (95% CI) 
 n/N a Model 1 b P-value Model 2 c P-value 
 124/4,668     
Renal  0.94 (0.78, 1.13) 0.51 0.95 (0.78, 1.15) 0.58 
Metabolic  1.21 (0.98, 1.49) 0.08 1.16 (0.94, 1.44) 0.16 
Cardiovascular  1.12 (0.95, 1.34) 0.18 1.08 (0.87, 1.34) 0.46 
Lipid  1.10 (0.90, 1.35) 0.37 1.06 (0.85, 1.31) 0.61 
      
Components Incident clinically relevant depressive symptoms, hazard ratios (95% CI) 
 n/N a Model 1 b P-value Model 2 c P-value 
 867/4,668     
Renal  0.96 (0.90, 1.03) 0.24 0.97 (0.90, 1.04) 0.39 
Metabolic  1.09 (1.01, 1.18) 0.03 1.08 (1.00, 1.18) 0.05 
Cardiovascular  1.14 (1.05, 1.22) <0.001 1.14 (1.05, 1.23) 0.002 
Lipid  0.99 (0.91, 1.07) 0.77 0.98 (0.92, 1.05) 0.64 
Biomarkers Components 
 Cardiovascular Metabolic a Renal Lipid 
NT-proBNP 0.85 0.08 0.07 -0.14 
CRP 0.32 0.77 0.02 0.21 
Glucose -0.09 0.70 -0.10 -0.14 
Cholesterol -0.02 0.02 0.04 0.94 
HDL-C 0.31 -0.44 -0.35 0.33 
Cystatin C 0.46 0.05 0.66 -0.03 
Uric Acid -0.23 0.24 0.74 0.10 
Creatinine -0.06 -0.14 0.87 -0.08 
Homocysteine 0.23 -0.12 0.70 0.02 
Eigenvalues 1.07 1.36 2.76 1.02 
% of variance 11.87 15.14 30.67 11.29 
 
 
 
 
DISCUSSION 
In this prospective population-based study of older adults, we found that higher levels of 
NT-proBNP and CRP were each related to a higher risk of incident clinically relevant 
depressive symptoms. Higher levels of NT-proBNP were also associated with incident 
MDD. When biomarkers were tested jointly, cardiovascular and metabolic biomarkers 
were associated with an increased risk of incident depressive symptoms. 
We found that NT-proBNP was associated with both incident MDD and depressive 
symptoms. This finding extends the results from cross-sectional studies, which 
demonstrated higher levels of NT-proBNP in depressed patients.5,6,33 NT-proBNP, which is 
a well-documented prognostic marker of cardiovascular disease, is also an emerging 
marker for the presence of subclinical cardiovascular disease in apparently healthy 
individuals.16 We also found that CRP, an inflammatory marker, predicted clinically 
relevant depressive symptoms. Previous studies have also suggested that immune 
dysregulation might result in depression in older adults.  
When testing biomarkers jointly, the cardiovascular and metabolic components were 
associated with incident depressive symptoms. The cardiovascular component comprised 
NT-pro-BNP and cystatin C, of which, NT-proBNP was the principal loading, showing 
consistency with the analyses of individual biomarkers. These observed associations of NT-
proBNP and cardiovascular component with incident depression, even after adjusting for 
cardiovascular events and risk factors, suggest a role of subclinical cardiovascular disease 
in the development of depression. Studies have suggested that ischemic lesions in the 
cerebral white matter may disrupt neural connections in regions regulating mood and 
cognition, such as the hippocampus. Such disruptions might lead to development of 
depression. Moreover, it is also possible that a reduction in cerebral blood flow can impair 
regional brain function, contributing to affective and cognitive symptoms.34 In joint 
analyses, the metabolic component was also associated with incident depressive 
symptoms. This factor comprised CRP, glucose, and HDL. Therefore, these findings were 
consistent with those of the individual biomarker analyses, and suggest the interplay of 
inflammatory and metabolic pathways in the etiology of depression. There are studies 
that tested CRP individually in relation to risk of depression, and found that CRP was 
associated with depressive symptoms both cross-sectionally and longitudinally.8,9 There 
could be a few possible explanations for these findings. It is possible that immune 
dysregulation promotes the development of depressive disorders in elderly by affecting 
neurotransmitters levels such as monoamines.34 Moreover, it is also possible that 
metabolic imbalance may lead to subclinical vascular damage, which in turn may produce 
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consistent with those of the individual biomarker analyses, and suggest the interplay of 
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depressive symptoms. It is therefore important to note that in most cases, depression is 
perhaps a result of interaction of multiple pathways such as vascular and inflammatory, 
which is also reflected in our findings. In our study, we could show that CRP is part of a 
group of related factors that leads to depressive symptoms. These findings are in line with 
the previous literature.35 In a recent review, metabolic risk factors, such as central obesity 
and hypertriglyceridemia were associated with a higher risk of depression.35 However, in 
the analyses of individual metabolic biomarkers in our study, glucose and HDL were not 
associated with depressive symptoms after adjusting for all potential confounders. Other 
studies that found an association of glucose and HDL with depression,35,36 did not adjust 
for the confounding effects of social factors such as marital status, home status and 
education, which might explain the differences in results. 
We did not find any associations of renal biomarkers with MDD or depressive symptoms. 
Several cross-sectional and few prospective studies investigated the association of these 
biomarkers with depressive disorders with conflicting results.4,7,10,14 It is possible that 
these associations are only observed in patients with severe kidney disease. Therefore, 
the null association observed in our study might be a result of possible selection on health, 
as persons with more severe kidney disease are less likely to attend the examination 
rounds. 
Strengths of the study include the population-based design, large sample size, long follow-
up and a large number of incident depressive symptoms and MDD cases. The novelty of 
this study is that we analyzed several relevant biomarkers individually and jointly, in 
relation to incident MDD and clinically relevant depressive symptoms. The joint analysis 
allowed to assess the correlation patterns of biomarkers, and reduced multiple testing 
problems. Additionally, we also tested the confounding effects of social factors such as 
marital status, home status and education, all of which are associated with both physical 
and psychiatric health in the elderly.27 There are certain limitations as well. First, we did 
not have information about prior depression in this population. Second, there is a 
possibility of selection bias, as persons with more severe kidney or cardiovascular disease 
are less likely to attend the examinations. Third, as biomarkers were assessed only at 
baseline, their levels might have changed over time, resulting in regression dilution.37 
In conclusion, cardiovascular, inflammatory, and metabolic pathways, or their interactions 
have a role in the etiology of depression in older adults. 
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This thesis is based on longitudinal studies assessing the associations of psychiatric 
determinants, life-style factors, and new biomarkers with neurological outcomes and 
mortality. All studies included in this thesis are embedded in the Rotterdam Study, an 
ongoing population-based cohort of older adults in Ommoord, a district of Rotterdam.1 In 
1990, 7,983 participants aged 55 and older were enrolled in the Rotterdam Study referred 
to as the Rotterdam Study I. In 2000, an expansion of the cohort was made by enrolling 
3,011 participants, the Rotterdam Study II, who fulfilled the inclusion criteria. Finally, in 
2002, the cohort was again expanded by 3,486 participants, the Rotterdam Study III, now 
including those aged 45 years or older. In addition to detailed interviews and examinations 
every 3-4 years, all participants are continuously monitored for all major life events via a 
computerized linkage of the study database with the files from general practitioners. 
The strengths and limitations of individual studies have been described previously per 
chapter. In the general discussion, I will discuss the key findings of this thesis, and 
elaborate general methodological considerations. Lastly, I will provide clinical implications 
of this research and a broad viewpoint on directions for future research. 
 
KEY FINDINGS 
Depression and dementia 
One of the key findings of this thesis is that depressive symptoms in older age represent a 
prodrome of dementia. A prodrome can be defined as a predementia syndrome in which 
underlying dementing process which is yet subclinical, manifests as neuropsychiatric 
symptoms.2 Thus, appearance of depressive symptoms in late-life might mark the onset of 
dementia in near future. 
Although the psychiatric symptoms of neurodegenerative pathology are not limited to 
depression,3 I focus on depression associated with dementia because it is the most 
common psychiatric comorbidity of dementia.4,5 Furthermore, comorbid depression in 
dementia is associated with accelerated cognitive decline, distress, poor quality of life, 
increased caregiver burden, and worsening of functional impairment.3 The other common 
psychiatric manifestations of underlying neurodegenerative changes include anxiety, 
apathy, and sleep disturbance.4,6 To assess the association between depression and 
dementia in this thesis, I used depressive symptoms as assessed by the Center for 
Epidemiological Studies Depression Scale (CES-D). CES-D assesses symptoms of depression 
 
 
 
 
which do not reach the threshold to be diagnosed as major depression but are still of 
clinical relevance, and are associated with impairment similar to major depression.7  
In chapter 2.1, I found that presence of clinically-relevant depressive symptoms in older 
adults predicted dementia and Alzheimer’s disease, only in the short term, but not in the 
long-term. Associations were strongest for the short follow-up time, and attenuated with 
incrementally longer periods of follow-up time. The short-term associations became even 
stronger when excluding individuals who were also positive for depressive symptoms in a 
previous and a next round of depressive symptoms assessment, thereby eliminating the 
diluting effect of chronic symptoms. These findings of a short-term association suggested 
the role of reverse causality, suggesting that depressive symptoms did not increase the 
risk of incident dementia but rather manifested in response to the underlying cognitive 
impairment. It can be argued that the results of a null-finding in the long-term could be a 
case of regression dilution, which can frequently affect studies as the follow-up prolongs.8 
In this case, where depressive symptoms were measured at baseline, and were tested in 
relation to incident dementia over a long follow-up period, and in discrete follow-up 
periods, indeed results could have been diluted during 13 years. Therefore, the calculated 
results might be an underestimation of the true associations present. However, I observed 
a similar pattern of results when using the depressive symptoms from a previous 
assessment round, which reinforced that the pattern of results showing an increased risk 
of dementia in the short-term and a null association in the longer term was robust. Also, 
when I defined discrete time periods ensuring equal number of participants in each 
period, results were consistent. Nevertheless, use of one-time assessment of depression 
to investigate the associated risk of incident dementia (or any other long-term health 
outcome) was not only problematic because it might have led to regression dilution, but 
also because depression has a remitting and relapsing nature. By doing that, the course of 
depression over time was neglected, which was of crucial importance, as persons with 
more chronic high depressive symptoms might be at a higher risk of dementia than those 
who just had high symptoms acutely. This was not captured by a single assessment of 
depression. Therefore, as a further step, I used repeated measures of depressive 
symptoms to study the course of depression in relation to risk of dementia.  
Therefore in chapter 2.2, using repeated measures of depression served two important 
purposes. First, the possibility of regression dilution was minimized. Second, and more 
important, repeated measures enabled to study the course of depression in relation to 
risk of dementia. Moreover, I exploited repeated measures of depressive symptoms to 
employ the latent-class trajectory modelling, which identified latent classes of depressive 
symptoms. The “term” latent signifies that there are existent classes of different courses 
Chapter 5
218
General discussion
219
 
 
 
 
This thesis is based on longitudinal studies assessing the associations of psychiatric 
determinants, life-style factors, and new biomarkers with neurological outcomes and 
mortality. All studies included in this thesis are embedded in the Rotterdam Study, an 
ongoing population-based cohort of older adults in Ommoord, a district of Rotterdam.1 In 
1990, 7,983 participants aged 55 and older were enrolled in the Rotterdam Study referred 
to as the Rotterdam Study I. In 2000, an expansion of the cohort was made by enrolling 
3,011 participants, the Rotterdam Study II, who fulfilled the inclusion criteria. Finally, in 
2002, the cohort was again expanded by 3,486 participants, the Rotterdam Study III, now 
including those aged 45 years or older. In addition to detailed interviews and examinations 
every 3-4 years, all participants are continuously monitored for all major life events via a 
computerized linkage of the study database with the files from general practitioners. 
The strengths and limitations of individual studies have been described previously per 
chapter. In the general discussion, I will discuss the key findings of this thesis, and 
elaborate general methodological considerations. Lastly, I will provide clinical implications 
of this research and a broad viewpoint on directions for future research. 
 
KEY FINDINGS 
Depression and dementia 
One of the key findings of this thesis is that depressive symptoms in older age represent a 
prodrome of dementia. A prodrome can be defined as a predementia syndrome in which 
underlying dementing process which is yet subclinical, manifests as neuropsychiatric 
symptoms.2 Thus, appearance of depressive symptoms in late-life might mark the onset of 
dementia in near future. 
Although the psychiatric symptoms of neurodegenerative pathology are not limited to 
depression,3 I focus on depression associated with dementia because it is the most 
common psychiatric comorbidity of dementia.4,5 Furthermore, comorbid depression in 
dementia is associated with accelerated cognitive decline, distress, poor quality of life, 
increased caregiver burden, and worsening of functional impairment.3 The other common 
psychiatric manifestations of underlying neurodegenerative changes include anxiety, 
apathy, and sleep disturbance.4,6 To assess the association between depression and 
dementia in this thesis, I used depressive symptoms as assessed by the Center for 
Epidemiological Studies Depression Scale (CES-D). CES-D assesses symptoms of depression 
 
 
 
 
which do not reach the threshold to be diagnosed as major depression but are still of 
clinical relevance, and are associated with impairment similar to major depression.7  
In chapter 2.1, I found that presence of clinically-relevant depressive symptoms in older 
adults predicted dementia and Alzheimer’s disease, only in the short term, but not in the 
long-term. Associations were strongest for the short follow-up time, and attenuated with 
incrementally longer periods of follow-up time. The short-term associations became even 
stronger when excluding individuals who were also positive for depressive symptoms in a 
previous and a next round of depressive symptoms assessment, thereby eliminating the 
diluting effect of chronic symptoms. These findings of a short-term association suggested 
the role of reverse causality, suggesting that depressive symptoms did not increase the 
risk of incident dementia but rather manifested in response to the underlying cognitive 
impairment. It can be argued that the results of a null-finding in the long-term could be a 
case of regression dilution, which can frequently affect studies as the follow-up prolongs.8 
In this case, where depressive symptoms were measured at baseline, and were tested in 
relation to incident dementia over a long follow-up period, and in discrete follow-up 
periods, indeed results could have been diluted during 13 years. Therefore, the calculated 
results might be an underestimation of the true associations present. However, I observed 
a similar pattern of results when using the depressive symptoms from a previous 
assessment round, which reinforced that the pattern of results showing an increased risk 
of dementia in the short-term and a null association in the longer term was robust. Also, 
when I defined discrete time periods ensuring equal number of participants in each 
period, results were consistent. Nevertheless, use of one-time assessment of depression 
to investigate the associated risk of incident dementia (or any other long-term health 
outcome) was not only problematic because it might have led to regression dilution, but 
also because depression has a remitting and relapsing nature. By doing that, the course of 
depression over time was neglected, which was of crucial importance, as persons with 
more chronic high depressive symptoms might be at a higher risk of dementia than those 
who just had high symptoms acutely. This was not captured by a single assessment of 
depression. Therefore, as a further step, I used repeated measures of depressive 
symptoms to study the course of depression in relation to risk of dementia.  
Therefore in chapter 2.2, using repeated measures of depression served two important 
purposes. First, the possibility of regression dilution was minimized. Second, and more 
important, repeated measures enabled to study the course of depression in relation to 
risk of dementia. Moreover, I exploited repeated measures of depressive symptoms to 
employ the latent-class trajectory modelling, which identified latent classes of depressive 
symptoms. The “term” latent signifies that there are existent classes of different courses 
Chapter 5
220
General discussion
221
 
 
 
 
of the depressive symptoms in populations, but are unidentified or indistinct. This method 
served to sort individuals into groups that followed similar course of depressive symptoms 
over time. This was important as risk of dementia might differ significantly with the course 
of depressive symptoms over time. I hypothesized that depression affecting individuals at 
a point in time followed by full remission, might not contribute to any long-term health 
risks. Therefore, groups with transient depressive symptoms that perhaps are not the high 
risk groups for incident dementia should be reclassified, delineating those with sustained 
high or increasing symptoms, which are more likely the ones having a higher risk of 
dementia. In this study, I could demonstrate that the trajectory with increasing depressive 
symptoms was associated with a higher risk of dementia, reinforcing the prodromal 
hypothesis, and suggesting that indeed increasing depressive symptoms represent an 
early stage or prodrome of dementia. Further, as anticipated, the trajectories with 
decreasing or remitting depression were not associated with a higher risk of dementia. As 
a sensitivity analysis, I also performed survival analyses with incremental years of follow-
up starting with a follow-up of 2 years and adding a year in every step, to test for reverse 
causality. The increasing trajectory was consistently associated with a higher risk of 
dementia in throughout the increments of follow-up. Interestingly, I observed that the 
remitting trajectory also showed a higher risk of dementia  until the 5th year of follow-up, 
which declined thereafter. This could mean that the escalation and peak of the remitting 
trajectory might also represented an early stage of dementia, which was reflected in 
higher risk of dementia in the early years of follow-up. In this case, the remitting trajectory 
might be following a similar course as the increasing one, with the only difference 
between the time of their peaks. To prove this proposition, it would have been useful if 
the course of depressive symptoms was known before the study period. This could be 
regarded as a limitation of the study, however, such limitations are inherent to adult 
cohort studies. Interestingly, the trajectory with sustained high depressive symptoms did 
not show a statistically significant higher risk, although I hypothesized that chronic high 
symptoms would be associated with a higher risk of dementia. However, it is very likely 
that I was unable to detect the risk difference because of insufficient power in this group. 
Nevertheless, for this group, it remains questionable that weather sustained high 
depression in older age poses a higher risk of dementia or not, as with younger ages.  
An added advantage of using repeated measures was that in the increasing trajectory, I 
could demonstrate that depressive symptoms started to escalate several years before the 
diagnosis of dementia, indicating the long preclinical stage of dementia. This depicted that 
symptoms of depression appear as soon as individuals perceive a change in their cognitive 
abilities. It can be implied that depressive symptoms might only be apparent through a 
 
 
 
 
phase in which participants are able to “recognize” this cognitive decline, or are “aware” 
of their deteriorating condition. Similarly, depressive symptoms might ameliorate once 
the neurodegenarative damage is severe enough to impact cognition and autonomy. This 
makes it imperative to timely recognize such behavioral or non-cognitive symptoms in the 
course of neurodegeneration, as earlier recognition might provide a wider window of 
opportunity for interventions. Therefore, as a further step to study the association of 
neurodegenerative damage and affective symptoms, I took a step back from clinical 
dementia to Mild Cognitive Impairment (MCI).  
In Chapter 2.6, I studied MCI in association with incident depression and anxiety disorders, 
which further elucidated this complex association of neurodegenarative pathology with 
affective symptoms. Presence of MCI strongly predicted the incidence of both depressive 
and anxiety disorders. In this study, DSM depressive and anxiety disorders were studied 
instead of clinically relevant symptoms of depression and anxiety. Although I studied the 
association of MCI and depressive symptoms (Clinically relevant depressive 
symptoms=CES-D ≥ 16), I only reported results for disorders to maintain uniformity in the 
manuscript, since data on anxiety symptoms were not available. In the analyses 
depressive symptoms, I studied the associations of MCI with depressive symptoms as a 
continuous variable, both cross-sectionally and longitudinally using multiple linear 
regression models. In cross-sectional analysis, MCI was associated with depressive 
symptoms, difference 2.33 (95% confidence interval (CI): 1.77, 3.18). In longitudinal 
analysis also, MCI was associated with an increase in depressive symptoms over time, 
difference 0.92 (95% CI: 0.04, 1.81). The change in depressive symptoms was studied from 
the baseline round to the next examination round using multiple linear regression models 
which were adjusted for baseline depressive symptoms scores. However, I take caution in 
making any definitive comments about the associations of subtypes of MCI with 
depression or anxiety, because although these analyses were performed and reported, 
they included relatively smaller number of individuals, and thus results might not be very 
precise . 
From these consistent findings, I inferred that depression or clinically relevant depressive 
symptoms constitute a neuropsychiatric stage on the continuum of cognitive decline, 
between preclinical dementia and clinical dementia. However, this stage of 
neuropsychiatric symptoms might only affect or more strongly affect those who are more 
vulnerable either genetically or environmentally, or both. 
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Coffee and dementia 
As the most widely used beverage worldwide, coffee is considered more a part of a 
lifestyle, rather than just a dietary constituent. In chapter 3.1, I studied the longitudinal 
associations of coffee consumption and risk of dementia. The most robust finding of the 
several analyses carried out to test this association was that coffee consumption of 3 or 
more cups per day was protective of incident dementia in the short-term only, whereas no 
associations were found in the long-term. A recent systematic review concluded that 
evidence from population-based studies suggests a protective association of coffee intake 
with incident dementia and cognitive decline, particularly from studies with a shorter 
follow-up period.9 However, a more recent meta-analysis of observational studies 
studying caffeine intake from tea or coffee, reported no association between caffeine 
intake by tea or coffee and risk of cognitive disorders, though a protective association was 
found for cross-sectional reports.10 
The finding of a short-term protective association, and finding a similar pattern of 
associations using a repeated measure of coffee assessment in the same cohort strongly 
suggested reverse causality; a “healthy coffee-drinker effect”, implying that those who 
were healthier, and socially and physically active, drank more coffee than those who were 
less healthy, and less active. In addition, perhaps the latter reduced their coffee intake 
due to the declining health or cognition, or switched to the generally perceived healthier 
options such as tea. However, it could not be completely ruled out if coffee actually has a 
beneficial influence on cognition, as there are several proposed biological pathways that 
may underlie this protective effect of coffee on neurodegeneration or its symptoms. The 
beneficial effects of coffee might be attributed to caffeine, antagonizing A1 adenosine 
receptors in the hippocampus and cortex11-13 or reducing the permeability of blood brain 
barrier, with consequent reduction in the amount of amyloid passing into the brain, thus 
providing a neuroprotective response.14 Although these highly specific biological 
underpinnings might have an active role in the protective effects conferred by coffee, it is 
more likely that more generic mechanisms are involved. Regarding the effects of caffeine 
metabolites on adenosine receptors, the antagonism of A1 receptors by caffeine in the 
renal tubules and vasculature results in vasodilation and consequent diuresis, which 
lowers the blood pressure.15 In addition, the chlorogenic acid in coffee is a potent 
antioxidant, which maintains the endothelial and vascular integrity by increasing the 
availability of nitric oxide.16 Whether these systemic effects operate through the anti-
inflammatory, anti-oxidant, or vasoprotective pathways, they all contribute to 
cardiovascular health of individuals. Therefore, the lower risk of dementia in habitual 
coffee-consumers might be due to their improved cardiovascular health. These 
 
 
 
 
mechanisms do not hold for total dementia or dementia of vascular origin only, but also 
for Alzheimer’s disease (AD), and suggest a role of vascular pathology in AD. However, this 
hypothesis of protective effect of coffee on CVD is relatively recent, as earlier studies 
investigating the effects of coffee consumption and risk of cardiovascular diseases 
suggested a harmful association, and a higher incidence of cardiovascular diseases and 
hypertension among coffee drinkers.17-22 Recent studies however tend to report neutral or 
favorable effects of coffee on cardiovascular health.23,24 As concluded in a recent review, 
“coffee is safe to drink by healthy subjects or those with preexisting cardiovascular 
diseases or hypertension.”16  
As a further step to investigate whether the beneficial effects of coffee consumption only 
represent a healthy-volunteer effect, or there is an actual beneficial effect also, I 
investigated the association of coffee consumption with MRI markers and cognitive 
decline in chapter 3.2. I observed that moderate coffee consumption (1-3 cups/day) was 
associated with a lower prevalence of lacunar infarcts, and a better processing speed and 
executive function. This is plausible as studies show that executive function is a cognitive 
domain that is primarily affected by vascular brain disease, including white matter lesions 
and lacunar infarcts.25,26 However, the association of coffee and better executive function 
was independent of lacunar infarcts suggesting the involvement of other pathways or 
presence of changes that were not detectable on MRI. Nonetheless, these findings 
reinforced the hypothesis that coffee intake might be protective against dementia or 
cognitive decline by improving vascular health. Although the cross-sectional design of this 
study precluded any conclusions about causality, it does provide evidence for 
cardiovascular health as a potential link between coffee intake and lower risk of dementia. 
There were certain intriguing findings that I observed with the consumption of 3 or more 
cups of coffee per day with incident dementia longitudinally, and with cognition and brain 
volumes cross-sectionally. In chapter 3.1, after excluding the first few years of follow-up 
with a protective effect, a harmful effect of coffee consumption was observed in the later 
years, with 3 or more cups per day. This effect was not observed for moderate 
consumption of 1-3 cups per day. In addition, in the cross-sectional analyses of chapter 
3.2, coffee consumption was associated with a smaller hippocampal volume and worse 
speed of color naming, interference of automated processing and attention, and retrieval 
from verbal memory. Where the null association over the overall follow-up period in 
chapter 3.1 could be a case of regression dilution,8 as coffee assessment was only assessed 
at baseline, the harmful effect observed after excluding the first few years is difficult to 
explain. Perhaps continued coffee consumption could mask the underlying cognitive 
deficits to a certain extent, and delayed the dementia diagnosis which resulted more 
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diagnoses in the later period. Alternatively, the symptoms might manifest only when 
cognitive decline reaches a certain threshold, and individuals reduce their coffee intake as 
part of a general change in their lifestyle as they perceive cognitive decline, hence 
alleviating the protective/masking effects of coffee. However, both these explanations are 
valid only if coffee actually has short-acting protective effects only, and therefore, 
maintaining regular consumption might be the key to maintain cognitive health. To test 
this, I also investigated change in coffee consumption and risk of dementia in chapter 3.1, 
which indeed showed that participants maintaining their coffee consumption over the 
years had a lower risk of dementia compared to those who reduced intake. However, 
another explanation could be that coffee consumption in older adults is beneficial in the 
short-term only, but becomes harmful after continued use. To disentangle whether this 
harmful association is a result of coffee or some other factors or a combination of both is 
a challenge. This is because habitual coffee consumption might be associated with certain 
other factors which are hazardous to health, such as smoking, or alcohol use. Moreover, 
certain ways of preparation like boiling are associated with an increase in total serum 
cholesterol.27-31 However, we did adjust for smoking habits and alcohol consumption, and 
BMI as a general physical health indicator. In chapter 3.2, the association of 3 or more 
cups of coffee per day with a smaller hippocampal volume and poor memory was 
conflicting with the existing evidence. Previously, a U-shaped association between coffee 
and hippocampal volume has been reported, showing that low and high intakes of coffee 
are associated  with larger hippocampal volumes, as compared to moderate intake.32 
Although the cross-sectional design precludes any conclusions about causality, higher 
coffee consumption was also associated with a poor memory in our study. Animal studies 
have shown that although short-acting effects of caffeine were neurostimulatory, long-
term use of low-dose caffeine resulted in a slowed hippocampal-dependent learning and 
impaired long-term memory. In addition, caffeine consumption for 4-weeks significantly 
reduced hippocampal neurogenesis in rats.33 For any dietary constituent, it is more likely 
that the effects are small and accumulate over time to produce an effect. However, even if 
coffee has neuroprotective effects , its consumption might be able to counteract or mask 
the effects of neurodegeneration to a certain threshold only. 
Taken together, moderate intake of 1-3 cups of coffee, appeared beneficial and protected 
against dementia, cognitive decline, and vascular brain lesions, whereas, daily 
consumption of 3 or more cups of coffee were associated with an increased risk of 
incident dementia in later years, and a smaller hippocampal volume and poor memory 
cross-sectionally. These findings suggest that moderate consumption confers 
neuroprotection whereas higher consumption can prove to be harmful. Coffee is a 
 
 
 
 
mixture of more than 1000 compounds,16 and perhaps not all of them are advantageous 
to health. At higher intakes, the effects of such detrimental constituents of coffee might 
accumulate over time and result in unfavorable effects on cognition. Additionally, 
consumption of moderate amounts of coffee is certainly reflective of a healthy and active 
lifestyle in older adults. 
Vascular pathology and Alzheimer’s disease  
The focus on the role of cardiovascular diseases and vascular impairment in the pathology 
of dementia including Alzheimer’s disease is continuously growing. In chapter 4.1, I 
investigated the association of NT-proBNP with dementia, Alzheimer’s disease, vascular 
dementia, and cognitive decline, both with and without including participants with overt 
cardiovascular disease. NT-proBNP is an emerging marker of cardiovascular diseases,34,35 
and is also suggested to be a marker of cardiovascular disease at a subclinical stage.36 The 
association of NT-proBNP with cognitive dysfunction was shown in some clinical and 
smaller population-based studies,37-41 but its association with incident dementia was not 
known even in clinical settings. Interestingly, NT-proBNP, which is an inactive amino 
terminal of proBNP, predicted dementia even after adjustment for several cardiovascular 
risk factors, and excluding participants with diagnosed cardiovascular diseases and events. 
Although the estimates were more strong for vascular dementia which is plausible, they 
were also significant for Alzheimer’s disease. Thus providing further support to the 
involvement of vascular pathology in the etiology of Alzheimer’s disease. I also observed 
that higher NT-proBNP was associated with a decline in processing speed and executive 
function. This finding suggested that neurodegenerative changes start very early in the 
course of vascular impairment, which may provide a wider window of opportunity for 
intervention. Interestingly, this finding was also consistent with the findings in chapter 
3.2, and suggest that of all cognitive domains, the executive function is affected primarily 
by vascular dysfunction, and is perhaps affected earlier than other domains of cognition. 
Cognitive reserve and dementia 
In chapter 3.3, I investigated the role of cognitive reserve in the protection against 
dementia after clinical cerebrovascular events. I used level of education as a measure of 
cognitive reserve which is most widely used measure,42 and found that risk of dementia 
was higher after a stroke or TIA in persons with low or intermediate education only. Those 
with higher education were protected against dementia after a stroke or TIA. However, 
this effect was present only in men, where I observed a dose-response association, 
showing a decreasing risk of dementia after a stroke or TIA with the increasing level of 
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education. A possible explanation for this discrepancy in results for men and women was 
the lack of power in analyses of women, particularly for the high education category 
where there was only one case of dementia that occurred after a cerebrovascular event. 
However, there could be other reasons as well, but before I discuss further, I would 
elaborate on the concept of reserve.  
The concept of reserve comprises two distinct but not mutually exclusive components, the 
brain reserve, and the cognitive reserve.43 The brain reserve refers to the amount of 
“available neural substrate”, i.e. brain volume and neuronal and synaptic counts, and is 
thus referred to as the passive model of reserve. In contrast, the cognitive reserve is an 
active model which is the “ability” to maintain function to a certain extent despite brain 
damage.43,44 Scientists believe that it’s cognitive reserve which explains why some people 
can endure more brain damage than others and still maintain function, or how people 
with similar brain damage have different cognitive abilities.43-46 Cognitive reserve is built 
and maintained throughout life by cognitively engaging activities such as educational and 
occupational attainment and also leisure activities.47,48 Cognitive reserve in turn comprises 
two sub-concepts, the neural reserve and the neural compensation. As the name implies, 
neural reserve means functionally better and flexible cognitive networks which have the 
ability to better cope with damage. Instead, neural compensation pertains to the ability to 
compensate for the damage of standard brain networks by forming or utilizing alternative 
networks.43 Although level of education, complexity of occupation, intelligence quotient, 
and participation in cognitively active activities throughout life are considered to build 
cognitive reserve, a comprehensive model of cognitive reserve is still lacking.42,45 It is a 
challenging yet promising field. It is challenging because, first, a working model to 
operationalize cognitive reserve lacks,42 second, it is difficult to understand completely 
how cognitive reserve works, third, it is difficult to discriminate cognitive reserve and brain 
reserve, and their overlap, and finally, it is hard to find ways not only to maintain, but also 
increase cognitive reserve in the older ages. At the same time, it is a promising domain to 
study because it is dependent on factors which are modifiable and thus there is room for 
intervention.  
The two concepts of brain reserve and cognitive reserve are overlapping and a distinction 
is difficult. For instance, it can be argued that those with a higher brain volume and thus 
higher brain reserve are more likely to continue education or adopt more challenging and 
complex fields of education, and thus occupation also. This means that cognitive reserve is 
largely dependent on the brain reserve. On the other hand, a higher cognitive reserve may 
lead to a protective mechanism, resulting in less neuronal loss.42 
 
 
 
 
To operationalize cognitive reserve is a challenge. Since cognitive reserve builds up by a 
range of activities and is dependent on several factors throughout life, assessment of no 
single factor precisely reflects cognitive reserve. An individual factor can thus serve only as 
a rough proxy of cognitive reserve. Also, a single factor such as education may depict 
cognitive reserve better in some groups than others. One such example is men and 
women as in our study where we faced the challenge that education seemed an 
acceptable measure of cognitive reserve for men but not for women. In an older 
population like the Rotterdam Study, women did not have equal opportunities for 
acquiring education as men. Thus, educational level of women was not reflective of their 
true potential. Therefore, assessment of other measures of cognitive reserve or a 
combination of many factors, which are considered to build cognitive reserve, might have 
served as a better indicator. However, we did not have information on any of the other 
factors in our study which could contribute towards cognitive reserve such as leisure or 
social engagements, which might have served better for women. We did have information 
about occupation, but similar to education, women in the study were mostly working at 
home and men were the main bread-winners. Therefore, occupation was also not a good 
measure of cognitive reserve for women. To investigate this further, I ran a sensitivity 
analysis in couples only (n=1,731). I assigned the educational level of men (head of the 
household) to their spouses to explore if that serves as a better indicator for cognitive 
reserve in married/partnered women. However, these analyses were underpowered, and 
this construct also did not provide any useful information. In this small group of married 
women, I first ran the analyses using the their own educational level. In these analyses, 
risk of dementia after a stroke or TIA tended to be lower in the low education group, 
hazard ratio (HR) (0.83, 95% CI: 0.46, 1.51), but high in the intermediate education group, 
HR 2.84 (95% CI: 1.38, 5.83). Risk could not be calculated in the high education group 
because there were no cases in this group. When I assigned the educational level of men 
to women in this group, results were similar. Women with low education tended to have a 
lower risk of dementia after a stroke or TIA, HR 0.91 (95% CI: 0.43, 1.93), whereas those 
with intermediate or high education tended to have a higher risk, HR 1.34 (95% CI: 0.74, 
2.42), and HR 1.46 (95% CI: 0.30, 7.25) respectively. However, these estimates were not 
precise due to the lack of power, and thus inconclusive. Also, in our study, we could not 
adjust for any measure of brain reserve, such as total brain volume, as data on brain 
volumes were not available. We did have brain volumes in a small subset of individuals but 
were assessed several years after the baseline. 
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METHODOLOGICAL CONSIDERATIONS 
Definition of depression 
In the Rotterdam Study, depression is assessed by a two-step approach. The first step 
screens individuals for clinically-relevant depressive symptoms, and in the next step, 
screen positives are subjected to a semi-structured psychiatric interview to diagnose 
depressive disorders according to the American Psychiatric Association Diagnostic and 
Statistical Manual of Mental Disorders (DSM).49  
In step 1, screening is performed by the Dutch version of the Center for Epidemiologic 
Studies-Depression Scale (CES-D) which is a self-report questionnaire comprising 20 items. 
CES-D is a frequently used valid and reliable instrument to assess symptoms of depression 
in older adults, and a cut-off score of 16 is established to indicate presence of clinically 
relevant depressive symptoms.7 This scale, which includes items to assess symptoms of 
negative affect, absence of positive affect, behavior, sleep, and appetite, requires 
participants to indicate the frequency of experiencing these feelings during past week. In 
addition, it includes 4 items pertaining to positive emotions. Therefore, CES-D not only 
measures clinically relevant depressive symptoms reliably, which indicate sub-threshold 
depression, but it assesses a general emotional state of individuals. This is particularly 
valuable in older adults. The general emotional state of these older individuals might 
reflect many relevant underlying conditions other than major depression. Such conditions 
could be social, such as loss of a partner, which is a devastating life event especially in 
older age groups, cardiovascular events such as stroke or myocardial infarction, diagnoses 
of distressing illnesses like cancer, or neurologic, such as cognitive decline.  
In the next step, screen positives undergo a semi-structured psychiatric interview, the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN).50 In contrast to the fully 
structured interview, SCAN retains features of a clinical examination. This construct adds 
the advantage to identify subjects, who do not have a depressive disorder, but suffer from 
anxiety or another psychiatric disorder, and thus can be excluded from depression 
analyses.  
The two-step approach used for depression assessment in the Rotterdam Study enabled 
to identify those who do not fulfill the criteria of DSM-depressive disorders, but have 
clinically-relevant depressive symptoms, and thus could be analyzed.  
This measure of sub-threshold depression was meaningful in addition to depressive 
disorders, as in older adults, clinically relevant depressive symptoms are not only much 
 
 
 
 
more common than depressive disorders, but they cause impairment similar to that of 
major depressive disorders.51 As compared to the point prevalence of depressive disorders 
of 2% to 3% in the older adults, clinically relevant depressive symptoms, on average, affect 
approximately 10%-15% community dwelling older adults.52,53 These clinically-relevant 
symptoms in older age-groups may stem from two broad categories of risk factors or their 
interaction, biological and psychosocial.54 The common biological risk factors include 1) 
genetic predisposition, 2) vascular diseases55 and events, such as myocardial infarction or 
stroke, 3) dementia,56 4) chronic diseases such as diabetes and cancer etc.57 Common 
psychosocial factors include 1) personality attributes,58 2) life events,59 3) social-
stressors,60 and 4) bereavement.61 
Therefore, in this thesis, to study the association of depression and risk of incident 
dementia, I have used data on these clinically-relevant depressive symptoms, which was 
also advantageous as symptoms could be used as a continuous score, which facilitated to 
use them repeatedly to follow the course of depression over time.  
Selection 
“Selection biases are distortions that occur from procedures used to select subjects and 
from factors that influence study participation.” 62 
Selection bias is a broad term which encompasses several types of biases, but here I will 
only enumerate those which are relevant for cohort studies, such as bias resulting from 
differential loss to follow-up, non-response bias, volunteer bias, and healthy-volunteer 
bias. However, the common consequence of any type of selection bias is that the 
association between the exposure and outcome is different in participants that were 
selected, than among those who were eligible, but not selected.63 For studies in this 
thesis, the frequently encountered selection biases were, bias due to differential loss to 
follow-up, and healthy-volunteer bias, which are common in cohort studies requiring 
active participation. Invariably, participants with more severe form of a disease under 
study (exposure), were more likely to be lost to follow-up, or, participants who are 
healthier were more likely to participate than those who were unhealthy. This 
phenomenon, which is referred to as the “healthy volunteer effect” might have resulted in 
an underestimation of the true associations between risk factors and diseases present in 
our population. For a cohort of older adults like the Rotterdam Study, this is particularly 
true as participation can be highly affected by progressing age and frailty. Studies from the 
Rotterdam Study showed that reasons for non-participation in order of frequency were, 
loss of interest, physical limitations, or frailty related to age.64 In this thesis, selection 
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effect might have affected studies which required a visit to the examination center than 
those which utilized data from home interviews. For instance, chapter 4.1 which studied 
the association of NT-proBNP in relation to incidence dementia, might be influenced by 
selection, as persons with severe cardiovascular disease were less likely to attend the visit 
to the examination center. However, when we investigated cognitive decline in this study, 
participants with substantial cognitive impairment were more likely to drop out from the 
cognitive reassessment resulting in possible underestimation of associations. 
In a more complex instance, possible selection bias occurred when using repeated 
measures of depressive symptoms in chapters 2.2 and chapter 2.3. If trajectories of 
depressive symptoms are defined by using repeated measures of depressive symptoms, 
the likelihood to be in a trajectory with remitting depression is higher for those who had 
at least two assessments. Therefore, when calculating risk of dementia or mortality across 
trajectories, results could have been influenced by selection bias, particularly for the 
remitting trajectory, as it might be conditioned on health. This was a situation with a very 
limited options of solutions. In the process of trajectories identification, those with mores 
assessments (and perhaps healthier) would invariably be more likely to fall in a remitting 
trajectory (if they had a remitting course), than the ones who only had one assessment. 
Although the research question, whether risk of dementia and mortality differ with the 
course of depression was a highly interesting and relevant, it was very challenging to 
design a valid study. I attempted to solve this concern of selection bias by only including 
participants with at least two assessments to identify trajectories. Although it could not 
eliminate the selection bias, it did condition all trajectories on somewhat similar criteria. 
With this approach, I obtained trajectories very similar to the ones which included all 
participants, with slight reclassification. Also, the results were consistent and showed that 
sustained high and increasing depression was associated with a higher risk of dementia 
and mortality, but not the trajectories with a remitting course. 
Reverse causation 
Another bias encountered when we studied psychiatric symptoms and lifestyle factors in 
relation to risk of dementia was “reverse causality”. For instance, when investigating the 
association of anxiety and risk mortality in chapter 2.5, I found very strong associations of 
anxiety with mortality in the first 3-4 years of follow-up, whereas no associations were 
found in the long-term (~20 years). Similarly, in chapter 3.1, I observed a short-term 
protective association between higher coffee intake (>3 cups/day) and incident dementia, 
which disappeared when I tested the association over a long follow-up of 20 years. These 
findings where strong associations between exposure and outcome were observed in 
 
 
 
 
short-term only, and disappeared in long-term follow-up, are classical examples of reverse 
causation. This meant that what appeared to be a strong causal association, was actually a 
phenomenon where preclinical symptoms of disease (for example dementia) led to 
exposure (for example anxiety). To confirm that these results were influenced by reverse 
causality, I repeated the analyses after excluding the first few years of follow-up, which is 
the most common strategy to address reverse causality. Further, I tested several cut-offs 
for follow up time for these studies, and also tested incrementally increasing years of 
follow-up to get a thorough understanding of our data.  
Regression dilution 
Studies included in this thesis have an average follow-up time of 10 years. For some 
studies with follow-up longer than 10 years in this thesis, for instance chapters 2.1, 2.4, 
3.1, I did not find an association in the long-term, which could be an effect of regression 
dilution.8 Therefore, the estimates presented in these studies might be underestimation of 
the true associations. 
Generally, in prospective studies, the risk ratios are estimated using the values of the 
determinant measured at baseline only. However, such an approach tends to 
underestimate the real associations. As exposures could change over time, the real 
associations would have been stronger, if the actual values of exposures were used to 
estimate the associations under study. The phenomenon of regression dilution is a general 
concern in long follow-up studies, and has been demonstrated with examples of 
measurements of blood pressure and serum cholesterol.8 One potential solution to this 
problem is the use of regression dilution ratios for correction of the derived estimates for 
regression dilution. These ratios describe the steepness of the uncorrected (obtained) 
estimates, to the steepness of the real association. These ratios can be calculated by, 
reassessing the level of exposure in a small but representative subsample of the study 
population after an interval which is approximately equivalent to the mid-point of the 
follow-up period under study. For most studies included in this thesis, I could not calculate 
regression dilution ratios to correct the calculated risk estimates, and therefore, it is 
limitation of studies with long follow-up. However, chapters 2.2 and 2.3 in this thesis 
utilize repeated assessments of the exposure of interest and thus overcome the influence 
of dilution by time.  
Competing risks 
In cohort studies, where the outcome of interest is not inevitable, participants may suffer 
from a competing risk, and thus get eliminated from the follow-up.62 For example, in a 
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study in which the outcome of interest is dementia, some subjects may die and thus 
removed from follow-up without getting demented. However, some participants may be 
lost to follow-up due to other reasons as well. In survival analyses, the usual practice is to 
treat both the losses to follow-up due to various reasons (true losses), and losses to 
competing risk (e.g. death) as forms of censoring. However, since loss to follow-up, and 
loss due to competing risks can have different relations to the study variables (both 
exposure and outcome), both forms of censoring can affect the results differently. For 
studies included in this thesis, dementia was largely the outcome of interest. For such 
studies, death was the main competing risk. 
In chapter 4.1, in which I studied NT-proBNP and the risk of dementia, a small number of 
participants were lost to follow-up, which could be because of several reasons which may 
or may not be related to both NT-proBNP and dementia. However, during follow-up, 
people were also lost to follow-up because they died (death as a competing risk for 
dementia).  
Similarly, in chapter 2.2, in which I studied the risk of dementia across different 
trajectories of depressive symptoms, death was an important competing risk. I identified 
different trajectories of depression in this study, namely, trajectory with no or few 
depressive symptoms, decreasing depressive symptoms, remitting symptoms, increasing 
symptoms, and a trajectory with persons who had sustained high depressive symptoms 
throughout the study period. It is well-documented that chronic depression is associated 
with a higher risk of mortality.65,66 Therefore, it was expected that death as a competing 
risk of dementia should have affected the estimates of dementia risk in the high 
symptoms trajectory most, than any other trajectory of depressive symptoms. In this case, 
not only competing risk was an issue but it was even complex as it could have differentially 
affected the risk estimates for dementia across trajectories. 
To address this, I conducted competing risk analyses in these studies, which were 
presented in the respective chapters. The competing risk analysis, models cumulative 
incidence of the outcome of interest (e.g. dementia) in the presence of competing risks 
(e.g. death), i.e. competing events are not censored. In this example, the probability of 
dementia is not only a function of the hazard of dementia, but a function of mortality as 
well, because death impedes dementia to occur. This analyses thus provides sub hazard 
ratios (SHRs) for dementia, which measures the effect of covariates on the cumulative 
incidence of dementia. 
 
 
 
 
 
Repeated measures and Latent-class trajectory modelling 
This thesis largely included longitudinal studies with a considerably long follow-up. In such 
studies, the use of repeated measures (where available) was valuable because it could 
handle the issue of regression dilution which arises when we study disease risks in the 
long-term, but the exposure assessment is only available from the baseline.8 More 
importantly, repeated measures are of importance when studying psychiatric of 
psychological traits and disorders, because such exposures are very likely to fluctuate over 
time. Therefore, an assessment of such a trait, for example depression, at a single time 
point is not sufficient to derive conclusions about the risk of a long-term health outcome, 
or might even result in invalid results.  
In this thesis, I investigated the associations of psychiatric disorders with dementia and 
mortality. Given the remitting and relapsing nature of depression, it was possible that the 
true long-term associations of depression with dementia and mortality were not captured 
by a single assessment of depression. Therefore, as a further step, I used repeated 
measures of depressive symptoms to define the course of depression in chapters 2.2 and 
2.3. Not only did I define the course of depression, but also identified different trajectories 
of depressive symptoms in the study population, and investigated the risks of dementia 
and mortality across these trajectories. 
For identification of different trajectories of depression, the Latent-Class trajectory 
modelling was employed, which is a specialized form of finite mixture modelling.67 This 
technique identifies latent classes of individuals following similar progression of an 
outcome over time or with age. In a simplistic manner, for each subject, a probability to 
belong to each class (trajectory) was calculated, and the trajectory with the highest 
probability was assigned to the subject. These trajectory classifications were then used as 
an indicator variables to calculate hazard ratios for However, I faced methodological issues 
when calculating trajectories and estimating risks, which I discussed in detail in the 
respective chapters.  
 
IMPLICATIONS AND DIRECTIONS FOR FUTURE RESEARCH 
Although the ultimate goals of medical research are to cure or even prevent the disease, a 
better understanding of the course of the disease, identification of disease markers, and 
risk factors that cause or modify the course of disease are the beginning steps to this aim. 
Therefore, there might not be direct clinical implications of many of the studies in this 
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thesis, but there are certainly important findings that fill many knowledge gaps in the 
respective literature and can guide future research. 
The first point of importance is that the appearance of depressive symptoms, or, more 
inclusively, affective symptoms in older age might be a sign of dementia and should be 
carefully considered. Any sign of the disease in its preclinical period may serve as a 
window for meaningful interventions. Since CES-D not only gauges depressive symptoms 
but a general emotional state of individuals, all behavioral change including symptoms of 
negative affect or lack of positive affect, life style habits, sleep or appetite might indicate 
underlying cognitive impairment. Although not much can be done to stop the pathologic 
process at this stage, steps can be taken to slow progression to delay the onset of 
dementia, or at least to improve the quality of life of patients, whether it is through 
pharmacological, or non-pharmacological interventions. Future studies should also 
explore the risks associated with chronic high depression of late-life, as in this thesis, there 
was an evidence of a high risk of dementia for chronic late-life depression, but the 
statistical power lacked to derive definitive conclusions. Moreover, etiological research 
should aim to unravel common etiological pathways between cognitive impairment and 
depression. In this regard, investigating depression in relation to subclinical vascular 
lesions such as microbleeds or white matter lesions may provide informative 
underpinnings for in depth etiologic research .  
I did not find any association between anxiety symptoms or anxiety disorders with 
dementia. It is possible that a single anxiety assessment was not sufficient to find 
associations, however, it is more likely that there are no health effects independently 
associated with anxiety. Finally, it would be highly interesting to assess the influence of 
anti-depressant or anti-anxiety medication on these associations by mediation studies.  
The second set of evidence which has more direct clinical implications is that 
cardiovascular health predicts dementia, and therefore improving and maintaining 
cardiovascular health  should be a priority not only to prevent cardiovascular events such 
as myocardial infarction, stroke, or transient ischemic attacks, but also to prevent 
dementia. More importantly, cardiovascular disease is not only an important risk factor 
vascular dementia, but for Alzheimer’s disease as well. I found that NT-proBNP reflects 
subclinical cardiovascular disease in persons who are free of any overt cardiovascular 
disease, and predicts dementia including Alzheimer’s disease. The importance of this 
finding is that it shows that subclinical cardiovascular disease leads to neurodegenerative 
damage early in its course and it can be detected by NT-proBNP. This may provide a wider 
window of opportunity for prophylaxis and treatment. Early detection of subclinical 
 
 
 
 
cardiovascular disease followed by vigorous intervention including treatment and 
controlling for modifiable risk factors might be very fruitful to reduce dementia burden by 
preventing it, or at least delay its onset. Moreover, these results should be taken further, 
and certain prerequisites such as predictive accuracy of NT-proBNP and cost-effectiveness 
should be assessed, as it may prove to be a non-invasive and cost-effective way to identify 
persons at a higher risk for dementia. 
The third point of interest is that how lifestyle can affect the risk of dementia. In the realm 
of modifiable risk factors, education is a factor which can be modified to increase the 
cognitive reserve and consequently reduce the risk of dementia. The role of education is 
substantial in gaining cognitive reserve, however, it is only a part of many other factors 
that build up cognitive reserve. Similarly, cognitive reserve cannot be operationalized by 
educational level only, and a comprehensive construct to gauge cognitive reserve is 
lacking . Therefore, future studies should aim to build a model of cognitive reserve which 
is comprehensive and encompasses several determinants of cognitive reserve, such as 
education, occupation complexity, leisure and social activity, and other cognitive 
exercises. Since the concept of cognitive reserve deals with modifiable factors, and is 
thought to build up throughout life by cognitively active endeavors, it is highly promising 
for its preventive potential for dementia. 
 
EPILOGUE 
This thesis presents longitudinal studies investigating the associations of depression and 
anxiety with dementia and mortality. From very consistent finding across studies, I suggest 
the following chronological order of events in the process of cognitive decline: Subclinical 
neurodegeneration/cognitive impairment →neuropsychiatric symptoms →overt 
dementia. I also argue that cognitive symptoms are mental health symptoms, and that the 
interface of psychiatric and cognitive symptoms is not a well-defined one. These 
symptoms, which are the non-cognitive symptoms of neurodegenerative disease include 
changes in comportment or behavior, emotion, or personality. Examples of such 
symptoms include mood fluctuations, restlessness, agitation, apathy, loss of empathy, lack 
of motivation or initiative, inattention, reduced interest, social withdrawal, or even 
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not only might reflect underlying cognitive impairment, but also indicate that 
interventions are possible. Other studies in this thesis suggest an important role of 
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Since all these studies were based on considerably long follow-up, this thesis also 
highlights some common but frequently neglected methodological problems and biases in 
studies with a longer follow-up, and some potential solutions to these problems. For 
instance, if short follow-up studies are influenced by reverse causation, studies with long 
follow-up might be affected by regression dilution. Therefore, as discussed, common 
approaches to solve common methodological problems in epidemiology should be 
undertaken to prevent reporting of spurious results. 
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SUMMARY 
Dementia and neuropsychiatric disorders are mental disorders, which frequently co-occur, 
and have indistinct boundaries. Although they both are very important public health 
issues, their comorbidity is associated with an even greater public health impact. The 
association of depression and anxiety with dementia is complex and debated. One 
hypothesis suggests that psychiatric disorders are risk factors for dementia, while the 
other suggests that pathological changes in the preclinical phase of dementia, lead to 
neuropsychiatric symptoms. This might also be true for lifestyle factors which could be 
influenced when participants perceive a decline in their cognitive abilities, but are yet non-
demented clinically. In addition, it is also suggested that both dementia and psychiatric 
symptoms result from a common pathological process, such as vascular impairment. 
Therefore, in Chapter 2, we studied psychiatric determinants of dementia, cognitive 
decline and mortality. In Chapter 2.1, we investigated the association of depressive 
symptoms with risk of dementia. Depressive symptoms only predicted dementia in the 
short-term but not in the long-term. This suggested that depressive symptoms are a 
response to the underlying cognitive impairment which accumulates over decades before 
manifesting as clinical dementia. Therefore, they are more likely to be a prodrome of 
dementia rather than a risk factor (Analyses: Cox proportional hazards models). This was 
further supported by our findings in Chapter 2.2. In this chapter we used repeated 
measures of depressive symptoms to study the course of depression. We related this 
course to the risk of dementia and found that the trajectory with increasing depressive 
symptoms was, in particular, associated with a higher risk of dementia. This also suggests 
that depressive symptoms escalate with the cognitive impairment and are a prodrome of 
dementia rather than a risk factor. High depression at one time point followed by 
remission was not associated with a higher risk of dementia (Analyses: Latent class 
trajectory modelling, and Cox proportional hazards models with competing risk analyses). 
In Chapter 2.3, we studied trajectories of depressive symptoms and risk of mortality 
associated with these trajectories. Chronic high depression was associated with a higher 
risk of mortality, whereas high symptoms at one time point followed by remission were 
not associated with a higher risk. The chronicity and course of depression predicted 
mortality better than depression assessed at one time point (Analyses: Latent class 
trajectory modelling, and Cox proportional hazards models). In Chapter 2.4, we studied 
the association of anxiety with the risk of dementia. Neither participants with anxiety 
symptoms, nor those with anxiety disorders at baseline had a higher risk of dementia than 
those without anxiety. We concluded that anxiety is neither a risk factor, nor a part of 
prodrome of dementia (Analyses: Cox proportional hazards models). In Chapter 2.5, we 
 
 
 
 
studied anxiety symptoms and disorders in relation to risk of mortality. Anxiety symptoms 
were associated with a higher risk of mortality, but after adjusting for comorbid 
depression, this association disappeared. We concluded that anxiety is not associated with 
a higher risk of mortality. The associations observed with anxiety symptoms were largely 
explained by comorbid depression (Analyses: Cox proportional hazards models). As a 
further step, in Chapter 2.6, we studied associations of Mild cognitive impairment (MCI) 
with depressive and anxiety disorders. Persons with MCI were not only more likely to have 
prevalent depression and anxiety, but also had a higher relative risk of developing these 
disorders. We concluded that MCI is not only a forerunner of dementia but also a 
harbinger of affective disorders suggesting common etiological pathways between the 
two entities (Analyses: Multiple logistic regression).  
In Chapter 3, we, studied lifestyle factors in relation to dementia and cognitive function. In 
Chapter 3.1, we studied the association of coffee consumption and risk of incident 
dementia over short and long follow-up periods. We found that drinking >3 cups/day was 
protective of dementia only in the short-term (~4 years), but not in the long-term. We 
found a similar result when we tested these associations, 4 years later in the same group 
of people. This phenomenon was a classic example of reverse causation, which means that 
those who were consuming more coffee were healthier, and had a healthier lifestyle. In 
older age, coffee consumption, like other lifestyle factors is perhaps a proxy of good 
health and general well-being (Analyses: Flexible parametric models for survival analyses). 
To extend these findings, in Chapter 3.2, we assessed the associations of coffee 
consumption with MRI markers of brain volume and brain damage, namely, total brain 
volume, hippocampal volume, lacunar infarcts, and white matter lesions, and cognitive 
function. Habitual coffee consumption (≥1 cup/day) was associated with a lower 
prevalence of lacunar infarcts and a better information processing speed. However, coffee 
consumption of > 3 cups/day was also associated with a smaller hippocampal volume and 
worse information processing speed and memory. We concluded that the beneficial 
effects of coffee might be attributable to its beneficial effect on the cardiovascular system. 
However, the harmful associations require further investigation in longitudinal designs 
(Analyses: Multiple linear, and logistic regression). In Chapter 3.3, we studied the role of 
cognitive reserve in protecting against dementia after a stroke or TIA. Education was used 
as a measure of cognitive reserve, and was stratified in three categories, low, 
intermediate, and high. Risk of dementia after a stroke or TIA was higher in persons with 
low and intermediate education groups but not in the high group. This effect was more 
pronounced in men. We concluded that cognitive reserve might protect against dementia 
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after clinical cerebrovascular events (Analyses: Cox proportional hazards models with 
stroke or TIA as time-varying exposure). 
In Chapter 4, we assessed serum biomarkers in relation to incident dementia and 
depression. In Chapter 4.1, the association of NT-proBNP (a cardiovascular disease 
marker) with dementia and cognitive decline was assessed, both including and excluding 
persons with overt cardiovascular disease. Higher NT-proBNP was associated with a higher 
risk of dementia, including Alzheimer’ disease, and was associated with a decline in 
processing speed and executive function, even in the absence of cardiovascular risk 
factors or disease. We concluded that NT-proBNP reflecting subclinical cardiovascular 
disease, predicts dementia, and can be a useful marker of imminent cognitive decline and 
dementia in absence of clinical cardiovascular disease (Analyses: Cox proportional hazards 
models with competing risk analyses, and multiple linear regression). In Chapter 4.2 we 
examined the association of cardiovascular, renal, and metabolic biomarkers with incident 
depression. NT-proBNP was associated with major depression and depressive symptoms 
both, whereas CRP predicted incident depressive symptoms only. Additionally, we used 
Principle Component Analyses to combine correlating biomarkers in groups: 
cardiovascular, renal, and metabolic. We found that the cardiovascular component (NT-
proBNP and cystatin C) and metabolic component (CRP, glucose, and HDL cholesterol) 
were associated with a higher risk of depressive symptoms. These findings suggested a 
role of cardiovascular, inflammatory,  and metabolic factors in the etiology of depression 
in older adults (Analyses: Principle Component Analyses, Cox proportional hazards models, 
and Generalized Estimation equations). 
 
 
 
 
SAMENVATTING 
Dementie en neuropsychiatrische stoornissen zijn mentale stoornissen die vaak samen 
voorkomen, hun scheidslijn is onduidelijk. Beiden zijn het erg belangrijke problemen van 
de volksgezondheid en hun comorbiditeiten zijn met nog grotere 
volksgezondheidsproblemen geassocieerd. Hoe depressie en angst tot dementie 
gerelateerd zijn is onduidelijk en of er zo’n associatie is valt te betwisten. Er is een 
hypothese die suggereert dat psychiatrische stoornissen risicofactoren zijn voor dementie 
en een andere suggereert dat de pathologische veranderingen in de preklinische fase van 
dementie leiden tot neuropsychiatrische symptomen. Dit zou ook het geval kunnen zijn 
voor leefstijlfactoren die beïnvloed kunnen worden als deelnemers een afname van 
cognitieve functie merken, maar nog niet dement zijn. Daarnaast kan het zo zijn dat 
dementie en psychiatrische symptomen beiden komen door een gedeeld pathologisch 
proces, bijvoorbeeld vasculaire schade. Om hier meer inzicht in te krijgen, bestudeerden 
we in Hoofdstuk 2 de psychiatrische determinanten van dementie, cognitieve 
achteruitgang en mortaliteit. In Hoofdstuk 2.1 onderzochten we de relatie tussen 
depressieve symptomen en het risico op dementie. Depressieve symptomen voorspelden 
dementie alleen op de korte termijn, niet op de lange termijn. Dit suggereert dat 
depressieve symptomen een reactie zijn op een onderliggende cognitieve achteruitgang. 
Deze achteruitgang is een proces van jaren voordat het zichtbaar wordt als dementie. 
Depressieve symptomen zijn dan ook eerder een voorstadium dan een risicofactor voor 
dementie (Analyses: Cox proportional hazards modellen). Dit werd verder ondersteund 
door onze bevindingen in Hoofdstuk 2.2. In dit hoofdstuk gebruikten we herhaalde 
metingen van depressieve symptomen om het beloop van depressie te bestuderen. Dit 
beloop relateerden we tot het risico op dementie en we vonden dat voornamelijk een 
toename van depressieve symptomen gerelateerd was aan een hoger risico op dementie. 
Dit suggereert ook dat depressieve symptomen gelijk opgaan met de cognitieve 
achteruitgang en meer een voorstadium zijn van dementie dan een risicofactor. Veel 
depressieve symptomen op één tijdspunt gevolgd door een remissie was niet geassocieerd 
met een hoger risico op dementie (Analyses: Latent class trajectory modelling en Cox 
proportional hazards modellen met competing risk analyses). In Hoofdstuk 2.3 
bestudeerden we het beloop van depressieve symptomen en het risico op overlijden 
geassocieerd met dit beloop. Chronisch veel depressie was geassocieerd met een 
verhoogd risico op overlijden, terwijl het hebben van veel symptomen op één tijdspunt 
gevolgd door een remissie niet geassocieerd was met een verhoogd risico. De duur en het 
beloop van depressie voorspelden het risico op overlijden dus beter dan depressie 
gemeten op één tijdspunt (Analyses: Latent class trajectory modelling en Cox proportional 
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hazards modellen). In Hoofdstuk 2.4 onderzochten we hoe angst gerelateerd is aan het 
risico op dementie. Zowel deelnemers met angstsymptomen als deelnemers met 
angststoornissen aan het begin van de studie hadden geen hoger risico op dementie 
vergeleken met deelnemers zonder angst. We concludeerden dat angst geen risicofactor 
en geen voorstadium van dementie is (Analyses: Cox proportional hazards modellen). In 
Hoofdstuk 2.5 onderzochten we hoe angstsymptomen en angststoornissen gerelateerd 
zijn aan het risico op overlijden. Angstsymptomen waren geassocieerd met een hoger 
risico op overlijden, maar deze associatie verdween na het corrigeren voor depressie. We 
concludeerden dat angst niet gerelateerd is aan een hoger risico op overlijden. De 
associaties die we met angstsymptomen vonden werden grotendeels verklaard door het 
gemeenschappelijk optreden van depressie (Analyses: Cox proportional hazards 
modellen). Als volgende stap bestudeerden we in Hoofdstuk 2.6 hoe een milde cognitieve 
achteruitgang (Mild cognitive impairment, MCI) geassocieerd is met depressieve 
stoornissen en angststoornissen. Deelnemers met MCI hadden niet alleen vaker prevalent 
depressie en angst, maar hadden ook een groter risico om deze stoornissen te 
ontwikkelen. We concludeerden dat MCI niet alleen een voorstadium is van dementie, 
maar ook van angst- en gemoedsstoornissen. Dit suggereert dat beide processen een 
gezamenlijke ontstaanswijze hebben (Analyses: Multiple logistic regression).  
Hoofdstuk 3 richt zich op leefstijlfactoren in relatie tot dementie en cognitieve functie. In 
Hoofdstuk 3.1 bestuurden we de associatie tussen koffieconsumptie en het risico op 
dementie gedurende korte en lange follow-up periodes. We vonden dat het drinken van 
>3 koppen koffie per dag beschermend was tegen dementie op de korte termijn 
(ongeveer 4 jaar), maar niet op de lange termijn. We vonden hetzelfde resultaat toen we 
deze associaties op een tijdspunt vier jaar later testten in dezelfde groep mensen. Dit 
fenomeen is een klassiek voorbeeld van een omgekeerde causaliteit (reversed causality). 
Dit betekent dat de mensen die meer koffie dronken gezonder waren en een gezondere 
levensstijl hadden. Op oudere leeftijd is koffieconsumptie, net als andere leefstijlfactoren, 
mogelijk een weerspiegeling van een goede fysieke en mentale gezondheid (Analyses: 
Flexible parametric models voor survival analyses). Om hierop door te gaan, onderzochten 
we in Hoofdstuk 3.2 de associaties tussen koffieconsumptie en MRI markers van 
hersenvolume en hersenschade, namelijk totaal hersenvolume, hippocampusvolume, 
lacunaire infarcten en wittestofafwijkingen, en cognitieve functie. Het drinken van koffie 
(≥1 kop per dag) was geassocieerd met een lagere prevalentie van lacunaire infarcten en 
een betere informatieverwerkingssnelheid. Een consumptie van >3 koppen per dag was 
echter ook geassocieerd met een kleinere hippocampusvolume en een slechtere 
informatieverwerkingssnelheid en geheugen. We concludeerden dat de gunstige werking 
 
 
 
 
van koffie zou kunnen komen door het gunstige effect op het cardiovasculaire systeem. 
Voor de schadelijke associaties is verder onderzoek nodig in de vorm van een 
longitudinale studieopzet (Analyses: Multiple linear and logistic regression). In Hoofdstuk 
3.3 bestudeerden we de rol van een cognitieve reserve in het beschermen tegen dementie 
na een beroerte of TIA. Onderwijsniveau was gebruikt als maat voor deze cognitieve 
reserve en was gestratificeerd in drie categorieën, namelijk laag, gemiddeld en hoog. Het 
risico op dementie na een beroerte of TIA was verhoogd in de mensen met een laag of 
gemiddeld opleidingsniveau, maar niet in de mensen met een hoog opleidingsniveau. Dit 
vonden we voornamelijk voor mannen. We concludeerden dat een cognitieve reserve 
mogelijk beschermt tegen dementie na een beroerte of TIA. (Analyses: Cox proportional 
hazard modellen met beroerte of TIA als time-varying exposure).  
Hoofdstuk 4 beschrijft serum biomarkers in relatie tot het ontstaan van dementie en 
depressie. In Hoofdstuk 4.1 onderzochten we de associatie tussen NT-proBNP (een 
marker voor cardiovasculaire ziekten) en dementie en cognitieve achteruitgang, zowel 
inclusief als exclusief de mensen met klinische cardiovasculaire ziekten. Een hoger NT-
proBNP was geassocieerd met een verhoogd risico op dementie, inclusief de ziekte van 
Alzheimer, en was geassocieerd met een afname in verwerkingssnelheid en uitvoerende 
functie, zelfs in de afwezigheid van cardiovasculaire risicofactoren of cardiovasculaire 
ziekten. We concludeerden dat NT-proBNP, als marker voor subklinische cardiovasculaire 
ziekte, leidt tot een hoger risico op dementie. Het zou dan ook een waardevolle marker 
kunnen zijn voor een dreigende cognitieve achteruitgang en dementie, in de afwezigheid 
van klinische cardiovasculaire ziekten (Analyses: Cox proportional hazard models met 
competing risk analyses, multiple linear regression). In Hoofdstuk 4.2 onderzochten we 
hoe verschillende cardiovasculaire, renale en metabole biomarkers samenhangen met het 
risico op depressie. Een hoger NT-proBNP was gerelateerd aan een hoger risico op zowel 
depressie als depressieve symptomen, terwijl een hoger CRP alleen gerelateerd was aan 
incidente depressieve symptomen. Daarnaast gebruikten we een ‘Principle Component 
Analysis’ om de markers in groepen in te delen, namelijk cardiovasculair, renaal en 
metabool. We vonden dat zowel het cardiovasculaire component (NT-proBNP en cystatine 
C) als het metabole component (CRP, glucose en HDL cholesterol) geassocieerd waren met 
een verhoogd risico op depressieve symptomen. Deze bevindingen suggereren een rol van 
cardiovasculaire en metabole factoren in het ontstaan van depressie in ouderen (Analyses: 
Principle Component Analyses, Cox proportional hazards modellen, en Generalized 
Estimation equations).  
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Voor de schadelijke associaties is verder onderzoek nodig in de vorm van een 
longitudinale studieopzet (Analyses: Multiple linear and logistic regression). In Hoofdstuk 
3.3 bestudeerden we de rol van een cognitieve reserve in het beschermen tegen dementie 
na een beroerte of TIA. Onderwijsniveau was gebruikt als maat voor deze cognitieve 
reserve en was gestratificeerd in drie categorieën, namelijk laag, gemiddeld en hoog. Het 
risico op dementie na een beroerte of TIA was verhoogd in de mensen met een laag of 
gemiddeld opleidingsniveau, maar niet in de mensen met een hoog opleidingsniveau. Dit 
vonden we voornamelijk voor mannen. We concludeerden dat een cognitieve reserve 
mogelijk beschermt tegen dementie na een beroerte of TIA. (Analyses: Cox proportional 
hazard modellen met beroerte of TIA als time-varying exposure).  
Hoofdstuk 4 beschrijft serum biomarkers in relatie tot het ontstaan van dementie en 
depressie. In Hoofdstuk 4.1 onderzochten we de associatie tussen NT-proBNP (een 
marker voor cardiovasculaire ziekten) en dementie en cognitieve achteruitgang, zowel 
inclusief als exclusief de mensen met klinische cardiovasculaire ziekten. Een hoger NT-
proBNP was geassocieerd met een verhoogd risico op dementie, inclusief de ziekte van 
Alzheimer, en was geassocieerd met een afname in verwerkingssnelheid en uitvoerende 
functie, zelfs in de afwezigheid van cardiovasculaire risicofactoren of cardiovasculaire 
ziekten. We concludeerden dat NT-proBNP, als marker voor subklinische cardiovasculaire 
ziekte, leidt tot een hoger risico op dementie. Het zou dan ook een waardevolle marker 
kunnen zijn voor een dreigende cognitieve achteruitgang en dementie, in de afwezigheid 
van klinische cardiovasculaire ziekten (Analyses: Cox proportional hazard models met 
competing risk analyses, multiple linear regression). In Hoofdstuk 4.2 onderzochten we 
hoe verschillende cardiovasculaire, renale en metabole biomarkers samenhangen met het 
risico op depressie. Een hoger NT-proBNP was gerelateerd aan een hoger risico op zowel 
depressie als depressieve symptomen, terwijl een hoger CRP alleen gerelateerd was aan 
incidente depressieve symptomen. Daarnaast gebruikten we een ‘Principle Component 
Analysis’ om de markers in groepen in te delen, namelijk cardiovasculair, renaal en 
metabool. We vonden dat zowel het cardiovasculaire component (NT-proBNP en cystatine 
C) als het metabole component (CRP, glucose en HDL cholesterol) geassocieerd waren met 
een verhoogd risico op depressieve symptomen. Deze bevindingen suggereren een rol van 
cardiovasculaire en metabole factoren in het ontstaan van depressie in ouderen (Analyses: 
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WORD OF THANKS
Alhamdulillah after almost 4 years of effort, this journey ends successfully into a brand 
new beginning, and this journey could not have been possible without the support of 
several inspirational colleagues and friends around, and especially the love and 
understanding of my family who despite being thousands of miles away, kept on 
supporting me with their love. 
I would like to sincerely thank Dr. Ikram and Prof. Tiemeier for this life-changing 
opportunity. I have been super lucky to have mentors who are not only “the best” in their 
field, but are also humble and great human beings. I will always cherish the fortnightly 
scientific meetings where I not only enjoyed the scientific discussions with both my 
supervisors, but their epidemiological humor as well. The stay at the department of 
Epidemiology at the Erasmus MC has been a blessing, which enabled me to grow 
immensely as a person, a team-player, and a researcher.  I would like to express my 
gratitude to Prof. Hofman for the opportunity to study and train at his department, for 
being a part of the Rotterdam Study,  and for all his support that ensured that I graduate 
from the department of epidemiology as a successful upcoming epidemiologist. 
Henning! Thank you for giving me this opportunity, encouraging me, having confidence in 
my work, having patience (most of the times), and for your scolding and teasing, all of 
which helped to get the best out of me during these years. Besides all the epidemiological 
training, I have immensely enjoyed the mini English language lessons from you. From the 
warm welcome dinner on my arrival in Rotterdam to the sheer support for finalizing my 
thesis, I cannot thank you enough for everything you did to make these years a success. I 
would also like to thank you for listening to my problems and trying to solve them, and for 
all the sincere advice on every step of my PhD. Thank you! 
Arfan! Thank you so much for this wonderful opportunity. I will never forget that phone 
call from you in which you told me that I have been selected for the PhD position. I know 
you remember my reaction, but I really hope that you forget it . I have learnt a million 
things from you, but besides all the epidemiological lessons, in particular, if I ever write a 
nice introduction, I will certainly give the credits to you. I sincerely thank you for your 
patience, your encouragement, your help, your unique subtle way of constructive 
criticism, listening to all my work related or non-work related problems and providing 
solutions, making the arrangements for extending my stay here, and helping on every step 
of this training. You are a true inspiration to every young researcher out there. Thank you! 
 
 
 
 
A special and sincere word of thanks to the expert promotion committee, Prof. Skoog, 
Prof. Hoogendijk, Prof. Koudstaal, Dr. Geerlings, Dr. Rizopoulos, and Dr. White for their 
valuable time and encouragement. 
Thank you Meike, Najaf, and Sonja for your support and being so approachable and 
friendly. I would also like to thank all my coauthors, and those with whom I have 
collaborated with. Thank you all for you knowledge and you constructive critique and 
feedback. 
All these years, I have bugged three wonder women and 2 supermen, Gabrielle, Erica, 
Solange, Nano, and Frank so many times (on purpose, so that they never forget me ). 
Besides everything that you all did for me, dear Gabrielle! a hug for you, for helping me 
when I had lost my passport, dear Erica! a hug for you for sending my form 2 while you 
were still on holiday and sharing the panic, dear Solange! a hug for you for ensuring my 
legal stay in the Netherlands, and not losing patience with my frequent visits to your 
office, dear Nano, a special thanks to you for rescuing my PC in cases of emergency, and 
dear Frank! Thanks for not losing patience with all the data requests. A sincere thanks also 
to Hetty and Jacqueline for their support and friendly attitude. 
My colleagues/friends at work! Ana, Annamarie, Ayesha, Ben, Daniel, Deepti, Desana, 
Frank, Hazel, Heidi, Hieab, Hoyan, Jasper, Jelena, Jory, Larissa, Lisette, Lisselot, Liz, Lotte, 
Marileen, Marius, Mayara, Nese, Olivera, Raluca, Renee, Rens, Rosanne, Saloua, Sanaz, 
Sirwan, Sven, Tavia, Unal, and Vincent. The people who have made me laugh and be 
happy despite being miles away from home and being alone in Rotterdam, who have 
shared my problems and sad moments, and have cheered me up with their support 
through these years. The presence of each one of you has its own peculiar value, and I had 
been blessed to be surrounded by such friendly people as you all. My sweet roommies, 
Marileen (paranymph) and Hoyan! It feels like I know you two since ages. The chit chat, 
visits to the coffee machine, talking about our frustrations, convincing each other at times 
that eating junk food is very healthy, and hating trajectories together and are only some of 
the million memories . Marileen! A special thanks to you for being so understanding, for 
all your help and support, and for agreeing to be my paranymph; it has been a pleasure 
working and sharing the room with you. Together with all this, I will also remember two 
golden lines uttered by you which I wish to quote here: (1) Dr. Portegies: “After PhD, you 
do neurology residency, and then you have to do other things..and then you die….”, (2) Dr. 
Portegies: “I still take manuscript rejections as personal” . Hoyan! Thank you for being a 
sweet, understanding and funny roommate , for offering candy, chips and cookies, and 
for baking such tasty cakes. Rosanne! Working with you has been wonderful, but is even 
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more joyous to have you as a friend. Thank you for always being there despite the 
distance, and for being so sweet. I wish to see you soon, may be in Rotterdam, Toronto or 
Melbourne. Hieab the genius! Thank you for always being so helpful and kind, 
understanding and laughing at the weirdest jokes , and for the charming company. 
Besides your smartness, I will always remember your scientist look (reference: AAIC 2014) 
and your flying pose (reference: your dreams). Saloua! Thanks for all the warm love, 
sincere advice and motivation, and in particular, the motivation to go on holiday. I have 
enjoyed the long corridor chats, and thanks for the fantastic Moroccan dinner. I hope you 
forgive me for the Pocahontas picture that I made for your PhD defense gift booklet. 
Vincent! Thanks for always being helpful, for all the fun times on the Ee-21st floor, and 
consistently asking to join for lunch. I apologize if few times I couldn’t join . Frank! 
Thanks for always helping and being so sweet, funny, charming, and friendly. I will never 
forget you laziness during the sightseeing in Washington, where I had to bribe you for ice-
cream to get going . Hazel! Thanks for always smiling and helping. No one speaks English 
as cutely as you do. You were a wonderful company in Copenhagen, and through all these 
years in Rotterdam. If I would have seen you outside of the Erasmus MC for the first time, 
I would have thought you were a fashion model . Lotte! (The Barbie )Thank you for the 
charming and cheerful company in Copenhagen and in Rotterdam, and for always greeting 
so enthusiastically. Hearing your cheerful voice always brings a smile to my face. Rens! 
Thank you for the consistently calm, kind and friendly attitude. Sanaz! Thank you for all 
the help and long funny corridor chats. Renee! Thanks for helping always, and having the 
most refreshing laughter . Lisette! Thank you for the very first Christmas wish in the 
Netherlands and all the good times spent together. Nese! Thank you for the birthday 
lollipop and all the love and support. Liz! Thank you for being there with me in the Dutch 
conversations , and for all the fun times. Daniel! Thank you for being so kind and 
helping. Tavia! Thank you for all the fun conversations . Ana! Thank you for the 
compliments and your charming presence. Raluca! Thank you for sharing the anxiety . 
Annamarie! Thanks for all the help and your wonderful company. Sven! Thank you for 
adopting my plant and saving it, and all the fun times. Zubair! Thank you for the help all 
these years. From arranging a house for me to listening to all my problems. I can’t thank 
you enough. Thank you all for your concern and support, and I wish all of you the very best 
in the years to come. 
I would like to say thank you to the friends and family at a distance. Sana! Thank you for 
always being there and for all the prayers, Nazish and Adnan Bhai! Thank you for the 
company and rescuing Mansoor from boredom , Masooma, Kashif, Kiran, Nosheen, 
Kanwal, Fahad, Owais, Kamran Bhai, Samreen, Kamran, Maha, Sadia, Yasir, and Ambreen! 
 
 
 
 
Thank you for your encouragement and support, and being there on facebook or 
whatsapp in times of deadly boredom . 
A genuine and heartfelt thanks to my life-my loving family. This achievement would have 
not at all been possible without the prayers, love and support of my family. Dear Abbu je! I 
couldn’t have done it without your prayers. Your strong support throughout my life is 
something that enabled me to stay strong in these years. Amman! Every day during these 
years, I have recalled how you had taught me. I owe everything to you. Thank you for your 
love, your support, your prayers, and your ambition, which I reflect. Baji! Thank you for all 
the love, support, protection, prayers, and always being by my side  since we were kids. 
You are no less than a mother to me. Thank you for flying all the way from Pakistan to 
attend my PhD defense. Sadia- The little elder sister! Thank you for your sheer support 
and care through all these years, for being my paranymph, for designing the cover for this 
book, and for always being there. You both are strong and wonderful women just as 
Amman! God bless you. Faiz bhai! Thank you for all the motivation , and being a part of 
the family. Ahsan bhai! Thank you for warmly welcoming my uncountable visits to your 
home in these years. Thanks for being a part of family. Areeb, Warisha, and Aahil! Thank 
you for being so loving. You three are little packets of joy for the family. Thank you for all 
the love and affection!  
Behind every successful woman, there is her strong and supportive husband. Last but not 
the least, I want to thank my better half, my dear husband Mansoor, without whom, this 
was not at all possible. Mansoor! Thank you for your kindness, your love and your intense 
support. Thank you for bearing with me, for tolerating fast food for all these years and not 
complaining, for staying connected, for being there in difficult times, for cheering me up 
when I had been down, and a special thanks for the cozy and beautiful apartment of our 
own to start my new life when I move to Toronto!  
I thank you all for flying to Rotterdam from miles away to make my special day even more 
special. The time that I have spent or will spend with all of you is priceless, and I wish that 
Allah Subhana-o-Tala always keep your love and blessings with me till I live. 
I cannot forget to mention those whom I lost during these 3.5 years: My grandfather, Dr. 
Mirza, who would have been the happiest person on this occasion, my father-in-law, who 
would have definitely come to attend my PhD defense, and my loving friend Dr, Shehla, 
who would have been sincerely happy to see my achievement. 
I will always be thankful to Allah for this life, for health, for wealth, for peace of mind, for 
food, for a job, for a home, for loving parents, for a supporting family, for a wonderful 
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